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The viral protein integrase (IN) catalyzes the integration of the HIV-1 cDNA into the host 
cellular genome. We have recently demonstrated that IN is acetylated by a cellular histone 
acetyltransferase, p300, which modifies three lysines located in the C-terminus of the viral 
factor (Cereseto et al., 2005). This modification enhances the catalytic activity and the 
DNA affinity of IN, as demonstrated by in vitro assays (Cereseto et al., 2005). 
Consistently, mutations introduced in the targeted lysines greatly decrease the efficiency 
of HIV-1 integration (Cereseto et al., 2005; Terreni et al., 2010; Apolonia et al., 2007). 
Acetylation was proven to regulate protein functions by modulating protein-protein 
interactions. HIV-1 to efficiently complete its replication steps, including the integration 
reaction, requires the interaction with numerous cellular factors. Therefore, we sought to 
investigate whether acetylation might modulate the interaction between IN and cellular 
factors. To this aim we performed a yeast two-hybrid screening that differs from the 
screenings so far performed for using as bait IN constitutively acetylated. From this 
analysis we have identified thirteen cellular factors (seven are nuclear and four are 
cytoplasmic) involved in transcription, chromatin remodeling, nuclear transport, RNA 
binding, protein synthesis regulation and microtubule organization. Binding assays showed 
that acetylation increases the association of IN with four identified factors (KAP1 
(TRIM28), Exp2, eIF3h and RanBP9), while for three two-hybrid hits (BTF3b, THRAP3 and 
HMGN2), the acetylation does not modulate their binding with IN. KAP1, which belongs to 
the TRIM family of antiviral proteins, was investigated for its role in HIV-1 infection and for 
the determination of the molecular mechanisms that underlie its interaction with IN. We 
found that KAP1 binds preferentially acetylated IN and induces its deacetylation through 
the formation of a protein complex including the deacetylase HDAC1. Modulation of 
intracellular KAP1 levels in different cell types including T-cells, the primary HIV-1 target, 
revealed that KAP1 curtails viral infectivity by selectively affecting HIV-1 integration. KAP1-
dependent viral inhibition was found to require HDAC1 activity since cells deficient for this 
deacetylase were insensitive to KAP1-induced resistance. This study reveals that KAP1 is a 
novel cellular factor restricting HIV-1 infection and underscores the relevance of IN 






AIMS OF THE THESIS 
 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that belongs to the lentivirus 
genus (Coffin et al., 1997). HIV-1 infects mainly CD4+ human T lymphocytes and causes 
the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Popovic et 
al., 1984). AIDS is a human infectious disease that causes a progressive profound state of 
immune suppression characterized by a drop of the circulating CD4+ T lymphocyte 
number and leaves infected individuals susceptible to opportunistic infections and prone to 
develop tumors (Barre-Sinoussi et al., 1983; Popovic et al., 1984).  
An essential step in the retroviral life cycle is the integration of the viral DNA into the host 
cellular genome; a reaction catalyzed by the viral protein integrase (IN) (Coffin et al., 
1997). Purified HIV-1 integrase displays 3‘ end processing and DNA strand transfer 
activities that are sufficient to catalyze the cDNA integration reaction in vitro (Lewinski and 
Bushman, 2005; Vandegraaff and Engelman, 2007). However, in vivo numerous cellular 
proteins are required for efficient integration. The host factors regulate integrase 
enzymatic functions by modulating its stability and by mediating nuclear import and access 
to specific regions of the chromatin (Busschots et al., 2009). We have recently 
demonstrated that p300, a histone acetyl transferase, binds integrase and acetylates three 
lysines (K264, K266, K273) located in its C-terminus leading to enhanced integrase activity 
and DNA binding affinity (Cereseto et al., 2005). Acetylable lysines are necessary for virus 
integration and thus for optimal replication, as demonstrated by the inefficient infectivity 
observed following their mutations into arginine residues (K264, 266, 273R) (Apolonia et 
al., 2007; Cereseto et al., 2005; Terreni et al., 2010). Since it has been demonstrated that 
acetylation modulates the activities of cellular and viral proteins by affecting protein-
protein interactions (Bannister et al., 2000; Berro et al., 2006; Bres et al., 2002; Das and 
Kundu, 2005; Dorr et al., 2002; Glozak et al., 2005; Kouzarides, 2000; Mujtaba et al., 
2002; Mujtaba et al., 2004; Polesskaya and Harel-Bellan, 2001; Spange et al., 2009; 
Sterner and Berger, 2000), the aim of this study is to investigate whether integrase 
acetylation could affect its interaction with cellular factors and to reveal the possible 






To reach this aim, four research steps were involved:  
1- The identification of cellular proteins binding acetylated integrase by employing the 
tethered catalysis two-hybrid system in yeast, a method previously reported to 
efficiently identify factors binding specifically to acetylated proteins (p53, histones 
H3 and H4) (Acharya et al., 2005; Guo et al., 2004).   
2- The validation of the interactions between acetylated integrase and the candidate 
cellular factors, identified from the yeast two-hybrid screening, by in vitro pull down 
assays and in vivo co-immunoprecipitation experiments.  
3- The study of one identified candidate (KAP1 or TRIM28) through the investigation 
of its role in HIV-1 replication and specifically at the level of integration.  
4- The search of the molecular mechanisms that underlie the role of KAP1 in HIV-1 
infection. 
Identification and study of novel cellular proteins interacting with HIV-1 acetylated 
integrase would provide more knowledge on host factors that promote or inhibit HIV-1 
infection. Such information might be useful for alternative HIV-1 therapies based on the 
inhibition of viral and cellular protein-protein interactions when the interactions enhance 
HIV-1 replication or on the stimulation of the viral and cellular protein associations when 
the interactions impair HIV-1 infectivity (Busschots et al., 2009). In fact, the current highly 
active antiretroviral therapy (HAART) for HIV-1 that is based on the combination of 
effective drugs that inhibit specifically the viral proteins (reverse transcriptase, protease 
and recently integrase) resulted in the emergence of HIV-1 resistant strains. This 
resistance is due to the virus short replication cycle and to the high error rate of its 
reverse transcriptase that allow the virus to mutate very quickly (Busschots et al., 2009). 
Therefore, targeting interactions between cellular and viral proteins is a novel therapy 
strategy that might decrease the risk of HIV-1 drug resistance induced by targeting 
directly viral proteins (Busschots et al., 2009; Christ et al., 2010). 











HIV-1 replication  
HIV-1 was discovered on 1983 by Montagnier‘s group, two years after the first description 
of AIDS. In this study, HIV-1 was called LAV (lymphadenopathy associated virus) and was 
described to be involved in several infectious syndrome including AIDS (Barre-Sinoussi et 
al., 1983). In 1984, Gallo‘s group gave also evidence that HIV-1 is the causal agent of 
AIDS; HIV-1 was termed as HTLVIII (Popovic et al., 1984). In 1985 came the cloning and 
sequencing of HIV-1 genome with identification of new open reading frames specific for 
lentiviruses (Ratner et al., 1985; Sanchez-Pescador et al., 1985; Wain-Hobson et al., 
1985). In 1986, a second retrovirus strain, known as HIV-2 and having 40-60% homology 
with HIV-1, was isolated from West African patients with AIDS (Clavel et al., 1986). The 
majority of the studies reported that HIV-2 is less pathogenic than HIV-1 and causes AIDS 
only in the minority of infected individuals; HIV-2 infection is mainly asymptomatic (de 
Silva et al., 2008). 
 
1- HIV-1 genome and structure  
HIV-1 is a human retrovirus that is related most closely to other animal lentiviruses  
(Coffin et al., 1997). Lentiviruses are ―complex‖ retroviruses that encode a number of 
regulatory and accessory proteins not encoded by the genome of prototypical ―simple‖ 
retrovirus (Coffin et al., 1997).  
The HIV-1 genome is approximately 9 Kb in length and encodes 15 distinct proteins 
(Figure 1) (Frankel and Young, 1998). From the 5‘- to 3‘- ends of the genome are found 
the gag (for group-specific antigen), pol (for polymerase) and env (for envelope 
glycoprotein) genes. The gag gene encodes a polyprotein precursor, pr55Gag that is 
cleaved by the viral protease (PR) to produce Gag proteins matrix (also known as MA or 
p17), capsid (CA or p24), nucleocapsid (NC or p7) and p6. Two spacer peptides p2 and p1 
are also generated upon pr55Gag processing. The pol gene encodes HIV-1 enzymes, 
protease (PR), reverse transcriptase (RT), integrase (IN) which are cleaved from 
pr160GagPol precursor by the viral protease (Frankel and Young, 1998). The envelope (Env) 
glycoprotein is also synthesized as a polyprotein precursor (Figure 1). Unlike the Gag and 
Pol precursors which are cleaved by the viral protease the Env precursor, known as gp160, 
is processed by a cellular protease (furin or furin like enzyme) during Env trafficking to the 
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cell surface. gp160 processing results in the generation of the surface (SU) Env 
glycoprotein gp120 and the trans-membrane (TM) glycoprotein gp41 (Freed, 2001). gp120 
contains the determinants that interact with target cell receptor and co-receptors, while, 
gp41 anchors the gp120/gp41 complex in the membrane and also contains domains that 
are critical for catalyzing the membrane fusion reaction between viral and host lipid 
bilayers during virus entry (Freed, 2001). Comparison of env sequences from large 
number of virus isolates revealed that gp120 is organized into five conserved regions (C1-
C5) and five highly variable domains (V1-V5). gp41 is composed of three major domains: 
the ectodomain (which contains determinants essential for membrane fusion), the trans-
membrane anchor sequence and the cytoplasmic tail (Freed, 2001).  
 
Figure  1: . Organization of the HIV-1 genome. The relative locations of the HIV-1 open reading frames 
gag, pol, env, vif, vpr, vpu, nef, tat, and rev are indicated. The 5' and 3' long terminal repeats (LTRs) are 
shown, with U3, R, and U5 regions noted. The  indicates the position of the RNA packaging signal. The 
major Gag domains (MA, CA, NC, p6) and the Gag spacer peptides (p2 and p1) are shown under the gag 
gene. The site of Gag N-terminal myristylation is denoted as ―myr‖. Under the pol gene are indicated the PR, 
RT (p66 and p51 sub-domains), and IN coding regions. The SU and TM Env glycoproteins (gp120 and gp41, 
respectively) are enlarged to show the position in gp120 of the major conserved (C1-C5) and variable (V1-
V5) regions and in gp41 the location of the fusion peptide, the N- and C-helices, membrane-spanning 
domain, and the cytoplasmic tail (Freed, 2001). 
 
In addition to gag, pol and env genes HIV-1 encodes two regulatory proteins: Tat and Rev 
and four accessory proteins: Vpu (viral protein u), Vpr (viral protein r), Vif (viral infectivity 





2- HIV-1 replication cycle  
HIV-1 replication proceeds in a series of events that can be divided in infection phase and 




Figure 2: The replication cycle of HIV-1. The viral envelope protein (Env) of HIV-1 binds CD4 first, 
undergoes a conformational change, then binds one of two chemokine receptors — CCR5 (R5 strains) or 
CXCR4 (X4 strains) — and enters cells by fusion of the viral and cellular membranes. Reverse transcription 
begins, yielding double-stranded viral cDNA. The HIV-1 PIC enters the nucleus without cell division with the 
help of the viral and cellular proteins and the viral cDNA flap. Integrase (IN) catalyzes the insertion of the 
viral cDNA into the host geneome. The un-integrated viral cDNA is circularized in the nucleus into 1-LTR or 
2-LTR circles. The provirus transcription, which is stimulated by Tat, yields the viral mRNAs. Rev transports 
partially spliced and unspliced genomic transcripts from the nucleus to the cytoplasm. Viral structural and 
enzymatic proteins are synthesized and transported to the plasma membrane, where they localize in lipid 
rafts. Late domains in group-specific antigen (Gag) then recruit components of multivesicular bodies to the 
site of budding, so that progeny virions are released from the infected cell (Peterlin and Trono, 2003). 
 
2.1- Cellular entry 
HIV-1 enters the body through the exchange of bodily fluids, and it infects mainly T helper 
cells, macrophages and to some extent microglial cells and dentritic cells (Peterlin and 
Trono, 2003). This tropism is determined at the level of viral entry by the use of CD4 as a 
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primary receptor and the use of co-receptors that are strain and target specific. R5 strains 
of HIV-1 use CC-chemokine receptor 5 (CCR5) as their co-receptor and can therefore 
enter macrophages, dentritic cells and T cells, whereas X4 strains of HIV-1 use CXCR4 co-
receptors and infect only T cells (Doms and Trono, 2000). R5/X4 HIV-1 isolates have dual 
tropism and uses both CCR5 and CXCR4 co-receptors. The V3 loop of gp120 is 
demonstrated to play major role in determining HIV-1 tropism (O'Brien et al., 1990). HIV-
1 entry in target cells was showed to occur mainly by viral and cellular membranes fusion 
that involve the following events: gp120 first binds CD4 receptors, a ternary complex 
composed of gp120, CD4 and co-receptor then forms, and finally conformational changes 
in gp41 ultimately trigger membrane fusion (Berger et al., 1999). Recent work entailing 
live cell imaging demonstrates that HIV-1 entry also occurs after virion endocytosis and 
shows that the cellular protein dynamin plays a pivotal role in this process (Miyauchi et al., 
2009). Following entry, the viral core is delivered into the cytoplasm. The viral core is 
composed of a capsid (CA) protein shell that encapsidates the single stranded, dimeric 
viral RNA genome in complex with the viral nucleocapsid (NC) protein and the viral 
enzymes reverse transcriptase (RT) and integrase (IN) (Adamson and Freed, 2007; 
Ganser-Pornillos et al., 2008).  
 
2.2- Reverse transcription  
Following entry, the core  is partially disassembled in a poorly understood process known 
as uncoating to form reverse transcription complex (RTC) and then pre-integration 
complex (PIC) (Adamson and Freed, 2007; Ganser-Pornillos et al., 2008). It should be 
noted that distinction between RTCs and PICs is somewhat arbitrary, since uncoating is 
believed to occur progressively, but PICs are usually defined as the integration competent 
complexes, whereas reverse transcription is incomplete in RTCs (Iordanskiy et al., 2006; 
Nisole and Saib, 2004). Reverse transcription, a hallmark step of retroviruses, which 
converts HIV-1 RNA genome into double stranded DNA, early post-infection is catalyzed by 
the reverse transcriptase enzyme (Coffin et al., 1997). The HIV-1 reverse transcriptase is a 
heterodimer of two subunits p66 and p51 domains (Freed, 2001). These two subunits are 
both derived from Pr160GagPol precursor protein; p51 is formed when the C-terminal, 15 
KDa RNaseH domain of p66 is removed by viral protease. The HIV-1 reverse transcription 
is primed by the annealing of the cellular tRNALys3 to the primer binding site (PBS) at the 5‘ 
end of the viral RNA downstream the LTR and involves ―jumps‖ from one template to 
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another along the viral RNA (Kleiman, 2002). Reverse transcription generates a formation 
of a trimeric structure in the middle of HIV-1 cDNA called ―central DNA flap‖ which has 
been demonstrated to play an important role in the PIC nuclear import and in HIV-1 
replication (De Rijck and Debyser, 2006; Zennou et al., 2000). HIV-1 reverse transcriptase 
enzyme has a high mutation rate (3 x 10-5 per cycle of replication) resulting in highly 
heterogeneous HIV-1 sequence populations (Mansky and Temin, 1995). As a 
consequence, HIV-1 is able to rapidly evade host immune response and develop resistance 
to antiviral drugs.  
 
2.3- Nuclear import  
Unlike other retroviruses, HIV-1 does not require disintegration of the nuclear membrane 
during cell division to enter nucleus, thus it replicates efficiently in non-dividing cells such 
as differentiated macrophages and dentritic cells (Fassati, 2006). Moreover, HIV-1 was 
found to be able to infect cells arrested in cell cycle by treatments with aphidicolin or -
irradiation and HIV-1 derived vectors infect hematopoietic stem cells and neurons (Fassati, 
2006). The viral DNA is eventually transported to the nucleus as part of pre-integration 
complex (PIC). Nevertheless, the composition of the PIC and the mechanism by which the 
PIC translocates into the nucleus are still subject of debate (Fassati, 2006; Yamashita and 
Emerman, 2006). Matrix, Vpr and integrase were demonstrated to be components of the 
PIC and reported to contain several putative nuclear localization signals (NLSs) that 
showed to be important for the PIC nuclear import in non-dividing cells (Bukrinsky et al., 
1993; Heinzinger et al., 1994; Popov et al., 1998; von Schwedler et al., 1994). However, 
there is no agreement in the existence of NLSs in HIV-1 matrix argued by the similar 
effect of HIV-1 mutant viruses in matrix putative NLS on nuclear import of the PICs in 
cycling and non-dividing cells (Depienne et al., 2000; Fouchier et al., 1997; Freed et al., 
1995). The transferable NLSs on Vpr protein were extensively confirmed but their role in 
HIV-1 PIC nuclear import in non-dividing cells is under discussion since Vpr mutations in 
NLSs reduce mildly the ability of HIV-1 to replicate in macrophages (Fouchier et al., 1998; 
Le Rouzic and Benichou, 2005; Rey et al., 1998). The role of integrase in HIV-1 PIC 
nuclear import was also widely investigated and many reports attributed its role to its 





2.4- Integration  
Following nuclear import of the viral pre-integration complex, the 32 KDa integrase 
catalyzes the insertion of the linear double stranded viral DNA into the host cell 
chromosome preferentially (see chapter HIV-1 replication section n°3) (Lewinski and 
Bushman, 2005; Vandegraaff and Engelman, 2007).  
In resting lymphocytes there are several barriers that preclude the completion of the early  
HIV-1 replication steps, described above, as an incomplete reverse transcription (Zack et 
al., 1990; Zack et al., 1992) or an inefficient nuclear import of the PICs (Bukrinsky et al., 
1992). It has been also shown that in resting cells double stranded viral cDNA accumulate 
extra-chromosomally unable to integrate (Stevenson et al., 1990). Nevertheless, once they 
have been activated, even partially, T cells become fully permissive for HIV-1 infection. A 
recent study described that in activated T cells,  HIV-1 integrase is phophorylated by c-jun 
kinase (JNK) and then stabilized by Pin1 isomerization which allow the virus to achieve an 
efficient nuclear import and integration (Manganaro et al., 2010). The lack of these 
integrase modifications in resting T cells, due to the dowregulated levels of JNK in these 
cells, contributes to the non-permessivness to HIV-1 infection.  
 
2.5- Gene expression   
Once integrated into the host genome, the provirus behaves like any human gene, with 
transcription being initiated at the 5‘ end and terminating at the 3‘ end. The 5‘ LTR 
contains enhancer and promoter sequences, with binding sites for several transcription 
factors and the 3‘ LTR contains a polyadenylation signal (Peterlin and Trono, 2003). 
Moving upstream from the transcription start site, the initiator, the TATA BOX and three 
SP1-binding sites are found (Peterlin and Trono, 2003). These elements position RNA 
polymerase II at the correct site for initiating transcription. In the absence of Tat, HIV-1 
transcription begins but elongation is inefficient (Jones and Peterlin, 1994). Tat acts upon 
an RNA structure known as transactivation response region (TAR) which is found at the 5‘ 
end of all the viral transcripts (Berkhout et al., 1989). Tat binds TAR and recruits the 
positive elongation transcription factor b (P-TEFb) complex that contains cyclin T1 
(CYCT1) and cyclin dependent kinase 9 (CDK9) heterodimer (Wei et al., 1998). The 
recruitment of P-TEFb to TAR results in the phosphorylation of the Carboxy-terminal 
domain of RNA polymerase II by CDK9 and a dramatic stimulation of transcription 
elongation (Wei et al., 1998). Memory CD4 lymphocytes have been demonstrated to be 
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involved in the establishment of a latent reservoir of infected cells harbouring a silent 
integrated provirus (Chun et al., 1995; Han et al., 2007). The mechanisms of HIV-1 post-
integration latency are poorly understood, however, many studies suggested a main role 
of a transcription inhibition involving Tat and P-TEFb (Ghose et al., 2001; Kao et al., 1987; 
Marcello, 2006). 
Transcription from HIV-1 LTR leads to the generation of more than 30 viral mRNAs (Freed, 
2001). These fall into three major classes: 1) unspliced RNAs which function as the 
mRNAs for Gag and GagPol and are packaged into progeny as genomic RNA; 2) partially 
spliced mRNAs encoding to Env, Vif, Vpu and Vpr proteins and 3) multiply spliced mRNAs 
which are translated into Rev, Tat and Nef (Freed, 2001; Peterlin and Trono, 2003). To 
export the unspliced and partially spliced viral mRNAs from nucleus to cytoplasm, HIV-1 
uses the Rev protein which acts on the cis-acting RNA element, the Rev responsive 
element (RRE) (Freed, 2001; Peterlin and Trono, 2003). RRE is a highly stem-looped RNA 
structure located in the env gene and is present in all unspliced and partially spliced HIV-1 
mRNAs (Pollard and Malim, 1998). Rev binds RRE and forms a complex capable of the 
interaction with the cellular nuclear export machinery resulting in the export of HIV-1 
mRNAs to the cytoplasm and then Rev shuttles back to the nucleus using its nuclear 
localization signal (Pollard and Malim, 1998).  
 
2.6- Assembly and release  
Following the synthesis of the full component of viral proteins using the cellular translation 
machinery, the assembly process begins within the plasma membrane (Adamson and 
Freed, 2007). Assembly is directed by Gag, which coordinates the incorporation of each of 
the viral components, together with the number of host cell factors, into the assembling 
particle (Adamson and Freed, 2007). The N-terminus domain of matrix is co-translationally 
modified by myristic acid; this fatty acid modification is essential for Gag-membrane 
binding. Capsid, the central domain of Gag,  homo-oligomerizes in an ordered manner 
during assembly and is a critical determinant of particle morphology (Bieniasz, 2009). The 
GagPol precursor (Pr160GagPol), which is synthesized as the result of a frame shifting event, 
is packaged into virions via its Gag domain, largely using the same Gag-Gag interactions 
that drive Gag assembly (Freed, 2001). The zing finger motifs and basic residues domain 
of nucleocapsid bind specifically the RNA packaging signal located in 5‘ of the gag 
initiation codon and encapsidates two positive single-stranded copies of the genomic RNA 
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into each viral particle (Freed, 2001). The Env glycoprotein precursor, gp160, is 
synthesized in the rough endoplasmic reticulum where gp120 domain is heavily 
glycosylated and oligomerized (Freed, 2001). gp160 is transported to the cell surface via 
the secretory pathway; during its trafficking through the Golgi, gp160 is cleaved by a host 
protease (furin or furin like enzyme) to generate the mature envelope glycoproteins, 
gp120 and gp41 (Freed, 2001). Although, the process by which the Env glycoproteins are 
incorporated into virions remains incompletely understood, a number of lines of evidence 
suggest that a direct or mediated interaction between the gp41 cytoplasmic tail and matrix 
domain of Gag recruits Env into virions (Lopez-Verges et al., 2006; Murakami and Freed, 
2000). HIV-1 Gag particles are also able to incorporate heterologous glycoprotein 
envelopes such as amphotropic Env of murine leukemia virus (A-MLV), VSV-G of vesicular 
stomatitis virus (VSV) (Reiser et al., 1996), and many other viral envelopes (e.g. Ebola 
virus).  
Virus particle production is completed upon budding of the nascent virion from the plasma 
membrane (Adamson and Freed, 2007). To facilitate virus release, the p6 domain of Gag 
hijacks components of the cellular endosomal sorting machinery complexes (ESCRTs), 
which normally function to promote the budding of vescicles into late endosomes to form 
multi-vescicular bodies (Bieniasz, 2009). The p6 domain of Gag contains two small 
peptides, called ―late domains‖ PTAP and YPLTSL which bind Tsg101 (a component of 
ESCRTI) and ALIX (an ESCRT-I and ESCRT-III binding protein), respectively and trigger 
viral budding (Bieniasz, 2009). Concomitant with virus release, viral protease (PR) cleaves 
Gag and GagPol precursors into their respective protein domains leading to virion 
maturation. Following cleavage, capsid forms a conical shell around the RNA/protein 
complex within the core, a hallmark of mature HIV-1 virions (Freed, 2001).  
 
2.7- Roles of accessory proteins in HIV-1 replication  
In addition to the roles of HIV-1 structural (MA, CA, NC and Env), enzymatic (PR, RT and 
IN) and regulatory (Tat and Rev) proteins in the HIV-1 replication, HIV-1 accessory 
proteins (Vpu, Vif, Vpr and Nef) were shown to increase markedly HIV-1 infectivity and 
production. These proteins are known as ―accessory‖ proteins because they are 
dispensable for virus growth in some cell culture. Nevertheless, they have essential roles 
in viral replication and progression to AIDS in vivo (Peterlin and Trono, 2003).  
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Vpu (viral protein u) is unique to HIV-1 except the highly related lentivirus chimpanzee 
simian immunodeficiency virus (SIVcpz). Vpu stimulates the viral release of budded 
particles from the plasma membrane and induces CD4 degradation in order to liberate 
gp160 from Env/CD4 complexes in the endoplasmic reticulum thereby increasing the 
amount of Env glycoprotein available for transport to cell surface (Freed, 2001). The virus 
particle release of HIV-1 viruses defective in Vpu is inhibited in certain human cells (such 
as HeLa) and is not affected in other human (for example HOS, HEK293T and HT1080) or 
in African green monkeys (COS-7) cell lines (Neil et al., 2006; Neil et al., 2007; Varthakavi 
et al., 2003).   
Vif (viral infectivity factor) is conserved among lentiviruses except equine infectious 
anaemia virus (EIAV) (Freed, 2001). HIV-1 deleted in Vif is defective in viral cDNA 
synthesis (von Schwedler et al., 1993). The defective phenotype is cell-type dependent 
and is determined not by the target cells but by the virus producing cells (von Schwedler 
et al., 1993). For instance, HeLa, HEK293T, SupT1, CEMss and Jurkart cell lines are 
―permissive‖ for Vif deleted viruses; virus produced from these cell lines is fully infectious 
regardless of the target cell used (Gabuzda et al., 1992; Madani and Kabat, 1998; Simon 
et al., 1998). In contrast, CEM T cells, primary lymphocytes and macrophages are ―non 
permissive‖ cells (Gabuzda et al., 1992; Madani and Kabat, 1998; Simon et al., 1998). The 
cell type dependency of the permissiveness to HIV-1 defective in Vpu or in Vif has 
suggested for long time the existence of specific cellular restriction factors that are 
counteracted by these accessory proteins. Recent studies have revealed new HIV-1 
restriction factors tetherin (CD317/BST2) and APOBEC3G (CEM15) that are antagonized 
respectively by Vpu and Vif in the ―non permissive‖ cells types (see chapter HIV-1 
restriction factors) (Neil et al., 2008; Sheehy et al., 2002).  
Vpr (viral protein r) is incorporated into the viral particles through its specific interaction 
with a Leucine rich motif located near the C-terminus of p6 (Freed, 2001). Vpr was found 
in the PIC and shown to promote HIV-1 nuclear import (Heinzinger et al., 1994). Vpr was 
reported to induce cell arrest in G2 phase probably to delay or to prevent apoptosis of 
infected cells (He et al., 1995).  
Nef (negative effecter) is a membrane-associated protein that is expressed at high levels 
in infected cells and was shown to stimulate HIV-1 pathogenesis progression by 
stimulating the viral load in the infected individuals (Deacon et al., 1995). Nef was 
reported to down-regulate the cell-surface expression of the major histocompatibility 
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complex I (MHC-I) and of the CD4 chemokine receptors (Aiken et al., 1994; Collins et al., 
1998). The correlation between Nef functions and the induction of the disease in vivo is 
not yet established, although CD4 down-regulation may prevent super-infection and impair 
the functions of T helper cells and MHC-I down-modulation may impair the cytotoxic T 
lymphocytes (CTLs) to detect and eliminate virus-expressing cells (Adamson and Freed, 
2010).   
In every step of its life cycle HIV-1 takes advantage of host cell factors and pathways to 
promote successful replication (Adamson and Freed, 2010; Al-Mawsawi and Neamati, 
2007; Goff, 2007; Suzuki and Craigie, 2007; Van Maele et al., 2006; Vandegraaff and 
Engelman, 2007). However, it has become clear in recent years that the host cell has set 
up antiretroviral barriers in the form of restriction factors that impair specific steps in the 
replication cycle (chapter HIV-1 restriction factors) (Bieniasz, 2007; Goila-Gaur and 
Strebel, 2008; Huthoff and Towers, 2008; Malim, 2009; Nakayama and Shioda, 2010; 
Nisole et al., 2005; Strebel et al., 2009). In some cases, HIV-1 have responded by 
evolving counter-defense mechanisms to overcome these restriction factors (Neil et al., 
2008; Sheehy et al., 2002).  
 
3- HIV-1 integration 
For an efficient production of progeny virions, the retroviral DNA must become covalently 
integrated into the host cell chromosome (Coffin et al., 1997). Some expression from un-
integrated viral DNA can be detected but is not sufficient to sustain spreading infection 
(Engelman et al., 1995). The study of integrase mutants revealed that  viral integrase (IN) 
encoded by the C-terminal pol gene is essential to catalyze retroviral cDNA insertion into 
the host genome (Panganiban and Temin, 1984).   
 
3.1- Integration steps 
Integration of HIV-1 cDNA into the host cell chromosome involves three main steps 
(Figure 3): 1) 3‘ processing of the viral DNA ends, 2) DNA strand transfer by joining the 
processed viral ends to the cellular target DNA and 3) the repair of the gaps of the 
recombination intermediate. The first two reactions are catalyzed by integrase, whereas 
the last is mediated by still undefined factors likely cellular DNA repair proteins (Lewinski 
and Bushman, 2005). Reverse transcription yields a copy of the long terminal repeat (LTR) 
at each end of the nascent reverse transcript. Integrase binds to short DNA sequences 
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called attachment sites at the U3 and U5 viral DNA ends of respectively 5‘ and 3‘ LTRs and 
cleaves two nucleotides from each 3‘ termini end (Katzman and Katz, 1999; Li et al., 
2006). Following terminal cleavage, a recessed hydroxyl group (3‘-OH) is exposed that 
immediately follows a CA dinucleotide (Figure 3a). This CA motif is the more conserved 
among retroviruses and many related transposons and it showed fundamental for initial 
integrase-viral DNA binding (Esposito and Craigie, 1998; Lewinski and Bushman, 2005). 
The 3‘ processing reaction is a defining moment in the formation of the pre-integration 
complex (PIC) (Vandegraaff et al., 2006). PICs are nucleoproteins complex isolated from 
acutely infected cells and able to catalyze endogenous retroviral cDNA integration inside a 
heterologous target DNA in vitro (Farnet and Haseltine, 1990). Only purified PICs 
containing viral cDNA correctly cleaved by integrase at the  3‘ ends were demonstrated 
competent to integrate in vitro (Miller et al., 1997).  
 
Figure 3:  Mechanism of HIV-1 DNA integration. (a) A tetramer of integrase (grey circles) engages two 
ends of human immunodeficiency virus type 1 (HIV-1)DNA(blue lines) within a synaptic nucleoprotein 
complex. During 3‘ processing, water is used by integrase to effect hydrolytic clips (vertical arrows), which 
trim off dinucleotides from both HIV-1 ends. Opened triangle, U3 DNA sequences in the upstream LTR  
recognised by integrase; closed triangle, downstream U5 sequences recognised by integrase. (b) After 
nuclear entry and locating a suitable target acceptor site within chromatin (orange lines), integrase uses the 
3‘-hydroxyl groups of the cleaved viral DNA to cut the target in a staggered fashion (vertical arrows), which 
concomitantly joins the viral 3‘ ends to the 5‘-phosphates of the cut. (c) The recombination intermediate 
formed by integrase‘s DNA-strand-transfer activity comprises joined viral 3‘ends but free 5‘ends. (d) Gap 
repair of the DNA recombination intermediate yields the integrated provirus flanked by a 5 bp duplication of 
target DNA (bracketed green lines). The sequence of the target-site duplication is defined by the sequence 




In cells, PICs must access the nucleus to target chromosomes for integration. Unlike the 
―simple‖ gammaretroviruses, such as the Moloney murine leukemia virus (M-MLV), which 
infection is restricted to cycling cells (Roe et al., 1993), lentiviruses including HIV-1 infect 
cycling and non-dividing cells (Lewis et al., 1992). Although, several mechanisms were 
suggested about the ability of HIV-1 to infect non-dividing cells explaining the nuclear 
import of the PICs, the consensus mechanism is far from complete (Fassati, 2006; 
Yamashita and Emerman, 2006). The role of integrase and its cellular interacting factors in 
HIV-1 PIC nuclear import are discussed below in the section N° (5.4-) of this chapter. 
Once inside the nucleus, the PIC must engage a DNA sequence within chromatin for 
integrase to catalyse DNA-strand transfer. In this trans-esterification reaction integrase 
first uses the 3‘-OH groups at the viral DNA ends to attack phosphodiester bonds on 
opposite strands of the target DNA at positions staggered by five nucleotide bases in the 
5‘ direction and then uses the energy of the broken phosphodiester bonds to join 
covalently the recessed 3‘ ends of the viral cDNA to the 5‘ phosphates of the cleaved 
chromosomal DNA (Figure 3b) (Vink et al., 1990).  
 
3.2- Post-integration repair           
The product of DNA-strand transfer reaction is a recombination intermediate harboring 
single-stranded gaps flanking either side of the virus. Gap repair of the DNA recombination 
intermediate yields the integrated provirus flanked by a 5 bp duplication of target DNA 
(Figures 3c and d) (Vink et al., 1990). The gap repair consists on filling in the missing 
nucleotides, removing the short flap on the 5‘ ends of the viral DNA, ligation to newly 
synthesized 3‘ end of the host DNA and, likely, reconstitution of appropriate chromatin 
structure and composition. The mechanisms of this post-integration repair are not yet fully 
understood. Studies based on depletion of DNA repair proteins and monitoring of cell 
death following retroviral infection, as surrogate marker of defective DNA repair, 
suggested the involvement of components of non homologous end joining repair pathway 
(NHEJ) such as DNA-PK, Ku, XRCC4 and ligase IV (Daniel et al., 2004; Daniel et al., 1999). 
In addition, it has been also suggested that the gaps of the integration intermediate are 
sensed by ATM and ATR kinases, usually activated by DNA double-strand breaks (DSB), 
which in turn trigger the DNA repair response by activating the NHEJ pathway (Daniel et 
al., 2003; Daniel et al., 2001; Daniel et al., 2005; Lau et al., 2005). Nevertheless, the 
described roles of DNA-PK, Ku, ATM and ATR in HIV-1 replication were criticized in several 
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reports. On one hand, because the NHEJ associated proteins are known to repair DSBs 
and not single-stranded gaps and on the other hand because no effect on HIV-1 infectivity 
was shown following depletion of these proteins in different cell types (Ariumi et al., 2005; 
Baekelandt et al., 2000; Dehart et al., 2005). Another studies proposed that the activation 
of the NHEJ pathway is due to the un-integrated viral cDNA ends sensed by cells as DSB 
instead of the un-repaired proviruses (Jeanson et al., 2002; Kilzer et al., 2003; Li et al., 
2001). In these reports it has been shown that NHEJ proteins, specifically Ku, XRCC4 and 
ligase IV, catalyze the ligation of the 5‘ and 3‘ LTRs leading to the formation of the 2-LTR 
circles (Jeanson et al., 2002; Kilzer et al., 2003; Li et al., 2001). The circularization of the 
viral cDNA was proposed as a way to prevent cell apoptosis induced by the un-integrated 
DNA (Kilzer et al., 2003; Li et al., 2001). 
 
3.3- The un-integrated viral cDNA forms 
Not all reverse transcribed retroviral cDNAs are integrated into host genome (Coffin et al., 
1997). It has been estimated that about 5% and 15% of total HIV-1 reverse transcripts 
are integrated in HEK293T and in SupT1 cells, respectively (Butler et al., 2001). The un-
integrated viral cDNA is usually circularized by non homologous end joining repair (NHEJ) 
to form 2-LTR circles or by homologous recombination between the 5‘ and 3‘ LTRs to form 
the 1-LTR circles (Kilzer et al., 2003; Li et al., 2001). A third circularized un-integrated viral 
cDNA, that does not require the cellular DNA repair machinery, is formed by the 
integration of the viral cDNA inside itself, yielding internally rearranged circular forms 
(Coffin et al., 1997). The formation of circularized viral cDNA is believed to be the result of 
failure in integration process since retroviruses carrying integrase mutants catalytically 
inactive are characterized by the nuclear accumulation of the 1-LTR and 2-LTRs circles 
(Coffin et al., 1997; Engelman, 1999; Engelman et al., 1995; Jurriaans et al., 1992). These 
circle un-integrated forms can be transiently expressed but they are unable to sustain a 
spreading infection (Engelman, 1999; Engelman et al., 1995). The exclusively nuclear 
location of the 1-LTR and 2-LTRs circles has been confirmed among diverse combinations 
of retroviruses and host cells, therefore, they are used as a surrogate marker for 






3.4- Integration site selection  
Retroviral DNA integration is not tightly sequence specific, however, integration site 
selection is not random. Genome-wide surveys of retroviral DNA-integration site selection 
revealed that retroviruses target the genome in different ways  (Bushman et al., 2005). 
Lentiviruses like HIV-1 prefer to integrate into genes, displaying a greater propensity for 
active genes, whereas, gammaretroviruses such as M-MLV display marginal preference for 
genes and integrate preferentially within 5 Kb of either side of transcriptional start site 
(Mitchell et al., 2004; Schroder et al., 2002; Wu et al., 2003). Consistently with the 
preference of HIV-1 to integrate in transcription units, these studies showed that human 
endogenous retroviruses (HERVs), long interspersed nuclear elements (LINEs) and -
satellite DNA, which are all genome DNA sequences repeats depleted from gene-rich 
regions and enriched in heterochromatin regions, strongly disfavor HIV-1 integration. 
Moreover, recent studies performed by sequence analysis using the ENCODE annotation 
(Wang et al., 2007b)  and by a visualization analysis (Albanese et al., 2008) demonstrated 
that HIV-1 targets decondensed regions of the chromatin. All these lines of evidence 
suggest that one the mechanisms that define the HIV-1 integration site selection is the 
accessibility of the host DNA defined by the chromatin structure. HIV-1 integrase would 
also seem to mediate global access to specific regions of chromatin. An HIV-1-M-MLV 
chimera virus carrying gammaretroviral integrase targeted integration to regions nearby 
gene start sites similar to wild type M-MLV (Lewinski et al., 2006). LEDGF/p75, a cellular 
protein that binds tightly HIV-1 integrase, has been reported to be involved in HIV-1 
targeting. LEDGF/p75 partial depletion from human cells diminished HIV-1 integration in 
transcription units without changing its preference to active genes (Ciuffi et al., 2005). 
More recent studies using LEDGF  knockout mouse cells or more intensified LEDGF/p75 
knockdown human cells showed a greater reduction of HIV-1 integration in transcription 
units and an increase of integration near transcription start sites, as M-MLV, and in CpG 
islands, normally disfavored for HIV-1 integration (Marshall et al., 2007; Shun et al., 
2007). Although in both studies integration remained still favored in transcription units, 
the significant reduction of the integration events in genes in different cells types 
attributed a predominant role of LEDGF/p75 in lentiviral target site selection (Shun et al., 
2007). Importantly, LEDGF/p75 demonstrated to bind exclusively lentiviral integrases and 
not integrases from other retrovirus genera (Busschots et al., 2005; Cherepanov, 2007; 
Llano et al., 2004b). Moreover, another integrase binding factor the histone acetyl 
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transferase p300 which is a broad transcriptional co-activator has been proposed to be a 
good candidate to target HIV-1 integration in active gene (Cereseto et al., 2005; Van 
Maele et al., 2006; Vandegraaff and Engelman, 2007). Integrase interactor 1 (INI1) is a 
component of SWI/SNF chromatin remodeling complex that interacts with integrase has 
been also hypothesized as integration targeting factor (Kalpana et al., 1994). However, 
INI1 binds only HIV-1 integrase and not integrases from related lentiviruses that integrate 
preferentially in active genes, such as SIV, which reduced its potentiality as integration 
site selection factor (Vandegraaff and Engelman, 2007; Yung et al., 2004).  
 
4- HIV-1 integrase structure and functions  
HIV-1 integrase catalyzes two essential reactions for the virus integration into host 
genome: the 3‘ end processing and DNA strand transfer (Figure 3). Purified HIV-1 
integrase is able to catalyze in vitro  the 3‘ processing and integration of recombinant DNA 
substrates that mimic the ends of the viral reverse transcripts (Bushman and Craigie, 
1991). HIV-1 integrase belongs to a protein super-family of nucleotidyl transferases that 
include RNase H, Holliday junction resolvase (RuvC), bacterial Mu and Tn5 transposases 
and RAG1/2 recombinase (Dyda et al., 1994; Rice and Baker, 2001; van Gent et al., 
1996). These enzymes break and/or join nucleic acids via their phosphodiester backbones. 
Moreover, they have active sites that harbor conserved amino acid residues aspartic acid 
(D) and glutamic acid (E) that coordinate Mg2+ or Mn2+ metal ions to catalyze bimolecular 
in-line nucleophilic substitution reactions (Sn2) at the scissile phosphodiester bond (Dyda 
et al., 1994).  
 
4.1- Integrase domains  
HIV-1 integrase comprises three protein domains (Figure 4): the N-terminal domain 
(NTD), the catalytic core domain (CCD) and the C-terminal domain (CTD), which function 
together to catalyze 3‘ processing and DNA strand transfer (Engelman et al., 1993; van 
Gent et al., 1993). The NTD (1-49 amino acid residues) adopts a helix-turn-helix protein 
fold and contains a pair of conserved histidine and cysteine residues (HHCC zinc binding 
motif) that coordinate a single zinc atom (Zn2+) (Cai et al., 1997). Zinc binding contributes 






Figure 4: Retroviral integrase protein domains and structures. Domain organisation and amino acid residues 
conserved among retroviral integrase proteins. The enzyme comprises the N-terminal domain (NTD, HIV-1 
residues 1–49), catalytic core domain (CCD, residues 50–212) and C-terminal domain (CTD, residues 213–
288). The histidine (H) and cysteine (C) residues within the NTD are additionally conserved among 
retrotransposon integrase proteins. The aspartic acid (D) and glutamic acid (E) residues in the CCD form the 
DDE motif (red font) that likewise forms the catalytic centers of retrotransposon integrases and some 
bacterial transposases (Vandegraaff et al., 2006). (b) Structure of the prototype foamy virus integrase in 
complex with recombinant DNA mimicking processed LTR (PFV intasome). Views along (left) and 
perpendicular to (right) the crystallographic two-fold axis. The inner subunits of the IN tetramer, engaged 
with viral DNA, are blue and green; outer IN chains are yellow. The reactive and non-transferred DNA 
strands are magenta and orange, respectively. Side chains of D128, D185 and E221 active-site residues are 
red sticks; Zn2+ atoms are grey spheres. Locations of the canonical IN domains (NTD, CCD and CTD) are 




The CCD (50-212 amino acids residues) is composed of mixed alpha helix and beta sheets 
and harbors three acidic residues D64, D116 and E152 known as DDE active site 
responsible for coordination of a pair of Mg2+ ions for Sn2 chemistry (Dyda et al., 1994; 
Engelman and Craigie, 1992; Engelman et al., 1995; van Gent et al., 1992). Site-directed 
mutagenesis of conserved amino acids (DDE) in the catalytic core resulted in integrase 
catalytically inactive in 3‘ end processing and DNA strand transfer (Engelman and Craigie, 
1992; van Gent et al., 1992). HIV-1 viruses carrying mutations in the DDE active site, 
called class I IN mutants, are integration defective and characterized by the accumulation 
of the dead end products (1-LTR and 2-LTRs circles) (Engelman, 1999). In addition to 
catalysis of the integration reactions, CCD contains conserved amino acid residues tyrosine 
143 (Y143) and glutamine (Q148 ) that showed responsible for the binding to the viral 
DNA ends in vitro (Esposito and Craigie, 1998). Moreover, lysines 156 and 159 (K156 and 
K159), were suggested to be essential for the interaction between integrase and viral LTRs 
(Jenkins et al., 1997). HIV-1 virus containing mutations in K156 and K159 residues is 
integration defective (Jenkins et al., 1997). Furthermore, the serine 119 (S119) of CCD 
was shown to critical for the integrase-cellular DNA interaction and target site selection 
(Harper et al., 2001).  
The CTD (213-288 amino acid residues) which is the least conserved among the three 
integrase domains, adopts a Src homology region 3 (SH3) protein fold (Vandegraaff and 
Engelman, 2007). SH3 domains are small (approximately 60 amino acids) structures that 
are involved in protein-protein interactions and in signal transduction pathways (Mayer, 
2001). The CTD binds the viral cDNA ends and might also contribute to binding of 
chromosomal DNA during integration (Engelman et al., 1994). The CTD has strong but 
nonspecific DNA binding activity and thus has been called DNA binding domain (Engelman 
et al., 1994). The minimal region of CTD required for DNA binding comprises residues 
from 220 to 270 and mutations in K264 showed a strong reduction of integrase DNA 
binding and catalytic activities in vitro (Lutzke et al., 1994). In addition to K264, the CTD 
domain contains other amino acid residues, that have been identified important for DNA 
binding by protein-DNA cross-linking assays: E246, K258, P261, R262 and with some 
weaker involvement : S230 and R231 (Gao et al., 2001). Moreover, mutations in leucines  
241 and 242 (L241 and L242) along CTD dimer interface have been shown to disrupt 
integrase tetramerization and to reduce its catalytic activity in vitro (Lutzke and Plasterk, 
1998). Interestingly, lysines K264, K266 and K273 in the CTD are acetylated by the 
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histone acetyl transferase p300 (Cereseto et al., 2005). Moreover, GCN5 HAT acetylates 
these lysines and also K258 (Terreni et al., 2010). Acetylation of the CTD enhances DNA 
binding affinity and catalytic activity of integrase (Cereseto et al., 2005; Terreni et al., 
2010).  
 
4.2- Integrase structure 
The three-dimensional structure of full length HIV-1 integrase either separately or in 
complex with viral DNA is still not determined due to the insolubility of the protein which 
hampered crystallization assays. The introduction of mutation points inside the integrase 
protein, that increase protein solubility, led to the resolution of single domains or fused 
domains crystals. The isolated NTD, CCD, CTD, NTD-CCD and CCD-CTD showed self 
association proprieties usually in dimers (Jaskolski et al., 2009). Integrase has been shown 
to function in multimeric form since mixing deleted mutants, each individually inactive, 
was sufficient to catalyze 3‘ end processing and DNA strand transfer in vitro (Engelman et 
al., 1993). Furthermore, a catalytically inactive integrase, mutant in DDE motif, could be 
complemented by an inactive integrase truncated at its C-terminal domain (van Gent et 
al., 1993). Such functional complementation was also reported in virions (Fletcher et al., 
1997). Based on biochemical, mutagenesis and atomic force microscopy assays, the most 
suggested functional form of HIV-1 integrase is a tetramer (Faure et al., 2005; Li et al., 
2006; Ren et al., 2007). Moreover, a recent study that resolved the crystal structure of 
NTD-CCD in complex with the integrase binding domain (IBD) of LEDGF/p75 showed a 
tetrameric structure of integrase composed of two dimers that were flexibly stabilized 
inside the integrase tetramer via salt bridges and hydrophobic interactions involving 
residues of NTD and CCD from each dimer (Hare et al., 2009). NTD-CCD tetramer 
structure showed an important role of salt bridge interaction between residues E11 of NTD 
and K186 of CCD in maintaining dimer-dimer interface stability (Hare et al., 2009). 
Interestingly, single point mutations of  these residues E11K and K186E separately or in 
the same protein abolished concerted integration in vitro and viral infectivity by disturbing 
the integrase tetramer structure (Hare et al., 2009). However, complementation assays by 
mixing equal quantities of each integrase mutant or by introducing E11K and K186E 
mutations in the same protein restored the salt bridge interaction of the dimer-dimer 
interface and thus restored the concerted integration and the viral infectivity (Hare et al., 
2009). In the same study, the addition of the IBD LEDGF/p75 stabilized the integrase 
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tetramer and rescued some activities of E11K and K186E IN mutants in vitro. A more 
recent study succeed to report for the first time a crystal structure of a full length 
retroviral integrase of prototype foamy virus (PFV) in complex with its cognate pre-
processed viral DNA; all the structure was called PFV intasome (Figure 4b) (Hare et al., 
2010). The integrase-DNA complex structure revealed a tetramer of integrase associated 
with a pair of viral DNA ends (Hare et al., 2010). As previously reported for HIV-1 NTD-
CCD structures (Hare et al., 2009), the integrase tetramer was formed by a pair of dimers 
stabilized by intermolecular NTD-CCD interactions, however, the dimer-dimer interface 
was constrained and not flexible like in HIV-1 NTD-CCD structure. The inner subunits of 
the tetramer were responsible for all contacts involved in tetramerization and viral DNA 
binding. The CCDs of the outer subunits seemed to provide supporting function. In this 
intasome,  the integrase-DNA interactions involved amino acid residues from each domain 
of the inner subunits, their interdomain linkers and 17 nucleotides from each viral cDNA 
end. The integrase-DNA intasome showed an intimate interaction between the pre-
processed viral DNA end and the active site loop containing the DDE motif. Moreover, 
each DDE active site loop of the inner subunits coordinated two metal ions (Mn2+); one ion 
was bound by the DD amino acid residues and the second ion was bound by the DE 
carboxylates of the same active site. This observation confirmed the expected two-metal 
binding mode of retroviral integrases suggested by their similarities to Tn5 transposase 
and RNAse H. In this model, the metal ions would serve as Lewis acids during Sn2 
chemistry: the metal ion bound by DE would activate the 3‘-OH group of the pre-
processed viral end, whereas the other metal ion coordinated by DD would destabilize the 
scissile phosphodiester group in the target DNA; during the 3‘ end processing the DE 
bound metal ion would activate the nucleophile water.   
In addition to its role in the integration reactions, integrase may play several roles in HIV-
1 replication cycle. Indeed, several replication defective HIV-1 viruses carrying integrase 
mutations, different from the DDE active site residues, called class II mutants, have shown 








5- HIV-1 integrase interacting host factors 
Although purified HIV-1 integrase is sufficient to catalyze 3‘ end processing and DNA 
strand transfer in vitro, mounting evidence highlights important roles for host cell factors 
in enabling HIV-1 to accomplish integration in infected cells. Such factors might influence 
non catalytic aspects of pre-integration complex (PIC) biology such as stability, nuclear 
import and access to specific regions of chromatin and/or more directly influence integrase 
enzymatic function. Several host proteins have been shown to interact with HIV-1 
integrase in vivo; however, so far the functional role of only few factors has been 
validated in HIV-1 integration process.  
 
5.1- Lens Epithelium-derived Growth Factor: LEDGF/p75  
Lens epithelium-derived growth factor/p75 (LEDGF/p75), a member of the hepatoma 
derived growth factor (HDGF) related protein (HRP) family, was initially implicated in 
lentiviral biology through its association with ectopically expressed Flag-tagged HIV-1 
integrase in HEK 293T cells by immunoprecipitation assays (Cherepanov et al., 2003; 
Maertens et al., 2003). The association of HIV-1 integrase and LEDGF/p75 was 
independently confirmed by analyzing cellular proteins associated with integrase in HeLa 
cells (Turlure et al., 2004) and by yeast two hybrid screen for integrase interactors 
(Emiliani et al., 2005).   
LEDGF/p75 was proven to bind specifically lentiviral integrases but not alpharetroviral, 
betaretroviral, gammaretroviral, deltaretroviral and spumaretroviral integrases (Busschots 
et al., 2005; Cherepanov, 2007; Llano et al., 2004b). LEDGF/p75 was found as component 
of purified HIV-1 pre-integration complexes (PICs) that were functional in the in vitro 
integration assays (Llano et al., 2004b). LEDGF/p75 is a ubiquitous nuclear protein tightly 
associated with chromatin throughout the cell cycle (Engelman and Cherepanov, 2008; 
Van Maele et al., 2006). LEDGF/p75 contains 530 amino acids and several functional 
domains (Figure 5a). In the N-terminal region of LEDGF/p75, a PWWP (proline-
tryptophan-tryptophan-proline) domain is present and that functions as protein-protein 
interaction domain and/or chromatin binding domain. In the same region, a functional 
nuclear localization signal (NLS) and dual copy of the AT-hook DNA binding motif are 
present (Van Maele et al., 2006). The binding of LEDGF/p75 to DNA in vitro is mediated by 
the NLS and AT-hook motif, whereas the PWWP domain supplies a critical chromatin 




Figure 5: (a) Domain Organization of LEDGF/p75. The binding of LEDGF/p75 to DNA in vitro is mediated by 
the NLS and a nearby dual copy of the AT-hook DNA binding motif, whereas the N-terminal PWWP domain 
supplies a critical chromatin recognition function. Charged regions (CRs) 1–3 work in concert with the PWWP 
domain and AT-hooks to affect the wild type chromatin binding phenotype. The LEDGF/p75 IBD is critical for 
stimulation of HIV-1 IN function in vitro and for HIV-1 infection. The N-terminal 325 residues within 
LEDGF/p75 and LEDGF/p52 are identical, whereas the p52 isoform harbors a unique 8–amino acid residue 
tail. (b) Crystal structure of the LEDGF/p75-IN interaction. Left panel: cartoon representation of the CCD-IBD 
complex. IN CCD molecules are colored green and blue, whereas the LEDGF/p75 IBDs are magenta and 
yellow. The side chains of IN active site residues D64, D116, and E152 (Figure 5) are shown as red sticks. 
Right panel: details of the CCD-IBD interface. LEDGF/p75 hotspot residues I365 and D366, situated at the 
base of the loop between IBD helices 1 and 2, project into a pocket at the CCD dimer interface. I365 is 
buried into a hydrophobic pocket predominantly formed by IN residues (A128), W132, Leucine 102 (L102) 
and Methionine 178 (M178) if HIV-1 IN. Hydrogen bonds and salt bridges are shown as dotted lines 




Consistent with its ability to interact with integrase, an evolutionary conserved integrase-
binding domain (IBD) (347-429 residues) was mapped on the LEDGF/p75 C-terminus 
(Cherepanov et al., 2004).  LEDGF gene (PSIP1) encode two splice variants the p75 and 
p52 isoforms (Figure 5a). The p52 isoform shares the N-terminal 325 amino acid residues 
and lacks the IBD and consequently failed to bind integrase (Maertens et al., 2003). 
 
In live cells, the N-terminal and the core catalytic domains (NTD and CCD) of integrase 
were shown involved in the binding to LEDGF/p75 (Maertens et al., 2003). CCD is the 
minimal domain required for this interaction, whereas NTD enhances the affinity of binding 
between integrase and LEDGF/p75 (Maertens et al., 2003). By site directed mutagenesis, 
isoleucine 365 (I365), aspartic acid 366 (D366) and phenylalanine 406 (F406) in the IBD 
region of LEDGF/p75 were revealed important for the interaction with integrase in vitro  
(Cherepanov et al., 2005b). Their principal involvement in the protein-protein interaction 
was confirmed through determination of the crystal structure of IBD in complex with the 
CCD (Figure 5b) (Cherepanov et al., 2005a). The complex of IBD with CCD consists of a 
dimer of CCD bound to two IBDs in a fully symmetric fashion. Each IBD burrows into a 
cleft created by the integrase dimer interface. The side chains carbonyl of LEDGF/p75 
D366 forms a bidentate hydrogen bond with the backbone amides of residues glutamic 
acid 170 (E170) and histidine 171 (H171) from one integrase monomer, while I365 and 
F406 participate in multiple hydrophobic interactions with residues primarily donated from 
the other integase monomer. In particular, the side chain of I365 becomes buried within a 
hydrophobic pocket (Cherepanov et al., 2005a). Two regions within the CCD were 
identified to be indispensable for the interaction with LEDGF/p75 (Busschots et al., 2007). 
The first region centers around residues W131 and W132, while the second extends from 
I161 up to E170 amino acids of integrase (Busschots et al., 2007). A number of single 
amino acid substitutions to alanine (A) within these CCD two regions were shown to 
impair integrase-LEDGF/p75 interaction: W131A, I161A, arginine 166A (R166A), E170A  
(Busschots et al., 2007), glutamine 168 A (Q168A) (Busschots et al., 2007; Emiliani et al., 
2005) and valine 165A (V165A) (Turlure et al., 2004). Interestingly, based on the 
graphical analysis of IBD-CCD crystal structure (Figure 5b), W131 forms hydrogen bond 
with IBD R405 and Q168 has electrostatic interaction with IBD lysine 402 (K402) 
(Busschots et al., 2007). Moreover, analysis of modeled mutant structures of W131A and 
Q168A CCD with IBD showed a disruption of the hydrogen and electrostatic interactions 
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that involve these residues and additionally an alteration of significant number of 
hydrophobic interactions between CCD and IBD (Busschots et al., 2007).  
The purified recombinant LEDGF/p75 stimulated the DNA strand transfer activity of HIV-1 
integrase in vitro (Cherepanov et al., 2003) and increased its affinity to DNA (Busschots et 
al., 2005). The LEDGF/p75 knockdown was shown to have three consequences on the 
feature of the ectopically expressed HIV-1 integrase: 1) re-distribution of integrase from 
the nucleus to the cell cytoplasm (Emiliani et al., 2005; Llano et al., 2004b; Maertens et 
al., 2003); 2) loosen of integrase chromosomal association (Emiliani et al., 2005; Llano et 
al., 2004b; Maertens et al., 2003) and 3) significant reductions in the steady-state levels 
of integrase (Emiliani et al., 2005; Llano et al., 2004a). Thus LEDGF/p75 tethers integrase 
to the chromatin and participates in its karyophilic proprieties, although no evident role of 
LEDGF/p75 in integrase or pre-integration complex (PIC) nuclear import was 
demonstrated. In addition, LEDGF/p75 protects integrase from proteasomal degradation 
(Llano et al., 2004a). The accumulation of integrase in the nucleus might be a 
consequence of the chromosomal tethering of integrase by LEDGF/p75 and the protection 
of integrase from proteasomal degradation. In fact, a mutant integrase (Q168A) that fails 
to bind LEDGF/p75 was unable to bind chromosomes (Emiliani et al., 2005) and 
proteasome inhibitor added to cells defective for LEDGF/p75 restored the nuclear 
accumulation of integrase (Llano et al., 2004b). 
 
The role of LEDGF/p75 in HIV-1 infection was studied by three approaches: 1) using HIV-1 
viruses carrying mutant integrases impaired for LEDGF/p75 interaction but catalytically 
active in vitro; 2) down-regulation of the endogenous LEDGF/p75 by knockdown assays or 
using LEDGF mouse knockout cells and 3) trans-dominant over-expression of the IBD. A 
Q168A integrase mutant HIV-1 virus is replication defective and showed a specific block at 
the integration step, whereas, reverse transcription and nuclear import were mildly 
hampered (Busschots et al., 2007; Emiliani et al., 2005). Furthermore, the HIV-1 virus 
harboring a mutant integrase (W131A) exhibited mildly impaired replication and 
integration (Busschots et al., 2007). The first studies performed partial LEDGF/p75 
knockdowns and consequently failed to reveal an important role of the cellular factor in 
HIV-1 infection (Llano et al., 2004b; Vandegraaff et al., 2006; Zielske and Stevenson, 
2006). Subsequently, efficient transient and stable LEDGF/p75 knockdowns resulted in a 
residual HIV-1 integration of 20-50% comparing to not silenced cells, without affecting 
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reverse transcription and nuclear import steps (Vandekerckhove et al., 2006). In the same 
study, HIV-1 infection was rescued upon back-complementation with a LEDGF/p75 shRNA-
resistant expression vector. A more pronounced shRNA stable knockdown assuring the 
depletion of LEDGF/p75 chromatin fraction, which might be responsible for tethering 
integrase to chromosome, reduced HIV-1 integration to less than 10% of that observed in 
the normal LEDGF/p75 levels (Llano et al., 2006). Consistently, mouse embryo fibroblasts 
(MEFs) derived from LEDGF knockout animal supported 10% of HIV-1 integration 
comparing to control cells (Shun et al., 2007). In both cases HIV-1 infection was fully 
restored to LEDGF/p75-depleted cells by ectopic expression of the cell factor. Back-
complementation studies in silenced cells highlighted two regions within LEDGF/p75, the 
IBD and the N-terminal PWWP/AT-hook chromatin and DNA binding motifs (Figure 5a), 
as crucial for HIV-1 infection (Llano et al., 2006; Shun et al., 2007). The requirement of 
the N-terminal elements suggested that LEDGF/p75 might primarily function to tether HIV-
1 PICs to chromatin for integration (Engelman and Cherepanov, 2008). Importantly, over-
expression of GFP-IBD fusion proteins inhibited HIV-1 integration while no inhibition was 
observed in cell over-expressing the integrase interaction deficient IBD (D366A) (De Rijck 
et al., 2006). These observations implicate the competitive role of the over-expressed IBD 
with endogenous LEDGF/p75 in binding viral integrase and consequently impairing its 
chromatin tethering (De Rijck et al., 2006). An HIV-1 mutant selected for its ability to 
replicate in MT4 T cell lines over-expressing the C-terminal portion of LEDGF/p75 (residues 
326-530), that contains IBD, (Figure 5a) acquired two mutations in integrase: A128T  
and E170G (Hombrouck et al., 2007). Consistently with the IBD-CCD crystal structure  
(Figure 5b) (Cherepanov et al., 2005a) where E170 is involved in a salt bridge with K364 
of IBD and A128 contributes to the hydrophobic pocket that buries LEDGF/p75 hotspot 
residue (I365), A128T and E170G mutations reduced the affinity of integrase interaction 
with LEDGF/p75 (Hombrouck et al., 2007; Rahman et al., 2007). Intriguingly, HIV-1 
A128T/E170G was partially defective and its replication capacity was further reduced upon 
LEDGF/p75 knockdown suggesting that the integrase mutant still depended on LEDGF/p75 
for integration (Hombrouck et al., 2007).  
 
Since LEDGF/p75 is a lentivirus specific binding factor that tethers integrase to the 
chromatin, it has been hypothesized that LEDGF/p75 might contribute to the HIV-1 
integration target site selection into the transcription units. LEDGF/p75 partial knockdown 
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in human cells showed a significant modest reduction of HIV-1 integration in transcription 
units, however, without shifting the bias toward these chromosomal regions (Ciuffi et al., 
2005). More recent studies using LEDGF mouse knockout cells or more intensified 
LEDGF/p75 knockdown human cells showed a greater reduction of HIV-1 integration in 
transcription units (Marshall et al., 2007; Shun et al., 2007). Therefore, LEDGF/p75-
dependent pathway is predominant for targeting lentiviral integration in transcription 
units.  
Due to the crucial role of LEDGF/p75 in HIV-1 integration, the IBD-CCD interface 
represents a good target for molecules that might disturb the IN-LEDGF/p75 protein-
protein interaction and induce a block of integration in vivo. A recent study described new 
small molecules 2-(quinolin-3-yl)acetic acid derivatives, known as LEDGIN compounds, as 
inhibitors of LEDGF/p75-IN interaction and HIV-1 replication in T cells (Figure 6) (Christ 
et al., 2010). 
 
 
Figure 6: Crystal structure of LEDGIN compound 6 bound to the LEDGF/p75 binding pocket of the integrase 
catalytic core domain (CCD). (a) LEDGIN compound 6 (yellow) bound in the crystal structure of the CCD. 
Two chains of the IN dimer are shown in pale green and pale yellow. Hydrogen bonds made by the carboxyl 
moiety of LEDGIN compound 6 to the protein backbone near residues E170, H171 and T173 are shown as 
green dashed lines. (b) Cartoon representation of the IN CCD dimer (pale green and pale yellow) with the 
soaked LEDGIN compound (yellow stick) superimposed with the IBD-CCD complex structure reveals mimicry 
of the protein-protein interaction by the LEDGIN inhibitor. This validates the pharmacophore model, which 
was based on the interacting amino acids of the IBD such as the I365, D366 and the L368. These amino 





These molecules may act by mimicking IBD residues and binding integrase in the same 
residues involved in LEDGF/p75 binding. Consistently, the same study resolved the CCD-
LEDGIN compound 6 crystal structure (Figure 6a) showing that these molecules occupied 
the same space of the LEDGF/p75 binding pocket in the cleft between the two monomers 
of the CCD dimer. Interestingly, overlaying CCD-LEDGIN structure with the previously 
described CCD-IBD co-crystal structure (Figure 5b) (Cherepanov et al., 2005a) showed 
that the main chain nitrogen of residues  E170 and H171 of integrase formed hydrogen 
bonds with carboxyl moiety of LEDGIN compound 6 (Figure 6b) (Christ et al., 2010). 
Therefore, this interaction might preclude the formation of the bidentate hydrogen bond 
between CCD E170 and H171 residues and the IBD D366 amino acid essential for IN-
LEDGF/p75 interaction. Moreover, the CCD A128 residue that is important for CCD-IBD 
hydrophobic interactions is packed directly on the LEDGIN compound 6 (Christ et al., 
2010). 
 
5.2- Histone acetyl transferases: p300 and GCN5 
p300 is a histone acetyl transferase (HAT) protein that was demonstrated to directly bind 
and acetylate HIV-1 integrase in vitro and in vivo (Cereseto et al., 2005).  
HAT family proteins functions enzymatically by transferring an acetyl group from acetyl-
coenzyme A (acetyl-CoA) to the -amine group of specific lysine residues within the 
histone basic N-tail region or the non-histone protein substrates (Roth et al., 2001). The 
HAT p300 is a transcriptional co-activator with a broad activity in gene transcription 
through its interaction with a number of transcription factors (Chan and La Thangue, 
2001; Wang et al., 2008). HAT p300 has 2414 amino acid residues and contains several 
functional domains (Figure 7a): 1) three cysteine-histidine (CH)-rich domains (CH1, CH2 
and CH3); 2) a KIX domain; the CH1, CH3 and the KIX domains bind a number of cellular 
and viral proteins and mediate protein-protein interactions; 3) the bromodomain, which is 
frequently found in mammalian HATs, recognizes and binds acetylated lysines; 4) the 
central HAT domain (1195-1673 amino acid residues) is the catalytic domain of p300 
responsible for transferring acetyl group to target lysines and 5) the steroid receptor co-
activator interaction domain (SID, also the SRC-1 interaction domain) (Chan and La 
Thangue, 2001; Wang et al., 2008).  
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HAT p300 binds HIV-1 integrase through the C-terminal domain (CTD) of integrase 
(Cereseto et al., 2005). Consistently, p300 acetylates in vitro and in vivo three lysine (K) 
residues in integrase CTD: K264, K266 and K273 (Cereseto et al., 2005; Topper et al., 
2007). Interestingly, a modeled structure of HIV-1 integrase in complex with p300 
predicted that the CTD tail between amino acids 271 and 288 due to its high flexibility, 
could easily adapt to the binding pocket of p300 (Figure 7b) (Di Fenza et al., 2009; 
Terreni et al., 2010). Thus, in this model, the K273 is expected to be the most prone for 
acetylation by p300 and the acetylation of the close lysines K264 and K266 might require 
more complex unfolding of their stable structure.  The acetylation of K264, K266 and K273 
by the recombinant p300 enhanced the binding affinity of integrase to a viral mimicking 
DNA in vitro (Cereseto et al., 2005). Interestingly, the CTD has been shown to have a 
strong but nonspecific DNA binding activity (Engelman et al., 1994). Importantly, it has 
been reported that the minimal region of CTD required for DNA binding is from 220 to 270 
and mutations in K264 showed a strong reduction of integrase DNA binding and catalytic 
activity in vitro (Lutzke et al., 1994). Furthermore, a footprint analysis has revealed that 
K273 is also among the amino acids involved in DNA binding (Dirac and Kjems, 2001). In 
agreement with the increase of DNA binding affinity, acetylation enhanced integrase DNA 
strand transfer activity, while, 3‘ end joining activity was not affected (Cereseto et al., 
2005). The role of integrase acetylation in HIV-1 infection was investigated by using a 
mutant HIV-1 virus carrying an integrase containing single amino acid substitutions of 
acetylation lysine sites to arginines (Cereseto et al., 2005). The replication of 
(K264,K266,K273R)-HIV-1 mutant virus was severely impaired in T cells comparing to the 
wild type virus. The impairment was specific to integration (95% reduction), while, reverse 
transcription and nuclear import were not affected (Cereseto et al., 2005). Importantly, 
the (K264,K266,K273R)-HIV-1 mutant virus formed more 2-LTR circles comparing to the 
wild type virus  indicating that the inhibition in viral replication is due to an integration 






Figure 7: (a) Schematic representation of p300 domains. The functional domains in p300 (1-2414 amino 
acid residues) include the cysteine/histidine-rich domains CH1, CH2 and CH3, the KIX domain, the 
bromodomain (Br), the HAT domain (1195-1673 amino acids) and the steroid receptor coactivator 
interaction domain (SID, also the SRC-1 interaction domain). The regions that have been shown to bind to 
target proteins, together with the identity of the interacting proteins, are shown (Liu et al., 2008). (b) 
Three-dimensional model of IN complex with p300. IN is represented in green and p300 in light grey. The 
three lysine residues in the C-terminal domain of IN that are acetylated by p300 (Lys 264, Lys 266, and Lys 
273) are shown in yellow. HAT p300 is rendered as surface, while IN as a cartoon to highlight the C-terminal 





The role of integrase acetylation lysines in HIV-1 infection was further investigated by 
three subsequent studies (Apolonia et al., 2007; Terreni et al., 2010; Topper et al., 2007). 
The first subsequent report (Topper et al., 2007) confirmed the p300 acetylation of 
integrase at the same described lysine sites (Cereseto et al., 2005), however, they 
attributed the severe integration impairment of the (K264,K266,K273R)-HIV-1 mutant 
virus (Cereseto et al., 2005) to the acidic Flag tag fused to the viral integrase CTD that in 
combination with the RRR mutations might disturb the functionality of the viral integrase 
in vivo. The same study (Topper et al., 2007) reported an untagged (K264,K266,K273R)-
HIV-1 mutant virus that although was able to replicate in T-cells it gave a reproducible 
reduction (40%) in integration accompanied with a significant 4 fold increase in 2-LTR 
circles with respect to wild type virus. In the two other subsequent studies, the untagged 
triple mutant HIV-1 viruses gave a more pronounced significant decrease (80%) in HIV-1 
infectivity and integration (Apolonia et al., 2007; Terreni et al., 2010). Moreover, an 
untagged (K264,K266,K273R)-HIV-1 mutant virus (Terreni et al., 2010) in a multiple-
round replication showed a reduced virus production and a delay in the peak of infectivity 
comparing to the wild type virus. All these reports showed that integrase acetylation by 
p300 is not an absolute requirement for HIV-1 integration but it significantly participates 
to optimal integration.  
HIV-1 integrase has been shown to be also acetylated by another HAT protein, GCN5, at 
the same lysine residues targeted by p300 (K264, K266 and K273) and at an additional 
CTD lysine K258 (Terreni et al., 2010). Similarly to p300, GCN5 demonstrated to bind 
integrase in vitro and in vivo and this interaction required the integrase C-terminal 
domain. Transient and stable knockdowns of GCN5 decreased HIV-1 integration by almost 
50% consistent with an increase of the 2-LTR circles (Terreni et al., 2010). Moreover, an 
untagged quadruple mutant (K264,K266,K273,K258R)-HIV-1 virus exhibited the same 
integration deficiency (80% decrease) of the triple mutant HIV-1 virus (K264,K266,K273R) 
(Terreni et al., 2010). This study demonstrates that K264, K266 and K273 residues which 
are acetylated by both p300 and GCN5 are required for optimal viral integration, while, 
K258, acetylated exclusively by GCN5, does not appear to affect HIV-1 infection (Terreni 






5.3- Integrase interactor 1: INI1 
INI1 is the first cellular factor that was identified to interact with HIV-1 integrase by yeast 
two hybrid screen (Kalpana et al., 1994). INI1 is the human homolog of yeast SNF5, 
transcriptional activator and component of the chromatin remodeling SWI/SNF complex. 
Likewise, INI1 was shown to be part of mammalian SWI/SNF complex that utilizes the 
energy of ATP hydrolysis to remodel chromatin (Wang et al., 1996).  INI1 is  a 385 amino 
acid protein with three conserved regions, including two direct imperfect repeats, repeat 1 
(Rpt1) and repeat 2 (Rpt2), a C-terminal coiled-coiled domain and a homology region 3 
(Morozov et al., 1998).  
The interaction INI1-integrase is specific to HIV-1 and not other related lentiviruses (Yung 
et al., 2004). INI1 has been shown to be incorporated into the virions through integrase 
dependent manner (Yung et al., 2001; Yung et al., 2004) and also to be a component of 
the reverse transcription complex (Al-Mawsawi and Neamati, 2007). The minimal INI1 
binding region of integrase spans amino acid residues 53-153, and lysine 71 (K71) is 
critical for INI1 binding (Al-Mawsawi and Neamati, 2007). The INI1 amino acid residues 
183-243 are responsible for integrase binding (Maroun et al., 2006).  
Recombinant INI1 as well as high molecular weight INI1 containing protein complexes 
partially purified  from  mammalian cells stimulated integrase DNA-strand transfer activity 
in vitro 10-20 fold as compared with reactions lacking INI1 (Kalpana et al., 1994). These 
results suggested a potential important role for INI1 during HIV-1 infection and specifically 
integration. However, no effect of INI1 on HIV-1 integration has been reported following 
potent down-regulation of endogenous INI1 by small RNA interference (siRNA) (Boese et 
al., 2004) or by short hairpin RNA (shRNA) (Ariumi et al., 2006). In contrast, another 
report has suggested that INI1 participates in an anti-viral cellular response by interfering 
with early steps of viral replication likely pre-integration complex (PIC) nuclear import 
since the transient knockdown of INI1 enhanced both 2-LTR circles and integrated viral 
cDNA (Maroun et al., 2006). This finding was in agreement with a previous observation 
that showed 30 min after HIV-1 infection INI1 as well as promyelocytic (PML) protein are 
exported from the nucleus to the cytoplasm to co-localize with the incoming  PIC (Turelli 
et al., 2001).  
The role of the incorporation of INI1 inside the HIV-1 virion particles was also 
investigated. HIV-1 particles lacking INI1 protein were shown to be defective for reverse 
transcription, indicating a potential role of INI1 in promoting HIV-1 infection in very early 
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steps of HIV-1 infection instead of integration (Sorin et al., 2006). Moreover, a critical role 
of INI1 in HIV-1 production and release has been also described based on the use of a 
peptide mimicking INI1 fragment able to bind integrase, called S6, that acted as trans-
dominant inhibitor (Yung et al., 2004). The presence of S6 fragment in producer cells 
reduced the viral assembly and release dramatically, whereas, mutations in the S6 
fragment that disturbed the integrase interaction abrogated the inhibitory effect on virus 
production (Yung et al., 2004). Furthermore, in the same study it has been demonstrated 
that the S6 inhibition was specific to integrase as part of Gag-Pol polyprotein precursor 
that is synthesized in producer cells and not to the free integrase protein separated from 
Gag-Pol during virus release and proteolytic maturation by the viral protease (Yung et al., 
2004).     
 
5.4- Host factors binding integrase and involved in HIV-1 nuclear import   
 
a- Karyophilic properties of integrase and its association with importin factors  
The tight association between integrase and the viral cDNA within the pre-integration 
complex (PIC) supported integrase as a good candidate to mediate HIV-1 nuclear import 
(Farnet and Haseltine, 1991). HIV-1 integrase is a karyophilic protein (Bouyac-Bertoia et 
al., 2001; Depienne et al., 2000; Devroe et al., 2003) and several putative nuclear 
localization signal (NLSs) have been mapped in its core catalytic domain (Armon-Omer et 
al., 2004; Bouyac-Bertoia et al., 2001) and in its C-terminal domain (Ao et al., 2005; 
Gallay et al., 1997). Since the reported integrase putative NLSs have been shown to 
interact with importin  (Armon-Omer et al., 2004; Gallay et al., 1997), importin  (Hearps 
and Jans, 2006) and importin 7 (Ao et al., 2007), classical importin pathways have been 
proposed for integrase nuclear import. However, based on in vitro nuclear import assays, 
it has been shown that integrase was imported to the nucleus by a rapid, ATP-dependent 
saturable mechanism that did not require cytosolic factors and independent from the 
classical NLS import mechanisms (Depienne et al., 2001). Moreover, it has been reported 
that integrase might lack a transferable NLS and its tight association with the 
chromosomal DNA, mainly by LEDGF/p75, might facilitate its nuclear accumulation 
(Devroe et al., 2003; Emiliani et al., 2005). In the attempt to establish a correlation 
between the karyophilic proprieties of integrase and the HIV-1 PIC nuclear import during 
HIV-1 infection, several HIV-1 mutant viruses have been described. An HIV-1 mutant virus 
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in one putative integrase NLS (161-173 amino acid residues) showed a replication defect 
in cycling and non-dividing cells indicating that karyophilic proprieties of integrase are 
required to promote an efficient HIV-1 infectivity in host cells (Bouyac-Bertoia et al., 
2001). Nevertheless, later reports demonstrated that the same HIV-1 mutant virus is 
replication defective owing to defective integrase catalytic activity and not to nuclear 
import block since same amounts of nuclear viral cDNA were detected with wild type and 
HIV-1 virus mutant in NLS integrase (Dvorin et al., 2002; Limon et al., 2002). Later on the 
same integrase NLS region (161-173 residues) has been shown to be a hotspot interface 
for IN-LEDGF/p75 interaction essential for HIV-1 integration in vivo (Busschots et al., 
2007). Indeed, several integrase viral mutations have been shown to have pleiotropic 
effects often complicating viral phenotypes interpretations (Engelman, 1999; Engelman et 
al., 1995). Two studies (Bukrinsky et al., 1992; Riviere et al.) reported defective HIV-1 
viruses deleted in integrase that were able to form 2-LTR circles, a surrogate marker of 
retroviral nuclear import (Coffin et al., 1997), as well as wild type virus suggesting that 
functional integrase is not necessary for HIV-1 nuclear import.  
Among the importins binding integrase, the role of importin 7 has been investigated by 
performing a transient knockdown by small interfering RNA (siRNA) in dividing cells and by 
testing an HIV-1 mutant virus carrying an integrase impaired for the importin 7 binding by 
single amino acid substitutions (Ao et al., 2007). In this report, HIV-1 infectivity was 
reduced by almost 50% in importin 7 knockdown cells comparing to not depleted cells and 
the mutant HIV-1 virus was replication defective due to a block in the nuclear import 
indicating an efficient role of IN-importin 7 interaction in the PIC nuclear translocation (Ao 
et al., 2007). However, in a previous study, it has been reported that a good importin 7 
siRNA-mediated knockdown did not affect HIV-1 nuclear import, based on the formation of 
the 2-LTR circles, in dividing and non dividing cells (Zielske and Stevenson, 2005).  
Several other studies have suggested and reported that HIV-1 PIC nuclear import is 
mediated by integrase binding cellular factors different from importin proteins. The first 
proposed candidate was LEDGF/p75 because it binds tightly HIV-1 integrase 
(Cherepanov et al., 2003), it was found as a component of the HIV-1 PICs (Llano et al., 
2004b) and it contains an N-terminal transferable NLS (Maertens et al., 2004). However, 
LEDGF/p75 depletion in macrophages or in dividing cells has been shown to affect only 
HIV-1 integration and based on the 2-LTR circles formation HIV-1 nuclear import was 
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unchanged (Llano et al., 2006; Shun et al., 2007; Vandekerckhove et al., 2006; Zielske 
and Stevenson, 2006). 
 
b- Transportin-SR2 
Recent study described a new integrase cellular binding factor, transportin-SR2 (TRN-SR2 
or TNPO3), that has been identified by yeast two hybrid screen and has an important role 
in HIV-1 PIC nuclear import (Christ et al., 2008). TRN-SR2 is a member of karyopherin  
protein family and shuttles essential splicing factors, the serine/arginine rich splicing 
factors (SR proteins), between the nucleus and the cytoplasm and therefore is involved in 
the regulation of the mRNA splicing. Importantly, transportin-SR2 was identified essential 
for HIV-1 early steps in two independent genome wide short interfering RNA (siRNA) 
screens for host factors required by HIV-1 for infection (Brass et al., 2008; Konig et al., 
2008). The knockdown of transportin-SR2 in cells reduced HIV-1 replication by 80% 
(Christ et al., 2008). The analysis of viral cDNA species revealed that reverse transcription 
in transportin-SR2 knockdown cells was not affected while 2-LTR circles were decreased 
by 3 to 4 fold consistent with a severe decrease in HIV-1 integration and implicated an 
important role of transportin-SR2 in HIV-1 nuclear import (Christ et al., 2008). This role 
was corroborated by an in vivo HIV-1 PIC nuclear import assay (Albanese et al., 2008) 
which demonstrated a decreased number of visualized HIV-1 PIC in the nucleus when 
transportin-SR2 was depleted comparing to not silenced cells (Christ et al., 2008). The 
effect of transportin-SR2 on HIV-1 nuclear import was similar in dividing and non dividing 
cells (Christ et al., 2008).  Later studies confirmed the requirement of transpotin-SR2 for 
HIV-1 infectivity and nuclear import, however, in capsid dependent manner (Krishnan et 
al., 2010; Lee et al., 2010). Indeed, it has been described an HIV-1 capsid mutant virus 
(N74D) pseudotyped with VSV-G envelope that was insensitive to transportin-SR2 
knokdown (Lee et al., 2010). In contrast, a more recent study showed that the N74D 
mutant virus carrying the wild-type HIV-1 envelope is still dependent on transportin-SR2,  
which revealed a link between the viral entry of HIV-1 and its interaction with this cellular 
factor (Thys et al., 2011). 
 
c- JNK and Pin1 
C jun N-terminal kinase (JNK) is a member of MAP kinases that has been shown to bind 
and phosphorylate in vitro and in vivo HIV-1 integrase (Manganaro et al., 2010). The 
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phosphorylation occurs at serine 57 (S57) of the core catalytic domain (CCD) of integrase 
which is also the region required for the binding with JNK (Manganaro et al., 2010). This 
modification is required for integrase interaction with peptidyl-prolyl cis-trans isomerase 
Pin1 which in turn catalyzes conformational modification of integrase to increase its 
stability (Manganaro et al., 2010). Interestingly, in quiescent T cells non-permissive for 
HIV-1 infection JNK is low expressed and viral integrase was not detected at 8 hours after 
infection in contrast to activated T cells (Manganaro et al., 2010). Drug inhibition of JNK in 
activated T cells does not affect HIV-1 reverse transcription, however, decreases viral 
integration and 2-LTR circle formation indicating a defect in the nuclear import of viral 
cDNA (Manganaro et al., 2010). It has been proposed that in activated T cells integrase 
phophorylated by JNK is stabilized by Pin1 thus allowing efficient infection, conversely, in 
resting T cells lacking JNK activity integrase is unstable unable to sustain efficient nuclear 
import and integration (Manganaro et al., 2010). 
   
d- NUP153 
NUP153 is an essential nuclear pore complex (NPC) protein that binds directly HIV-1 
integrase (Woodward et al., 2009). The C-terminal domain of NUP153 containing 
phenylalanine-glycine rich repeats (FG-repeats) is the region required for binding integrase 
(Woodward et al., 2009). The over-expression of NUP153 FG-repeats induced an inhibition 
of HIV-1 cDNA nuclear translocation suggesting that integrase-NUP153 interaction 
mediates the PIC nuclear import (Woodward et al., 2009).  
 
5.5- Gemin2 
Gemin2,  has been identified as HIV-1 integrase interacting factor by yeast two hybrid 
screen (Hamamoto et al., 2006). Gemin2 is an integral protein component of the survival 
of motor neurons complex (SMN). The SMN complex is involved in many aspects of 
cellular RNA function. It acts as a macromolecular assembly complex for various 
ribonucleoproteins and has been implicated in fundamental cellular processes including 
transcription, RNA metabolism and mRNA or rRNA processing (Al-Mawsawi and Neamati, 
2007). Gemin2-IN interaction was further confirmed in vitro and in vivo and required the 
C-terminal domain of integrase with partial contribution of the core catalytic domain 
(Hamamoto et al., 2006). A transient Gemin2 knockdown mediated by short interfering 
RNA (siRNA) in macrophages and in dividing cells reduced HIV-1 infectivity by almost 75% 
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comparing to not depleted cells (Hamamoto et al., 2006). The reduction of infectivity in 
Gemin2 knockdown cells was pinpointed at the level of reverse transcription (Hamamoto 
et al., 2006). Thus, although Gemin2 is an integrase interacting factor it contributes to 
HIV-1 infectivity at the early viral cDNA synthesis step (Hamamoto et al., 2006).     
 
5.6- Human polycomb group EED protein  
EED protein (embryonic ectoderm development) was identified as integrase binding factor 
by yeast two hybrid screen (Violot et al., 2003). EED is encoded by eed gene which is a 
member of the highly conserved polycomb group (Pc-G) of genes, whose products 
regulate and maintain the silent state of chromatin (Al-Mawsawi and Neamati, 2007). The 
EED-IN  interaction was confirmed by in vitro  binding assays (Violot et al., 2003). In 
addition, EED protein stimulated integrase catalytic activity in vitro (Violot et al., 2003). In 
the same study, EED and integrase were found to co-localize predominantly in the nucleus 
near to the nuclear pores six hours post-infection and at 24 hours post-infection no co-
localization has been observed (Violot et al., 2003). The functional role of EED protein in 
HIV-1 infection is still not investigated. However, based on the nature of EED as a 
chromatin associated protein and on the IN-EED co-localization observations it has been 
suggested possible roles of EED in integration site selection and in HIV-1 nuclear import 
(Vandegraaff and Engelman, 2007; Violot et al., 2003).  
   
5.7- Heat shock protein 60: HSP60 
The yeast HSP60, which is the counterpart of human HSP60, was identified to bind HIV-1 
integrase by in vitro interaction assays between the recombinant viral protein and the 
yeast cell protein extracts (Parissi et al., 2001). Heat shock proteins (HSP) bind and 
facilitate the proper folding of newly synthesized peptide chains. HSP60 functions in 
complex with HSP10 and drives the folding of newly synthesized peptides in an ATP-
dependent manner (Parissi et al., 2001). The human HSP60 was also able to bind HIV-1 
integrase in vitro and this interaction was shown to involve at least the catalytic core 
domain of integrase (Parissi et al., 2001). Moreover, integrase has been shown to be a 
specific substrate of HSP10-HSP60 chaperonin complex in vitro in an energy dependent 
manner (Parissi et al., 2001). The recombinant human HSP60 stimulated integrase 3‘ end 
processing and DNA strand transfer activities in vitro (Parissi et al., 2001). Finally, the 
lethal phenotype induced by HIV-1 integrase expression in yeast (Caumont et al., 1999) 
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was abolished in strains mutated in HSP60 gene suggesting that HSP60-IN interaction 
might have a role on the functionality of integrase in vivo (Parissi et al., 2001). The role of 
IN-HSP60 interaction in HIV-1 replication is still not established.  
 
5.8- Uracil DNA glycosylase isoform 2: UNG2 
UNG2 was initially identified as cellular protein interacting with Vpr by yeast two hybrid 
screen (Bouhamdan et al., 1996) and a subsequent study revealed that UNG2 is 
incorporated into HIV-1 virions (Willetts et al., 1999). However, UNG2 is incorporated into 
virions not in Vpr-interaction dependent manner but through integrase (as domain of Gag-
Pol precursor) interaction dependent manner (Willetts et al., 1999). UNG2 excises uracils 
present in G:U base mismatch of the DNA preventing the genome  G to A mutations and 
resulting in abasic sites further repaired through the base excision repair pathway (Willetts 
et al., 1999). The UNG2 binding region of integrase was mapped on 170-180 amino acid 
residues (Willetts et al., 1999). There are conflicting results about the role of UNG2 in HIV-
1 replication. In one study an HIV-1 mutant virus containing an integrase unable to 
incorporate UNG2 into the virions, by single point mutations in 170-180 amino acid region, 
was replication defective by a specific block at the integration step (Priet et al., 2003). In 
contrast, another report showed that the infectivity of HIV-1 virions produced in UNG 
knockout B cell lines was not affected (Kaiser and Emerman, 2006).      
 
5.9- Von Hippel-Lindau binding protein 1: VBP1 
VBP1 has been identified to bind HIV-1 integrase by yeast two hybrid screen (Mousnier et 
al., 2007). VBP1 is a component of the cellular prefoldin chaperone. Mousnier et al (2007), 
showed that VBP1 binds integrase at 43-195 amino acid residues and bridges integrase 
with the cullin2-based von Hippel-Lindau ubiquitin ligase (cul2/VHL). This tethering 
induced integrase poly-ubiquitination and subsequently its proteasomal degradation. In 
this reported mechanism integrase degradation serves at a post-integration step to allow 
efficient transition from integration to viral transcription. Consistently, in VBP1 knockdown 
cells or in cul2/VHL mutant cells the HIV-1 gene expression was inhibited only when the 
viral genome had been integrated through an integrase dependent pathway and not 





5.10- TRAF and TNF receptor associated protein: TTRAP  
The study from Zhang et al (2009) reports that TTRAP binds HIV-1 integrase in yeast two 
hybrid assay, in vitro and in in vivo in human cells (Zhang et al., 2009). TTRAP is a 
promyelocytic leukemia nuclear body (PML-NB) associated protein. In the same study, 
TTRAP knockdown or over-expression diminished or enhanced HIV-1 infectivity 
respectively. However, the molecular mechanism of TTRAP activity on HIV-1 infection has 
not been elucidated yet. 
 
HIV-1 restriction factors  
In response to HIV-1 infection, cellular innate immunity has evolved proteins that interfere 
with several steps of HIV-1 replication, the restriction factors. The most described HIV-1 
restriction factors are TRIM5, member of TRIM family proteins, APOBEC3G/F and the 
newly described tetherin (CD317/BST-2). These factors affect HIV-1 in cytoplasmic 
replication steps which are post-entry for TRIM5, reverse transcription for APOBECs and 
viral release for tetherin. TRIM22, another TRIM protein, has been suggested to inhibit 
HIV-1 transcription and recently has been shown to inhibit viral assembly. So far, few 
reports described inhibitor proteins that interfere with HIV-1 integration or nuclear pre-
integration events (p21Cip1/Waf1, RAD52, Rad18, XPB and XPD) with not yet establishment 
of molecular mechanisms.   
 
1- TRIM family proteins  
1.1- TRIM proteins: characteristics and implications in the innate immunity 
The TRIM family is an expanding family of RING (really interesting new gene) proteins 
that contain an N-terminal tripartite motif called RBCC (Figure 8) (Reymond et al., 2001; 
Short and Cox, 2006). RBCC motif comprises a RING domain, one or two B-boxes and a 
predicted coiled-coil region (Reymond et al., 2001; Short and Cox, 2006). This RBCC motif 
is usually followed by either one or two C-terminal domains which are specific for each 
TRIM protein (Ozato et al., 2008; Short and Cox, 2006). The C-terminal domains 
determine the classification of the 72 human TRIM proteins into 11 subfamilies while one 
group remains unclassified due to the lack of the RING domain (Figure 8) (Ozato et al., 
2008; Short and Cox, 2006). The architecture of TRIM proteins is conserved not only in 
human genes but also from other species, indicating that the RBCC is responsible for all 
common features of TRIM proteins (Ozato et al., 2008). The RING domain of some TRIM 
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proteins (such as TRIM5TRIM21, TRIM22 and TRIM25) possesses an E3 ubiquitin ligase 
activity that catalyses the addition of ubiquitin to substrate proteins targeting them for 
proteasomal degradation (Kajaste-Rudnitski et al., 2010; Ozato et al., 2008). The B-boxes 
and coiled coil domains are believed to participate in protein-protein interaction, 
oligomerization and formation of macromolecular complexes (Nisole et al., 2005; Ozato et 
al., 2008). The C-terminal sequences most commonly found in TRIM proteins are the PRY 
and SPRY domains (Figure 8) (Nisole et al., 2005; Ozato et al., 2008). The SPRY domain 
is found in 39 human TRIM family members including TRIM22, and is fused to the PRY 
domain to form PRYSPRY domain (also called B30.2) in 24 family members including 
TRIM5 and TRIM25 (Ozato et al., 2008). The cellular functions of the PRYSPRY domain 
are still unclear but it has been proposed that PRYSPRY domain has been evolved only in 
vertebrate under selective pressures for immune defense (Ozato et al., 2008). The C-
terminus of TRIM family can also contain various other domains (Figure 8). For instance, 
the C-VI TRIM subfamily proteins that include TRIM24, TRIM28 (KAP1 or TIF1) and 
TRIM33 are characterized by a C-terminus containing a plant homeodomain (PHD) zinc 
finger always followed by a bromodomain (BROMO) (Figure 8) (Ozato et al., 2008). The 
PHDs are found in nuclear proteins and are thought to be involved in transcriptional 
regulation and in binding histone methylated lysines, while, bromodomains are functional 
motifs that recognize acetylated lysine residues of histone and non histone proteins 
(Mujtaba et al., 2007; Zeng and Zhou, 2002). In regard to their structure, TRIM proteins 
form high-molecular-mass complexes that localize to specific sub-cellular compartments 
present either in the cytoplasm or in the nucleus (Reymond et al., 2001). For example, 
TRIM19, also known as promyelocytic leukemia protein (PML), exists in sub-nuclear 
structures known as ―PML nuclear bodies‖, whereas TRIM5 is normally located in distinct 




Figure 8:  Human TRIM proteins. Classification of human TRIM proteins based on the nature of their C-
terminal domains(s) (Ozato et al., 2008; Short and Cox, 2006). The TRIM protein family is composed of 11 
sub-families, from C-I to C-XI, whereas some TRIM proteins remain unclassified (UC), since they do not 
have a RING finger domain as ‗‗true‘‘ TRIM proteins. NHL, NHL repeats; COS, COS box motif; FN3, 
fibronectin type III motif; PHD, plant homeodomain; BROMO, bromodomain; MATH, meprin and TRAF 
homology domain; TM, transmembrane domain; AR, acid-rich region (Carthagena et al., 2009). 
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TRIM family proteins have been involved in a variety of cellular processes, such as signal 
transduction, transcriptional regulation, cell proliferation, oncogenesis, and apoptosis 
(Nisole et al., 2005; Ozato et al., 2008). Furthermore, mounting evidence highlights the 
important role of TRIM proteins in the innate immunity. Indeed, in the recent years an 
increasing number of TRIM proteins have been found to display antiviral activities or to be 
involved in processes associated with immune response (Nisole et al., 2005; Ozato et al., 
2008). For example, among the 72 TRIM human genes, 27 have been found to be up-
regulated in response to interferons, the main mediators of the innate immunity against 
viral infection (Carthagena et al., 2009). Consistently, TRIM25 has been shown to control 
the retinoic acid inducible gene I protein (RIG-I) which is the cytosolic receptor of viral 
RNA that induces type I interferon–mediated host protective innate immunity against viral 
infection (Gack et al., 2007). It has been demonstrated that TRIM25 E3 ubiquitin ligase 
catalyzes the ubiquitination of RIG-I which is an essential modification for triggering the 
downstream immune signaling pathway upon viral infection (Gack et al., 2007). Moreover, 
TRIM19 (PML) has been shown to be involved in the cellular antiviral response against a 
wide range of RNA and DNA viruses including HIV-1, adenoviruses, herpes simplex virus 
(HSV) and cytomegalovirus (CMV) (Everett and Chelbi-Alix, 2007). Importantly, many 
indications suggest the important role of TRIM family proteins in the inhibition of 
retroviruses (Nisole et al., 2005). First, because TRIM5 from different primate species 
(humans, Old and New World monkeys) showed crucial role in the species-specific 
resistance to retroviruses (Huthoff and Towers, 2008; Nakayama and Shioda, 2010). 
Moreover, the resistance to HIV-1 and feline immunodeficiency virus (FIV) in the New 
World owl monkeys and in the Old World pig tailed monkeys, respectively, is mediated by 
a TRIMCyp protein that conserves the N-terminal RBCC tripartite motif of TRIM5 (Luban, 
2007; Sokolskaja and Luban, 2006; Wilson et al., 2008). In addition, a wide screen 
performing an exogenous over-expression of 55 TRIM proteins from human and murine 
origins identified 20 TRIM proteins that affect viral entry and release of HIV-1, murine 
leukemia virus (MLV) and avian leukosis virus (ALV) (Uchil et al., 2008). Recently, TRIM28 
(also known as KAP1 or TIF1) has been shown to restrict MLV, visna, spuma and Mason-
Pfizer monkey retroviruses in embryonic stem cells (Wolf and Goff, 2007; Wolf et al., 
2008b). Interestingly, eight human TRIM genes (TRIM10, TRIM15, TRIM26, TRIM27, 
TRIM31, TRIM38, TRIM39 and TRIM40) are located in the major histocompatibility 
complex region of chromosome 6 which has protective impact on HIV-1 progression 
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(Carthagena et al., 2009; Fellay et al., 2007). The most described TRIM proteins that 
inhibit HIV-1 are the rhesus macaque TRIM5(Stremlau et al., 2004) and the owl monkey 
TRIMCyp (Sayah et al., 2004) proteins that inhibit HIV-1 at early infection steps. The 
human TRIM22, also known as Staf50, has been described to inhibit HIV-1 in the later 
viral steps of transcription (Bouazzaoui et al., 2006) and viral assembly and release (Barr 
et al., 2008). 
 
1.2-TRIM5and TRIMCyp 
The TRIM5 was identified as restriction factor of HIV-1 in the Old Word rhesus monkey 
cells in 2004 (Stremlau et al., 2004). Before that time TRIM5 was referred in the reports 
as  the not yet identified proteins Ref1, that restricts N-tropic MLV (N-MLV) in human cells, 
and Lv1 that restricts HIV-1 in monkey cells (Hatziioannou et al., 2004; Huthoff and 
Towers, 2008; Nakayama and Shioda, 2010; Yap et al., 2004). The mechanism by which 
TRIM5exerts its antiretroviral effect is not fully understood. However, it is known that 
TRIM5targets intact or partially uncoated incoming viral cores via a pattern recognition 
function that identifies the structure formed by the capsid hexameric lattice (Luban, 2007; 
Sokolskaja and Luban, 2006; Towers, 2007). The block of replication appears to occur at 
pre-reverse transcription step impairing the efficient completion of the viral cDNA 
synthesis (Sokolskaja and Luban, 2006; Stremlau et al., 2004; Towers, 2007). Indeed, it 
has been suggested that TRIM5 blocks retroviral replication either by causing cores to 
undergo rapid or premature disassembly (Stremlau et al., 2004; Stremlau et al., 2006) 
and/or by recruiting cellular proteasome degradation machinery to the viral core-TRIM5 
complex (Anderson et al., 2006; Campbell et al., 2008). In addition, to pre-reverse 
transcription inhibition, it has been suggested that TRIM5 blocks HIV-1 reverse 
transcription and nuclear import. This hypothesis was suggested since it has been 
observed that following the inhibition of proteasomes, TRIM5 does not inhibit HIV-1 post 
entry leading to complete cDNA synthesis, however, the nascent reverse transcripts fail to 
sustain an efficient infection (Luban, 2007; Wu et al., 2006; Yap et al., 2006). To explain 
this subsequent block of HIV-1 infection in primate cells, it was also suggested that in the 
absence of proteasome activity the incoming viral core remains stably sequestered in 
complex with TRIM5 without degradation which allows HIV-1 to accomplish reverse 
transcription but not to complete the infection (Campbell et al., 2008; Huthoff and Towers, 
2008; Towers, 2007). Importantly, the antiretroviral effects of TRIM5are exerted in a 
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species–specific manner (Sokolskaja and Luban, 2006; Stremlau et al., 2004; Towers, 
2007). For example, HIV-1 replication is potently blocked by TRIM5 from the non human 
primate rhesus macaque (Stremlau et al., 2004). In contrast, human TRIM5is less 
effective on HIV-1 but it inhibits the gammaretrovirus N-MLV and also the lentiretrovirus 
equine infectious anemia virus (EIAV) in different cell types (Hatziioannou et al., 2004; 
Huthoff and Towers, 2008). The specificity of retroviral restriction correlates with the 
ability of the TRIM5 to recognize the incoming viral core by its PRYSPRY (or B30.2) C-
terminal domain (Sokolskaja and Luban, 2006; Towers, 2007); (Nakayama and Shioda, 
2010). The PRYSPRY domain is the main determinant of core recognition by its specific 
binding to the retroviral capsid (Stremlau et al., 2004; Stremlau et al., 2006; Stremlau et 
al., 2005). The shorter isoforms of TRIM5, TRIM5 and TRIM, that lack PRYSPRY 
domain and contain alternative C-terminus did not exhibit antiviral activity and when over-
expressed acted as dominant negative of TRIM5 restriction (Stremlau et al., 2004). The 
degree of capsid binding and restriction potency correlates with the amino-acid variations 
in the PRYSPRY domain and, remarkably, a single amino acid substitution (R332P) in the 
PRYSPRY domain is sufficient to enable human TRIM5 to restrict HIV-1 (Stremlau et al., 
2005). Conversely, mutations in capsid modulate the susceptibility of incoming core to 
TRIM5 restriction (Stremlau et al., 2006). 
Interestingly, in the New Word owl monkeys, the PRYSPRY domain has been replaced by 
cyclophilin A (CypA) by a LINE-1-mediated retrotransposition event to generate TRIMCyp 
protein that restricts HIV-1 (Sayah et al., 2004). TRIMCyp protein was also discovered in 
Old World pig tailed monkeys that restricts HIV-2 and FIV and not HIV-1 (Wilson et al., 
2008). The CypA portion of TRIMCyp binds capsid and disruption of this interaction 
abolishes the HIV-1 restriction activity of TRIMCyp (Diaz-Griffero et al., 2006; Towers, 
2007).  Indeed, fusion of CypA to the C-termini of non restricting TRIM proteins such as 
TRIM1, TRIM18 or TRIM19 generated functional HIV-1 restriction factors (Yap et al., 
2006). The CypA portion of TRIMCyp therefore replaces the capsid-binding function of the 
PRYSPRY domain in TRIM-mediated retroviral restriction. CypA is an ubiquitously 
expressed peptidyl prolyl isomerase that was earlier shown to interact with HIV-1 capsid 
and catalyses its cis-trans isomerization in a conserved prolyl peptide bond (Towers, 
2007). The  disruption of the interaction between CypA and HIV-1 capsid by Cyclosporine 
A competitive inhibitors or by point mutations in the viral protein inhibited HIV-1 
replication (Luban, 2007; Towers, 2007). CypA is required in the released HIV-1 virions for 
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an efficient completion of reverse transcription in target cells (Braaten and Luban, 2001). 
It has been also shown that CypA confers protection to the incoming HIV-1 virus from 
cellular restriction factors (Towers et al., 2003). However, in non-human primate cells the 
disruption of capsid-CypA interaction or the down-regulation of CypA reduced the 
susceptibility of HIV-1 to the rhesus macaque TRIM5 restriction and rescued HIV-1 
infectivity (Towers, 2007; Towers et al., 2003). Thus, CypA functions in an opposite 
manner in non-human primate as compared to human cells by promoting restriction rather 
than replication (Luban, 2007; Towers, 2007; Towers et al., 2003).  
Although PRYSPRY domain is sufficient for capsid binding, TRIM5 restriction activity 
requires the contribution of all three domains of the N-terminal tripartite RBCC motif (Li 
and Sodroski, 2008; Luban, 2007; Perez-Caballero et al., 2005a). The primary function of 
the coiled-coil domain is to mediate oligomerization to increase capsid binding (Rold and 
Aiken, 2008). The B-box domain has been shown to induce higher-order self-association 
of TRIM5 oligomers to promote cooperative binding to the multimeric retroviral capsid (Li 
and Sodroski, 2008). The RING domain possesses E3 ubiquitin ligase activity in vivo and in 
vitro and was proposed to participate in HIV-1 restriction by recruiting proteasomal 
degradation machinery to the capsid-TRIM5 complex (Anderson et al., 2008; Campbell et 
al., 2008; Rold and Aiken, 2008). However, these findings have been debated due to the 
use of protease inhibitors that might affect several cellular and viral mechanisms 
complicating the interpretation of the true role of the RING E3 ubiquitin ligase in TRIM5 
restriction activity (Huthoff and Towers, 2008; Luban, 2007).  Moreover, TRIM5 is itself 
polyubiquitinated and its half-life is increased by the protease inhibitors (Luban, 2007). 
Finally, the formation of TRIM5 cytoplasmic bodies has been shown not to be required 
for retroviral restriction (Perez-Caballero et al., 2005a; Perez-Caballero et al., 2005b).  
 
1.3- TRIM22 
TRIM22, previously named ―Stimulated Trans-acting Factor of 50 kDa (Staf50)‖, is located 
on chromosome 11 adjacent to TRIM5. TRIM22 was identified and cloned as an 
interferon-inducible gene and has been shown to inhibit LTR-mediated expression of a 
reporter gene suggesting a potential role of TRIM22 in controlling HIV-1 transcription 
(Tissot and Mechti, 1995). In another study, the over-expression of TRIM22 in 
macrophages inhibited HIV-1 infectivity suggesting an effect on LTR-HIV-1 transcription 
(Bouazzaoui et al., 2006). Interference of TRIM22 on HIV-1 viral production has been also 
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proposed based on the observation that p24 Gag antigen levels were decreased in the 
supernatant of infected macrophages following TRIM22 over-expression (Bouazzaoui et 
al., 2006).  
A subsequent study showed that interferon induction of TRIM22 inhibits HIV-1 virion 
assembly in various human cell lines by interfering with Gag trafficking (Barr et al., 2008). 
Human TRIM22 binds and inhibits selectively HIV-1 Gag and not Gags from murine 
leukemia virus (MLV) or equine infectious anemia virus (EIAV) (Barr et al., 2008). TRIM22 
interferes with Gag plasma-membrane accumulation, required for virion assembly, and 
hence induces Gag cytoplasmic diffusion without affecting Gag expression (Barr et al., 
2008). The RING domain E3 ubiquitin ligase activity of TRIM22 is required for viral 
inhibition but not for Gag ubiquitination and degradation, suggesting that TRIM22 disturbs 
Gag cytoplasm trafficking by acting on another cellular or viral protein substrates (Barr et 
al., 2008).  
A recent study showed that in primary blood mononuclear lymphocytes (PBMCs) from 
HIV-1 infected persons, the expression level of TRIM22 is higher than in healthy cells 
(Singh et al., 2011). The increased levels of TRIM22 were negatively correlated to the viral 
load which suggested a role of this TRIM protein in the progression of AIDS. 
 
2- APOBECs (A3G and A3F) 
APOBEC3G (apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3G or A3G, 
initially known as CEM-15) acts at the level of HIV-1 reverse transcription. APOBEC3G was 
first identified as the cellular factor that renders human cells non permissive for infection 
by HIV-1 viruses lacking a Vif gene (HIV-1Vif) (Sheehy et al., 2002). APOBEC3G is a 
member of a family of cytidine deaminases that catalyses the hydrolysis of cytidines (C) to 
uridines (U) (Goila-Gaur and Strebel, 2008). APOBEC3G targets cytidines in the negative 
sense single-stranded DNA that is generated during HIV-1 reverse transcription, a process 
also called as DNA editing or hyper-mutation. The C to U editing leads to guanine (G) to 
adenine (A) substitutions in the positive sense DNA strand of the reverse transcripts 
(Malim, 2009). These G to A hypermutations in the newly synthesized viral cDNA 
potentially leads to its instability and might inactivate viral gene products or regulatory 
genetic elements (Huthoff and Towers, 2008; Malim, 2009). The APOBEC3G is 
incorporated into virus particles budding from the infected or producer cells and editing 
occurs during reverse transcription upon infection of the new target cell (Huthoff and 
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Towers, 2008). The HIV-1 encoded Vif protein (viral infectivity factor) counteracts 
APOBEC3G by targeting it for ubiquitination, likely mediated cullin-5 E3 ubiquitin ligase 
complex, and subsequent degradation by the proteasome (Goila-Gaur and Strebel, 2008). 
The direct effect of Vif-induced APOBEC3G degradation is to prevent APOBEC3G 
incorporation into the virions (Malim, 2009). Therefore, the permissiveness to HIV-1Vif is 
dependent on producer cells regardless the target cells used. APOBEC3G is not 
ubiquitously expressed in all cell types which determine the permissiveness to HIV-1Vif 
viruses (Sheehy et al., 2002). For instance, APOBEC3G is expressed in non-permissive 
CEM, H9 cell lines and also in primary blood lymphocytes and not in CEMss, HeLa and 
HEK293T permissive cells (Sheehy et al., 2002). In addition to APOBEC3G, several other 
members of the APOBEC3 protein family have been shown to act against a wide range of 
viruses and transposable elements (Goila-Gaur and Strebel, 2008). Human APOBEC3F 
(A3F) also inhibits HIV-1 in a Vif dependent manner (Malim, 2009). Some studies 
described also a role of APOBECs in conferring intrinsic resistance to HIV-1 in dentritic 
cells and macrophages as target cells (Peng et al., 2007; Pion et al., 2006). It has been 
also shown that APOBEC3G and APOBEC3F interact with HIV-1 integrase and inhibit HIV-1 
integration (Luo et al., 2007).  
 
3-Tetherin (CD317/BST-2) 
Tetherin, also known as CD317 or bone marrow stromal cell antigen 2 (BST-2), is a recent 
identified HIV-1 inhibitor factor that functions at the level of virus particle release from the 
cell surface (Neil et al., 2008; Van Damme et al., 2008). Tetherin is an interferon-inducible 
trans-membrane protein that retains virus particles of Vpu deleted HIV-1 viruses (HIV-
1Vpu) at the cell surface after they have budded from the plasma membrane (Neil et al., 
2008; Van Damme et al., 2008). Tetherin is not an ubiquitously expressed protein which 
determines the permissiveness to HIV-1Vpu viruses. Tetherin inhibits HIV-1Vpu release 
in non-permissive cells such as HeLa cells, while, in permissive cells such as HEK239T cells 
HIV-1Vpu release is unaffected (Neil et al., 2008; Van Damme et al., 2008). Tetherin 
inhibition is counteracted by Vpu in non permissive cells (Neil et al., 2008; Van Damme et 
al., 2008). The mechanism by which tetherin retains virus particles on the cell surface is 
still not defined (Bieniasz, 2009; Evans et al., 2010). Tetherin contains two trans-
membrane anchors that might allow it to tether virions on the cell surface (Bieniasz, 2009; 
Evans et al., 2010). The mechanism by which Vpu is counteracting tetherin during HIV-1 
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infection is also not yet clear (Bieniasz, 2009; Evans et al., 2010). The initial reports did 
not detect significant reductions in tetherin levels upon Vpu expression (Neil et al., 2008) 
or a down-regulation of tetherin from the cell surface induced by Vpu (Van Damme et al., 
2008). Subsequent studies, in contrast, were able to measure a significant reduction in 
total tetherin level following Vpu expression. It has been proposed that Vpu removes 
tetherin from the cell surface and induces its degradation in the lysosomes and/or in the 
proteasomes by serving as an adaptor between tetherin and the -TrCP/SCF E3 ubiquitin 
ligase complex (Bieniasz, 2009; Evans et al., 2010). It has been also proposed that Vpu 
induces the endocytosis and the sequestering of tetherin inside the endosomes avoiding 
its accumulation at the cell surface (Bieniasz, 2009; Evans et al., 2010). Importantly, 
because the Vpu expression is limited to HIV-1 and a small number of closely related 
simian immunodeficiency viruses (such as SIVcpz), other lentiviruses have likely evolved 
distinct approaches to counteract tetherin. For example, the Env glycoprotein of some 
strains of HIV-2 possess Vpu-like activity and the Nef proteins of several SIVs antagonize 
tetherin (Bieniasz, 2009; Evans et al., 2010). 
 
4- Factors inhibiting HIV-1 integration and nuclear pre-integration events 
 
4.1- p21CIP1/Waf1 
So far p21CIP1/Waf1 (p21) is the only described factor that targets specifically the HIV-1 
integration step (Zhang et al., 2005; Zhang et al., 2007). Notably, p21 is the principal 
mediator of cell cycle arrest in response to DNA damage by inhibiting G1-phase cyclin-
dependent kinases (CDKs) (Cazzalini et al., 2010). The inhibition of HIV-1 infectivity and 
integration by p21 was shown to occur in various cell types and to contribute to the 
intrinsic resistance of CD34+ hematopoietic stem cells to HIV-1 (Zhang et al., 2005; Zhang 
et al., 2007). Indeed, hematopoietic stem cells, the progenitor of either the myeloid or the 
lymphoid lineages, are one of a few cell types that resist HIV-1 infection despite the 
presence of functional HIV-1 CD4 and CXCR4 receptors (Weichold et al., 1998). A previous 
report indicated that a major block to HIV-1 infection in these cells is at virus entry, since 
infection can be achieved using pseudotyped HIV-1 virions that carry a heterologous 
envelope (VSV-G) (Shen et al., 1999). However, later work also suggested that a second 
block to HIV-1 replication is imposed by p21 (Zhang et al., 2005). Indeed, p21 knockdown 
using small interfering RNA (siRNA) enhanced the infectivity of pseudotyped HIV-1 vectors 
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about 3 fold (by measuring a reporter gene) and 7 fold (by measuring integrated viral 
cDNA) (Zhang et al., 2005). A subsequent study pinpointed the inhibition of HIV-1 
infection by p21 at the level of integration (Zhang et al., 2007). In this report, it has been 
shown that p21 knockdown in primary CD34+ hematopoietic stem cells or in CMK cell 
lines, a p53-deficient human megakaryoblastic cells, did not affect reverse transcription, 
while proviral DNA was increased correlated with a decreased 2-LTR circles. These results 
suggest that p21 acts specifically at the level of integration. The mechanism by which p21 
inhibits HIV-1 integration was not established, however, the same study demonstrates 
that the inhibition of integration was correlated with the presence of p21 in the purified 
HIV-1 pre-integration complex (PIC) from the restrictive hematopoietic stem cells and not 
from non restrictive T cell lines. Based on its viral phenotype and cellular functions, it has 
been suggested that p21 might recognize the incoming PIC and prevent HIV-1 integration 




RAD52 is a member of RAD52 epistasis group involved in DNA repair of double strand 
break by homologous recombination (Symington, 2002). RAD52 has been shown to inhibit 
HIV-1 infectivity and provirus formation and was proposed to act by targeting the 
incoming viral cDNA within the pre-integration complex (Lau et al., 2004). In this report it 
has been shown that in rad52 knockout mouse embryonic stem cells or following RAD52 
transient knockdown in HeLa cells, HIV-1 infectivity and integration were increased by 10 
fold in knockout cells and by 2 fold in knockdown cells. In rad52 knockout cells, 2-LTR 
circles were also increased of almost 5 fold as compared to wild type cells (Lau et al., 
2004). In this study, no information has been provided about reverse transcription or 
nuclear import although RAD52 showed to affect the amounts of the 2-LTR circles. The 
homologous recombination activity of RAD52 was not required for HIV-1 inhibition, 
however, the RAD52 DNA-binding activity was needed (Lau et al., 2004). Moreover, the 
same study showed that RAD52 competes with Ku in binding to HIV-1 LTRs in vivo. Ku is 
a cellular protein found in the PIC and required for the formation of the 2-LTR circles by 
non homologous end joining recombination (NHEJ) (Li et al., 2001). This observation 
suggested that RAD52 reduced the formation of the 2-LTR circles by displacing Ku from 
the viral ends of the un-integrated cDNA. However, in HeLa cells over-expressing RAD52, 
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there was no cell death (Lau et al., 2004) typically induced by the accumulation of the un-
integrated viral cDNA in the absence of Ku (Li et al., 2001). Thus, the authors suggested a 
model independent from the requirement of Ku and the NHEJ repair for the circularization 
of the un-integrated viral cDNA and the prevention of cell death (Lau et al., 2004). They 
hypothesized that RAD52 inhibits specifically HIV-1 integration step by displacing from the 
PIC, integrase or other viral or cellular co-factors required for integration. This 
displacement might occur through the direct competition of RAD52 with the PIC proteins 
in binding to viral cDNA ends or indirectly by removing Ku that might be essential for the 
recruitment of the PIC proteins.  
 
4.3- Rad18 
Rad18 is a post replication/transletion DNA repair protein. Rad18 has been reported to 
interact with HIV-1 integrase in vitro and in vivo (Mulder et al., 2002). The same study 
shows that Rad18 stabilizes an ectopically expressed integrase and co-localizes with it in 
nuclear structures. In the subsequent report investigating the role of Rad18 during viral 
replication, it has been described that Rad18 suppresses the HIV-1 infection independently 
from integration likely by targeting the incoming viral cDNA inside the nucleus (Lloyd et 
al., 2006). Indeed, in rad18 knockout murine embryonic fibroblasts, the infectivity of wild 
type HIV-1 or of mutant virus carrying an integrase catalytically inactive (D116A) was 
increased (based on the reporter gene) by 5 fold correlating with an accumulation of the 
HIV-1 late reverse transcripts that became evident after the eight hours of infection (Lloyd 
et al., 2006). Since Rad18 is nuclear, it has been suggested that the inhibitory effect of 
Rad18 might be by targeting linear viral cDNA, after has been crossed the nucleus, by 
inducing its degradation or its circularization (Lloyd et al., 2006).  
 
4.4- XPB and XPD 
Report from Yoder et al (2006) showed that XPB and XPD reduce HIV-1 integration 
efficiency by inducing the degradation of the viral cDNA available for integration (Yoder et 
al., 2006). XPB and XPD are DNA helicases with opposing polarity that function as integral 
components of the TFIIH protein complex. The helicase activity of TFIIH complex is 
required to separate DNA strands at promoters during transcription or at DNA damage 
sites during nucleotide excision repair (NER). HIV-1 infectivity was increased in either XPB 
or XPD mutant cell lines, susceptible for UV irradiation, comparing to the mutant cells 
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complemented with the expression of wild type genes, that restored an efficient DNA 
repair activity. The increase of infectivity in XPB and XPD mutant cells was correlated with 
an increase about 2,5 fold of the total viral cDNA, integrated proviruses and 2-LTR circles 
as compared to complemented cells. In XPB and XPD mutant cells the accumulation of the 
wild type HIV-1 cDNA was similar to a mutant virus encoding an integrase catalytically 
inactive. Moreover, upon treatment of cells with reverse transcriptase inhibitors the 
remaining viral cDNA was more accumulated in XPB and XPD mutant cells than in 
complemented cells. Thus, it has been concluded that XPB and XPD inhibit HIV-1 not by 
interfering with reverse transcription or integration efficiencies but by enhancing the 
degradation of the HIV-1 cDNA available for integration. Since XPB and XPD are 
exclusively nuclear, the Yoder et al (2006) suggested that this mechanism of defense is 
nuclear at pre-integration step. 
 
KAP1 (TRIM28)  
 
1- KAP1 structure and functions 
KRAB domain-associated protein 1 (KAP1), also called TRIM28, TIF1 or KRIP1, is an 
ubiquitous nuclear protein belonging to TRIM protein family (chapter II.3) (Reymond et 
al., 2001). KAP1 has been identified to bind directly to the highly conserved Kruppel 
associated box (KRAB) repression domain of the KRAB zing finger proteins and so far 
KAP1 is their universal co-repressor (Friedman et al., 1996; Urrutia, 2003). The KRAB 
domain is present in the N-terminal region of more than 220 zinc finger proteins and 
mediate their binding to the co-repressor, whereas the C2H2 zinc finger C-terminal motif 
serves to bind DNA including RNA polymerase I, II and III promoters (Abrink et al., 2001; 
Peng et al., 2000; Urrutia, 2003).  
KAP1 has 835 amino acid residues and contains on its N-terminus the RBCC motif 
composed of RING, two B-boxes (B1 and B2) and a coiled-coil domains and on its C-
terminus a tandem of plant homeodomain (PHD) and bromodomain (PHD-BROMO) 
characteristic of subfamily C-VI of TRIM proteins (Figures 8 and 9a) (Reymond et al., 
2001; Short and Cox, 2006). The RBCC motif is involved in KAP1 oligomerization, likely in 
trimer, and in protein-protein interactions (Peng et al., 2000). Notably, RBCC motif is 
responsible for KAP1 direct binding with KRAB domain (Peng et al., 2000). The PHD and 
BROMO domains act cooperatively for interaction with CHD3 (Mi2), which is a subunit of 
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NuRD histone deacetylase complex (Schultz et al., 2001), and with SETDB1 histone H3-K9 
methyl transferase (Schultz et al., 2002). The crystal structure of PHD and BROMO 
domains showed a difference from p300 PHD and BROMO structure in which two domains 
cooperate to bind acetylated lysines of histone and non-histone proteins (Ragvin et al., 
2004; Zeng et al., 2008). Indeed, PHD and BROMO domains of KAP1 failed to bind 
acetylated histone peptides in vitro (Zeng et al., 2008). The central domain of KAP1 
contains an heterochromatin 1 (HP1) binding box domain (HP1BD) carrying a PxVxL motif 
that binds directly the chromoshadow domain of HP1 (Lechner et al., 2000). KRAB zing 
finger proteins and KAP1 have been shown to co-localize in nucleoplasmic foci called KAKA 
foci that are adjacent to PML bodies and have been proposed to contain the sumoylated 
KAP1 (Briers et al., 2009).  
KAP1 has been shown to be post-translationally modified by either sumoylation or by 
phosphorylation which regulate its cellular functions in transcription and in DNA damage 
response. KAP1 PHD domain binds to ubiquitin conjugating enzyme (Ubc9) and directs 
SUMO conjugation of the adjacent BROMO domain at two main lysines K779 and K804 
(Ivanov et al., 2007). KAP1 sumoylation has been shown important for the interaction with 
SETDB1 and CHD3, that both contain specific SUMO interacting motifs (SIM) (Ivanov et 
al., 2007). KAP1 has been reported to be phosphorylated by ATM kinase upon DNA 
damage at its C-terminal domain at the serine 824 (S824) (Figure 9a) (White et al., 





Figure 9: (a) Schematic representation of KAP1 domains. RBCC motif: RING, B boxes and CC (coiled–coil 
domains); HP1BD: HP1-binding domain, the PHD: plant homeodomain and BROMO: bromodomain (Ziv et 
al., 2006). (b) A schematic model for KRAB-KAP1-mediated repression. Following the interaction between 
the KRAB domain of the zinc finger protein with RBCC KAP1 domain at the target DNA to be repressed. The 
PHD domain of KAP1 catalyzes the sumoylation of the adjacent bromodomain mainly at lysines: K779 and 
K804. SUMO family proteins are conjugated to target lysines via a cascade of E1-activating, E2 transfer, and 
E3 ligase enzymes. The PHD-Ubc9 interaction is required for the Bromo sumoylation. Once modified by 
SUMO, the KAP1 bromodomain serves as a scaffold and recruits repression machinery through the 
recognition of the conjugated SUMO moieties by the SIM motifs of CHD3 (Mi2) and SETDB1 and their 
associated proteins. The KAP1 scaffold is further exploited through recruitment of HP1, which recognizes the 
H3-K9 methyl mark and establishes a repressive chromatin state. Ultimately, the concerted action of these 
effector molecules leads to chromatin reorganization at the promoter region resulting in silent chromatin 
(Ivanov et al., 2007). 
 
KAP1 expression is important for normal development in mice (Cammas et al., 2000). 
Germ line homozygous knockout of KAP1 gene results in embryonic lethality at early 
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implementation step (E5.5) (Cammas et al., 2000). KAP1 has been mainly described as 
transcriptional co-repressor through KRAB zing finger proteins by inducing formation of 
hetrochromatin at DNA targeted for silencing (Friedman et al., 1996; Lechner et al., 2000; 
Nielsen et al., 1999; Schultz et al., 2002; Schultz et al., 2001; Sripathy et al., 2006). 
Moreover, KAP1 has been also described to tether histone deacetylases (HDACs) to non-
histone proteins such as p53, E2F1 and STAT3 to induce their deacetylation and 
consequently their inactivation (Tian et al., 2009; Tsuruma et al., 2008; Wang et al., 
2005a; Wang et al., 2007a). In addition, KAP1 has been also reported as DNA damage 
response factor (White et al., 2006; Ziv et al., 2006) and as restriction factor of murine 
leukemia virus (MLV), visna, spuma and Mason-Pfizer monkey retroviruses in embryonic 
stem cells (Wolf and Goff, 2007; Wolf et al., 2008b).  
 
2- Transcriptional co-repressor activity of KAP1 
KAP1 is a hallmark scaffold protein that recruits and coordinates complexes and 
components of heterochromatin formation (Figure 9b) (Lechner et al., 2000; Schultz et 
al., 2002; Schultz et al., 2001; Sripathy et al., 2006). KAP1 is recruited to target promoters 
by KRAB zinc finger proteins through a direct interaction between its RBCC motif with 
KRAB domain (Ayyanathan et al., 2003; Groner et al., 2010; Sripathy et al., 2006). The 
PHD domain then binds Ubc9 and catalyzes the sumoylation of the adjacent bromodomain 
mainly at lysines K779 and K804 (Ivanov et al., 2007; Lee et al., 2007). Sumoylated KAP1 
has been demonstrated to be the active form in KRAB-KAP1-mediated transcription 
repression (Ivanov et al., 2007; Lee et al., 2007; Li et al., 2007). Indeed, once modified by 
SUMO, KAP1 bromodomain serves as a scaffold and recruits repression machinery through 
the recognition of the conjugated SUMO moieties by the SIM motifs of CHD3 and SETDB1 
(Ivanov et al., 2007). CHD3, also called Mi2, is a subunit of NurD histone deacetylase 
complex that contains also HDAC1 and HDAC2 (Grozinger and Schreiber, 2002). CHD3-
KAP1 interaction is thus suggested to mediate the recruitment of NurD complex to 
catalyze histone deacetylation creating favorable environment for heterochromatin 
formation (Schultz et al., 2001; Sripathy et al., 2006). SETDB1 is a histone methyl 
transferase that catalyzes specifically the methylation of lysine 9 of histone 3 (H3K9) 
(Schultz et al., 2002; Sripathy et al., 2006). The function of KAP1 as scaffold is further 
exploited through the recruitment, by its PxVxL motif, of HP1 that binds the tri-methylated 
H3K9 mark and establish a repressive chromatin state or also called facultative 
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heterochromatin (Ayyanathan et al., 2003; Groner et al., 2010; Sripathy et al., 2006). An 
artificial tethering of KRAB-KAP1 to target DNA has been shown to induce the formation of 
heterochromatin along several tens of kilobases away from their binding DNA site (Groner 
et al., 2010). The direct tethering of KAP1 to promoters through heterologous DNA binding 
domain (Gal4-DBD) also induced repressive state through chromatin modification (Nielsen 
et al., 1999; Sripathy et al., 2006), however, weaker than in association with KRAB zinc 
finger proteins (Sripathy et al., 2006). Although KRAB-KAP1 repression mechanisms are 
well established, the mechanisms of target DNA choice to induce the formation of the 
heterochromatin are poorly understood. Intriguingly, a wide genome analysis of KAP1 
binding sites by chromatin immunoprecipitation showed an enrichment of KAP1 in the 
promoter regions of KRAB zing finger genes which suggested that zinc finger proteins 
auto-regulate their transcription by recruiting KAP1 (O'Geen et al., 2007). 
The first evidence of the role of histone deacetylase in KAP1 repression activity was 
demonstrated using a KAP1 deleted in HP1 binding box that was proven unable to 
completely relieve transcription repression only following cell treatment with HDAC 
inhibitor (trichostatin A or TSA) (Nielsen et al., 1999). Subsequently, the PHD-BROMO 
domain of KAP1 has been demonstrated to bind the CHD3 (Mi2), a component of NuRD 
histone deacetylase complex, by yeast two hybrid screening (Schultz et al., 2001). 
Consistently, the KAP1 full length co-immunoprecipitated in vivo with CHD3, HDAC1 and 
RbAp48, all components of NuRD complex (Schultz et al., 2001). Moreover, a KAP1 
deletion mutant lacking PHD and BROMO domains was unable to retain CHD3 in vivo, 
however, no data has been shown regarding the association of this mutant with HDAC1 or 
RbAp48 (Schultz et al., 2001). Data sustaining the role of HDACs in transcription 
repression showed that the PHD-BROMO mutant domains inactive in transcription 
repression were unable to interact with CHD3 (Schultz et al., 2001). In addition, the 
expression of dominant negative protein corresponding to binding region of CHD3 with 
KAP1 or treatment with TSA relieved the transcription repression activity of the PHD and 
BROMO domains (Schultz et al., 2001). Therefore, it has been suggested that PHD and 
BROMO domains following their tethering to promoters recruit NuRD histone deacetylase 
complex to induce histone deacetylation (Schultz et al., 2001). Moreover, KAP1 tethered to 
promoter by an heterologous DNA binding domain (Gal4-DBD) has been shown to induce 




Further evidence in support of HDAC role in KAP1 activities derive from the complex 
formation of KAP1 with the nuclear receptor core-repressor (NcoR) complex 1 (N-CoR-1) 
identified by mass spectrometry analysis (Underhill et al., 2000). In fact, NCoR-1 is a 
histone deacetylase and chromatin remodeling repressive complex that contains HDAC3 
and components of SWI/SNF complex: BRG-1, BAF 170, BAF 155 and BAF 47/INI1. KAP1 
has been shown to co-localize with N-CoR in nucleus, however, no role of KAP1 in N-CoR-
1 mediated transcription repression has been reported or the region of KAP1 involved in its 
association with this complex (Underhill et al., 2000). 
Finally, KAP1 has been shown to inhibit c-Myc transcription activation by binding MM-1, a 
c-Myc  co-repressor, and recruiting Sin3 histone deacetylase complex (Satou et al., 2001). 
In this study KAP1 associates with HDAC1 and Sin3A, components of Sin3 complex, 
however, no region of KAP1 has been mapped for the binding with HDAC1 or Sin3A (Satou 
et al., 2001).   
 
3- Involvement of KAP1 in the deacetylation of non-histone proteins  
KAP1 has been also described to tether histone deacetylases (HDACs) to non-histone 
proteins such as p53, E2F1 and STAT3 to induce their deacetylation and consequently 
their inactivation (Tian et al., 2009; Tsuruma et al., 2008; Wang et al., 2005a; Wang et 
al., 2007a). 
p53 was the first non-histone protein known to be regulated by acetylation (Gu and 
Roeder, 1997) and deacetylation (Luo et al., 2000). The p53 is a key component of a 
regulatory circuit that monitors signaling pathways from diverse sources, including DNA 
damage responses, abnormal oncogenic events, and normal cellular processes. The 
acetylation of p53 at several lysines in its DNA binding motif and on its C-terminal domain 
is catalyzed by histone acetyl transferases: p300, CBP/p300 and Tip60 (Ito et al., 2001; 
Tang et al., 2008). In response to DNA damage, the levels of p53 acetylation are 
enhanced which are correlated with an enhancement of its stabilization and activation (Ito 
et al., 2001; Tang et al., 2008). Although mutation of some acetylation sites is 
compensated by the modification of other target lysines, mutation of all acetylated lysines 
abolished completely the ability of p53 to activate p21 and to induce cell growth arrest in 
response to DNA damage (Tang et al., 2008). Phosphorylation of p53 failed to relieve and 
to compensate this inactivation (Tang et al., 2008). The p53 acetylation has been shown  
to increase its DNA binding affinity in vitro (Gu and Roeder, 1997), stabilization (Ito et al., 
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2002; Ito et al., 2001; Luo et al., 2000), transcription activity (Tang et al., 2008) and 
protein-protein interaction by enhancing its association with transcription co-activators 
such as CBP/p300 (Mujtaba et al., 2004) and by blocking its interaction with its repressors 
MDM2 and MDMX (Tang et al., 2008). In unstressed cells, p53 is maintained inactivated 
by MDM2 E3 ubiquitin ligase which binds p53 and induces its deacetylation by recruiting 
HDAC1 (Ito et al., 2002). Most of the deacetylated lysines are ubiquitinated by MDM2 and 
p53 is targeted for degradation (Ito et al., 2002). MDM2 does not bind directly HDAC1 and 
requires cellular factors to recruit HDAC1 to the acetylated p53 (Ito et al., 2002). KAP1 has 
been demonstrated to cooperate with MDM2 in bridging HDAC1 to p53 (Wang et al., 
2005a). KAP1 stimulates p53-HDAC1 complex formation and consequently deacetylation, 
degradation and inactivation of p53 (Wang et al., 2005a).  
KAP1 has been demonstrated to link p53 to DNA damage response through a 
phophorylation process involving the acetylation and deacetylation of p53 (Tian et al., 
2009). This pathway involves p53 binding to APAK, a KRAB zing finger protein, which 
bridges KAP1-HDAC1 complex to the acetylated p53 (Figure 10). This association 
maintains p53 deacetylated and inactivated in the absence of DNA damage. In response to 
DNA damage, ATM phosphorylates APAK and KAP1 causing their dissociations from p53 
and consequently re-acetylation of p53 leading to the transactivation of apoptotic genes 
(bax, noxa and puma).  
 
Figure 10. A model of the regulation of p53 acetylation mediated by KAP1 in the DNA damage response. 
Left panel: In the absence of DNA damage, APAK, a KRAB zinc finger protein, bridges KAP1-HDAC1 complex 
to p53 to maintain p53 deacetylated and inactivated. Right panel: In response to DNA damage, ATM 
phosphorylates APAK and KAP1 causing their dissociations from p53 and thus leading to the re-acetylation of 
p53 which becomes able to transactivate apoptotic genes (bax, noxa and puma) (Tian et al., 2009). 
 
E2F1 is a member of E2F family of transcription factors that play a key role in the 
regulation of expression of genes essential for DNA replication and cell cycle progression 
as well as in the surveillance of genomic integrity (Ren et al., 2002). In addition, E2F1 is 
activated following DNA damage by phosphorylation and acetylation modifications 
(Martinez-Balbas et al., 2000; Marzio et al., 2000; Ren et al., 2002). E2F1 acetylation is 
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mediated by p300/CBP and PCAF histone acetyl transferases and occurs at three specific 
lysines in the N-terminal portion of this factor, adjacent to its DNA binding domain 
(Martinez-Balbas et al., 2000; Marzio et al., 2000). Acetylation stabilizes E2F1 and 
enhances its DNA binding and transcriptional activities in order to up-regulate pro-
apoptotic genes in response to DNA damage (Martinez-Balbas et al., 2000; Marzio et al., 
2000). KAP1 has been reported to contribute to the functional regulation of E2F1 by 
reversing its acetylation state (Wang et al., 2007a). Indeed, it has been shown that KAP1 
binds E2F1 and stimulates E2F1-HDAC1 complex formation leading to its deacetylation and 
inactivation (Wang et al., 2007a). In this study, E2F1 transcriptional activity was inhibited 
by KAP1 full length over-expression in cells, while, a KAP1 deletion mutant lacking PHD 
and BROMO domains was transcriptionally ineffective (Wang et al., 2007a). It has been 
presumed, based on a previous report describing the association of PHD and BROMO 
domains with NuRD histone deacetylase complex (Schultz et al., 2001),  that this deletion 
mutant fails to bind HDAC1 and consequently does not induce the deacetylation of E2F1 
(Wang et al., 2007a).  
 
STAT3 belongs to the  STAT protein family which are latent transcription factors in 
cytoplasm used by most cytokine receptors to rapidly turn on gene expression in the 
nuclei (Darnell, 1997). Following cell stimulation by interleukins or by interferons, STAT3 
becomes phosphorylated by tyrosine kinases and also acetylated by p300 or p300/CBP at 
one lysine residue (K685) (Wang et al., 2005b; Yuan et al., 2005). Acetylation stabilizes 
STAT3 dimers which are the required forms for STAT3 nuclear translocation and for DNA 
binding of target promoters (Wang et al., 2005b; Yuan et al., 2005). STAT3 acetylation is 
reversed by HDAC3 and with lesser extent by HDAC1 and HDAC2 to determine the 
transcriptionally inactive state of the protein in the absence of stimulus (Yuan et al., 
2005). It has been shown in a following study that KAP1 binds selectively the 
phosphorylated STAT3, the  transcriptionally active form, and tethers HDAC3 to induce its 
deacetylation and inactivation (Tsuruma et al., 2008). 
 
4- Involvement of KAP1 in DNA damage response  
KAP1 was demonstrated to be phosphorylated by members of phosphatidylinositol-3 
kinase-like family of kinases, ATM, ATR and DNA-PK, following DNA double strand breaks 
(DSBs) induced by either neocarzinostatin radiometric drug or ionizing radiation (White et 
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al., 2006; Ziv et al., 2006). KAP1 phosphorylation occurs at serine 824 (S824) located at 
its C-terminus domain adjacent to bromodomain (White et al., 2006; Ziv et al., 2006). 
Phosphorylation of KAP1 is an early and transient event in the DNA damage response 
(White et al., 2006; Ziv et al., 2006). Indeed, it has been shown that phosphorylation 
happens five minutes after genotoxic treatment of cells, it is at its maximum thirteen 
minutes and persists up to two hours (White et al., 2006; Ziv et al., 2006). KAP1 
phosphorylation catalyzed by ATM was detected exclusively at the DNA damage sites, 
from which the phosphorylated protein spreads rapidly throughout the nucleus (Ziv et al., 
2006). The displacement of phophorylated KAP1 from DSB sites induces transient 
chromatin relaxation allowing the recruitment of DNA repair machinery (Ziv et al., 2006). 
In fact, two later studies underlined the role of ATM in DNA damage repair within 
heterochromatic regions through the phophorylation of KAP1 which permits an increase in 
nucleosome accessibility for the DNA repair proteins in these regions (Goodarzi et al., 
2008; Goodarzi et al., 2009). Consistently, knockdowns of KAP1, HDAC1 or HP1, the KAP1 
downstream silencing effectors, alleviated the DSB repair defects in ATM knockout cells 
(Goodarzi et al., 2008; Goodarzi et al., 2009).  
Phosphorylation and sumoylation were reported to be antagonizing modifications that 
regulate KAP1 activity in response to genotoxic stress as well as in the control of cell cycle 
arrest and apoptosis (Lee et al., 2007; Li et al., 2007). In unstressed cells, sumoylated 
KAP1 is the transcription active form that establishes repression of genes involved in cell 
cycle arrest and apoptosis such as p21, Gadd45, bax, puma and noxa. Conversely, 
phosphorylated KAP1, activated in response to DNA damage, determines the de-
repression of these genes (Lee et al., 2007; Li et al., 2007).   
 
5- Involvement of KAP1 in retroviral inhibition  
KAP1 (TRIM28) from murine origin was shown to restrict MLV replication by promoting 
gene silencing (Wolf and Goff, 2007). KAP1-mediated MLV restriction occurs in embryonic 
stem cells through KAP1 association with the nuclear repressor complex that binds to the 
retroviral ―repressor binding site‖ (RBS) (Wolf and Goff, 2007). The RBS element 
comprises 17 base pairs that overlap closely with the 18 base pairs of primer binding site 
(PBS) of MLV. The MLV PBS has a sequence complementary to the cellular proline tRNA 
(tRNApro) that primes minus-strand DNA synthesis during reverse transcription (Wolf and 
Goff, 2007). Notably, differentiation of F9 murine embryonic stem cells by retinoic acid 
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leads to the relief of MLV restriction which is correlated with dissociation of nuclear 
repressor complex from RBS and a decrease of KAP1 expression levels (Wolf and Goff, 
2007). KAP1-mediated restriction in embryonic cells is also effective on PBS 
complementary to lysine 1 and 2 tRNA (tRNALys-1,2) found in visna, spuma and Mason-
Pfizer monkey retroviruses (Wolf et al., 2008b). The KAP1 interaction with HP1 is required 
for PBS-dependent restriction of MLV in embryonic cells indicating the relevance of 
heterochromatin formation in this inhibition (Wolf et al., 2008a). KAP1 does not bind 
directly to PBS and a novel KRAB zinc finger protein, ZFP809, was identified as a 
recognition molecule bridging the MLV integrated proviral DNA with KAP1 (Wolf and Goff, 
2009). Expression of ZFP809 is sufficient to render differentiated cells, such as HEK 293T 
cells, resistant to MLV infection, however, this restriction is always mediated by KAP1 
(Wolf and Goff, 2009). Consistently, the expression levels of ZFP809 in MLV non-restrictive 
NIH3T3  cells is lower than embryonic stem cells (Wolf and Goff, 2009). The role of 
ZFP809 was investigated for other viruses showing that ZFP809 potently inhibits 
transcription from DNA constructs of the human T cell lymphotropic virus-1 (HTLV-1) that 
utilizes tRNA (tRNApro) as MLV, however, non effect has been found on transcription of 
HIV-1 that utilizes tRNALys3 (Kleiman, 2002; Wolf and Goff, 2009). Artificial zinc finger 
proteins that contain KRAB domains engineered to bind specifically HIV-1 PBS were able 
to induce transcriptional silencing of an integrated HIV-1 provirus (Eberhardy et al., 2006; 
Pengue et al., 1995). KAP1 has been also shown to silence endogenous retroviruses 
particularly intracisternal A-type particles (IAP) in mouse embryonic stem cells by inducing 
the heterochromatinization of 5‘ un-translated regions (5‘UTR) of various IAPs without 
interfering with their PBS (Rowe et al., 2010). In inducible KAP1 knockout mouse 
embryonic stem cells, IAP repression was relieved and correlated with a decrease in tri-
methyl H3K9 and an increase in H4 acetylation (Rowe et al., 2010). In conclusion 
repression of endogenous or exogenous retroviruses in embryonic stem cells is crucial for 
protecting genome integrity during early embryogenesis which underlies the relevance of 
the cellular role of KAP1.  
  
Acetylation and deacetylation of histone and non-histone proteins 
Acetylation and deacetylation of histone and non-histone proteins is a dynamic process 
controlled by the antagonistic actions of two large families of enzymes: the histone acetyl 
transferases (HAT) and the histone deacetylases (HDACs). The balance between the 
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actions of these enzymes serves as a key regulatory mechanism for gene expression, 
stability and activities of the proteins and also modulates protein-protein, DNA-protein and 
RNA-protein interactions (Glozak et al., 2005; Sadoul et al., 2008; Spange et al., 2009; 
Sterner and Berger, 2000). Moreover, HAT and HDACs regulate cellular functions of the 
proteins by acetylation and deacetylation cycles which in most cases correspond 
respectively to activation and inactivation. Reversible acetylation modulates the activities 
of proteins involved in several cellular processes such as transcription, DNA replication and 
DNA repair (Figure 11) (Yang and Seto, 2007).  
 
Figure 11: Schematic illustration of the prevalence of reversible lysine (K) acetylation in diverse cellular 
processes. The hexagon with the letter A refers to acetylation. For each process, only representative 
proteins are listed. In particular, acetylation of acetyl-CoA synthase is a key regulatory mechanism conserved 
from bacteria to humans. Cdk9, cyclin-dependent kinase 9; FEN1, Flap endonuclease 1; NBS1, Nijmegen 
breakage syndrome protein 1; PCNA, proliferating cell nuclear antigen; PTEN, phosphatase and tensin 
homolog; Rb, retinoblastoma suppressor protein (Yang and Seto, 2007).  
 
1-Acetylation mediated by HATs 
Histone acetyl transferase family proteins (HATs) transfer, through their HAT catalytic 
domain, an acetyl group from acetyl-coenzyme A (acetyl-CoA) to the -amine group of 
specific lysine residues within the histone basic N-tail region (Roth et al., 2001). The 
addition of an acetyl group on lysines neutralizes their positive charges which has an 
impact on the electrostatic proprieties of the proteins. Histone acetylation facilitates the 
access of transcription machinery to DNA by loosening the interactions between both 
adjacent nucleosomes and DNA, as well as by serving as recognition site for the 
recruitment of accessory regulatory factors (Strahl and Allis, 2000). In addition to 
histones, HATs have been described to acetylate cellular and viral proteins mainly involved 
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in transcription such as E2F1, p53, STAT3, MyoD, HIV-1 Tat and adenovirus E1A (Sterner 
and Berger, 2000). HIV-1 integrase is also a substrate for histone acetyl transferases p300 
and GCN5 (Cereseto et al., 2005; Terreni et al., 2010). Moreover, non-histone chromatin 
associated proteins such as HMG I(Y), HMG14 and HMG17 and cytoplasmic proteins like -
tubilin are also substrates for HAT acetylation (Sterner and Berger, 2000). The acetylation 
of the non-histone proteins has been shown to modulate their activities by affecting their 
interactions with other proteins, DNA or RNA and also by altering their cellular localization 
(Glozak et al., 2005; Sadoul et al., 2008; Spange et al., 2009; Sterner and Berger, 2000). 
HATs are evolutionary conserved from yeast to man and are grouped into two general 
classes: nuclear A- and cytoplasmic B-type HATs (Kimura et al., 2005; Roth et al., 2001; 
Sterner and Berger, 2000). Nuclear A-type HATs are further grouped into five families: 
GNAT, MYST, p300/CBP, basal/general transcription factors and nuclear receptor cofactors 
(Kimura et al., 2005; Roth et al., 2001; Sterner and Berger, 2000). The A-type HATs 
acetylate nucleosomal histones within the chromatin and are potently linked to 
transcription by activating transcription factors through acetylation or by acting as co-
activators at the level of gene promoters (Roth et al., 2001; Sterner and Berger, 2000). 
The cytoplasmic B-type HATs acetylate de novo synthesized free histones, promoting their 
nuclear localization and deposition onto newly synthesized DNA (Sterner and Berger, 
2000). Although most HATs are able to acetylate free histones in vitro when assayed as a 
single polypeptide, in cells are usually found in conserved, cooperatively acting high-
molecular-weight complexes such as GCN5/PCAF (human homologue of yeast SAGA 
complex), Tip60, HBO1 and MOZ/MORF complexes that contain several transcription 
regulators and chromatin binding proteins (Grant and Berger, 1999; Lee and Workman, 
2007; Sterner and Berger, 2000). Many HATs such as p300 and CBP/p300 have an 
evolutionarily conserved bromodomain that recognizes specifically acetylated lysines and 
also directs chromatin associated proteins to acetylated histones (Lee and Workman, 
2007; Mujtaba et al., 2007). Notably, p300 seems to have the broadest substrate 
acceptance for histones and non-histone proteins (Kimura et al., 2005).  
Acetylation of numerous transcription factors such as p53, E2F1, STAT3, NFkB, p73 and 
MyoD has been shown to enhance their DNA binding affinity, transcription activities and/or 
stability (Glozak et al., 2005; Spange et al., 2009). For some transcription factors such as 
YY1, HMG-A1 and HMG-N2 acetylation induces their dissociation from DNA or chromatin to 
allow the accessibility of transcription factors for target genes (Glozak et al., 2005; Spange 
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et al., 2009). Notably, acetylation of HIV-1 integrase enhances its DNA binding affinity and 
its catalytic activity (Cereseto et al., 2005; Terreni et al., 2010). Integrase lysines targeted 
for acetylation by p300 and GCN5 (K264, K266 and K273) have been shown important to 
achieve optimal HIV-1 infection specifically at the level of integration (Apolonia et al., 
2007; Cereseto et al., 2005; Terreni et al., 2010). Another HIV-1 viral protein, Tat, is 
modified by acetylation which promotes its transactivation functions. Tat acetylation at 
lysine 50 (K50) by p300 induces its dissociation from TAR RNA during early transcription 
elongation which allows the recruitment of PCAF to the elongating RNA polymerase II 
(Kiernan et al., 1999). Subsequently, PCAF acetylates Tat at lysine 28 (K28) which 
enhances its binding to CDK9 of P-TEFb complex in order to promote transcription 
elongation (Kiernan et al., 1999). Acetylated Tat at lysines K50 and K51 has been shown 
to bind with more affinity p32, a cellular splicing regulator, rather than the unmodified Tat 
(Berro et al., 2006). It has been suggested that this interaction recruits p32 at the LTR 
promoter to inhibit HIV-1 splicing needed for the production of full-length transcripts 
(Berro et al., 2006). Acetylation modulates protein-protein interaction of other several 
proteins. For instance, acetylated lysine 382 (K382) at the C-terminal domain of p53 is 
recognized specifically by CBP/p300 bromodomain (Mujtaba et al., 2004). That recognition 
enhances p53-CBP/p300 association which stimulates p53 transcriptional activity (Mujtaba 
et al., 2004). Similarly, bromodomains of either CBP/p300 or p300 recognize MyoD 
acetylated lysines (K99 and K102) enhancing the binding between these proteins 
(Polesskaya et al., 2001). This interaction serves to recruit CBP/p300 and p300 by MyoD at 
the target promoters to induce histone acetylation and transcription activation (Polesskaya 
et al., 2001). Moreover, acetylation also modulates interactions between proteins that do 
not have bromodomains. Indeed, importin  acetylation enhances its heterodimerization 
with importin  and promotes the nuclear import of cargo proteins implicated in mRNA 
regulation such as HuR (Glozak et al., 2005; Spange et al., 2009). Acetylation of the tumor 
suppressor retinoblastoma (Rb) inhibits its phosphorylation, leading to cell cycle arrest, 
and enhances its interaction with MDM2 ubiquitin ligase (Glozak et al., 2005; Spange et 
al., 2009). Erythroid kruppel like factor (EKLF) acetylation enhances its association with 
SWI/SNF complex resulting in an open chromatin at the -globin gene promoter (Glozak et 
al., 2005; Spange et al., 2009). Acetylation can also induce the dissociation between 
interacting proteins. For example, in unstressed cells, unmodified Ku70 has been shown to 
sequester bax apoptotic protein in cytoplasm (Cohen et al., 2004). In response to 
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apoptosis inducing agent, Ku70 becomes acetylated by p300 allowing the release of bax 
from its sequestration and enabling bax translocation to the mitochondria to initiate 
apoptotic cascade (Cohen et al., 2004). Acetylation of the adenoviral transcriptional 
activator, E1A, by p300 and PCAF was found to disturb its interaction with its co-repressor 
protein CtBP and with importin 3 which obstructs its nuclear import (Das and Kundu, 
2005; Glozak et al., 2005; Spange et al., 2009). 
 
2- Deacetylation mediated by HDACs 
The mechanism of action of histone deacetylase enzymes (HDACs) involves removing of 
the acetyl group from histone and non-histone protein substrates (de Ruijter et al., 2003; 
Yang and Seto, 2007). Hypo-acetylation of histones results in a decrease in the space 
between nucleosomes and the DNA that is wrapped around it (Strahl and Allis, 2000). 
Tighter wrapping of the DNA diminishes accessibility for transcription factors leading to 
transcription repression (Strahl and Allis, 2000). Eighteen mammalian HDACs have been 
identified to date and are grouped into two families: the classical family of Zn2+-dependent 
HDACs that includes class I, II and IV HDACs and the second one consists of the NAD+-
dependent HDACs that includes class III sirtiuns HDACs (Haberland et al., 2009; Spange 
et al., 2009). HADC classes are subdivided based on their homology to yeast HDACs. Class 
I HDACs (HDAC1, 2, 3 and 8) show homology to the yeast protein RPD3, are usually 
detected in the nucleus, and show ubiquitous expression in various mammalian cell lines 
and tissues (de Ruijter et al., 2003; Spange et al., 2009). Class II HDACs (HDAC4, 5, 6, 7, 
9 and 10) have a high degree of homology to the yeast Hda1 protein and can shuttle 
between the nucleus and the cytoplasm (de Ruijter et al., 2003). Class III HDACs are 
homologous to the yeast Sir2 HDACs and HDAC11 is the unique member of the class IV 
HDACs (de Ruijter et al., 2003; Spange et al., 2009). HDACs lack intrinsic DNA binding 
activity and are recruited to target genes via their direct association with transcription 
activators and repressors as well as their incorporation into multi-protein transcription 
complexes (Sengupta and Seto, 2004).  
HDAC1 has a nuclear localization signal (NLS) and is an ubiquitous exclusively nuclear 
protein due to the lack of nuclear export signal (NES) (de Ruijter et al., 2003). HDAC1 
contains 482 amino acid residues in which the deacetylase catalytic domain on its N-
terminus forms the major part of the protein (390 amino acids) (de Ruijter et al., 2003; 
Haberland et al., 2009). HDAC1 is inactive when produced by recombinant techniques and 
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in vitro, displays activity only in the presence of cellular complexes and proteins (de Ruijter 
et al., 2003; Sengupta and Seto, 2004). These complexes consist of proteins necessary for 
modulating its deacetylase activity and its recruitment to target genes or non-histone 
proteins (de Ruijter et al., 2003). Indeed, HDAC1 together with the nearly identical HDAC2 
(82% of sequence identity) are integral components of at least four histone deacetylase 
complexes (Sin3, NuRD, CoREST and NcoR). The Sin3 complex comprises HDAC1, HDAC2, 
RbAp48, RbAp46, mSin3A and Sin3-associated proteins 18 and 30 (SAP18 and SAP30) and 
interacts with DNA binding transcription factors, including MAD, Ikaros, REST and nuclear 
hormone receptors (de Ruijter et al., 2003; Grozinger and Schreiber, 2002). RbAp46 and 
RbAp48 serve for binding histones, SAP18 and SAP30 stabilize protein associations and 
mSin3A acts as scaffold for the assembly of the complex (Grozinger and Schreiber, 2002). 
The nucleosome remodeling and deacetylating (NRD or NuRD) complex includes HDAC1, 
HDAC2, RbAp48, RbAp46, CHD3 (Mi2) and CHD4 (Mi2), MBD3 and MTA2 (de Ruijter et 
al., 2003; Grozinger and Schreiber, 2002). CHD3 and CHD4 possess DNA helicase/ATPase 
domains found in SWI/SNF family of chromatin remodeling proteins (Sengupta and Seto, 
2004). MBD3 and MTA2 are necessary for histone deacetylase stimulation (Zhang et al., 
1999). The NurD complex combines deacetylation by HDAC proteins with ATP-dependent 
nucleosome remodeling to affect transcription (Sengupta and Seto, 2004). HDAC1 and 
HDAC2 are also component of CoREST complex that contain MTA1 and MTA2 and p110. 
MTA1 and MTA2 serve to stimulate catalytic activity of HDAC1 and HDAC2 (de Ruijter et 
al., 2003; Sengupta and Seto, 2004). HDAC1 and HDAC2 are also part of NcoR-2 complex 
that contains NcoR, mSin3A and SAP30 (Underhill et al., 2000). In addition to functioning 
through these complexes HDAC1 can also binds directly to target proteins such as YY-1, 
MyoD or to DNA binding proteins such as Rb-binding protein 1 and Sp1 (de Ruijter et al., 
2003; Sengupta and Seto, 2004). HDAC1 has been shown to be modulated by post-
translational modifications at its C-terminal domain mainly by phosphorylation which 
promotes its enzymatic activity and complex formation (Galasinski et al., 2002; Pflum et 
al., 2001) or by sumoylation which affects its ability to induce transcription repression 
(David et al., 2002).   
The acetylation of p53, E2F1, STAT3, Tat, Ku70, EKLF, YY1 and MyoD is reversed by 
HDACs leading to reversion of the acetylation protein impacts discussed in the previous 
section (Das and Kundu, 2005; Glozak et al., 2005; Spange et al., 2009). HDACs can bind 
their substrates directly or mediated adaptor proteins that bridge HDACs to the target 
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proteins (Das and Kundu, 2005; Glozak et al., 2005; Spange et al., 2009). KAP1 has been 
shown to tether HDACs to non-histone proteins and to stimulate their deacetylation and 

































 MATERIALS AND METHODS 
 
1- Vectors and constructs 
pASK-IN-HATw and pASK-IN-HATm to express and purify IN-HATw and IN-HATm in 
bacteria were constructed by cloning integrase codon optimized (IN-CO) in frame with the 
HAT domain of p300  (a.a. 1195-1673) wild-type or mutated (D1395Y) in the pASK-IBA37 
plus vector (IBA GmbH) containing at 5‘ of the MCS a 6xHis tag. During the cloning 
procedure a 3‘ HA tag and a Tobacco Etch Virus (TEV) protease cleavage site between IN 
and HAT were introduced by PCR. From the pASK-IBA37-IN-HATw/m vectors the IN-
HATw/m, HATw/m and IN were PCR amplified and cloned in frame with the Gal4 DNA 
Binding Domain (GBD) in the pBD-Gal4 vector (Stratagene) for expression in yeast cells. 
HATw-HA was cloned in pASK-IBA37 plus vector by PCR starting from pASK-IBA37-IN-
HATw. BTF3b, THRAP3, HMGN2, Exp2, RanBP9, eIF3h and KAP1 cDNAs were cloned by 
PCR in pFlag-CMV2 vectors starting from their truncated cDNAs isolated in the two-hybrid 
screening (RESULTS, Table 1). 6xHis-IN, GST-IN and GST-IN truncated domains (IN-Nt, 
IN-Cat and IN-Ct) have been previously described (Cereseto et al., 2005). pFlag-IN-CO 
was kindly provided by Alan Engelman (Dana-Farber Cancer Institute, Boston, MA). 
pcDNA3.1-HA expressing IN-CO was obtained by PCR cloning starting from the pFlag IN-
CO. pFlag-IN-CO containing K264,266,273R mutations was constructed using recombinant 
PCR starting from the pFlag-IN-CO vector. Untagged INw and INm were cloned by PCR in 
pCDNA3.0 vector starting from their respective pFlag IN-CO constructs. Full-length KAP1 
cDNA, in pOTB7 non expression vector, was purchased from Open Biosystems and cloned 
by PCR in pcDNA3.0, pcDNA3-HA and pFlag-CMV2 vectors. HA-KAP1 full length was cloned 
by PCR in pAIP lentiviral vector which was kindly provided by Jeremy Luban (Geneve 
University, Switzerland). KAP1 and KAP1 deletion mutants (1-381, 1-616 and 617-835) 
cDNAs were cloned by PCR in pCDNA3.1-HA. HA tagged KAP1 and deletion mutants 
cDNAs were cloned by PCR in pAIP lentiviral vector. HA-KAP1 (S824A) and HA-KAP1 
(S824D) were cloned in pAIP by PCR starting from constructs obtained from Yossi Shiloh 
(Tel Aviv University, Ramat Aviv, Israel). pFlag-HDAC1 and pFlag-HDAC3 have been 
previously described (Sabo et al., 2008). pFlag-Luciferase (Flag-Luc) was purchased from 
Stratagene. pNL4.3.Luc.R-E- and pD64E were obtained from the NIH AIDS Research and 
Reference Reagent Program. pNL4.3-Luc-3mut (K264,266,273R) was previously described 
(Terreni et al., 2010). pGIPZ-shMM was obtained by cloning in pGIPZ lentiviral vector 
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(Open Biosystems) pre-synthesized oligonucleotides containing four mismatched 
mutations inside sh-1-KAP1. Lentiviral packaging plasmid p8.91, MLV transfer gene pLNC-
CMV-eGFPT2A-fLuc and MLV packaging plasmid pCMVintronMLVgag-pol were kind of gifts 
from Zeger Debyser and Jan De Rijck (KU Leuven University, Belgium). 
 
2- Yeast assays 
 
2.1- Immunoprecipitations from yeast cells  
AH109 yeast cells were transformed with pBD-Gal4-IN-HATw-HA, pBD-Gal4-IN-HATm-HA 
or pBD-Gal4 vector according to LiAc/ssDNA/PEG protocol described by (Gietz et al., 
1995). For expression, one transformed colony was inoculated in 200 ml (-Trp) selective 
medium for 48 hours at 30°C. Yeast cells were then harvested and resuspend in 500 μl of 
lysis buffer (300 mM sorbitol, 10 mM Tris HCl pH 7.4, 500 mM NaCl, 5 mM MgCl2 and 5 
mM EDTA) provided before use with 1mM PMSF and complete,mini,EDTA-free protease 
inhibitor cocktail tablets (Roche). Next, 1 g of glass beads, acid washed (425-600 μM 
diameter) (Sigma) was added to the lysates that were vortexed four times for 1 min each 
and 1 min of break chilled on ice. Lysed yeasts were then clarified at 4°C for 5 min at 
maximum, and 1% of Triton X-100 was added to the collected supernatant. After 
vortexing for 30 s, lysates were re-clarified at 4°C for 15 min at maximum. For 
immunoprecipitation, 200 μg of total yeast protein extracts were incubated with 0.8 μg of 
Rat anti-HA monoclonal antibodies (Clone 3F10) (Roche) for 2 hours at 4°C on rotating 
wheel and then 30 μl of protein G immobilized on trisacryl beads (Pierce) were added for 
additional 2 hours. Beads were then washed three times, for 10 min each, with 1 ml 
binding buffer (50mM Tris-HCl pH 7.4, 250 mM NaCl, 50 mM NaF and 0.1% NP-40). 
Immunoprecipitates were eluted by boiling beads in 15 μl of Leammli buffer (2% SDS, 
10% glycerol, 5% Beta 2-mercaptoethanol, 0.002% bromophenol blue, 0.0625 M Tris HCl 
pH 6.8) for 10 min at 100°C and analyzed by Western blot. 
 
2.2- Yeast two hybrid screen  
In order to identify cellular factors interacting with constitutively acetylated HIV-1 
integrase, we used GBD-IN-HATw-HA as ―bait‖ in yeast two hybrid screen of human 
lymphocytes cDNA library (BD biosciences Clontech) expressed as Gal4 Activating Domain 
(GAD) fusion in pACT yeast expression vector. Amplification and purification of the cDNA 
69 
 
library were performed following manufacturer‘s instructions. The two hybrid screen was 
performed in AH109 yeast strain (James et al., 1996) which has as reporter genes ADE2, 
HIS3 and MEL1 under the control of distinct Gal4 upstream activating sequences (UASs) 
and TATA boxes. Library transformation and screening with GBD-IN-HATw-HA bait were 
performed following the protocols described in Matchmaker GAL4 two hybrid system 3 and 
libraries user manual of Clontech (http://www.clontech.com/images/pt/PT3247-1.pdf). 
The GAD prey cDNAs (Results, Table 1) and GBD and HA hybrid cDNAs: IN-HATw, IN-
HATm, IN, HATw, HATm were co-transformed in AH109 yeast cells to check the 
specificities of interactions. The co-transformants were let to grow either in the two hybrid 
selective medium (-Trp, -Leu, -Ade and -His) or in the transformation selective medium (-
Trp, -Leu) for at least 5 days at 30°C. Co-transformants of GAD-KAP1 with the GBD and 
HA hybrids cDNAs were streaked in -Trp, -Leu medium and then transferred on the 
nitrocellulose filters for the X-alpha-gal lift assay. Streaked colonies immobilized on the 
nitrocellulose filters were lysed by freezing them in liquid nitrogen and thawing at room 
temperature three times. The filters carrying lysed yeast were then deposed upon 
wattman paper pre-soaked in petri dish with 5 ml of X-alpha-gal solution containing 84 μl 
X-alpha-gal stock solution (20mg/ml) (Clontech) and 5 ml of Z buffer (60 mM 
Na2HPO4.7H2O, 40 mM NaH2.PO4.H2O, 10 mM KCl, 1 mM MgSO4, 50 mM Beta 2-
mercaptoethanol, the final pH was adjusted to 7). The filters were incubated at 30°C for a 
maximum of 8 hours. 
 
3- Recombinant IN-HATw, IN-HATm and HATw purifications and TEV digestion 
pASK-IN-HATw/m and pASK-HATw encoding for 6xHis-IN-TEV-HATw/m and HATw were 
transformed in E. coli Arctic Express RIL competent cells (Stratagene) and induction of 
protein expression was performed using 43 mM anhydrotetracycline hydrochloride (AHT) 
for  24 hours at 13 °C.  Bacteria culture was lysed in binding buffer (1M NaCl, 20 mM Tris 
HCl pH 7.9 and 0.5% Triton X-100) containing 1mM PMSF and protease inhibitor cocktail  
(Roche). TALON Metal Affinity Resin (BD Biosciences) incubated for 2 hours at 4°C was 
used to recover the 6xHis-IN-HATw/m proteins. Following two washes in binding buffer 
containing 5 mM imidazole, proteins were eluted using binding buffer containing 200 mM 
imidazole and dialyzed in buffer containing 150 mM NaCl, 50 mM Tris HCl pH 8, 10% 
glycerol and 0.5 mM EDTA.  For TEV digestion 20 μg of 6xHis-IN-HATw/m purified 
proteins were incubated with 30 units of AcTEV protease (Invitrogen) in 120 mM NaCl, 50 
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mM Tris-HCl pH 8, 0.5 mM EDTA and 1 mM of DTT in 250 μl total volume. To recover 
6xHis-IN from the digested product the TEV treated samples were adjusted to 1 M NaCl 
and incubated with Ni-NTA agarose resin (Qiagen) for 2 hours at 4°C. Following washes in 
binding buffer containing 5 mM imidazole, 6xHis-IN was eluted using the binding buffer 
containing 250 mM imidazole and dialyzed in 1 M NaCl, 20 mM Tris-HCl pH 7.5, 1 mM DTT 
and 10% glycerol. 
 
4- In vitro binding assays  
In vitro translated 35S-Met-KAP1 was produced using TNT T7 Reticulocyte Lysate System 
(Promega) and using as a template pcDNA3-KAP1. GST-IN and its truncated domains (N-
terminus (Nt), Core (Cat) and C-terminus (Ct)) were prepared as already described 
(Cereseto et al., 2005). For binding assays, 2 μg of recombinant purified GST proteins 
immobilized on S-glutathione beads were treated for 1 hour in rotating wheel at room 
temperature with DNase I (0.02U/μl) and RNase H (0,02 U/μl), to remove contaminant 
bacterial nucleic acids, in 1 ml buffer containing 50 mM Tris-HCl pH 8, 5 mM MgCl2, 25 mM 
CaCl2, 5% glycerol and 1 mM DTT. GST treated proteins were then mixed with 1000 c.p.m 
of 35S-Met-KAP1 in 50 l total volume in NETN buffer (20 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM DTT and 1 mM PMSF) which is supplemented with 
0.1 mg/ml ethidium bromide to inhibit aspecific interactions between residual DNA and 
proteins. Binding reactions were incubated 1 hour in the shaker at 4 °C, and then bound 
complexes were washed 5 times with 300 l of NETN buffer containing ethidium bromide 
(0.1 mg/ml) and resolved by SDS-PAGE electrophoresis. Radioactive proteins were 
visualized by phosphoimaging (Cyclone).  
For In vitro binding between IN-HATw/m and 35S-Met-KAP1, 100 ng of either 6x-His-IN-
HATw-HA or 6xHis-IN-HATm-HA purified proteins, pre-treated with DNase I and RNase H, 
as described above, were incubated with 1000 c.p.m of 35S-Met-KAP1, 20 μg of BSA and 
15 μl of Ni-NTA agarose beads (settled beads volume) in 1000 μl of pull down buffer (150 
mM NaCl , 2 mM MgCl2, 25 mM imidazole, 0.1 % NP-40, 25 mM imidazole and 50 mM Tris-
HCl  pH 7.4) for 5 hours at 4 °C on rotating wheel. The beads were then washed trice with 
1 ml pull down buffer for 10 min each. Finally beads were boiled in 20 μl Leammli buffer. 
Eluted proteins were separated by SDS-PAGE electrophoresis and radioactive 35S-Met-
KAP1 was detected by phosphoimaging (Cyclone).   
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5- Cell lines and purification of primary blood lymphocytes (PBLs), Naïve 
(CD45RA+) and Memory (CD45RO+) CD4+ T cells 
HEK293T and HeLa cells were maintained in standard growth medium: Dulbecco‘s 
Modified Eagle‘s Medium (DMEM) low glucose (Euroclone), supplemented with 10% Fetal 
Bovine Serum (FBS), 100 U/ml Penicillin and 100 μg/ml Streptomycin. CEMss T cells were 
maintained in RPMI medium supplemented with Glutamax (GIBCO) and with 10% FBS and 
100 U/ml Penicillin and 100 μg/ml Streptomycin.  
Primary blood lymphocytes (PBLs) were isolated from buffy coats of healthy donors using 
Ficoll Histopaque gradient (Sigma). 25 ml of buffy coat, pre-diluted twice in RPMI medium, 
were overlayed on 12.5 ml Ficoll solution in 50 ml Falcon tubes. The gradient was 
obtained by centrifugation at 950 g with the break off for 15 min. Primary blood monocyte 
cells (PBMCs) were collected with Pasteur pipette at the interface between Ficoll and 
plasma-medium layers. PBMCs were washed twice with the RPMI medium, stained with 
trypan blue solution and counted. 200x106 PBMCs were resuspend in 3 ml RPMI medium, 
overlayed onto 10 ml of hyper-osmotic percoll solution (48.5 % Percoll (Sigma) and 160 
mM NaCl) and centrifuged for 15 min at 580 g with break off. Monocytes fraction at the 
interface was discarded and the pellet of lymphocytes was washed with RPMI medium. 
PBLs were stimulated for 24 hours with 2 g/ml of phytohaemagglutinin (PHA-P) (Sigma) 
and then PBLs were washed and maintained in complete RPMI medium supplemented 
with 25 U/ml of human interleukin-2 (hIL-2) (Roche). The medium was replaced every two 
days and activated PBLs were cultured for 5 to 6 days before nucleofection with siRNAs.  
Resting CD4+ T cells were isolated from purified PBLs by negative selection using CD4+ T 
cells isolation kit (Miltenyi Biotec). Naïve (CD45RA+) and Memory (CD45RO+) T cells were 
isolated from the CD4+ population using respectively CD45RA and CD45RO antibodies 
immobilized on microbeads (Miltenyi Biotec) and then were lysed in NEHN buffer (300 mM 
NaCl, 50 mM Hepes pH 7.5, 0.5% NP-40, 20% glycerol and 1 mM EDTA) and analyzed by 
Western bolt.  
All cell types were cultured at 37°C with 5% CO2 in an humidified atmosphere. 
 
6- Anti-Flag beads pull down assays  
HEK293T cells expressing Flag-proteins (KAP1, BTF3b, THRAP3, HMGN2, Exp2, eIF3h and 
Flag-Luc) were lysed in 50 mM Hepes pH 7.4, 150 mM NaCl and 0.5% NP-40 provided 
with 1 mM PMSF and protease inhibitor cocktail tablets. 250 μg lysate was mixed with 250 
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ng of recombinant proteins (6xHis-IN-HATw-HA, 6xHis-IN-HATm-HA, 6xHis-HATwt-HA, 
6xHis-IN or 6xHis-IN TEV digested from IN-HATw/m: IN-Ac+/-) together with 5 μM of Lys-
CoA (synthesized at the ICGEB Peptide Synthesis Core Faculty, Trieste, Italy) in 500 μl 
total volume with lysis buffer. Following 1 hour incubation at 4 °C, 20 μl of monoclonal 
anti-Flag M2 antibodies immobilized on agarose beads (Sigma) were added and incubated 
for 1 hour. Following three washes in 1 ml lysis buffer, 10 min each, samples were eluted 
in 15 μl of Leammli buffer analyzed by Western blot using polyclonal anti-HA (Santa Cruz) 
or monoclonal anti-IN (Santa Cruz) and polyclonal anti-Flag (Sigma) antibodies.  
 
7- Co-mmunoprecipitation experiments  
HEK293T cells were transfected with different constructs using standard calcium 
phosphate (CaPO4) co-precipitation procedure or with polyethylenimine (PEI) (Sigma) or 
polyfect (Qiagen) transfectant reagents. HeLa cells were transfected exclusively with 
polyfect reagent.  
The expression time for the majority of constructs was 36 hours. When Flag-tagged or 
untagged INw and INm were expressed for co-immunoprecipitations with endogenous 
KAP1, cells were harvested 24 hours post-transfection and pre-treated for 8 hours with 1 
μM Trichostatin A (TSA) (Sigma). Induction of endogenous phosphorylated KAP1 was 
performed by treating cells, half hour prior harvest, with 200 ng/ml neocarzinostatin 
(Sigma), while ATM inhibitors (KU55933) were used at 20 M for 2 hours. For the co-
immunoprecipitation between Flag-IN and KAP1 phosphomutants (S824A and S824D), 
1,5x106 HEK293T cells were transduced simultaneously with 45 g p24 of LKO.1-sh-
3‘KAP1 and 30g p24 AIP-HA-S824A or AIP-HA-S824D. Cells were transfected with pFlag-
IN at 48 hours post-transduction and harvested at 72 hours post-transduction.   
Following construct expressions of Flag-tagged proteins (INw, INm, HDAC1 or HDAC3) 
alone or with HA-IN, CMV-INw or CMV-KAP1, HEK293T cells or HeLa transfected cells 
were harvested and lysed in NEHN buffer containing 300 mM NaCl, 50 mM Hepes pH 7.5, 
0.5% NP-40, 20% glycerol and 1 mM EDTA and provided with 1 mM PMSF, 1 mM Na3VO4, 
20 mM NaF and protease inhibitor cocktail tablets. Then 500 to 2000 μg of lysates 
expressing Flag-proteins were incubated with 30 μl Anti-Flag M2 agarose beads (Sigma) in 
1 ml total volume, for 8 hours at 4°C on rotating wheel. Beads immobilizing 
immunoprecipitates were washed five times with 1 ml NEHN buffer for 10 min each at 4°C 
and one last washing with 1 ml NEHN buffer containing 600 mM instead of 300 mM. The 
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anti-Flag beads were resuspend in 15 μl Leammli buffer and boiled for 10 min at 100°C. 
Eluted immuno-complexes were analyzed by Western blot.  
HEK239T cells expressing untagged INw or INm were lysed in NEHN buffer and 2000 g 
of lysates were incubated for 8 hours at 4°C with 2.5 g of polyclonal anti-KAP1 antibodies 
(Bethyl) in 1 ml total volume. 30 l protein A immobilized on trisacryl beads were added 
for additional 4 hours incubation. Beads bound immuno-complexes were washed three 
times with 1 ml NEHN buffer at 4 °C, 10 min each, and then boiled in 15 μl Leammli 
buffer. Eluted immunoprecipitates were analyzed by Western blot.  
Cells co-expressing Flag-HDAC1 or Flag-Luc with either HA-KAP1 or HA-KAP1 deletion 
mutants (1-381, 1-616 and 617-835) in HEK239T cells were lysed in RIPA buffer (1% 
deoxycholic acid, 0.1 % SDS, 150 mM NaCl and 50 mM Tris HCl pH 7.5). 500 g lysates 
were incubated with 20 l anti-Flag M2 agarose beads for 5 hours at 4°C in 1 ml total 
volume. Beads bound immuno-complexes were washed three times with 1 ml RIPA buffer, 
10 min each, and then boiled in 15 μl Leammli buffer at 100°C for 10 min. Eluted 
immunoprecipitates were analyzed by Western blot. 
 
8- Western blot analysis and antibodies  
Whole cell extracts and immunoprecipitates were separated by 10% or 8% sodium 
dodecyl sulfate polyacrilamide gel electrophoresis (SDS-PAGE) and electro-blotted onto 
nitrocellulose membranes Hybond-C-Extra (Amersham Biosciences). Membranes were 
blocked with 5% skimmed milk powder in TBS containing 0.1% Tween 20, and detection 
was carried out using specific primary antibodies. Primary antibodies for Western blot 
analyses were: monoclonal HIV-1 IN antibody (8G4) (NIH AIDS Research and Reference 
Reagent Program), polyclonal anti-HA (Y-11) (Santa Cruz Biotechnology), polyclonal anti-
HDAC1 (Upstate). Antibodies anti-acetylated IN were previously described (Terreni et al., 
2010). Polyclonal anti-KAP1 recognizing the N-terminal domain of KAP1 and polyclonal 
anti-phospho-KAP1 (KAP1) recognizing phosphorylated serine 824 were purchased from 
Bethyl. Polyclonal anti-Flag, monoclonal anti-Flag M2 (Clone M2), monoclonal anti-Tubulin 
(CloneB-5-1-2) were all purchased from Sigma. Secondary antibodies HRP-conjugated 
anti-mouse or anti-rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. 





9- In vitro HDAC assay 
Quantification of HDAC activity of Flag and Flag-IN immunoprecipitates (2 mg lystaes 
each) was measured using HDAC Fluorometric Activity Assay kit (Upstate) following 
manufacturer‘s instructions. The HDAC Activity assays were measured with an excitation 
and emission wavelength set to 355 and 460, respectively.  
 
10- Virus and vector productions  
NL4.3-Luc, D64E, NL4.3-Luc-3mut HIV-1 viruses pseudotyped with the Vesicular Stomatitis 
Virus-G (VSV-G) envelope were produced by transfecting 5x106 HEK293T cells (in 100-mm 
diameter culture dish) with 20 g pNL4.3.Luc.R-E-, pD64E or pNL4.3-Luc-3mut 
respectively together with 5 g p-MDG-VSV-G using 150 nM polyethylenimine (PEI) 
reagent (Sigma). Lentiviral vectors GIPZ, AIP or LKO.1 empty or encoding for KAP1 
shRNAs (GIPZ-sh-1-KAP1, GIPZ-shMM, LKO.1-sh-5-KAP1, LKO.1-sh3‘KAP1) or cDNAs (AIP-
HA-KAP1, AIP-HA-(1-381), AIP-HA-(1-616), AIP-HA-(617-835), AIP-HA-S824A, AIP-HA-
S824D) were produced by transfecting 5x106 HEK293T cells (in 100-mm diameter culture 
dish) with 20 g lentiviral transfer gene, 10 g lentiviral packaging plasmid (p8.91) and 5 
g p-MDG-VSV-G using 180 nM PEI. Transfections of lentiviral viruses and vectors were 
performed in 5 ml OPTIMEM supplemented with Glutamax (GIBCO) and antibiotic free 
medium, while viral productions were obtained by replacing transfection medium 24 hours 
post-transfection with 10 ml OPTIMEM medium containing antibiotics (100 U/ml Penicillin 
and 100 μg/ml Streptomycin). Viral supernatants were collected 72 hours post-
transfection, quantified for their HIV-1 p24 antigen content using Innotest HIV Antigen 
mAb kit (INNOGENETICS).  
The MLV production conditions were identical to those of lentiviral vectors. It has been 
used 20 g MLV transfer gene pLNC-CMV-eGFP-T2A-fLuc, 10 g MLV packaging plasmid 
pCMVintronMLVgag-pol and 5 g p-MDG-VSV-G for the transfection of 5x106 HEK239T 
cells with 180 nM PEI in 100-mm dish. The quantification of MLV transduction units (TU) 
was performed by serial infections of HeLa cells and detection of GFP positive cells at 48 
hours post-infection using the Fluorescence-activating cell sorter (FACS).  
 
11- Transient and stable knockdowns and back-complementation experiments  
Transient knockdowns mediated by siRNAs were performed using si-Genome smart pool 
siRNAs pre-designed by Dharmacon. 1x105 HeLa cells were treated with 200 nM KAP1 
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siRNAs or 150 nM HDAC1 siRNAs  and equivalent amounts of control siRNAs (ON-TARGET 
plus Non-targeting Pool) using the Gene Silencer siRNA transfection reagent (Gene 
Therapy System). 3x105 HEK293T cells were transfected with 100 nM HDAC1 siRNAs using 
Gene Silencer reagents. Five to six days activated PBLs (5x106) were transfected with 600 
nM KAP1 siRNAs or control siRNAs by electroporation  using the nucleofector II Amaxa 
biosystems instrument (Lonza), program number T23, in 100 l T-cell Nucleofector 
solution (Lonza). The KAP1 pool contains the following four siRNAs: 1) 5‘-
GACCAAACCUGUGCUUAUG-3‘; 2) 5‘-GAUGAUCCCUACUCAAGUG-3‘; 3) 5‘-
GCGAUCUGGUUAUGUGCAA-3‘; 4) 5‘- AGAAUUAUUUCAUGCGUGA-3‘. The HDAC1 pool 
contains the following four siRNAs: 1) 5‘-CUAAUGAGCUUCCAUACAA-3‘; 2) 5‘-
GAAAGUCUGUUACUACUAC-3‘; 3) 5‘-GGACAUCGCUGUGAAUUGG-3‘; 4) 5‘-
CCGGUCAUGUCCAAAGUAA-3‘.  
CEMss cells were transiently knocked down by transducing a pool of 5 LKO.1 lentiviral 
vectors each expressing a shRNAmir against the KAP1 gene (sh-5-KAP1) (Open 
Biosystem): 1) 5‘-CCTGGCTCTGTTCTCTGTCCT-3‘ (sh-3‘KAP1); 2) 5‘-
GAGAATTATTTCATGCGTGAT-3‘; 3) 5‘-GAGGACTACAACCTTATTGTT-3‘; 4) 5‘-
CTGAGACCAAACCTGTGCTTA-3‘; 5) 5‘-GACCACCAGTACCAGTTCTTA-3‘. CEMss cells (1x105) 
were transduced for 2 hours by spinoculation at 1200 g using 400 ng p24 from each 
LKO.1-shRNA (a total of 2 g p24). Control cells were transduced with 2 g p24 GIPZ 
lentiviral vector.   
For back-complementation experiments, 1x105 HeLa, CEMss or HEK239T cells were 
transiently knocked down by transducing 3 g p24 of LKO.1-sh3‘KAP1 (5‘-
CCTGGCTCTGTTCTCTGTCCT-3‘) targeting the 3‘ untranslated region (3‘UTR) of KAP1 
gene and HA-KAP1, HA-(1-381), HA-(1-616), HA-(617-835), HA-S824A, HA-S824D), 
containing only KAP1 coding region, were expressed using 2 g p24 AIP-HA-KAP1,AIP-HA-
KAP1, AIP-HA-(1-381), AIP-HA-(1-616), AIP-HA-(617-835) and 4 g p24 AIP-HA-S824A 
and AIP-HA-S824D. Control cells were transduced with 5 g p24 of GIPZ or AIP lentiviral 
vectors. The above described LKO.1, AIP and GIPZ lentiviral vectors were transduced 
simultaneously for 2 hours by spinoculation at 1200 g.   
Stable KAP1 knockdown cells were obtained by expressing a shRNAmir (sh-1-KAP1: 5‘-
CCACTGAGGACTACAACCTTA-3‘) (Open Biosystem) through a lentiviral vector system 
(GIPZ-sh-1-KAP1). As control a mismatch oligonucleotide (sh-MM: 5‘-
CCACTGAGCTGAACAACCTTA-3‘) containing four mutations in sh-1-KAP1 sequence was 
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expressed through the GIPZ lentiviral vector (GIPZ-shMM). 5x104 HEK293T or HeLa cells 
were seeded in 10-cm diameter dish and transduced by 500 ng p24 of lentiviral vector in 
10 ml total volume. After 24 hours incubation, the supernatant was removed and replaced 
by 10 ml DMEM medium. 48 hours post transduction, 10 ml DMEM medium supplemented 
with puromycin (2 μg/ml) were added. After 10 days of selection, changing fresh selection 
medium every 2 days, single colonies were picked and expanded to form monoclonal 
clones. Pools were formed by mixing at least 10 single colonies. The control cells were a 
pool of transduced cells with GIPZ-shMM. Expanded pools and monoclonal clones cells 
were maintained in DMEM medium containing 10 μg /ml puromycin.  
Transient and stable knockdowns were controlled by Western blot analysis performed from 
the same cell populations used for infections.  
  
12- Cell infections and measurement of HIV-1 infectivity  
NL4.3-Luc, D64E and NL4.3-Luc-3mut HIV-1 viruses pseudotyped with VSV-G envelope 
and quantified for p24 antigen levels, were treated with 80 U/ml of DNAse I (Applied 
Biosystems) for 1 hour at 37°C prior to infections. Infections were performed for 2 hours 
at 37°C in 0.5 to 1ml total volume in well plates or in Flacons.  
For the transiently knocked down cells the following infection conditions were used: 100 
ng p24 for 6x105 HeLa cells 48 hours after siRNA transfection; 250 ng p24 for 5x105 
CEMss cells 60 hours post-transduction with KAP1 LKO.1-shRNAs lentiviral vectors; 500 ng 
p24 for 2x105 of activated PBLs 24 hours after siRNA transfection.  
For back-complementation experiments, 5x105 HeLa, HEK239T or CEMss cells were 
infected 60 hours post LKO.1-sh3‘KAP1 and AIP-HA-KAP1, AIP-HA-(1-381), AIP-HA-(1-
616), AIP-HA-(617-835), AIP-HA-S824A or AIP-HA-S824D transductions using 250 ng p24.  
Infections of stable KAP1 knockdown HeLa clones cells (3x105) were performed using 300-
1200 ng p24. KAP1 stable knockdown HEK293T clones and pools cells (2.5x105) were 
infected using 25 ng p24.  
Infections of HEK293T cells transfected 24 hours in advance with pCDNA3-KAP1, 
pCDNA3HA-KAP1, pCDNA3HA-(1-381), pCDNA3HA-(1-616) or pCDNA3HA-(617-835) (6.25 
g of DNA for 1.2x106 cells with PEI) were performed using 125 ng p24 for 2.5x105 cells. 
Same conditions were used for HEK239T transfected 48 hours prior infections with HDAC1 
siRNAs and 24 hours prior infection with pcDNA3-KAP1.  
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5x105 HeLa cells were treated with 800 nM trichostatin A (TSA) (Sigma) or with equal 
volume of DMSO (Sigma) for 2 hours previous infection, during 2 hours infection (200 ng 
p24) and till 24 hours post-infection.   
Infectivity of NL4.3-Luc, D64E and NL4.3-Luc-3mut HIV-1 viruses was measured 48 hours 
post infection by luciferase activity quantification using the Luciferase Assay System Kit 
(Promega) and normalized to total protein concentrations.  
HeLa cells (2x105) were infected with MLV at 48 hours post siRNAs transfection at a MOI 
0.1 based on the transduction units obtained by FACS. 
3x105 HEK293T or CEMss cells were infected with 60 g p24 NL4.3-Luc and harvest at 
different time points post infection (1, 2, 3 and 4 hours) and were then lyzed in NEHN 
buffer supplemented with 1 mM Na3VO4 and 20 mM NaF phosphatase inhibitors to be 
analyzed by Western blot for phophorylated KAP1. Cells were treated 2 hours prior 
infections with 20 M ATM inhibitors KU-55933.  
 
13- Quantifications of retroviral cDNA species by real time quantitative PCR (Q-
PCR) and their statistical analysis 
Genomic DNA extraction from HeLa, HEK293T, CEMss and PBLs cells was performed using 
DNeasy Blood and Tissue DNA purification Kit (Qiagen). Amplification reactions were 
performed with the Light cycler 480 instrument (Roche Diagnostics). HIV-1 late reverse 
transcripts were analyzed using primers and PCR conditions previously described (Butler et 
al., 2001). Integrated HIV-1 copies by Alu-PCR and 2 LTRs circles were analyzed by Q-PCR 
following protocols previously described (Brussel and Sonigo, 2003).  
HIV-1 total and integrated DNA quantifications in cells carrying GIP-Z, LKO.1 and AIP 
lentiviral DNAs were performed by using primers and probes specific for the luciferase 
gene in NL4.3-Luc or NL4.3-Luc-3mut 24 hours and 15 days post infection respectively to 
avoid cross reactivity between LTRs. Quantifications of MLV total and integrated viral DNA 
at 24 hours and 15 days post infection respectively were also performed using primers and 
probes specific to the luciferase gene in LNC-CMV-eGFP-T2A-fLuc MLV viral vector.  
Primers and probes specific for the luciferase gene and PCR conditions were previously 
described (Terreni et al., 2010). Briefly, primers and probe sequences are as follows: 
forward primer, LucFw: 5-GAAGAGATACGCCCTGGTTCC-3; reverse primer, LucRev: 5-
TGTGATTTGTATTCAGCCCATATCG-3; and probe, LucProbe: 5-FAM-
TTCATAGCTTCTGCCAACCGAACGGACA-3-BlackBerry Quencher. Reaction mixtures 
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contained 500-1500 ng of total genomic DNA, 1x Light Cycler 480 Probe Master (Roche 
Diagnostics), 300 nM each forward and reverse primers and 200 nM probe in a total 
volume of 20 l. After incubations at 50°C for 2 min and 95°C for 10 min, 40 cycles of 
amplification were carried out at 15 s at 95 °C followed by 1 min at 60 °C. A kinetic PCR 
assay for human beta-globin DNA was also carried out as endogenous control of analyzed 
samples. The primers and probes used have been previously described (Tan et al., 2006). 
Reaction mixture contained 100-1500 ng DNA template, 1x Light Cycler 480 Probe Master 
(Roche Diagnostics), 300 nM each forward (BGF) and reverse (BGR) primers and 100 nM  
probe (BGX-P ) in a total volume of 20l. After an initial denaturation step (95°C for 10 
min), the cycling profile was 45 cycles consisting of 95°C for 10 s and 65°C for 10 s. 
Statistical analyses of HIV-1 late reverse transcripts, 2-LTR circles and integrated DNA 
were performed using two-tailed Student's t-tests assuming equal variance between 
samples to determine differences at the 5% level of significance. 
 
14- HIV-1 LTR transcription assays in KAP1 knockdown HeLa and J-lat A1 cells 
HeLa KAP1 knockdown and control cells (4x105) were transfected with 200 ng 
pNL4.3.Luc.R-E- and 200 ng CMV-Renella (for normalization of transfection efficiencies) 
using polyfect (Qiagen). Luciferase activities were measured 48 hours post transfection 
using the DualGlo Luciferase assay Kit (Promega). J-lat A1 cells (Jordan et al., 2003) 
(1x105) untreated or TPA treated (10 nM TPA (Sigma), for 24 hours) were transduced with 
2 g p24 of LKO.1-sh-5-KAP1 lentiviral vectors (as described above for CEMss cells) or AIP 
lentiviral vector as control. Western blot analysis and percentage of GFP positive cells 















1- Production of constitutive acetylated integrase fused to the HAT domain of 
p300  
We have recently demonstrated that p300, a histone acetyltransferase, binds integrase 
and acetylates three lysines (K264, K266, K273) located in its C-terminus leading to 
enhanced enzymatic activity and DNA binding (Cereseto et al., 2005). Acetylable lysines 
are necessary for virus integration and thus for optimal replication, as demonstrated by 
the inefficient infectivity observed following their mutations into arginine residues (K264, 
266, 273R) (Apolonia et al., 2007; Cereseto et al., 2005; Terreni et al., 2010). Since it has 
been demonstrated that acetylation modulates the activities of cellular and viral proteins 
by affecting protein-protein interactions (Bannister et al., 2000; Berro et al., 2006; Bres et 
al., 2002; Das and Kundu, 2005; Dorr et al., 2002; Glozak et al., 2005; Kouzarides, 2000; 
Mujtaba et al., 2002; Mujtaba et al., 2004; Polesskaya and Harel-Bellan, 2001; Spange et 
al., 2009; Sterner and Berger, 2000), in this study we investigated whether this protein 
modification could affect the interaction of integrase with cellular factors. To this aim we 
have employed the tethered catalysis two-hybrid system, a method previously reported to 
efficiently identify factors binding specifically to acetylated proteins (p53, histones H3 and 
H4) (Acharya et al., 2005; Guo et al., 2004). The tethered catalysis system allows 
obtaining a constitutively acetylated factor by exploiting the cis enzymatic activity of a HAT 
domain on a target factor within a single fusion protein. 
To produce constitutively acetylated IN, a cDNA cassette was constructed containing a 
codon-optimized sequence for IN (IN-CO) fused to the acetyl transferase catalytic domain 
of p300 (IN-HATw). As control, IN was also fused to a sequence coding for a catalytically 
inactive HAT containing a D1395Y mutation (IN-HATm). The IN-HAT fusion proteins 
produced by these constructs contain at the N-terminus a histidine tag (6 x His) which 
allows affinity purification of the protein product by means of cobalt based resin columns 
(see Materials and Methods). In addition, the C-terminus of the chimera is in frame with a 
hemagglutinin (HA) epitope tag used to analyze the fusion protein by  immunoblot with 
anti-HA antibodies. Finally, between the IN and the HAT domains a Tobacco Etch Virus 
(TEV) proteolytic cleavage site was introduced allowing IN separation from the HAT 
domain (Figure 1a). We initially produced and purified the chimera from bacteria by 
means of a 6xHis-tag fused to the N-terminus of the chimera (Figure 1a) to verify the 
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levels of acetylation. Western blot analysis using antibodies specific for acetylated 
integrase (Terreni et al., 2010), showed a high molecular size band corresponding to the 
full length chimera containing integrase fused to wild-type HAT catalytic domain (IN-
HATw) (Figure 1b, left panel). Additional smaller molecular size products, positive for 
acetylation, are also visualized. Conversely, no signals are detected in the lane 
corresponding to integrase fused to a catalytically inactive HAT domain (IN-HATm) 
(Figure 1b, left panel) indicating a specific acetylation of the chimera IN-HATw. The 
same blot was then tested with antibodies against IN to check for protein loading (Figure 
1b, right panel): a higher band corresponding to IN-HAT full length is clearly visible at 
similar amounts in both lanes corresponding to IN-HATw and IN-HATm. Additional smaller 
molecular size bands are also visible and are probably deriving from degradation of the 
single HAT domain expressed in bacteria. 
We next sought to check whether integrase isolated from the HAT domain was positive for 
acetylation. To his aim the chimera was digested with the TEV protease and integrase 
separated from the HAT domain by means of the His-tag at the N-terminus of integrase 
(Figure 1a) using nickel columns. The purified digested product deriving from IN-HATw+ 
TEV showed by Western blot with antibodies specific for acetylated integrase, a main band 
at the same size of integrase, while no bands were visible in the samples containing 
integrase from IN-HATm+TEV (Figure 1b, left panel). Same amounts of the digested 





Figure 1: Constitutive acetylation of IN fused to the HAT domain of p300. (a) Schematic representation of 
IN-HATw (left) and IN-HATm (right) chimeras. IN codon optimized is fused to the p300 HAT domain either 
wild-type (HATw) or mutated (HATm). Between the IN and the HAT domains a TEV protease cleavage site is 
inserted to allow separation of the two domains. (b) IN from the IN-HATw chimera is highly acetylated. IN-
HATw and IN-HATm fusion proteins undigested (-TEV) or TEV digested (+TEV) were immunoblotted with 
anti-acetylated IN specific antibodies (AcIN) (left panel). The immunoblot was re-probed with IN 
antibodies for total IN (right panel). (c) IN from the IN-HATw chimera is acetylated in yeast cells. The IN-
HATw and IN-HATm chimeras fused to Gal4 DNA Binding Domain (GBD) were expressed in yeast cells 
(AH109), immunoprecipitated with HA antibodies and immunoblotted with AcIN antibodies to detect 
acetylated IN. The blot was re-probed with IN antibodies for total IN.  
 
To further verify the specific acetylation signal shown with IN-HAT wild type chimera 
(Figure 1b, left panel), the recombinant purified IN-HATw protein was sequenced and 
analyzed by mass spectrometry (MS). MS-MS analysis (MALDI-TOF/TOF) enabled the 
identification of three acetylated lysine residues on the C-terminal domain of integrase: 
K264, K266 and K273 (Figure 2). These identifications were supported by an adequate 
ladder of y (and b) ion family and by the presence of known marker ions for acetylated 
lysine: the acetylated lysine immonium ion at m/z 143.1 and the ion at m/z 126.1, which is 
a fragment ion induced by the loss of NH3 from the ions at m/z 143.1 (Kim et al., 2002; 
Trelle and Jensen, 2008). The analysis confirmed the in vivo acetylation of lysines K264, 
K266 and K273 by p300 HAT previously identified by site-direct mutagenesis assays 
(Cereseto et al., 2005). Therefore, these data indicate that integrase is efficiently 
acetylated within the IN-HATw chimera, while no acetylation occurs on integrase derived 
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from the HAT-INm chimera. The IN-HAT cDNA cassette was then expressed in yeast cells 
in frame with the Gal4 DNA-binding domain (GBD) under the control of a yeast promoter 
(GBD-IN-HATw/m). Lysates from yeast cells expressing the control GBD, GBD-IN-HATw or 
GBD-IN-HATm were immunoprecipitated with anti-HA tag antibodies and the levels of 
integrase acetylation and expression were checked by immunoblot analysis. As shown in 
Figure 1c (upper panel) antibodies directed against acetylated integrase revealed a 
strong signal in the GBD-IN-HATw immunoprecipitates while no acetylation was detected 
either in GBD-IN-HATm or GBD control sample. Anti-integrase antibodies against the same 
membrane detected similar amounts of GDBD-IN-HATw and GDBD-IN-HATm 
immunoprecipitated with anti-HA antibodies (Figure 1c, lower panel). In conclusion, 
these results demonstrate that IN expressed as a fusion product with the HAT domain of 


















Figure 2:  Identification of Ac-K264, Ac-K266 and Ac-K273 by MS-MS (MALDI-TOF/TOF) in the IN-HATw 
fusion recombinant protein. These identifications were supported by an adequate ladder of y (and b) ion 
family and by the presence of known marker ions for acetylated lysine: the acetylated lysine immonium ion 
at m/z 143.1 and the ion at m/z 126.1, which is a fragment ion induced by the loss of NH3 from the ions at 
m/z 143.1(Kim et al., 2002; Trelle and Jensen, 2008).  (a) Mass spectrum of AcK264 and AcK266 lysines. 
Fragmentation for bi-acetylated ion AcK264AAcK266IIR. (b) Mass spectrum of AcK273. Fragmentation for 
acetylated ion DYGAcK273QMAGDDCamCVASR. CamC stands for carbamidomethylated cysteine. In (a) and (b) 
AcK stands for acetylated lysines. Mapped y ion family sequence in red. Mapped b ion family sequence in 
green. Lysine acetylation marker ions marked in yellow. 
 
2- Two-hybrid screening analysis using the constitutively acetylated integrase  
To identify the cellular factors interacting with acetylated IN, we used the GBD-IN-HATw 
(Figure 1c) as a bait to screen a human lymphocytes cDNA library fused to the Gal4 
activation domain (GAD). The two-hybrid screening was performed in the AH109 yeast 
strain. This strain contains ADE2 and HIS3 genes as reporters which allows the selection 
of positive clones using the selective medium (-Ade and -His). From almost 10.6 x 106-
screened transformants, 746 were positive clones encoding thirteen cellular proteins which 
are listed in Table 1.  
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Table 1: Cellular factors identified by yeast two-hybrid screening using constitutively            
acetylated IN (IN-HATw) as bait. 
Protein names 











derived growth factor: 
LEDGF/p75  (6 
clones) 
Transcription coactivator.  
Factor interacting with lentiviral 
INs determining IN association to 
chromatin.  
Putative tethering factor for HIV-1 
integration.  
530: 344-530 AF063020.1 
(Cherepanov et al., 2003; 
Emiliani et al., 2005; Ge et al., 
1998 ; Maertens et al., 2003; 




KAP1 (3 clones) 
Transcription co-repressor. 
damage response factor. 
Regulator of acetylated non 
histone proteins. 
Factor inhibiting infectivity of MLV 
in embryonic stem cells. 
835: 304-835 HSU78773 
(Sripathy et al., 2006; Schultz 
et al., 2001; Tian et al., 2009; 
Wang et al., 2005a; Ziv et al., 
2006; Tsuruma et al., 2008; 
Wang et al., 2007a; Wolf and 
Goff, 2007). 
Basic transcription 
factor 3 isoform b:   
BTF3b (1 clone) 
Component of the RNA 
polymerase II complex required 
for transcription initiation.  
162: 1-162 NM_001207.4 (Zheng et al., 1990). 
Thyroid hormone 
receptor protein 3: 
THRAP3 (1 clone) 
Subunit of the large transcription 
mediator TRAP complex; positive 
regulator of RNA polymerase II 
promoters transcription.  




HMGN2 (1 clone)  
Component of the HMG non 
histone chromatin remodeling 
family of proteins.  
Inducer of chromatin 
decondensation and  transcription 
activity. 
90: 1-90 BC014644.1 (West, 2004). 
Ran-binding protein 9: 
RanBP9 (8 clones) 
Ran binding protein involved in  
nuclear transport pathway NLS 
mediated. 
A centrosomal protein that 
induces microtubule nucleation.  
729: 149-179 BC063849.1 
(Gorlich, 1998; Nakamura et 
al., 1998; Yudin and Fainzilber, 
2009). 
Exportin 2 
(synonyme :  CAS):  
Exp2 (1 clone) 
Importin  binding protein. 
Mediator of importin  nuclear 
export after NLS cargo release 
into the nucleus. 
971: 244-971 BC108309.1 
(Kutay et al., 1997; Solsbacher 
et al., 1998). 
Eukaryotic translation 
initiation factor 3 
subunit H:  
eIF3h (726 clones) 
Component of the eIF3 complex: 
promotes translation pre-initiation 
complex formation, mRNA 
recruitment and scanning for AUG 
recognition in the ribosomes. 
352:12-352; 172-
352 
BC000386.2 (Hinnebusch, 2006). 
Elongation factor 1 
alpha 1:  
eEF1A-1 (1 clone) 
Component of the alpha subunit 
of EF1 complex: promotes protein 
biosynthesis by delivering 
aminoacylated tRNA to 
ribosomes.  
Binds HIV-1 matrix and 
nucleocapsid and stimulates HIV-
1 transcription.  
Its yeast homologue binds HIV-1 
IN. 
46: 268-462 BC082268.1 
(Calado et al., 2002; Cimarelli 




hnRNPA2 (1 clone) 
RNA binding protein containing 
two RNA recognition motifs 
(RRM): involved in mRNA 
regulation (splicing and 
trafficking).  
Regulator of HIV-1 RNA 
trafficking. 
341: 1-180 NM_002137.2 
(Beriault et al., 2004; Shyu 
and Wilkinson, 2000). 
Stathmin 1:  
STMN1 (2 clones) 
Tubulin binding protein: involved 
in microtubule depolymerization 
and signal transduction cascade.  
149: 1-149 BC082228.1 (Cassimeris, 2002).  
Ribosomal protein L23: 
RPL23 (1 clone) 
Structural component of 60S 
subunit of ribosomes. Activates 
p53 by inhibiting MDM2. 
140: 18-140 NM_000978.3 (Berchtold and Berger, 1991). 
Coiled-coil domain 
containing 32 
isoform1: CCDC32  (2 
clones) 
Unknown functions. 185: 12-185 BC001673.2 (Ota et al., 2004). 
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According to their properties and proposed functions, these cellular factors could be 
divided into three categories: 
1- Transcription regulatory and chromatin remodeling factors: LEDGF/p75, KAP1, BTF3b, 
THRAP3 and HMGN2.  
2- Translation regulatory and RNA binding proteins: eIF3h, eEF1A-1 and hnRNPA2.   
3- Nuclear import-export proteins: Exp2 and RanBP9. 
In addition to factors grouped in categories, we also identified RPL23, a structural 
ribosomal subunit, STMN1, a factor involved in microtubule organization and finally 
CCDC32, a protein with still unknown functions. 
These newly identified factors, were subsequently tested by two-hybrid analysis with the 
IN-HATw chimera, as well as with each single domain (IN and HATw), to verify their 
association properties with the acetylated or unmodified IN and also with the HAT domain 
contained in the chimera. In addition, the analysis was performed with the GBD to check 
the bait specificity. Results shown in Table 2 indicate that all identified factors associate 
with IN as a separate domain and that the majority do not bind the HAT domain except 
for THRAP3, HMGN2, RanBP9, eEF1A-1 and CCDC32.  
 
Table 2: Interactions in yeast between GAD prey proteins and GBD hybrid baits             
(IN-HATw, IN and HATw). 
 IN- HATw IN HATw GBD 
LEDGF/p75 + + - - 
KAP1 + + - - 
BTF3b + + - - 
THRAP3 + + +            - 
HMGN2 + + - - 
Exp2 + + - - 
RanBP9 + + - - 
EIF3h + + - - 
EEF1A-1 + + + - 
HnRNPA2 + + - - 
STMN1 + + + - 
RPL23 + + - - 
CCDC32 + + + - 
+: interaction, -: no interaction 
In conclusion, thirteen new factors binding to acetylated IN have been identified. These 
factors positively interact also with IN separated from the HAT domain, suggesting that 




3-Analysis of binding interactions between two-hybrid factors and acetylated 
or un-modified integrase 
To verify the interaction between IN and the cellular factors identified by two-hybrid 
screening (Table 1), pull down assays with the same factors expressed in human cells 
have been performed. Experiments were carried out with few selected factors based on 
their possible involvement in HIV-1 replication: transcription related proteins (BTF3b, 
THRAP3 and HMGN2) potentially involved in tethering viral integration in transcription 
units; a nuclear transport factors (Exp2 and RanBP9) possibly involved in nuclear-
cytoplasmic translocation. In addition, eIF3h, a factor involved in protein synthesis, was 
tested due to its high frequency of identification (726 clones) in the two-hybrid screening.  
These factors were fused to a Flag tag and expressed in HEK293T cells. The derived cell 
lysates were incubated with either IN-HATw or IN-HATm recombinant proteins. 
Subsequently, the immunocomplexes were recovered with anti-Flag antibodies and 
analyzed by Western blot with anti-HA and anti-Flag antibodies. As an experimental 
control for binding specificity, the same analysis was performed using HEK293T cells 
expressing an unrelated control protein, luciferase, fused to the Flag tag (Flag-Luc). As 
shown in Figure 3a, 3b and 3c higher amounts of IN-HATw than IN-HATm were found 
associated with Flag-Exp2, Flag-elF3h and Flag-RanBP9. Conversely, similar amounts of 
IN-HATw and IN-HATm bound Flag-BTF3b, Flag-THRAP3 and Flag-HMGN2 (Figure 3d, 
3e and 3f). Finally, no specific binding was observed with the unrelated control protein, 
Flag-Luc (Figure 3g). As shown in lower panels of Figure 3a-g, incubation of the same 
filters with anti-Flag antibodies proved that similar amounts of Flag proteins were 
immunoprecipitated with either IN-HATw or IN-HATm. These results suggest that Exp2, 
eIF3h and RanBP9 bind with higher affinity the acetylated form of IN, whereas BTF3b, 
THRAP3 and HMGN2 show no preferential binding for either forms of the viral protein. In 
the next section we describe KAP1, another identified cellular factor (Table 1), that binds 




Figure 3: Binding analysis between acetylated IN and proteins identified by the yeast two-hybrid screening. 
(a) Lysates from HEK293T cells expressing Flag-Exp2 (a), Flag-eIF3h (b), Flag-RanBP9 (c), Flag-BTF3b (d), 
Flag-THRAP3 (e), Flag-HMGN2 (f) and FLAG-Luc (g) were incubated with recombinant  IN-HATw or IN-
HATm-HA and immunoprecipitated (IP) with monoclonal anti-Flag antibodies. Immunoprecipitates were then 
analyzed by Western blot with anti-HA antibodies (-HA) (upper panels) and with polyclonal anti-Flag 
antibodies (-Flag) (lower panels).  
 
Next, the interaction between the two-hybrid hits and the single HAT and IN domains was 
verified using lysates of HEK293T cells expressing the Flag-tagged factors. No binding was 
observed with the HAT domain (Figure 4a, upper panel), even though high expression 
of two-hybrid Flag-tagged factors could be detected (Figure 4a, lower panel). Thus, 
these data demonstrate that the interaction between IN and the two-hybrid hits is specific 
and not mediated by the HAT domain. Moreover, this result suggests that the positive 
interactions observed by two-hybrid analysis with the HAT domain (Table 2), were likely a 
88 
 
result of the synergistic transactivation properties of these factors (THRAP3, HMGN2 and 
eEF1A-1) together with the HAT domain over the yeast promoter.  
Finally, the unmodified form of IN (6xHis-IN) was verified by pull down assays with Flag-
tagged two-hybrid hits expressed in HEK293T cells. High levels of IN was found associated 
with BTF3b, HMGN2 and THRAP3 (Figure 4b), while much lower amounts could be 
detected in complex with Exp2, eIF3h and KAP1.  
Therefore, these data are in agreement with results in Figure 3, showing that BTF3b, 
HMGN2 and THRAP3 bind efficiently unmodified IN and do not require IN acetylation. 
Conversely, the low amounts of Exp2, eIF3h and KAP1 bound to IN is indicative that IN 
acetylation enhances binding affinity. 
 
 
Figure 4: Binding between proteins identified by the two-hybrid screening and the HATw or IN domains. 
HEK293T cell lysates expressing Flag-eIF3h, Flag-BTF3b, Flag-THRAP3, Flag-HMGN2 or FLAG-Luc were 
incubated with either HATwt (a) or 6xHis-IN (b) recombinant proteins or immunoprecipitated (IP) with 
monoclonal anti-Flag antibodies. Immunoprecipitates were then analyzed by Western blot with anti-HA 
antibodies (-HA) (a, upper panel) or with anti-IN antibodies (b, upper panel) and with polyclonal anti-Flag 
antibodies (-Flag) (a and b lower panels).  
 
 
4- Interaction between KAP1 and acetylated integrase  
KAP1 was identified in the two hybrid screen to interact with acetylated integrase (Table 
1). KAP1 is an ubiquitous nuclear protein that belongs to the TRIM family and it has been 
described to restrict MLV and other retroviruses in mouse embryonic stem cells (Wolf and 
Goff, 2007; Wolf et al., 2008b). Beside, KAP1 has been reported to regulate the activity of 
several acetylated non-histone proteins by modulating their acetylation levels through 
HDACs (Tian et al., 2009; Tsuruma et al., 2008; Wang et al., 2005a; Wang et al., 2007a). 
Due to the involvement of KAP1 in the retroviral replication and also in the regulation of 
the acetylated proteins, we decided to investigate the role of KAP1 and its interaction with 
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acetylated integrase in HIV-1 infection. The first experiments aimed to verify the specificity 
of binding of KAP1 with acetylated integrase. To reach this aim, comparative analysis was 
performed by co-transforming GAD-KAP1 in yeast with the following GBD/HA fusion 
proteins: IN-HATw, IN-HATm, HATw, HATm or GBD alone. A higher interaction between 
KAP1 and acetylated integrase (IN-HATw) was observed with respect to unmodified 
integrase (IN-HATm) or the individual domains (HATw, HATm and GBD) in two hybrid 
selective medium (-Ade,-His) (Figure 5a, left panel). This result was also confirmed by 
X–alpha-gal filter lift assay showing specific interaction of GAD-KAP1 with IN-HATw 
(Figure 5a, right panel). In the large screen, some clones carrying GAD-KAP1 and GBD-
IN-HATm were positive, consistent with the interaction seen between KAP1 and GBD-IN 
(Table 2), indicating that KAP1 interacts even with unmodified integrase; however, as 
shown above (Figure 5a), this interaction is highly favored by integrase acetylation 
catalyzed by p300. 
To validate the interaction occurring between the acetylated integrase and KAP1 the 
binding of the two proteins was further analyzed in a mammalian system. KAP1 fused to a 
Flag-tag was expressed in HEK293T cells and the lysate incubated with the IN-HATw and 
IN-HATm recombinant proteins. The binding complexes were then pulled down with anti-
Flag antibodies immobilized on the agarose beads and analyzed by Western blot with 
antibodies anti-HA. Higher amounts of IN-HATw were shown to bind KAP1 as compared to 
IN-HATm (Figure 5b, left-upper panel). Incubation of the same membrane with 
antibodies anti Flag demonstrated that similar amounts of KAP1 protein were 
immunoprecipitated (Figure 5b, left-lower panel). The same experiment was 
performed using integrase isolated from the HATw or m domains following proteolytic 
cleavage of the recombinant chimeras with TEV protease (as schematized in Figure 1a). 
By incubating integrase derived from IN-HATw with lysates from cells expressing Flag-
KAP1 a doublet at the same molecular size of integrase is clearly visible by anti-IN 
antibodies following anti-Flag immunoprecipetation (Figure 5b, right-upper panel). 
Conversely no bands were detected when the same reaction was performed with integrase 
derived from the IN-HATm chimera (Figure 5b, right-upper panel). The doublet 
observed in the IN-HATw immunoprecipitation is probably due to degradation of the 
integrase protein during purification procedures since similar doublets are also observed in 
Figure 1b following TEV digestion. In conclusion, these data clearly demonstrate that 
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constitutively acetylated integrase binds Flag-KAP1 with a higher affinity than the non-
acetylated protein.  
To further verify the integrase/KAP1 in vivo interaction, Flag-tagged integrase (Flag-INw) 
was expressed in HEK293T cells and the amount of complexed endogenous KAP1 was 
evaluated following anti-Flag immunoprecipitation and anti-KAP1 Western blot analysis. 
Endogenous KAP1 is co-immunoprecipated with Flag-integrase, while no bands appear in 
samples expressing the control Flag (Figure 5c, upper panel). To verify the role of 
lysines acetylated by p300 in the carboxy-terminus of integrase (Cereseto et al., 2005) on 
the interaction with KAP1, the same immunoprecipitation experiment was performed using 
a plasmid expressing Flag-integrase mutated  in lysines targeted by p300 (K264,K266 and 
K273) (Flag-INm) (Cereseto et al., 2005). Lower amounts of endogenous KAP1 bound 
mutated integrase as compared to wild-type integrase (Figure 5c, upper panel). The 
level of integrase acetylation was verified by Western blot analysis of the same lysates 
used for the immunoprecipitation with antibodies specific for acetylated integrase (Figure 
5c, middle panel). The total level of Flag-integrase expression was also verified by 
Western blot using anti-Falg antibodies (Figure 5c, middle panel). In order to further 
verify the preferential binding of endogenous KAP1 to acetylated integrase in vivo, 
reciprocal co-immunoprecipitation experiments were performed. Lysates from HEK293T 
cells expressing untagged integrase wild type (pCMV-INw) or mutated at the three 
acetylation sites (pCMV-INm) were immunoprecipitated using anti-KAP1 antibodies. 
Detection of binding complexes with anti-integrase antibodies showed higher amount of 
wild integrase (pCMV-INw) associated with endogenous KAP1 comparing to the mutated 
integrase (pCMV-INm), while, no signal was detected with control cells (pCDNA3) (Figure 
5d, upper panel). Similar amounts of endogenous KAP1 were co-immunoprecipitated 
with pCMV-INw and pCMV-INm (Figure 5d, second panel from top). The expression of 
pCMV-INw and pCMV-INm in HEK293T cells detected by Western blot using anti-IN 
antibodies showed equal levels (Figure 5d, third panel from top). Finally, the 
endogenous levels of KAP1 in cells expressing either pCMV-INw or pCMV-INm were not 
modulated as compared to transfected control cells (pCDNA3) (Figure 5d, lower panel). 
Taken together (Figure 5 c and d), we conclude that endogenous KAP1 interacts with 
Flag-tagged and untagged integrases in vivo. In addition, a higher affinity of KAP1 was 





Figure 5: KAP1 interacts with acetylated integrase in vivo in yeast and in mammalian cells with higher 
affinity than non acetylated form. (a) Interaction efficiencies of the IN-HATw and IN-HATm chimeras and 
single domains (HAT, IN and GBD) with KAP1 in yeast two-hybrid on (–Ade,-His) selective two hybrid 
medium (left panel). Cotransformation efficiencies were controlled on no selective two hybrid medium 
(+Ade, +His) but lacking Trp and Leuc (-Trp, -Leuc) for the selection of GBD and GAD vectors, respectively 
(middle panel). All these cotransformants were subjected to X–alpha-gal filter lift assay assessing the 
efficiency of MEL1 reporter gene to produce -galactosidase in condition of positive interactions (right 
panel). (b) Flag-KAP1 binds acetylated IN with higher affinity than the non-acetylated form. HEK293T cell 
lysates expressing Flag-KAP1 were incubated with not digested IN-HATw/m recombinant chimeras (left 
panel) or with IN digested by TEV protease from wild type and mutated chimeras (IN-Ac+/-) (right panel); 
the binding complexes were pull downed with Flag agarose beads. Flag immunocomplexes were then 
blotted with HA antibodies to detect bound IN-HAT chimeras (left panel) or with anti-integrase antibodies 
(IN) to detect TEV digested integrases (INAc+/-)(right panel). The two membranes were re-probed with 
Flag antibodies to check for KAP1 expression. (c) and (d) Endogenous KAP1 binds preferentially acetylated 
IN in vivo. (c) HEK293T cells expressing either Flag-IN wild type (Flag-INw) or mutated at lysine acetylation 
sites (K264, 266, 273R) (Flag-INm) were immunoprecipitated with Flag antibodies and blotted using KAP1 
antibodies. The acetylation and expression levels of integrase wild type and mutated were detected by anti-
Ac-IN (-AcIN) and Flag antibodies, respectively (d) HEK293T expressing either untagged IN wild type 
(pCMV-INw) or mutated (K264, 266, 273R) (pCMV-INm) were immunoprecipitated with -KAP1 and blotted 
with -IN and -KAP1. Expression levels of IN and KAP1 were controlled with the indicated antibodies.  
 
Since acetylated lysines are localized in the carboxy-terminus of integrase, we sought to 
investigate whether this domain regulates KAP1 binding. To this aim pull-down 
experiments were performed incubating recombinant integrase domains fused to 
glutathione-S-transferase (GST) with in vitro 35S-Met labelled KAP1. The protein complexes 
were pulled down with S-glutathione agarose beads. Almost 10% of 35S-KAP1 binds GST-
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full length integrase (Figure 6a, upper panel and graph), while only 1.13% of the input 
was retained on the GST control demonstrating that integrase and KAP1 interact in vitro. 
The in vitro pull down assays were then performed with each single domain showing no 
interaction between KAP1 and either the N-terminus or the catalytic domain, while the C-
terminus retained 12.41% of 35S-KAP1 input indicating that C-terminal domain of HIV-1 
integrase is responsible for the IN/KAP1 complex formation in vitro (Figure 6a, upper 
panel and graph). Coomassie stained SDS-PAGE gel showed that similar amounts of 
GST-IN full length and single domains were used for the in vitro binding with 35S-KAP1 
(Figure 6a, lower panel).   
To investigate the relevance of the three acetylated lysines (K264, K266 and K273) of the 
C-terminal domain of integrase in IN/KAP1 in vitro binding, we incubated the 35S-Met 
labelled KAP1 with either 6xHis-IN-HATw or 6xHis-IN-HATm recombinant proteins (Figure 
1). The protein complexes were pulled down using Ni-NTA columns. Integrase 
constitutively acetylated (IN-HATw) showed double efficiency to bind 35S-KAP1 (100%) as 
compared to unmodified integrase (IN-HATm) (48%) (Figure 6b, upper panel and 
graph), while no significant signal was shown in the control reaction (35S-KAP1+ 6xHis). 
The amounts of IN-HATw and IN-HATm used in this in vitro binding, detected by 
Coomassie staining of the SDS-PAGE gel, were similar (Figure 6b, lower panel). 
Considering that K264, K266 and K273 lysine residues were found acetylated within the 
IN-HATw protein by mass spectrometry analysis (Figure 2), we conclude that the 
acetylation sites of integrase C-terminal domain are responsible for the enhancement of 
IN/KAP1 interaction in vitro. This result is in agreement with in vivo data where the 
integrase mutated at the lysine acetylation sites has lower affinity of binding with KAP1 
than the wild type integrase (Figures 5c and 5d).   
In conclusion integrase and KAP1 interact both in vivo and in vitro and acetylation of 






Figure 6:  IN/KAP1 in vitro binding occurs through the IN C-terminal domain and is enhanced by IN 
acetylation. (a) the C-terminal domain of integrase responsible of the direct binding with KAP1. In vitro 
translated KAP1 labeled with 35S-Met (35S-KAP1) was incubated with either recombinant full length IN fused 
to GST (GST-IN) or with each single recombinant IN domain fused to GST: N-terminus (GST-IN-Nt), catalytic 
(GST-IN-Cat) and C-terminus (GST-Ct). Pulled down complexes obtained using S-glutathione agarose beads 
were resolved on SDS-PAGE gel and analyzed by densitometry. The graph expresses the amounts of 35S-
KAP1 bound protein as percentages of the input (35S-KAP1). (b)IN/KAP1 direct binding is enhanced by 
integrase acetylation. In vitro translated KAP1 labeled with 35S-Met (35S-KAP1) was incubated with 6xHis-IN-
HATw or 6xHis-IN-HATm recombinant proteins and pulled down using Ni-NTA agarose beads.  The graph 
express  the amount 35S-KAP1 bound protein as percentages of 100% of 35S-KAP1 bound to IN-HATw. In (a) 
and (b) the upper panels show the gels exposed to Phosphoimaging (Cyclone) and the lower panels the 
Coomassie staining of the SDS-PAGE gels.   
 
5- Transient knockdown of KAP1 increases HIV-1 infectivity and integration  
 
To evaluate the role of KAP1 during HIV-1 infection, HeLa cells were transiently knocked 
down with a pool of small interfering RNAs (siRNA) directed against KAP1 gene and then 
infected with HIV-1 virus. Western blot analysis revealed that the expression of KAP1 was 
lowered in cells treated with KAP1 siRNAs (si-KAP1), as compared to cells untreated (UT) 
or transfected with a pool of control non targeting siRNAs (si-CTR) (Figure 7a). HeLa 
cells knocked down for KAP1 and control cells were infected, two days after siRNA 
treatment, by a single round HIV-1 virus clone carrying luciferase as reporter (NL4.3-Luc) 
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and pseudotyped with VSV-G envelope. Viral infectivity was measured by the levels of 
luciferase activity at 48 hours post-infection. In cells treated with KAP1 siRNA (si-KAP1) 
luciferase activities were three fold higher than cells treated with control siRNA (si-CTR) 
(Figure 7b). To better investigate which early viral replication step is affected by KAP1, 
quantitative real-time PCR (Q-PCR) have been performed to measure late reverse 
transcripts, 2-LTR circles and integrated viral DNA using primers that target specifically 
each viral cDNA form. The levels of late reverse transcripts quantified 24 hours post 
infection in KAP1 knockdown HeLa cells (si-KAP1) and in not silenced control cells (si-CTR) 
were not significantly different (Figure 7c) indicating that KAP1 does not affect reverse 
transcription. Two-LTR circles are viral cDNA molecules that translocate into the nucleus 
where they fail to integrate (Coffin et al., 1997; Engelman, 1999) and become circularized 
likely by the non homologous end joining (NHEJ) cellular repair (Li et al., 2001). 
Therefore, 2-LTR circles are a surrogate marker of retrovirus nuclear import (Coffin et al., 
1997) and are indicative of an abortive integration (Engelman, 1999). The quantification of 
the 2-LTR circles by Q-PCR was performed 24 hours post infection. In HeLa cells knocked 
for KAP1 (si-KAP1) 2-LTR circles were significantly lower than in control not silenced cells 
of almost 2 fold (Figure 7d), indicating that KAP1 knockdown might increase HIV-1 
integration efficiency or inhibit nuclear import of the viral cDNA. The detection of 
integrated HIV-1 proviruses by quantitative Alu-PCR at 48 hours post-infection showed 
that integrated viral DNA were significantly increased in KAP1 knockdown HeLa cells (si-
KAP1) about 5 to 9 fold as compared to not silenced control cells (Figure 7e). Therefore, 
siRNA-mediated transient Knockdown of KAP1 in HeLa cells does not affect reverse 
transcription, decreases the formation of the 2-LTR circles and significantly increases HIV-
1 integration. Since at similar amounts of late reverse transcripts, a decrease of the 2-LTR 
circles was correlated with an increase in the integration efficiency in the HeLa cells 
transiently knocked down for KAP1, we suggest that KAP1 affects the efficiency of HIV-1 






Figure 7: KAP1 transient knockdown increases HIV-1 integration in HeLa cells. (a) Expression of KAP1 in 
HeLa cells transiently knocked down with smart pool siRNAs (si-KAP1) and in control HeLa cells treated with 
a pool of non-targeting siRNAs (si-CTR). Immunoblot was performed using KAP1 antibodies and re-probed 
with Tubulin antibodies to check for protein loading. (b-e) Transient KAP1 knockdown HeLa cells were 
infected with NL4.3-Luc (VSV-G) HIV-1 virus and analyzed for luciferase activity (Luc Activity) 48 hours post-
infection (hpi) (b) and by Q-PCR for late reverse transcripts 24 hpi (c), 2-LTR DNA circles 24 hpi (d) and 
integrated HIV-1 DNA 48 hpi by Alu-PCR (e). (f-g) KAP1 knockdown HeLa cells (sh-3‘KAP1), back-
complementated (sh-3‘KAP1 + HA-KAP1) and control treated (GIPZ) were infected with NL4.3-Luc (VSV-G) 
HIV-1 virus and analyzed by Q-PCR for integrated viral DNA at 15 days post infection (dpi) (f) and for total 
viral cDNA at 24 hpi (g). Expression of KAP1 was verified by immunoblot. All graphs are represented in fold 
increase with respect to control cells (± s.d. from at least two independent experiments). 
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To verify the specificity of the KAP1 knockdown on HIV-1 infection, HeLa cells were 
silenced transiently for KAP1 using a short hairpin RNA that recognizes the 3‘ untranslated 
region of KAP1 (sh-3‘KAP1) and expressed from a lentiviral vector (LKO.1). These cells 
were back-complemented by the expression of KAP1 cDNA resistant to the sh-3‘KAP1 and 
then were infected with NL4.3-Luc HIV-1 virus and analyzed by Q-PCR for total HIV-1 at 
24 hours post infection and for integrated proviruses at 15 days post-infection. The control 
cells were treated with the GIPZ lentiviral vector. As shown in Figure 7f, the KAP1 
knockdown mediated by the sh-3‘KAP1 enhances significantly HIV-1 integration of almost 
three fold, while the KAP1 back-complemented cells (sh3‘KAP1 + KAP1) were able to 
reverse integration to the basal levels of not silenced cells (GIPZ). In addition, in all these 
conditions total viral cDNA was not changed (Figure 7g), indicating the specificity of 
KAP1 knockdown on HIV-1 integration.  
 
6- KAP1 stable knockdown increases HIV-1 infectivity and integration  
 
In order to further confirm the inhibitory role of KAP1 on HIV-1 integration with a different 
knockdown approach, HeLa and HEK293T cells were stably knocked down for KAP1 using 
a short hairpin RNA targeting KAP1 gene (sh-KAP1) expressed from a lentiviral vector 
(GIPZ). Control cells were a pool of cells expressing a mismatched shRNA (sh-MM) 
containing four point mutations inside the sh-KAP1. Stable KAP1 knockdown cells were 
viable and did not display cytotoxic effects comparing to wild type cells or to cells stably 
expressing sh-MM, however, KAP1 endogenous levels were rescued 1 to 2 months 
following selection in culture even under stringent conditions, indicating the physiological 
relevance of this protein and that pronounced down-regulation could not be obtained. The 
limited levels of transient and stable knockdowns of KAP1 in cells have been previously 
reported (Wang et al., 2005a; Wang et al., 2007a; Wolf and Goff, 2007). Therefore, KAP1 
expressions were checked by Western blot analysis simultaneously to each infectivity 
experiment (Figures 8a and 9a). Following infection with NL4.3-Luc HIV-1 virus  three 
KAP1 knockdown HeLa cell clones (H14a, H18 and H19)(Figure 8a) showed three fold 
more luciferase activity than the control cell pool (sh-MM) (Figure 8b). To investigate 
which step of viral infectivity is affected by KAP1, quantitative real time PCR (Q-PCR) were 
performed. HeLa KAP1-silenced and control cells were infected with NL4.3-Luc and at 24 
hours post infection, a fraction of cells was analyzed for total viral cDNA and for 2-LTR 
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circles and remained cells were passed in culture for two weeks and analyzed for the 
integrated viral DNA. Measurement of late reverse transcripts and integrated viral DNA in 
the knockdown (sh-KAP1) or control (sh-MM) HeLa clones could not be performed by 
primers that recognize LTR due to cross detection of integrated lentivirus (GIPZ). 
Therefore, these viral DNA forms were analyzed by Q-PCR using primers that target the 
luciferase gene of NL4.3-Luc (Terreni et al., 2010). No significant difference in the total 
viral cDNA has been observed between HeLa cell silenced clones (H14a, H18 and H19) 
and control cell pool (sh-MM) (Figure 8c), indicating that KAP1 does not affect reverse 
transcription. The amounts of 2-LTR circles have been significantly decreased in KAP1 
Knockdown HeLa cell clones of almost 2 to 10 fold with respect to not silenced cell pool 
(sh-MM) (Figure 8d). Consistently, integrated HIV-1 DNA in stable KAP1 knockdown HeLa 
cell clones at two weeks post infection were significantly increased by 2 to 3 fold as 
compared to not silenced cell pool (sh-MM) (Figure 8e).  
The same infectivity experiments were performed with a different cell line, HEK293T, 
stably knocked down for KAP1 (sh-KAP1) and control not silenced pool (sh-MM) (Figure 
9a). Infectivity of silenced HEK293T cell pool and clones (T-pool, T14 and T15) were 
increased about 4 to 6 fold with respect to not silenced pool (sh-MM) (Figure 9b). Total 
viral cDNA quantified by Q-PCR at 24 hours post infection was not changed in KAP1 
knockdown HEK293T cell pool and clones comparing to not silenced pool (sh-MM) (Figure 
9c). Whereas, 2-LTR circles at 24 hours post infection were decreased in KAP1 silenced 
HEK293T cells of almost 5 to 10 fold as compared to not knocked down pool (sh-MM) 
(Figure 9d). The observed decrease of the two-LTR circles was consistent with an 
enhancement of viral integration at two weeks post infection in KAP1 silenced HEK293T 
cell clones and pool about 2 to 3 fold with respect to not silenced cell pool (sh-MM) 
(Figure 9e).    
In conclusion stable knockdown of KAP1 in HeLa and HEK293T cells, obtained by the use 
of short hairpin RNA enhances HIV-1 integration, decreases the 2-LTR circles while the 
reverse transcription remains unaffected. These data are consistent with those observed 
with KAP1 transient knockdown in HeLa cells (Figure 7), mediated by the small 
interfering RNAs, and suggest that KAP1 decreases HIV-1 infectivity by impairing 







Figure 8: KAP1 stable knockdown increases HIV-1 integration in HeLa cells. (a) Expression of KAP1 in HeLa 
cells clones (H14a, H18 and H19) stably knocked down with KAP1 shRNA expressed by a lentiviral vector 
(GIPZ-sh-KAP1) and in control HeLa cells expressing a four point mutations mismatched KAP1-shRNA (GIPZ-
sh-MM). Immunoblot was performed using KAP1 antibodies and re-probed with Tubulin antibodies to 
check for protein loading. (b-e) HeLa cells stably silenced for KAP1 and control cells were infected with 
NL4.3-Luc HIV-1 virus (pseudotyped by VSV-G envelope) and analyzed for luciferase activity (Luc Activity) at 
48 hours post-infection (hpi) (b) and by Q-PCR for late reverse transcripts at 24 hpi (c), 2-LTR circles at 24 
hpi (d) and integrated HIV-1 DNA at 15 dpi (e). All graphs are represented in fold increase with respect to 





Figure 9: KAP1 stable knockdown increases HIV-1 integration in HEK293T cells. (a) Expression of KAP1 in 
HEK293T cells (T-pool) and cell clones (T14 and T15) stably knocked down with KAP1 shRNA expressed by a 
lentiviral vector (GIPZ-sh-KAP1) and in control HEK293T cells expressing four point mutations mismatched 
KAP1-shRNA (GIPZ-sh-MM). Immunoblot was performed using KAP1 antibodies and re-probed with 
Tubulin antibodies to check for protein loading. (b-e) HEK293T cells stably silenced for KAP1 were infected 
with NL4.3-Luc HIV-1 virus (pseudotyped by VSV-G envelope) and analyzed for luciferase activity (Luc 
Activity) at 48 hours post-infection (hpi) (b) and by Q-PCR for late reverse transcripts at 24 hpi (c), 2-LTR 
circles at 24 hpi (d) and integrated HIV-1 DNA at 15 dpi (e). All graphs are represented in fold increase with 
respect to control cells (sh-MM) (± s.d. from at least two independent experiments). 
 
7- KAP1 over-expression decreases HIV-1 infectivity and integration 
 
The enhancement of viral integration in conditions of low KAP1 expression suggests that 
this factor negatively regulates viral infectivity through integration. To further verify this 
hypothesis the reciprocal experiment was performed by infecting with NL4.3-Luc HIV-1 
virus cells transfected with a plasmid expressing KAP1. Cells over-expressing KAP1 
(Figure 10a) showed almost 50% less luciferase activity as compared to cells transfected 
with an empty plasmid (Figure 10b), demonstrating that KAP1 negatively affect viral 
infectivity. To investigate which step of viral replication is affected by high KAP1 
expression, Q-PCR were performed. Accordingly to luciferase results, quantitative Alu-PCR 
analysis revealed that proviral DNA is significantly reduced by almost 50% in cells over-
expressing KAP1 as compared to control cells (Figure 10c), while total viral DNA analyzed 
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with late reverse transcript primers remained significantly unaltered in these conditions 
(Figure 10d). 
In conclusion, KAP1 over-expression inhibits HIV-1 infectivity by affecting specifically viral 
integration. This confirms the reciprocal effects obtained by KAP1 knockdown experiments. 
 
 
Figure 10: KAP1 over-expression decreases HIV-1 integration in HEK239T cells. (a) Expression of KAP1 in 
HEK293T cells transfected with KAP1 (pcDNA-KAP1), empty vector (pcDNA) and un-treated cells. 
Immunoblot was performed using KAP1 antibodies and re-probed with Tubulin antibodies to check for 
protein loading. (b-d) HEK293T cells over-expressing KAP1 (pcDNA-KAP1) and control cells (pcDNA) were 
infected with NL4.3-Luc (VSV-G) HIV-1 virus and analyzed for luciferase activities (Luc Activity) 48 hpi (b), 
by Q-PCR for integrated HIV-1 DNA (Alu-PCR) at 48 hpi (c) and late reverse transcripts 24 hpi (d). All 
graphs are represented in fold increase with respect to control cells (± s.d. from at least two independent 
experiments). 
 
8- KAP1 does not affect HIV-1 transcription  
Since KAP1 is a transcriptional co-repressor (Sripathy et al., 2006), in order to assess its 
activity on viral events that do not depend on integrase activity, such as transcription, 
infectivity experiments were performed using a mutant HIV-1 viral clone containing an 
inactivating mutation in integrase gene (D64E) and a luciferase reporter gene under LTR 
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viral promoter. In fact, even though no proviruses originate from this viral clone, circular 
un-integrated viral cDNA forms could sustain gene expression from LTR (Engelman et al., 
1995). HeLa cells stably knocked down for KAP1 (H14a, H18 and H19) (Figure 8a) as 
well as HEK239T stably silenced for the same gene (T-pool, T14 and 15) (Figure 9a) and 
their respective not silenced control cells (sh-MM) were infected with D64E HIV-1 virus 
pseudotyped by VSV-G envelope and infectivity was assessed two days post infection by 
measuring luciferase activities. The levels of luciferase activity remained unchanged in 
either HeLa or HEK293T KAP1 knockdown cells comparing to the not silenced cells (sh-
MM) (Figure 11a and b), suggesting that KAP1 does not affect LTR transcription activity 
of HIV-1 at least in pre-integration steps.  To further verify the independence of HIV-1 
promoter from KAP1, pNL4.3-Luc was transfected in KAP1 Knockdown HeLa cells and 
luciferase produced exclusively upon viral promoter activation was evaluated. As shown in 
Figure 11c no differences in luciferase activity was observed in KAP1 silenced cells as 
compared to control cells, further proving the lack of activity of KAP1 on viral transcription 
even independently from virus infection.  
Finally, in order to investigate whether KAP1 affects HIV-1 transcription following 
integration and chromatinization of HIV-1 DNA, cell lines containing a stably integrated 
virus (J-Lat A1 cells) were knocked down for KAP1 to control the viral gene expression. In 
fact, J-Lat A1 are jurkat T cells that carry a latent single copy of HIV-1 vector containing 
green fluorescent protein (GFP) as reporter gene under LTR control (Jordan et al., 2003). 
HIV-1 transcription could be activated in J-Lat A1 cells following treatment with phorbol 
esters (TPA) (Jordan et al., 2003). Transient KAP1 knockdown of latent or activated J-Lat 
A1 cells has been performed using a pool of lentiviral vectors (LKO.1) that express five 
different short hairpin RNAs targeting KAP1 gene (sh-5-KAP1). Not silenced control cells 
were untreated (-) or transduced with AIP lentiviral vector. Three days post-transduction 
with LKO.1-sh-5-KAP1 and AIP vectors, latent and activated J-Lat A1 cells were analyzed 
for KAP1 expression by Western blot analysis and for GFP expression detected by the 
Fluorescence-activating cell sorter (FACS) (Figure 11d). The percentage of GFP positive 
cells in non-activated J-Lat A1 cells knocked down for KAP1 (sh-5-KAP1) was as low as the 
value of not silenced cells (- or AIP) about 0.6% (Figure 11d, graph, first three 
columns from left), suggesting that KAP1 does not activate transcription of latent 
integrated HIV-1 virus. Moreover, in TPA activated not silenced J-Lat A1 cells (J-Lat 
A1+TPA), the percentage of GFP positive cells was increased by 60% compared to that of 
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not activated cells, however, even under these conditions KAP1 knockdown (sh-5-KAP1) 
did not vary the percentage of GFP expressing cells (Figure 11d, graph, last three 
columns from left), indicating that KAP1 does not affect the transcription of an active 
integrated HIV-1 virus.  In conclusion KAP1 does not regulate HIV-1 transcription further 
sustaining its role specifically at the integration. 
 
Figure 11:  KAP1 does not regulate transcription activity of HIV-1 LTR promoter. (a) Stable KAP1 
knockdown HeLa cell clones (H14a, H18 and H19) and control cells expressing a mismatched KAP1 shRNA 
(sh-MM) were infected with D64E HIV-1 virus. Luciferase activity was evaluated at 48 hpi (Luc Activity). (b) 
As in (a) using HEK293T cells (T-pool) and cell clones (T14 and T15) KAP1 stably knocked down and control 
cells expressing a mismatched KAP1-shRNA (shMM). In (a) and (b) graphs are represented in fold increase 
of infectivity of KAP1 knockdown cells with respect to control cells. (c) HeLa cells KAP1 stably knocked down 
(H14a, H18 and H19) and control cells (sh-MM) were transfected with pNL4.3.Luc.R-E- HIV-1 together with 
pCMV-Renella luciferase to normalize for transfection efficiency. Results are represented as a ratio of firefly 
luciferase (pNL4.3.Luc.R-E-) to Renella luciferase (pCMV-Renella). (d) Percentage of GFP positive J-lat A1 
cells measured by FACS, non activated or TPA-activated following KAP1 knockdown (sh-5-KAP1). Expression 
of KAP1 in non activated or TPA-activated J-lat A1 cells following KAP1 knockdown (sh-5-KAP1) and in 
control cells (AIP) was verified by immunoblot using -KAP1 antibodies. Loaded protein amounts were 
controlled by -Tubilin antibodies. (± s.d. from at least two independent experiments). 
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9- Human KAP1 does not inhibit integration of murine leukemia virus (MLV) 
In order to investigate whether human KAP1 could inhibit infection of other retroviruses, 
integration assays were performed with a gammaretrovirus, Moloney murine leukemia 
virus (MLV). HeLa cells were transiently transfected with a pool of si-RNAs against KAP1 
gene (si-KAP1) and control cells were treated with a pool of non targeting si-RNAs (si-
CTR). KAP1 expression was checked by Western blot analysis and showed a decrease in 
the levels of the protein following siRNA treatment (siKAP1) as compared to control cells 
(siCTR) (Figure 12a). At this time point cells were infected with either NL4.3-Luc HIV-1 
or an MLV vector carrying luciferase reporter gene (MLV-Luc), both pseudotyped with 
VSV-G envelope. The luciferase activity, measured at 48 hours post infection, was 
increased about three fold in KAP1 knockdown HeLa cells (si-KAP1) infected with HIV-1 as 
compared to control cells (si-CTR) while the MLV infectivity was unchanged (Figure 12b). 
Total viral cDNA at 24 hours post infection and integrated viral DNA at 2 weeks post 
infection were measured by Q-PCR using primers that target luciferase gene of NL4.3-Luc 
and MLV-Luc. Consistently with the luciferase data, HIV-1 integrated DNA was increased in 
the KAP1 transiently knocked down HeLa cells (si-KAP1) of almost 4 fold as compared to 
not silenced cells (si-CTR), while MLV integrated DNA did not change following KAP1 
knockdown, suggesting that human KAP1 does not inhibit MLV integration (Figure 12c). 
The total viral cDNA of HIV-1 and MLV were not varied in silenced cells as compared to 
their respective not silenced infected cells, indicating that KAP1 does not affect reverse 
transcription neither of HIV-1 nor of MLV (Figure 12d). 
 
Figure 12: Human KAP1 does not affect MLV integration in HeLa cells. (a) Expression of KAP1 in HeLa cells 
knocked down with smart pool siRNAs (siKAP1) and control HeLa cells treated with a pool of non targeting 
siRNAs (siCTR). (b-d) HeLa KAP1 knockdown cells were infected with HIV-1 or with MLV viruses and 
analyzed for luciferase activity at 48 hpi (b) and analyzed by Q-PCR for integrated viral DNA at 15 dpi (c) 
and late reverse transcripts at 24 hpi (d). The si-CTR cells were infected separately with HIV-1 and with 
MLV, in the graph are represented in a unique column because both infections are normalized to one. (± 
s.d. from at least two independent experiments).  
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These data demonstrate that KAP1 specifically inhibits HIV-1 and not MLV at the 
integration level. The unchanged transcription activity of MLV in KAP1 Knockdown HeLa 
cells is perfectly in line with the previous report (Wolf and Goff, 2007) that showed that 
KAP1 does not affect MLV transcription in differentiated cells.  
 
10- KAP1 interaction decreases integrase acetylation 
Interaction assays reported in section n° 4 of RESULTS showed that KAP1 association with 
integrase is enhanced by acetylation of the viral protein. Therefore, in the attempt to 
delineate the molecular mechanism of KAP1 interference on viral infectivity, integrase 
acetylation has been analyzed relatively to KAP1 expression. To this aim integrase was 
expressed in HEK293T cells together with KAP1 and the acetylation levels were evaluated 
using antibodies against acetylated integrase in Western blot experiments. The over-
expression of KAP1 significantly decreases the acetylation of integrase as compared to 
integrase expressed in the absence of exogenous KAP1 (Figure 13a, upper panel). The 
expression of KAP1 and integrase was controlled by blotting the same membrane with 
anti-KAP1 and anti-integrase antibodies respectively (Figure 13a, middle and lower 
panels). The level of integrase acetylation was then analyzed in HeLa cell clones stably 
knocked down for KAP1 (H14a, H18 and H19) (Figure 8a). Flag-integrase was expressed 
in silenced HeLa cell clones and control cells and then immunoprecipitated with -Flag 
antibodies and analyzed by Western blot with antibodies specific for acetylated integrase. 
The acetylation levels of Flag-integrase were significantly higher in KAP1 knockdown HeLa 
cells as compared to control cells expressing a mismatched KAP1 shRNA (sh-MM) (Figure 
13b, upper panel). In this experiment total amounts of integrase were checked by 
blotting the same membrane with anti-Flag antibodies (Figure 13b, lower panel).   









Figure 13: KAP1 decreases HIV-1 integrase acetylation. (a) Flag-integrase (Flag-IN) was expressed in 
HEK293T with or without exogenous KAP1 (pcDNA-KAP1). Flag (IN) immunoprecipitates were blotted with 
anti-acetylated IN specific antibodies (AcIN) to determine IN acetylation levels. Expression of KAP1 and 
total IN was determined by immunoblot using KAP1 and IN antibodies respectively. (b) KAP1 knockdown 
increases IN acetylation. Flag-IN was expressed in either HeLa cell clones stably knocked down for KAP1 by 
shRNA (H14a, H18 and H19) or in HeLa cells expressing mismatched KAP1-shRNA (sh-MM). Flag (IN) 
immunoprecipitates were blotted with anti-acetylated IN antibodies (AcIN) to detect acetylation levels; total 
IN was detected by re-probing with Flag antibodies. 
 
11- KAP1 mediates HDAC1 binding to integrase 
KAP1 has been reported to tether HDACs to acetylated non-histones protein to induce 
their deacetylation such as p53 (Tian et al., 2009; Wang et al., 2005a), E2F1 (Wang et al., 
2007a) and STAT3 (Tsuruma et al., 2008). Therefore, since we found that KAP1 down-
regulates integrase acetylation we sought to investigate whether HDACs form a complex 
with integrase and KAP1. The initial investigations aimed to verify whether integrase 
acetylation is regulated by HDAC activity. To reach this aim, HEK293T cells expressing 
pCMV-IN were treated with an HDAC inhibitor, the trichostatin A (TSA). As shown in 
Figure 14a, the inhibition of cellular HDACs by TSA enhanced the acetylation level of 
integrase, indicating that this modification is regulated by the cellular deacetylases. To 
further verify this data, HEK293T lysates expressing Flag-IN were immunoprecipetated by 
anti-Flag antibodies and the deacetylase activity of these Flag-immunoprecipitates was 
detected using an in vitro fluorescence-based assay. Figure 14b shows that Flag-IN has a 
deacetylase activity indicating the association of HDACs with integrase in vivo. In addition, 
when the TSA was added to the in vitro deacetylase reaction, the Flag-IN deacetylase 
activity was inhibited further sustaining the specificifity of the association of HDACs with 
integrase (Figure 14b). In order to explore the cellular HDACs associated with integrase 
in vivo, HEK293T cells were co-transfected with Flag-tagged HDAC1 or HDAC3 together 
with integrase HA-tagged. Similar amounts of HDAC1 and HDAC3 were 
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immunoprecipitated (Figure 14c, third panel from top) and high levels of integrase was 
found associated with HDAC1 and much less with HDAC3 (Figure 14c, upper panel). 
Interestingly, by blotting the same membrane with anti-KAP1 antibodies, endogenous 
KAP1 was detected in the HDAC1 complex but not with HDAC3 (Figure 14c, third panel 
from top). Lysates were finally controlled for total amounts of integrase expression 
(Figure 14c, lower panel). These data suggest that integrase forms a complex with 
HDAC1 and KAP1. To explore the hypothesis that the association of integrase with HDAC1 
is mediated by KAP1, the binding of HDAC1 to integrase was checked in cells over-
expressing KAP1. Higher levels of HA-integrase were associated with Flag-HDAC-1 in cells 
over-expressing KAP1 as compared to control cells (Figure 14d, upper panel and 
second panel from top respectively). The levels of HDAC1 and integrase expression were 
verified with anti-Flag and anti-HA antibodies respectively (Figure 14d, third panel from 
top and lower panel). Same co-immunoprecipitation experiments (Figure 14d) were 
performed using an untagged IN (pCMV-INw). As shown in Figure 14e (upper panel) 
Flag-HDAC1 was more associated with untagged integrase when KAP1 was over-
expressed in HEK293T cells (Figure 14e, second panel from top). Same levels of Flag-
HDAC1 and untagged integrase were detected with anti-Flag and anti-integrase 
antibodies, respectively, in cells over-expressing or not exogenous KAP1 (Figure 14e, 
third panel from top and lower panel respectively). These results strongly suggest that 
KAP1 plays a role in integrase/HDAC1 complex formation. 
To further prove this hypothesis HeLa cells stably knocked down for KAP1 (H14a, H18 and 
H19) (Figure 8a) were transfected with both HA-integrase and Flag-HDAC1, and 
following HDAC1 immunoprecipitation the amounts of associated integrase were evaluated 
by Western blot. In conditions of low KAP1 expression the levels of integrase complexed 
with HDAC1 are strikingly lower than control cells expressing mismatched KAP1 shRNA 
(sh-MM) (Figure 14f, upper panel). The levels of integrase and HDAC1 expressed in 
control cells (sh-MM) and in HeLa cell silenced clones were similar (Figure 14f, middle 
and lower panel respectively). In conclusion these data clearly demonstrate that 







Figure 14:  HDAC1 associates with integrase and KAP1 mediates IN/HDAC1 complex formation. (a) 
HEK293T cells expressing pCMV-IN were treated or not with TSA and the lysates were analyzed by western  
blot with -AcIN and with -IN. (b) Graphic representation of HDAC activity associated with Flag and Flag-
IN immunoprecipitates treated or not with TSA determined using a fluorimetric-based assay. (c) HDAC1 is 
complexed with IN and KAP1. HA-IN was co-expressed with either Flag-HDAC1 or Flag-HDAC3 in HEK293T 
cells. Flag immunoprecipitates were blotted with HA (IN), KAP1 and Flag (HDAC1 and HDAC3) 
antibodies. Total IN was detected by HA immunoblot. (d) KAP1 increases the association of HDAC1 with 
HA-IN. HA-IN and Flag-HDAC1 were coexpressed in HEK 293T cells with or without exogenous KAP1 
(pcDNA-KAP1) and -Flag (HDAC1) immunoprecipitates were blotted with -HA (IN) antibodies. The 
expression levels of KAP1, HDAC1 and IN were controlled by immunoblot using the indicated antibodies. (e) 
KAP1 increases the association of HDAC1 with untagged-IN. IN and Flag-HDAC1 were co-expressed in 
HEK293T cells with or without exogenous KAP1 (pcDNA-KAP1). Flag (HDAC1) immunoprecipitates were 
blotted with -IN antibodies. The expression levels of KAP1, HDAC1 and IN were controlled by immunoblot 
using the indicated antibodies. (f) KAP1 knockdown decreases the HDAC1/IN complex formation. HA-IN and 
Flag-HDAC1 were co-expressed in KAP1 stably knocked down cell clones (H14a, H18 and H19) and in control 
mismatched shRNA HeLa cells (sh-MM). Flag (HDAC1) immunoprecipitates were blotted with HA (IN) 




12- KAP1 inhibits HIV-1 integration by targeting acetylated lysines of integrase 
through HDAC1  
Results here reported indicate that KAP1 lowers integrase acetylation through HDAC1 
tethering. Since our previous report demonstrate that acetylation of integrase positively 
regulates viral integration (Cereseto et al., 2005; Terreni et al., 2010), we therefore 
hypothesized that in opposition HDAC1 mediated deacetylase activity might down-regulate 
HIV-1 integration. To explore this hypothesis, we initially investigated whether the 
deacetylase activity regulates HIV-1 integration. Therefore, HeLa cells were treated with 
the HDAC inhibitor trichostatin A (TSA), infected with NL4.3-Luc HIV-1 and analyzed by Q-
PCR for the late reverse transcripts and for integrated viral cDNA (Alu-LTR) at 24 hours 
post infection. As shown in Figure 15a, the inhibition of cellular HDACs by TSA enhances 
HIV-1 integration about 3 fold as compared to control cells treated with DMSO, wihile the 
amounts of late reverse transcripts were unchanged (Figure 15b). This result 
demonstrates that the deacetylase activity inhibits viral integration. To verify the role of 
HDAC1 in this inhibition, HeLa cells were knocked down for HDAC1 and infected with HIV-
1 in order to control integration in these cells. HeLa were treated transiently with a pool of 
siRNA directed against HDAC1 (si-HDAC1) and control not silenced cells were treated with 
a pool of non targeting siRNA (si-CTR) (Figure 15c). Two days post siRNA treatment cells 
were infected with NL4.3-Luc HIV-1 virus. The proviral DNA was evaluated by quantitative 
Alu-PCR at 48 hours post-infection showing that in conditions of low HDAC1 expression 
the integration was significantly increased of almost 4 fold (Figure 15d). Accordingly, the 
amount of un-integrated 2-LTR circles was almost 2 folds decreased (Figure 15e). To 
verify that HDAC1 specifically affects the integration reaction the total viral DNA was also 
quantified showing no major alteration of HIV-1 reverse transcription in cells silenced for 






Figure 15: HDAC1 inhibits HIV-1 integration. (a-b) HeLa cells were treated with TSA or DMSO, infected 
with NL4.3-Luc (VSV-G) HIV-1 and analyzed by Q-PCR for integrated HIV-1 cDNA (Alu-LTR) at 24 hpi (a) 
and for late reverse transcripts at 24 hpi (b). (c) Expression of HDAC1 in HeLa cells transiently knocked 
down with smart pool siRNA (siHDAC1) and in control HeLa cells treated with a pool of non-targeting siRNA 
(si-CTR). Immunoblot was performed using HDAC1 antibodies and re-probed with Tubulin antibodies to 
check for protein loading. (d-f) HeLa cells transiently knocked down for HDAC1 were infected with NL4.3-
Luc (VSV-G) HIV-1 and analyzed by Q-PCR for integrated HIV-1 DNA (Alu-LTR) at 48 hpi (e) 2-LTR DNA 
circles at 24 hpi (e) and late reverse transcripts at 24 hpi (f). (± s.d. from at least two independent 
experiments). 
 
To verify whether KAP1 inhibition of viral integration might occur through HDAC1 
deacetylase activity tethered to integrase, infections were performed in cells where the 
expression of both proteins was simultaneously modulated. HEK293T cells over-expressing 
KAP1, by transfecting an ectopic cDNA (pcDNA-KAP1), were siRNA-silenced or not for 
HDAC1 gene (Figure 16a) and subsequently infected with NL4.3-Luc HIV-1 virus. Control 
cells were transfected with both an empty expression vector and a pool of non targeting 
siRNAs. To verify the level of KAP1 and HDAC1 expression Western blot analysis was 
performed in the same cells used for infection. As shown in Figure 16a the levels of KAP1 
is increased in both cells transfected with KAP1 regardless the anti HDAC1 siRNA 
treatment, while HDAC1 expression is specifically reduced in cells treated with specific 
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siRNAs. Accordingly to the data shown in Figure 10c, integration of viral cDNA, 
determined by quantitative Alu-PCR at 48 hours post infection, was reduced of almost 
50% in cells over-expressing KAP1 as compared to control cells (Figure 16b, first and 
second columns from left). However, over-expression of KAP1 does not show any 
inhibitory effect in cells that were simultaneously silenced for HDAC1 (Figure 16b, third 
column from left). Under these experimental conditions the total viral cDNA did not 
varied (Figure 16c). Therefore, these data clearly demonstrate that KAP1 integration 
inhibitory effect occurs through HDAC1 activity.  
 
Figure 16: KAP1 inhibits HIV-1 integration through HDAC1. (a) Expression of KAP1 and HDAC1 in HEK293T 
cells transfected with pcDNA-KAP1 and transiently knocked down with si-HDAC1. Immunoblots were 
performed using the indicated antibodies. (b-c) KAP1 inhibition of HIV-1 integration is reversed by HDAC1 
silencing. HEK 293T cells over-expressing KAP1 (pcDNA-KAP1) were co-treated or not with si-HDAC1, 
subsequently infected with NL4.3Luc (VSV-G) HIV-1 and analyzed by Q-PCR for integrated HIV-1 DNA (Alu-
PCR) at 48 hpi (b) and for total HIV-1 DNA at 24 hpi (c). (± s.d. from at least two independent 
experiments). 
 
In order to investigate the relevance of integrase lysine acetylation sites (K264, K266 and 
K273) in KAP1 inhibition during HIV-1 infection, HeLa cells stably knocked down for KAP1 
(H14a and H18) and not silenced control cells (sh-MM) (Figure 8a) were infected with 
single-round HIV1 viruses either wild type NL4.3-Luc or mutated in integrase at three 
acetylation sites to arginine (NL4.3-Luc-3mut). As previously shown (Terreni et al., 2010), 
this virus was almost 5-fold less infectious than the parental NL4.3-Luc as measured by 
luciferase activity 48 hours post infection (Figure 17a, first and third column from left). 
However, while the wild-type virus showed increased infectivity in KAP1 knockdown HeLa 
cells of almost  2 to 3 fold, the mutant virus was unaffected (Figure 17a). Similarly,  
integrated viral DNA of wild type virus at 15 days post infection were significantly  
increased about 2 to 2,5 fold in HeLa knockdown cells (sh-KAP1), while, integrated NL4.3-
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Luc3mut DNA were not significantly affected, comparing to not silenced control cells (sh-
MM) (Figure 17b). Therefore, KAP1 inhibition of HIV-1 integration is dependent on the 




Figure 17:  KAP1 does not affect integration of NL4.3-Luc-3mut carrying IN mutated at acetylable lysines 
(K264, 266, 273R). KAP1 knockdown (H14a and H18) and control (shMM) HeLa cell clones were infected 
with NL4.3-Luc or NL4.3-Luc-3mut and analyzed for luciferase activity at 48 hpi (a) and integrated HIV-1 
DNA by qPCR (Alu-PCR) 48 hpi (b). All graphs are represented in fold increase with respect to control cells 
(± s.d. from at least two independent experiments). 
 
13- Validation of KAP1 inhibition of HIV-1 integration in natural HIV-1 target T 
cells: CEMss and primary blood lymphocytes (PBLs) 
In order to confirm KAP1 inhibition of HIV-1 integration in natural HIV-1 target cells, 
CEMss cell lines and primary blood lymphocytes (PBLs) from four healthy donors were 
knocked down for KAP1 and infected with either wild type NL4.3-Luc HIV-1 virus or with 
NL4.3-Luc-3mut mutated virus at the integrase lysine acetylation sites  to arginine (K264, 
K266 and K273R). CEMss cells were silenced by a pool of five short hairpin RNAs (sh-5-
KAP1) expressed from lentiviral vector (LKO.1) that target KAP1 gene and control cells 
were transduced with GIPZ lentiviral vector (Figure 18a). Three days post transduction 
cells were infected with NL4.3-Luc or NL4.3-Luc3mut viruses and analyzed by quantitative 
real time PCR (Q-PCR) for total viral cDNA at 24 hours post infection and for integrated 
viral DNA at two weeks post infection. Consistently with results observed with HeLa and 
HEK293T cells in sections n° 5 and 6 of RESULTS, knockdown of KAP1 in CEMss cells does 
not affect reverse transcription (Figure 18c) but increases significantly viral integration of 
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almost 3 fold of NL4.3-Luc HIV-1 virus while affects marginally integration of mutated 
virus at the three lysines targeted for acetylation by p300 (NL4.3-Luc3mut) (Figure 18b).  
 
Figure 18: KAP1 inhibition of HIV-1 integration occurs in natural HIV-1 target cells: CEMss T cell lines and 
primary blood lymphocytes (PBLs). (a) Left panel: expression of KAP1 in a T-cell line (CEMss) transiently 
knocked down using a cocktail of lentiviral vectors (LKO.1) expressing five different shRNA sequences 
targeting the KAP1 gene (sh-5-KAP1). Right panel: expression of KAP1 in CEMss Tcells transiently knocked 
down for KAP1 using a shRNA that target 3‘UTR of KAP1 gene (sh-3‘KAP1) or back-complemented by 
expression of KAP1 cDNA resistant to sh-3‘KAP1 from a lentiviral vector (AIP). Control not silenced cells were 
transduced with GIPZ lentiviral vector. (b-c) KAP1 knockdown (sh-5-KAP1), (sh-3‘KAP1), back-
complemented (sh-3‘KAP1+ KAP1) and control (GIPZ) CEMss cells were infected with NL4.3-Luc (VSV-G) 
HIV-1 virus and analyzed by Q-PCR for integrated HIV-1 DNA 15 dpi (b) and for late reverse transcripts at 
24 hpi (c). KAP1 knockdown (sh-5-KAP1) and control (GIPZ) CEMss cells were simultaneously infected with 
NL4.3-Luc (VSV-G) HIV-1 virus and analyzed for the integrated provirus (b) and for the total viral cDNA(c). 
(d) Expression of KAP1 in stimulated primary T-cells (PBLs) transiently knocked down with smart pool siRNA 
(si-KAP1 and si-CTR) by Amaxa transfection. (e-f) KAP1 knockdown (si-KAP1) and control (si-CTR) T-cells 
were infected with NL4.3-Luc or NL4.3-Luc-3mut (VSV-G) HIV-1 viruses and analyzed by Q-PCR for 
integrated HIV-1 DNA (Alu-PCR) 48 hpi (e) and for late reverse transcripts at 24 hpi (f). All graphs are 
represented in fold increase with respect to control cells (± s.d. from at least three independent 
experiments). 
 
These results were further confirmed in stimulated PBLs from four healthy donors that 
were transiently silenced for KAP1 with a pool of siRNAs (siKAP1) (Figure 18d), infected 
with either NL4.3-Luc or NL4.3-Luc3mut viruses and analyzed by Q-PCR for late reverse 
transcripts at 24 hours post-infection and for integrated viral DNA (Alu-PCR) at 48 hours 
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post infection. The integration of wild type virus in silenced PBLs was significantly 
enhanced of almost 3 fold as compared to PBLs treated with control siRNAs (si-CTR), 
while, the integration of triple mutant virus was not affected (Figure 18e). Accordingly to 
cell lines KAP1 knockdown does not affect reverse transcription in stimulated PBLs (Figure 
18f). Furthermore, as shown before with HeLa cells in section n° of 5 RESULTS, the 
expression of an exogenous KAP1 (AIP-HA-KAP1) resistant to sh3‘KAP1 reversed the 
increase of integration in knockdown cells and showed no significant difference with basal 
levels of integration of not silenced cells (GIPZ) (Figure 18b), without affecting total viral 
cDNA (Figure 18c). 
These results indicate that the inhibitory effect of KAP1 on HIV-1 integration occurs in the 
natural target cells of the virus and depends on the acetylable lysines of integrase. 
 
14- Determination of the region of KAP1 required for the inhibition of HIV-1 
integration 
In order to determine which region of KAP1 is required for HIV-1 inhibition, different 
fragments of the cellular protein (schematized in Figure 19a) were tested in viral 
integration. HEK293T cells over-expressing the three KAP1 fragments fused to an HA tag, 
1-381, 1-616 and 617-835 (Figure 19b, left panel) were tested for viral infectivity. As 
shown in Figure 19b, right panel, integration of HIV-1 was inibited at the same extent 
as full length by the 1-381 and 1-616 fragments, while the 617-835 fragment showed no 
decreased integration. Rather, cells expressing the 617-835 fragment showed increased 
integration efficiency as compared to baseline. To further verify the role of each KAP1 
fragments in HIV-1 infectivity reciprocal experiments were performed in KAP1 knocked 
down CEMss cells expressing each single domain resistant to KAP1 shRNA (Figure 19c, 
left panel). Expression of 1-381, 1-616 restored viral integration to baseline at the same 
extent as full length KAP1, while the 617-835 fragment could not revert KAP1 knocked 











Figure 19. KAP1 domains required for HIV-1 inhibition. (a) Schematic representation of HA-tagged KAP1 FL 
(1-835) and deletion mutants (1-381, 1-616 and 617-835). (b) Integrated NL4.3-Luc HIV-1 DNA (Alu-LTR) 
48 hpi of HEK293T cells expressing KAP1 full length (1-835) or KAP1 deletion mutants (1-381, 1-616 and 
617-835). Protein expression was verified by immunoblot. (c) Integrated NL4.3-Luc HIV-1 DNA 25 dpi in 
CEMss cells knocked down for KAP1 (sh3‘KAP1) and back-complemented with either KAP1 full length (1-835) 
or KAP1 deletion mutants (1-381, 1-616 and 617-835). Protein expression was verified by immunoblot. (± 
s.d. from at least two independent experiments). 
 
Since our results indicate that KAP1 activity on HIV-1 integration occurs through HDAC1, 
we then evaluated the binding of each KAP1 fragment with HDAC1. HEK293T cells were 
co-transfected with Flag-HDAC1 together with each fragment analyzed for HIV-1 
integration. As shown in Figure 20a, left panel HDAC1 co-precipitated with fragment 1-
616 at the same extent as full length KAP1. Due to different migration conditions, a 
separate gel reported in the right panel of Figure 20a, shows that fragment 1-381 is 
positive for HDAC1 binding, while the 617-835 fragment is negative. Therefore, the 
associations of HDAC1 with the 1-381 and 1-616 correlate with the capacity of these 
fragments to inhibit viral integration and to reverse the KAP1 knockdown phenotype. On 
the contrary, fragment 617-835 unable to bind HDAC1 does not carry the inhibitory 
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activity of KAP1 both in over-expression and in knockdown experiments. In order, to 
further correlate the capacity of KAP1 fragments in the inhibition of HIV-1 integration, we 
also investigated the binding between KAP1 domains and HIV-1 integrase. For this aim, 
we performed in vivo co-immunoprecipitation experiments in HEK293T cells by using the 
KAP1 fragments (1-381, 1-616, 617-835) fused to HA and co-expressed with Flag-IN. As 
shown in Figure 20b, the fragment which corresponds to the RBCC domain (1-381) 
positively binds integrase. Conversely no binding was observed with the 617-835 fragment 
corresponding to the PHD-Bromo domain. To further investigate the specificity of 1-381 
fragment in the interaction with the acetylated integrase, we performed co-
immunoprecipitation experiments with integrase wild-type (Flag-INw) or mutated in the 
three acetylable lysines (K264R, K266R and K273R) (Flag-INm). These experiments 
showed that the 1-381 fragment binds preferentially the acetylated integrase (Figure 
20c). Therefore, these results further sustain the role of the RBCC N-terminal region in 
the association between KAP1 and acetylated integrase. Moreover, these interaction data 
are consistent with the infectivity results (Figure 19) showing that the KAP1 domain 
responsible for inhibiting viral integration spans the 1-381 region (RBCC) while the 617-
835 region (PHD-Bromo) which does not bind integrase had no effect on viral integration.  
Collectively, these data clearly show that KAP1 mediated recruitment of HDAC1 to 
integrase and the association of KAP1 with the acetylated form of integrase are both 
necessary for the inhibition of viral integration. These results further sustain the 















Figure 20. The minimal domain of KAP1 required for the inhibition of HIV-1 integration (1-381) binds 
HDAC1 and preferentially the acetylated form of integrase. (a) Lysates from HEK293T cells co-expressing 
Flag-HDAC1 with HA-KAP1 full length (1-835) or HA-KAP1 (1-616) (left panel) and lysates from HEK293T cell 
co-expressing Flag-HDAC1 with HA-KAP1 full length (1-835), HA-KAP1 (1-381) or HA-KAP1 (617-835) (right 
panel) were immunoprecipitated withFlag antibodies and blotted with -HA antibodies. Expression levels 
of KAP1 full length or deletion mutants and HDAC1 were verified using the indicated antibodies. (b) Lysates 
from HEK293T cells co-expressing Flag-IN with HA-KAP1 full length (1-835), HA-KAP1 (1-381), HA-KAP1 (1-
616) or HA-KAP1 (617-835) were immunoprecipitated withFlag antibodies and blotted with -HA 
antibodies. Expression levels of KAP1 full length or deletion mutants and IN were verified using the indicated 
antibodies. (c) Lysates from HEK293T cells co-expressing Flag-INw or Flag-INm with HA-KAP1 (1-381) were 
immunoprecipitated withFlag antibodies and blotted with -HA or -KAP1 antibodies. Expression levels of 
KAP1 (1-381) and IN were verified using the indicated antibodies. The acetylation levels of IN were detected 
using anti-acetylated IN antibodies (-AcIN).  
 
15- Expressions of KAP1 and HDAC1 in cells relevant in HIV-1 pathogenesis 
In order to investigate whether expression levels of KAP1 and HDAC1 vary in lymphocytes 
that play an important role in HIV-1 pre- or post-integration latencies, expressions of both 
proteins were checked in resting and activated primary blood lymphocytes (PBLs) and in 
CD45 RA+ naïve and CD45 RO+ memory CD4+ T cells, purified from healthy donors. 
Activated T lymphocytes are highly permissive to HIV-1 infection, whereas in resting T 
cells, despite the efficient entry of HIV-1 no viral progeny is produced. In resting 
lymphocytes there are several barriers that preclude the completion of the early steps as 
an incomplete reverse transcription or an inefficient nuclear import and integration 
(Bukrinsky et al., 1992; Zack et al., 1990; Zack et al., 1992). In addition, due to the lack 
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of c-jun kinase (JNK) activity in resting CD4 T cells,  HIV-1 integrase does not become 
phosphorylated and then stabilized by Pin1 which unable the virus to achieve an efficient 
nuclear import and integration (Manganaro et al., 2010). Memory CD4 lymphocytes have 
been demonstrated to be involved in the establishment of a latent reservoir of infected 
cells harbouring a silent integrated provirus (Chun et al., 1995; Han et al., 2007). The 
mechanisms of HIV-1 post-integration latency are poorly understood, however, many 
studies suggested a main role of a transcription inhibition (Ganesh et al., 2003; Ghose et 
al., 2001; Kao et al., 1987). As shown in Figure 21, the amounts of KAP1 and HDAC1 
were correlated to protein expressions of resting and activated PBLs, indicating no 
variation in their expression levels. Equal levels of KAP1 and HDAC1 were also detected in 
CD45RO+ memory and CD45RA+ naïve T cells (Figure 21). Therefore, these results 
indicate no variation in the expression levels of KAP1 and HDAC1 in HIV-1 permissive 
lymphocytes and in the main cells implicated in pre- and post-integration latencies.    
 
Figure 21:  KAP1 and HDAC1 expressions in Resting or Activated PBLs and in Naive (CD45RA+) or Memory 
(CD45RO+) CD4+ T cells. Equal number of Resting or Activated PBLs (2 x 106) was analyzed by western blot 
for KAP1 and HDAC1 expressions using the indicated antibodies (KAP1 and HDAC1). Protein loading was 
controlled by -Tubilin antibodies. Equal amounts of proteins (60 g) from CD45RA+ Naive or CD45RO+ 
Memory CD4+ T cells were analyzed by Western blot for KAP1 and HDAC1 expressions using the indicated 








16- Could KAP1 phosphorylation during HIV-1 infection be a way for the virus 
to escape KAP1 inhibition? 
Recently several studies reported that in response to double strand breaks (DSB) DNA 
damage, KAP1 becomes phophorylated by ATM kinase at serine 824 (S824) of its C-
terminal domain (Goodarzi et al., 2008; Goodarzi et al., 2009; White et al., 2006; Ziv et 
al., 2006). That modification has been demonstrated to displace KAP1 from DNA damage 
sites allowing chromatin relaxation and recruitment of DNA repair machinery to these sites 
(Ziv et al., 2006). Moreover, it has been shown that KAP1 phosphorylation serves to DSB 
repair in hetrochromatin region through the removal of KAP1 silencing effectors mainly 
HDAC1 and SETDB1 H3K9 methylase (Goodarzi et al., 2008; Goodarzi et al., 2009; Ziv et 
al., 2006). Interestingly, a recent study showed that in the absence of DNA damage KAP1-
HDAC1 complex is recruited to p53 through APAK, a KRAB zinc finger protein, to maintain 
p53 deacetylated and inactivated, however, in response to DNA damage ATM 
phosphorylates KAP1 causing the dissociation of KAP1 complex from p53 and therefore 
allowing the re-acetylation and the activation of p53 (Tian et al., 2009). Viral cDNA ends 
of un-integrated HIV-1 virus has been shown to be sensed by cells as DSBs thus triggering 
DNA response signaling mainly by the activation of ATM kinase (Jeanson et al., 2002; 
Kilzer et al., 2003; Lau et al., 2005; Li et al., 2001). Based on these observations, we 
asked whether HIV-1 may induce KAP1 phosphorylation which in turn would remove KAP1 
from the integrase complex. Detachment of KAP1 from integrase would then result in re-
acetylation of integrase by p300 and enhanced integration efficiency. Based on this model 
(Figure 22), induction of KAP1 phosphorylation may represent a way for HIV-1 to escape 
KAP1 inhibition. In order to explore this hypothesis, we initially investigated whether KAP1 
is phophorylated following HIV-1 infection. Therefore, HEK293T cells were infected with 
NL4.3-Luc HIV-1 virus and harvested at 2 and 4 hours post infection and then analyzed by 
Western blot using specific anti-phospho S824 of KAP1 (KAP1) antibodies. Western blot 
positive control for KAP1 antibodies was performed by treating HEK239T cells with 
neocarzinostatin (NCS) which is a radiometric drug that causes KAP1 phosphorylation by 
ATM kinase. As shown in Figure 23a (upper panel), no KAP1 phosphorylation signal has 
been detected (0 hour) in non infected cells, while, at 2 hours post infection KAP1 became 
phosphorylated and this signal was down-regulated at 4 hours post-infection. The levels of 
endogenous KAP1 were not modulated following HIV-1 infection and phosphorylation of 




Figure 22. An hypothesized model for HIV1 escape from KAP1 inhibition. The results reported above 
demonstrate that KAP1 binds acetylated integrase, decreases integrase acetylation, mediates the binding of 
integrase with HDAC1 and inhibits HIV-1 integration through HDAC1 and by acting on the acetylable lysines 
of integrase (a). To escape this KAP1 inhibition, we hypothesized that HIV-1 through its DNA ends triggers 
double strand break response which activates ATM kinase that would phosphorylate KAP1 to lead to the 
dissociation of KAP1-HDAC1 complex from integrase (b). This dissociation would result in the re-acetylation 





were barely detected in the infected HEK239T cells (Figure 23a, third panel from top 
and lower panel respectively). These data indicate that HIV-1 infection induces KAP1 
phosphorylation. In order to further investigate whether KAP1 phophorylation could occur 
in T cells following HIV-1 infection and whether is mediated by ATM kinase, CEMss cells 
were infected by NL4.3-Luc HIV-1 virus and were harvested at 1, 2, 4 and 6 hours post 
infection. In addition, CEMss cells were treated with a specific ATM inhibitor (KU55933 or 
ATMi) and harvested 2 hours post infection. To control the specificity of ATM inhibition, 
KU55933 was added to cells treated by NCS.  
Similarly to HEK293T cells, KAP1 phosphorylation was detected at 2 hours post-infection 
and no phosphorylation signal was revealed at 1, 4 or 6 hours post infection (Figure 
23b). KAP1 phosphorylation was down-regulated in cells treated by both NCS and ATMi 
comparing to cells treated only by NCS, however, the signal of KAP1 phosphorylation at 2 
hours post infection was not inhibited by ATMi (Figure 23b). This result suggests that 
KAP1 phosphorylation induced by HIV-1 is not mainly mediated by ATM kinase. In order to 
explore whether phosphorylation is somewhat related to KAP1 inhibition of HIV-1 
integration, we investigated a possible differential binding of integrase to KAP1 
phosphorylated and unmodified forms. HEK293T cells expressing Flag-IN were treated 
with the HDAC inhibitor Trichostatin A (TSA) in order to favor the in vivo acetylation of 
integrase and then were treated with NCS and KU55933. Following NCS treatment the 
phosphorylation levels of KAP1 were enhanced with respect to not treated cells or 
simultaneously treated with the ATM inhibitor (Figure 23c, third panel from top), while, 
the expression levels of KAP1 and Flag-IN were not varied under these conditions (Figure 
23c, fourth panel from top and lower panel respectively). Flag-IN was then 
immunoprecipitated and analyzed by Western blot for either total or phosphorylated KAP1. 
As shown in Figure 23c (upper panel) the levels of total KAP1 associated with Flag-IN 
were not changed neither following induction of phosphorylation nor following its inhibition 
by ATM inhibitors, indicating that KAP1 phosphorylation does not modulate the KAP1/IN 
binding. However, same membrane re-probed with anti-phospho KAP1 antibodies showed 
that no phosphorylated KAP1 was retained by Flag-IN (Figure 23c, second panel from 
top). In order to better clarify the affinity of binding of phosphorylated KAP1 to integrase, 
we wanted to investigate the binding between integrase and KAP1 phosphomutant 
(S824A), that is unable to be phosphorylated, and KAP1 phosphomimic (S824D), that 
mimics a constitutive phosphorylated KAP1. For this aim, Flag-IN was expressed in 
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HEK293T cells that were silenced for KAP1 by the sh-3‘KAP1 and back-complemented by 
the expression of either S824A or S824D phosphomutant cDNAs resistant to the sh-3‘KAP1 
in order to prevent the possible competition of binding to integrase by the endogenous 
KAP1. Flag-IN was then immunoprecipitated and analyzed by Western blot for KAP1. As 
shown in Figure 23d, upper panel, Flag-IN binds KAP1 phosphomutant (S824A) and 
KAP1 phosphomimic (S824D) with the same affinity. The expressions of Flag-IN (Figure 
23d, second panel from top) and of S824A and S824D (Figure 23d, lower panel) 
were similar. These results further indicate that the KAP1 phosphorylation does not 
modulate the affinity of binding of KAP1 with integrase. Finally, we aimed to investigate 
the role of KAP1 phosphorylation in HIV-1 integration. To reach this aim, CEMss T cells 
were knocked down for KAP1 by the sh-3‘KAP1 and back-complemented by the expression 
of the KAP1 wild type (KAP1), phosphomutant (S824A) and phosphomimic (S824D) 
resistant to the sh-3‘KAP1 (Figure 23e). At this time point, cells were infected with 
NL4.3-Luc HIV-1 virus and analyzed by Q-PCR for total HIV-1 cDNA at 24 hours post-
infection and for integrated proviruses at 15 days post-infection. Figure 23f, left panel, 
shows that KAP1 knockdown mediated by sh-3‘KAP1 enhances HIV-1 integration of almost 
2,5 fold and the KAP1 phosphomutant (S824A) was able to reverse HIV-1 integration to 
baseline as well as the wild type KAP1 (KAP1), while the KAP1 phosphomimic (S824D) 
does not have any effect on HIV-1 integration. The total viral cDNA did not vary under 
these conditions (Figure 23f, right panel). These results indicate that the 
phosphorylated form of KAP1 does not inhibit HIV-1 integration. 
In conclusion, these data demonstrate that KAP1 is phosphorylated at two hours following 
HIV-1 infection and this phophorylation is not mediated mainly by ATM kinase. Although 
KAP1 phosphorylation does not modulate the binding of KAP1 with integrase, the KAP1 
mutant (S824D) mimicking a constitutive phosphorylated KAP1 was not able to inhibit 












Figure 23: KAP1 phosphorylation in HIV-1 infection. (a) HEK293T cells were infected with NL4.3-Luc (VSV-
G) HIV-1 virus and harvested at 2 and 4 hours post infection and analyzed by Western blot for 
phosphorylated KAP1 (KAP1), total KAP1, integrase (IN) and acetylated IN (Ac-IN). (b) CEMss T cells were 
infected with NL4.3-Luc (VSV-G) HIV-1 virus and harvested at 1, 2, 4 and 6 hours post-infection; cells 
harvested at 2 hours were treated or not with ATMi (KU55933). (c) HEK239T cells expressing Flag-IN were 
treated or not with NCS and KU55933. -Flag immunoprecipitates were analyzed with -KAP1 and -KAP1 
antibodies. The expressions of phosphorylated KAP1, total KAP1 and Flag-IN were checked by immunoblot. 
(d) HEK239T cells expressing Flag-IN silenced for KAP1 (sh-3‘KAP1) were back-complemented with KAP1 
wild type (KAP1), phosphomutant (S824A) and phosphomimic resistant to the sh-3‘KAP1. -Flag 
immunoprecipitates were analyzed with -KAP1. The expressions of phosphorylated KAP1, total KAP1 and 
Flag-IN were analyzed by immunoblot. (e-f) CEMss T cells were knocked down for KAP1 (sh3‘KAP1), back-
complemented with KAP1 wild type (KAP1), phosphomutant (S824A) and phosphomimic resistant to the sh-
3‘KAP1 (e) were infected with NL4.3-Luc (VSV-G) HIV-1 virus and analyzed by Q-PCR for integrated HIV-1 





1- Potential roles in HIV-1 replication of the identified host factors binding 
acetylated integrase   
This study exploits the tethered catalysis system (Guo et al., 2004) to produce an HIV-1 
viral protein, integrase, constitutively acetylated by p300 (IN-HATw). Mass spectrometry 
analyses of the recombinant IN-HATw confirmed the in vivo acetylation of integrase at 
lysines K264, K266 and K273 by p300 HAT which are the same residues previously 
identified by site direct mutagenesis assays (Cereseto et al., 2005). The construct, verified 
to produce acetylated integrase in bacteria and in yeast, was used to screen by two-hybrid 
a human lymphocytes cDNA library. Most integrase interacting factors have been identified 
through the yeast two-hybrid approach (Al-Mawsawi and Neamati, 2007; Christ et al., 
2008; Emiliani et al., 2005; Rain et al., 2009; Van Maele et al., 2006). However, 
conventional two-hybrid screening does not allow identifying interacting factors that may 
require post translational modifications, such as acetylation, in order to bind a protein. 
From this screening we have identified thirteen cellular factors, twelve of which have 
never been reported to interact with HIV-1 integrase. The binding analyses performed by 
two-hybrid and pull down assays revealed a basal association of all factors with the 
unmodified integrase while the acetylation of the viral factor variably affects the affinity 
with the two-hybrid hits. Interestingly, Exp2, eIF3h RanBP9 and KAP1 showed higher 
affinity to acetylated integrase than to unmodified form, while acetylation did not 
modulate the binding of BTF3b, THRAP3 and HMGN2 to integrase. These results 
confirmed the starting hypothesis of this study according to which integrase acetylation 
might affect its protein-protein interactions with cellular factors.   
The newly identified factors interacting with acetylated or un-modified integrase showed 
no obvious simple sequence similarity. Nevertheless, it is plausible that integrase 
recognizes common elements present in these proteins. In fact, these factors can be 
grouped into three categories based on their functional properties: a) transcription 
regulatory and chromatin remodeling factors; b) translation regulatory and RNA binding 
proteins; c) nuclear import-export proteins.  
Interestingly, LEDGF/p75, one of the factors identified in this screening, is one of the most 
described integrase interacting protein required for efficient HIV-1 integration 
(Cherepanov et al., 2003; Emiliani et al., 2005; Llano et al., 2006; Maertens et al., 2003; 
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Shun et al., 2007; Vandekerckhove et al., 2006). This result validates the system of 
analysis employed in this study and proves that fusion of IN to the HAT domain does not 
significantly alter the integrase structure. LEDGF/p75 binds the core catalytic domain of 
HIV-1 integrase. Nevertheless, the N-terminal domain of integrase was proven to enhance 
the binding affinity with this factor (Maertens et al., 2003). Therefore, the identification of 
LEDGF/p75 in our screening might suggest that also the C-terminus of integrase and its 
acetylation could also affect IN/LEDGF-p75 interaction. Recently, it has been shown that 
integrase C-terminus is protected within HIV-1 pre-integration complex by cellular factors 
and mainly by the presence of LEDGF/p75 further sustaining the role of this domain in 
LEDGF/IN complex formation (Benkhelifa-Ziyyat et al., 2010). 
HIV-1 integration preferentially occurs in regions of the chromatin rich in transcriptionally 
active genes (Bushman et al., 2005; Mitchell et al., 2004; Schroder et al., 2002). Recent 
studies performed by sequence analysis using the ENCODE annotation (Wang et al., 
2007b) and by a visualization analysis (Albanese et al., 2008) demonstrated that HIV-1 
targets decondensed regions of the chromatin. It has been hypothesized that cellular 
factors interacting with integrase may tether the virus to appropriate sites for integration. 
Indeed, LEDGF/p75 knockdown and knockout cells show a significant reduction of 
integration frequency in transcription units (Bushman et al., 2005; Marshall et al., 2007; 
Shun et al., 2007). Nevertheless, since in the absence of LEDGF/p75 the virus still does 
not integrate randomly in the genome, additional factors may be required for integration 
specificity. The screening reported in this study, uncovered factors involved in 
transcription and chromatin structure regulation, thus good candidate proteins to tether 
HIV-1 integration. BTF3b and THRAP3, found in the two-hybrid screening, are positive 
regulators of gene transcription that act by associating with RNA polymerase II (Rachez 
and Freedman, 2001; Zheng et al., 1990). The HMNG2 protein, another two-hybrid hit, is 
involved in chromatin structure regulation by binding to nucleosomes in a DNA sequence 
independent manner (West, 2004). This factor induces chromatin decompaction, which in 
turn facilitates DNA transcription and replication (West, 2004). In fact, HMNG2 was found 
to localize in active transcription chromatin regions (Bustin, 2001; Hock et al., 1998). 
Finally, HMGA1, another HMG family member, was previously reported to stimulate HIV-1 
integration by promoting the formation of IN/cDNA complexes (Hindmarsh et al., 1999) (Li 
et al., 2000). 
125 
 
HIV-1 nuclear import occurs through still incompletely understood mechanisms (Fassati, 
2006; Yamashita and Emerman, 2006). One of the viral factors hypothesized to be 
involved in nuclear translocation is integrase which is a karyophilic protein that contains 
several putative nuclear localization signals (NLSs) (Ao et al., 2005; Armon-Omer et al., 
2004; Bouyac-Bertoia et al., 2001; Depienne et al., 2000; Devroe et al., 2003; Gallay et 
al., 1997). In our study, two proteins that regulate the nuclear importin pathway Exp2 
(CAS) and RanBP9 have been identified (Gorlich, 1998; Kutay et al., 1997; Solsbacher et 
al., 1998; Yudin and Fainzilber, 2009). These factors may trigger the nuclear import of 
integrase by importin  and β complex. However, the implications of importin factors and 
pathways have been explored for HIV-1 infectivity leading to contradictory results (Ao et 
al., 2007; Bouyac-Bertoia et al., 2001; Dvorin et al., 2002; Limon et al., 2002; Zielske and 
Stevenson, 2005). Indeed, it has been reported that integrase may lack functional NLSs 
(Depienne et al., 2001; Devroe et al., 2003) and the nuclear accumulation of integrase 
was attributed to LEDGF/p75 by tethering the viral protein to the chromatin and 
preventing its proteasomal degradation (Devroe et al., 2003; Emiliani et al., 2005; Llano et 
al., 2004b; Maertens et al., 2003). Although no role of LEDGF/p75 in pre-integration 
complex nuclear import has been found, a recent identified integrase interactor foctor, 
transportin SR2 (TNPO3) has been shown to mediate the transport of HIV-1 to the nucleus 
(Christ et al., 2008). RanBP9 is also a protein of microtubule organizing center (MTOC) 
that induces microtubule nucleation (Nakamura et al., 1998; Yudin and Fainzilber, 2009). 
Interestingly, visualization of HIV-1 particles in the cytoplasm showed that HIV-1 
accumulates near to the MTOC and associates with dynein and the microtubules network 
to migrate toward the nucleus (McDonald et al., 2002). In our two hybrid screening, we 
identified another protein that regulates microtubule organization, STMN1, through 
binding tightly tubulin and inducing microtubule destabilization (Cassimeris, 2002; Howell 
et al., 1999). These observations are in line with previous reports showing that HIV-1 
integrase binds microtubule-associated proteins such as the yeast STU2p, a centrosomal 
protein, and Dyn2p (dynein light chain protein) (de Soultrait et al., 2002; Desfarges et al., 
2009). It has been hypothesized that integrase interaction with these factors may be 
responsible for its nuclear import (de Soultrait et al., 2002; Desfarges et al., 2009). 
A recent two-hybrid screening performed with integrase of another retrovirus, the Moloney 
Murine Leukemia Virus (MoMLV),  identified  the  murine eIFs2, a subunit part of the 
translation initiation factor 3 (eIF3) complex (Studamire and Goff, 2008). Moreover, in this 
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study it was demonstrated that HIV-1 integrase does not interact with eIFs2. The human 
eIF3f, another component of eIF3 complex, was reported to inhibit HIV-1 replication at 
post-integration step by interfering with the 3‘ end processing of HIV-1 mRNAs (Valente et 
al., 2009). From our screening we identified eIF3h, another subunit belonging to the eIF3 
complex, as a factor interacting with acetylated HIV-1 integrase. Thus, since numerous 
studies report the association of retroviruses with the eIF3, this protein complex 
presumably plays an important function in the viral replication cycle, even though the 
detailed molecular mechanism has not yet been unraveled.  
One of the two-hybrid hits was eEF1A-1 factor which has been previously reported to be 
involved in HIV-1 biology. Most interestingly, in agreement with our results, a former 
study using a yeast expression experimental system suggested that integrase interacts 
with eEF1A-1 (Parissi et al., 2001). Moreover, eEF1A-1 was identified to be involved in 
HIV-1 replication by binding with the viral gag polyproteins (matrix and nucleocapsid) 
(Cimarelli and Luban, 1999) and also by activating the viral promoter (Wu-Baer et al., 
1996). All these reports imply the multi-roles of eEF1A-1 in HIV-1 replication cycle. 
One identified factor from the screening is hnRNPA2 involved in mRNA splicing and 
trafficking regulation and it has also been described to regulate HIV-1 RNA trafficking 
(Beriault et al., 2004; Shyu and Wilkinson, 2000). In line with this observation, HIV-1 
integrase has been shown to bind another RNA regulator protein Gemin2 that has been 
demonstrated to promote reverse transcription (Hamamoto et al., 2006).  
 
2- KAP1 targets acetylated integrase and inhibits HIV-1 integration through 
HDAC1  
One of the factors identified by the two hybrid screening, employed in this study, is KAP1. 
KAP1 is an ubiquitously expressed nuclear protein that belongs to TRIM family proteins 
recently implied in the innate immunity against viral infections (Kajaste-Rudnitski et al., 
2010; Nisole et al., 2005; Ozato et al., 2008; Reymond et al., 2001). The higher 
association of KAP1 with acetylated integrase as compared to the unmodified form has 
been confirmed in vivo by co-immunoprecipitation experiments in HEK293T cells, and in 
vitro by pull down assays. Interestingly, KAP1 binds the C-terminal domain of integrase 
that contains the three lysines targeted for acetylation by p300 and involved in the in vitro 
binding with p300 (Cereseto et al., 2005). Investigation on the role of KAP1 during viral 
replication cycle showed that KAP1 down-regulation enhances viral infectivity due to 
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specific increase in viral integration. Indeed, transient and stable knockdowns of KAP1 in 
HeLa and HEK239T cells did not alter HIV-1 reverse transcription, however, decreased 
two-LTR circles consistently with an increase of the integrated proviruses. Similar effects 
on HIV-1 viral cDNA forms have been reported following knockdown of another cellular 
factor, p21Cip1/Waf1, which inhibits specifically HIV-1 integration (Zhang et al., 2005; Zhang 
et al., 2007). The inhibition of HIV-1 integration was further confirmed by reciprocal 
experiments showing that KAP1 over-expression reduces provirus formation. While seeking 
to explore the mechanisms by which KAP1 inhibits HIV-1 integration, we found that this 
factor down-regulates integrase acetylation and mediates the association of HDAC1 to 
integrase. In conformity with these results, previous reports showed that KAP1 decreases 
acetylation of p53 (Tian et al., 2009; Wang et al., 2005a), E2F1 (Wang et al., 2007a) and 
STAT3 (Tsuruma et al., 2008) by tethering HDACs. The KAP1-mediated deacetylation of 
these cellular factors involved in DNA damage response induces their inactivation. Similarly 
to KAP1, the knockdown of HDAC1 enhanced HIV-1 integration. Interestingly, the 
inhibitory effect of the over-expressed KAP1 on HIV-1 integration was relieved when 
HDAC1 was knocked down. Consistently, KAP1 inhibition does not affect an HIV-1 viral 
clone carrying an integrase mutated at the three lysines targeted for acetylation by p300 
(K264, K266 and K273) to arginines. The dependence of KAP1 inhibition on HDAC1 and on 
integrase acetylable lysines suggests that KAP1 affects integration efficiency by inducing 
integrase deacetylation through HDAC1. The specificity of KAP1 inhibition was further 
confirmed in HEK293T and HeLa cells knocked down for KAP1 and back-complemented by 
the exogenous expression of KAP1 cDNA resistant to the shRNA. These cells were able to 
restore HIV-1 infectivity and integration to the basal levels of not silenced cells. KAP1-
mediated inhibition of integration was also confirmed in HIV-1 natural target cells, CEMss 
T cells and primary blood lymphocytes (PBLs). Similarly to the effect observed in HeLa and 
HEK293T cells lines, KAP1 knockdown in CEMss cells and PBLs enhances HIV-1 integration 
and its back-complementation by resistant cDNAs reverts this enhancement. Furthermore, 
the dependence of KAP1 inhibition on the presence of the three acetylable lysines (K264, 
K266 and K273) of integrase was also confirmed in T cells. 
 
Investigations on the regions of KAP1 required for the inhibition of HIV-1 integration 
determined that the N-terminal region (1-381), that corresponds to the RBCC domain, acts 
on integration as the full length protein. Moreover, the RBCC domain was able to retain 
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HDAC1 as the full length KAP1 further sustaining the relevance of KAP1-HDAC1 interplay 
in HIV-1 inhibition. These investigations also showed that the C-terminal region of KAP1 
(617-835), that corresponds to the PHD-BROMO domain, was not able to inhibit HIV-1 
integration. Consistently, the PHD-BROMO domain fails to bind HDAC1. The RBCC domain 
of KAP1 has been mainly described for its role in transcription repression by specifically 
recognizing the KRAB domain of KRAB zing finger proteins that bind the target promoters 
to be silenced (Ayyanathan et al., 2003; Groner et al., 2010; Sripathy et al., 2006). Our 
study reveals a new role of the RBCC domain in the inhibition of HIV-1 integration through 
HDAC1. The PHD-BROMO domain has also an important role in transcription repression. 
Indeed, following KAP1 recruitment to the target promoters by the KRAB zing finger 
protein, the PHD and BROMO regions act cooperatively for the interaction with CHD3 
(Mi2), which is a subunit of NuRD histone deacetylase complex (Schultz et al., 2001), 
and with SETDB1 histone H3-K9 methyl transferase (Schultz et al., 2002) in order to 
induce the heterochromatinization of the targeted DNA (Ivanov et al., 2007; Sripathy et 
al., 2006). Since, NurD complex contains also HDAC1 and HDAC2 (Grozinger and 
Schreiber, 2002), it has been presumed that the PHD-BROMO domain is responsible for 
the association of KAP1 with HDAC1 (Schultz et al., 2001). Our data show that the KAP1 
mutant deleted in the PHD-BROMO (1-616) is able to retain HDAC1 while the PHD-BROMO 
domain (617-835) fails to bind this HDAC. Notably, even though it has been 
experimentally shown that the PHD-BROMO regions bind the HDAC-containing NuRD 
complex, no report verified the capacity of the individual N-terminal RBCC domain (1-381) 
in associating with frees HDAC1 (or HDAC1 complexes different from the NurD). In fact, 
Schultz et al. (2001), reported that several mutations impair KAP1 association with Mi2 
(a PHD-BROMO 1-616 deletion mutant or single W664A in the PHD-BROMO domain); the 
same mutants were not verified for their binding capacity to  HDAC1 (Schultz et al., 2001).  
Similarly, Ivanov et al. (2007), reported that a KAP1 mutant deleted in the bromodomain 
(dB) is unable to bind Mi2; again the binding capacity of this deletion mutant with 
HDAC1 was not tested (Ivanov et al., 2007). In addition, the absence of association 
between HDAC1 and the single PHD-BROMO domain (617-835) observed in our 
experiments is consistent with the kinetic model determining KAP1-mediated 
transcriptional repression (Groner et al., 2010; Ivanov et al., 2007; Sripathy et al., 2006). 
Based on this model the PHD-BROMO domain recruits the silencing machinery, including 
the HDAC1 containing NurD complex, following the tethering of KAP1 to the targeted DNA 
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by the KRAB zing finger proteins or by the heterologous DNA binding domains. Therefore, 
our data suggest that the molecular mechanisms leading to the recruitment of HDAC1 by 
KAP1 in the integration inhibition (RBCC) do not correspond to the mechanisms involved in 
the transcription repression (PHD-BROMO). Consistently with the capacity of the RBCC 
domain to inhibit HIV-1 integration at the same extent of the full length KAP1, we found 
that this region (1-381) is responsible for the binding with integrase and determines the 
preferential association of KAP1 with the acetylated form of the viral protein. These results 
clearly show that the KAP1 domain responsible for inhibiting viral integration spans the 1-
381 region (RBCC) consistently with its ability to recognize preferentially acetylated 
integrase and to bind HDAC1 and further sustaining that KAP1 inhibits HIV-1 integration 
through the targeting of the acetylated integrase and the recruitment of HDAC1 to 
catalyze its deacetylation.    
Our results showed that the PHD-Bromo domain of KAP1 does not bind integrase and does 
not determine the specificity of KAP1 in associating the acetylated form of integrase. This 
data seems perplexing because it is well defined that the bromodomains bind specifically 
acetylated lysines and the PHD domain is cooperating to stabilize this association (Mujtaba 
et al., 2007). Nevertheless, even though the bromodomain of KAP1 is structured in ZA and 
BC loops similarly to other bromodomain proteins (p300, PCAF, CBP or BPTF) the three 
acetyl lysine binding residues of these loops are not conserved in  KAP1. In fact, the 
crystal structure of the PHD-BROMO tandem of KAP1 reported by Zeng et al. (2008) 
showed that the characteristic pocket structure between the ZA and BC loops in the 
bromodomain is distorted with comparison to the canonical bromodomain (Zeng et al., 
2008). This renders the bromodomain of KAP1 atypical. Consistently with the 
crystallographic analysis and similarly to our results, the tandem PHD finger–bromodomain 
of KAP1 was shown unable to bind the lysine-acetylated peptides derived from histones H3 
or H4 (Zeng et al., 2008).  
 
Human KAP1 does not inhibit integration of another retrovirus murine leukemia virus 
(MLV). Thus, unlike TRIM5 and APOBEC3G, KAP1 does not prevent human cells from 
MLV integration (Harris et al., 2003; Hatziioannou et al., 2004). A similar result has been 
reported with another HIV-1 inhibitor factor, TRIM22, that interferes selectively with viral 
assembly of HIV-1 and does not affect assembly of either MLV or equine infectious anemia 
virus (EIAV) (Barr et al., 2008). Moreover, p21CIP1/Waf1, that
 inhibits specifically HIV-1 
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integration, does not affect the replication of macaque simian immunodeficiency virus 
(SIVmac) (Bieniasz, 2007; Zhang et al., 2007).  
 
3- KAP1 does not affect HIV-1 gene expression and likely is not involved in viral 
latency     
Since KAP1 is a transcription repressor (Lechner et al., 2000; Schultz et al., 2002; Schultz 
et al., 2001; Sripathy et al., 2006) that has been described to inhibit transcription of MLV, 
visna, spuma and Mason-Pfizer monkey retroviruses as well as of endogenous retroviruses 
(IAPs) in embryonic stem cells (Rowe et al., 2010; Wolf and Goff, 2007; Wolf et al., 
2008b), we investigated whether it could affect HIV-1 transcription. In KAP1 knockdown 
cells, transcription of either an integration defective (D64E) or an integrated HIV-1 viruses 
was not modulated. These results are in agreement with the observations that KAP1 
affects transcription of retroviruses carrying primer binding sites (PBS) complementary to 
tRNApro such as MLV and HTLV-1 (Wolf and Goff, 2007, 2009) or to tRNALys-1,2 found in 
visna, spuma and Mason-Pfizer monkey viruses (Wolf et al., 2008b). Moreover, KAP1 
retroviral repression of PBSpro is mediated by a KRAB zinc finger, ZFP809, that has been 
shown unable to affect HIV-1 transcription (Wolf and Goff, 2009).  
Since HIV-1 latency of integrated HIV-1 is mainly explained by the transcription repression 
at the level of the LTR promoter (Marcello, 2006), a possible role of KAP1 in the latency 
could be suggested. However, the lack of the effect of KAP1 on HIV-1 transcription 
demonstrated by our results and by others (Wolf and Goff, 2009) and also our 
observations that KAP1 expression levels are unchanged in J-latA1 cells carrying a latent 
integrated HIV-1 or in memory (CD45 RO+) T cells involved in viral latency, disfavour this 
hypothesis. 
 
4- KAP1 as a restriction factor for HIV-1 infectivity 
The well described HIV-1 restriction factors are rhesus TRIM5, owl monkey TRIMCyp, 
APOBECs (A3G and A3F) and tetherin (CD317) (Bieniasz, 2009; Evans et al., 2010; 
Huthoff and Towers, 2008; Luban, 2007; Malim, 2009; Nakayama and Shioda, 2010; Neil 
et al., 2008; Sheehy et al., 2002; Towers, 2007; Van Damme et al., 2008). These 
restriction factors interfere with cytoplasmic steps of HIV-1 replication which are post-
entry for TRIM5, reverse transcription for APOBECs and viral release for tetherin. So far, 
few reports described HIV-1 inhibitor proteins that interfere with HIV-1 integration or 
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nuclear pre-integration events (p21Cip1/Waf1, RAD52, Rad18, XPB and XPD) with not yet 
establishment of molecular mechanisms (Lau et al., 2004; Lloyd et al., 2006; Yoder et al., 
2006; Zhang et al., 2005; Zhang et al., 2007). It has been proposed that these factors 
inhibit HIV-1 infection affecting the nuclear viral cDNA available for integration by inducing 
its degradation or circularization (Rad18, XPB and XPD) or by competing with proteins of 
the PIC in the binding of the viral cDNA ends (RAD52). The only inhibitor factor that has 
been described to decrease infectivity by interfering with viral integration is p21Cip1/Waf1. 
Since p21Cip1/Waf1 is a cell cycle checkpoint protein playing a role in DNA damage response, 
it has been speculated that DNA damage pathways activated by the virus are responsible 
for p21Cip1/Waf1 antiviral activity; however, the molecular mechanism underlying viral 
integration inhibition has not been delineated (Zhang et al., 2007). 
The knockdown experiments performed in our study, showed that siRNA-mediated 
knockdowns of KAP1 enhanced HIV-1 integration (5-9 fold) higher than the shRNA-
mediated knockdowns (2-4 fold) regardless they are transient or stable knockdowns. 
These differences of the magnitudes of the viral phenotype obtained by shRNAs and 
siRNAs was also observed with p21Cip1/Waf1 (Zhang et al., 2005; Zhang et al., 2007). Severe 
depletion of KAP1 endogenous levels could not be obtained due the incompatibility with 
cellular conditions and cell viability (Wang et al., 2005a; Wang et al., 2007a; Wolf and 
Goff, 2007), which might hindered us to assess the exact fold inhibition of KAP1 on HIV-1 
integration. Recently, it has been described an inducible KAP1 knockout in murine stem 
cells (Rowe et al., 2010) that might be a useful model to study HIV-1 integration in 
transient severe depletion of KAP1. However, the data obtained in the murine model 
should be carefully interpreted due to the differences with the human system. 
 
5- Models for KAP1 inhibition of HIV-1 integration  
Since acetylation of HIV-1 integrase by p300 has been shown to increase its binding 
affinity to the viral DNA and to enhance its catalytic activity and also it has been shown 
that acetylable lysines (K264, K266 and K273) contribute to an optimal HIV-1 integration 
(Apolonia et al., 2007; Cereseto et al., 2005; Terreni et al., 2010), a simplest model can 
be proposed in which KAP1 recognizes acetylated integrase through a high affinity of 
interaction with the modified viral protein, recruits HDAC1 to acetylated integrase, thus, it 
induces integrase deacetylation which affects negatively integrase catalytic and DNA 
binding activities and consequently reduces HIV-1 integration efficiency.  
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Since KAP1 binds the C-terminal domain of integrase which is the substrate for acetylation 
and notably is the region required for integrase-p300 complex formation, we can also 
propose a model in which p300 and KAP1-bridging-HDAC1 compete for the binding to the 
C-terminal region of integrase resulting in cycles of acetylation and deacetylation of the 
lysines carried in this domain which corresponds to activation and inactivation of 
integrase, respectively. This model might also explain the achievement of optimal HIV-1 
integration in several cell types where KAP1 is ubiquitously expressed.  
A third model can be proposed based on the properties of KAP1 as co-repressor scaffold 
that binds DNA binding proteins, mainly KRAB zing fingers, recruits HDACs, SETDB1 
histone methylase and HP1 to the chromatin regions to be silenced and induces 
heterochromatin formation (Ayyanathan et al., 2003; Groner et al., 2010; Sripathy et al., 
2006). Therefore, it can be proposed that KAP1 interacting with integrase at the 
integration target site, it induces integrase deacetylation by HDAC1 which may reduce the 
viral protein binding to host and viral DNAs and also KAP1 might induce the transient 
hetrochromatinization of the target site to render it inaccessible for integrase to perform 
an efficient integration of the viral genome.  
 
6- Could HIV-1 escape from KAP1 inhibition through the induction of KAP1 
phosphorylation?  
Recently, it has been demonstrated that following DNA double strand breaks damage the 
nuclear kinase ATM phosphorylates KAP1, diminishing KAP1 interaction with the chromatin 
(Goodarzi et al., 2008; Ziv et al., 2006). Perturbation of the chromatin by loss of the co-
repressor KAP1, adaptor of HP1, SETDB1 methylase, and HDACs, determines chromatin 
relaxation to enable DNA double strand breaks repair (Goodarzi et al., 2008; Ziv et al., 
2006). Notably, it has been suggested that un-integrated HIV-1 cDNA is a substrate for 
double-DNA strand break repair factors thus activating DNA damage response (Abrink et 
al., 2001; Baekelandt et al., 2000; Jeanson et al., 2002; Kilzer et al., 2003; Lloyd et al., 
2006). ATM that predominantly detects DNA double strand breaks has been demonstrated 
to be activated following HIV-1 infection and its inhibition through a small molecule (KU-
55933) drastically decreases cellular susceptibility to viral infection (Lau et al., 2005). 
Since KAP1 is ubiquitously expressed showing no major restriction of HIV-1 infectivity, we 
explored a hypothesis where ATM activated by un-integrated HIV-1 phosphorylates KAP1 
leading to the disassembly of the integrase/HDAC1 complex (see Figure 22 of RESULTS). 
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This would ultimately reverse HDAC1 deacetylase activity associated to integrase, thus, 
allowing the reconstitution of integrase acetylation by p300 and restored levels of 
integration efficiency. Our initial investigations of this hypothesis revealed that KAP1 is 
phosphorylated at two hours following HIV-1 infection and at four hours post infections 
the phosphorylation is down-regulated. Interestingly, it has been shown that upon double 
strand breaks damage, the phosphorylation of KAP1 is an early and transient event that is 
peaked at thirty minutes post damage and persists only up to two hours (White et al., 
2006; Ziv et al., 2006). Moreover, following infections with HIV-1, it has been shown that 
phosphorylation of p53 by ATM kinase persists up to eight hours post infection (Lau et al., 
2005). The persistence of the p53 modification has been correlated with the post-
integration repair of HIV-1. These observations suggest that KAP1 phosphorylation, as in 
DNA damage, is related to early HIV-1 infection events. Moreover, our results showed that 
the KAP1 phosphorylation induced by HIV-1 infection, was not inhibited by the ATM 
inhibitor (KU-55933) which suggest that, the phophorylation of KAP1 in HIV-1 infection is 
not mediated by ATM. 
In our model, the phosphorylated KAP1 is displaced from the pre-integration complex and 
would not interact with integrase. However, the interaction assays that were performed in 
our study between integrase and KAP1, following induction of its phosphorylation by DNA 
damage, or between integrase and KAP1 phosphomutants showed that KAP1 
phosphorylation does not modulate the KAP1/integrase complex formation. However, 
further interaction investigations are necessary to perform between phosphorylated KAP1 
and the viral integrase in the context of the pre-integration complex during HIV-1 infection 
instead of an integrase expressed in cells by transfection. These investigations would be 
useful, also because we found that the KAP1 phosphomimic (S824D) was unable to inhibit 
HIV-1 integration as the KAP1 wild type or phosphomutant (S824A). Therefore, the study 
of the phosphorylated KAP1/integrase interactions during HIV-1 infection would address 
whether the KAP1 phosphomimic (S824D) is unable to inhibit HIV-1 integration because it 
is not associated with the integrase during HIV-1 integration. In fact, the inability of the 
KAP1 phospho-mimic (S824D) to inhibit HIV-1 integration could be also explained by the 
nuclear localization of this mutant, which is not associated with the chromatin (Ziv et al., 
2006) where integration is occuring, that may consequently hamper its association with 







CONCLUSIONS AND FUTURE PERSPECTIVES 
In conclusion, we report a list of novel cellular proteins that interact with acetylated HIV-1 
integrase. These are new potential factors involved in HIV-1 replication by either inhibiting 
or favoring the virus at specific steps involving integrase activity. Further analyses are 
required to establish their roles in HIV-1 biology. Moreover, we identified a new HIV-1 
inhibitor factor, KAP1, that interferes specifically with HIV-1 integration and thus joins the 
very short list of cellular factors that inhibits this viral step. Investigations on the molecular 
mechanisms by which KAP1 is acting on integration led us to reveal that KAP1 regulates 
negatively integrase by inducing its deacetylation through the recruitment of HDAC1. 
Further investigations are needed to understand whether the virus escape from KAP1 
inhibition is mediated the induction of KAP1 phosphorylation or involved some other 
mechanisms.  
KAP1 might be a good candidate for AIDS therapy strategy. Therefore, it would be useful 
to investigate whether the delivery of KAP1 protein or RBCC peptides, the region of KAP1 
responsible for the association with acetylated integrase and with HDAC1, in infected T 
cells may delay and inhibit efficiently the HIV-1 replication. However, both strategies 
should be preceded by investigations on the potential of these molecules in the induction 
of resistant HIV-1 strains.  Therefore, it would be worthy to study the HIV-1 replication in 
T cells stably expressing KAP1 and RBCC domain and to monitor and sequence the 
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Abstract The viral protein integrase (IN) catalyzes the
integration of the HIV-1 cDNA into the host cellular
genome. We have recently demonstrated that IN is acety-
lated by a cellular histone acetyltransferase, p300, which
modifies three lysines located in the C-terminus of the viral
factor (Cereseto et al. in EMBO J 24:3070–3081, 2005).
This modification enhances IN catalytic activity, as dem-
onstrated by in vitro assays. Consistently, mutations
introduced in the targeted lysines greatly decrease the
efficiency of HIV-1 integration. Acetylation was proven to
regulate protein functions by modulating protein–protein
interactions. HIV-1 to efficiently complete its replication
steps, including the integration reaction, requires interact-
ing with numerous cellular factors. Therefore, we sought to
investigate whether acetylation might modulate the inter-
action between IN and the cellular factors. To this aim we
performed a yeast two-hybrid screening that differs from
the screenings so far performed (Rain et al. in Methods
47:291–297, 2009; Studamire and Goff in Retrovirology
5:48, 2008) for using as bait IN constitutively acetylated.
From this analysis we have identified thirteen cellular
factors involved in transcription, chromatin remodeling,
nuclear transport, RNA binding, protein synthesis regula-
tion and microtubule organization. To validate these
interactions, binding assays were performed showing that
acetylation increases the affinity of IN with specific factors.
Nevertheless, few two-hybrid hits bind with the same
affinity the acetylated and the unmodified IN. These results
further underlie the relevance of IN post-translational
modification by acetylation in HIV-1 replication cycle.
Keywords HIV-1 integrase  Histones acetyltransferase 
Acetylation  Tethered catalysis system 
Yeast two-hybrid screening  Integrase binding factors
Abbreviations
HIV-1 Human immunodeficiency virus-1
IN Integrase
PIC Pre-integration complex
GDBD Gal4 DNA binding domain
GAD Gal4 activation domain






TEV Tobacco etch virus protease site
HA Hemagglutinin epitope tag
WB Western blot analysis
a Antibodies
NLS Nuclear localization signal
Introduction
An essential step in the retroviral life cycle is the inte-
gration of the viral DNA into the host cellular genome;
a reaction catalyzed by the viral protein integrase (IN).
Following virus entry and uncoating in the cytoplasm, the
viral double strand cDNA is synthesized through reverse
transcription starting from the RNA genome (Coffin et al.
1997). The viral DNA molecules then translocate into the
nuclei of infected cells as part of a large nucleoprotein
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complex, the pre-integration complex (PIC), which is
formed by IN and other viral/cellular proteins (Suzuki and
Craigie 2007). Within PICs both ends of the linear DNA
molecule are processed by IN to form recessed 30 OH
termini. At the integration site, IN uses the recessed 30OH
groups to cut opposing strands of chromosomal DNA in a
staggered fashion, thus concomitantly connecting the viral
DNA 30 ends to the generated 50 overhangs. The resultant
DNA recombination intermediate harbors single strands
discontinuities that must be repaired by the host cellular
repair system to complete provirus formation (Vandegraaff
and Engelman 2007). Purified HIV-1 IN displays 30 pro-
cessing and DNA strand transfer activities that are suffi-
cient to catalyze the cDNA integration reaction in vitro.
However, in vivo numerous cellular proteins are required
for efficient integration. The host factors regulate IN
enzymatic functions by modulating its stability and by
mediating nuclear import and perhaps access to specific
regions of the chromatin (Goff 2007; Van Maele et al.
2006). We have recently demonstrated that p300, a histone
acetyltransferase, binds IN and acetylates three lysines
(K264, K266, K273) located in its C-terminus leading to
enhanced IN activity. Acetylable lysines are necessary for
virus integration and thus for optimal replication, as dem-
onstrated by the inefficient infectivity observed following
their mutations into arginine residues (K264, 266, 273R)
(Cereseto et al. 2005). Since it has been demonstrated that
acetylation modulates the activities of cellular and viral
proteins by affecting protein–protein interactions (Sterner
and Berger 2000), in this study we investigated whether
this protein modification could affect the interaction of IN
with cellular factors. To this aim we have employed the
tethered catalysis two-hybrid system, a method previously
reported to efficiently identify factors binding specifically
to acetylated proteins (p53, histones H3 and H4) (Guo et al.
2004). From this screening we identified thirteen new
factors binding IN with variable affinities based on the
acetylation level of the viral factor.
Results
Constitutive acetylation of IN fused to the HAT domain
of p300
To produce constitutively acetylated IN, a cDNA cassette
was constructed containing a codon-optimized sequence
for IN (IN-CO) fused to the acetyltransferase catalytic
domain of p300 (IN-HATwt). As control, IN was also
fused to a sequence coding for a catalytically inactive HAT
containing a D1395Y mutation (IN-HATmut). The IN-
HAT fusion proteins produced by these constructs contain
at the N-terminus a histidine tag (6xHis) which allows
affinity purification of the protein product by means of
cobalt based resin columns (see ‘Materials and methods’).
In addition, the C-terminus of the chimera is in frame with
a hemagglutinin (HA) epitope tag used to analyze the
fusion protein by immunoblot with anti-HA antibodies.
Finally, between the IN and the HAT domains a tobacco
etch virus (TEV) proteolytic cleavage site was introduced
allowing IN separation from the HAT domain (Fig. 1a).
Both IN-HATwt and IN-HATmut chimera were pro-
duced and purified in bacteria (Escherichia coli, BL21
strain). The purified products were immunoprecipitated
with anti His-tag antibodies and analyzed by Western blot
using anti-acetylated lysine (Ac-Lys) antibodies to assess
the acetylation status of the recombinant chimera. As
shown in Fig. 1b, upper panel, high levels of acetylation
were detected with the IN-HATwt chimera at the two
quantities tested (1 and 5 lg), while no signal was reported
with the same amounts of IN-HATmut chimera. In order to
verify appropriate protein loading the same filter was also
incubated with antibodies anti-IN (Fig. 1b, lower panel).
Since p300 HAT domain contains 44 lysine residues that
are substrate of auto-acetylase catalytic activity, we sought
to verify whether the acetylation reported with the IN-HAT
chimera (Fig. 1b) included modification of the individual
IN domain. To this end IN was separated from the fusion
protein through TEV digestion; the cleavage product was
purified with nickel affinity chromatography and checked
by Western blot analysis using anti-IN antibodies (Fig. 1c,
left panel). As shown in Fig. 1c, right panel, IN derived
from the IN-HATwt chimera gave a strong acetylation
signal with anti-Ac-Lys antibodies, while no acetylation
was detected with IN derived from the HATmut. Thus,
these results clearly demonstrate that IN is specifically
acetylated as a fusion product of HATwt but not of
HATmut.
The IN-HAT cDNA cassette was then expressed in yeast
cells in frame with the Gal4 DNA-binding domain (GDBD)
under the control of a yeast promoter (GDBD-IN-HATwt/
mut). The expression of the IN-HATwt/mut chimeras in
yeast cells (AH109 strain) showed that the IN-HATwt
chimera expressed high levels of acetylated IN, while
the IN-HATmut chimera was negative for acetylation
(A. Allouch et al., manuscript in preparation).
In conclusion, these results demonstrate that IN
expressed as a fusion product with the HAT domain of
p300 is highly acetylated. In addition to bacteria, acetylated
IN can be expressed in eukaryotic (yeast) cells.
Two-hybrid screening analysis using the IN-HATwt
fusion protein
To identify the cellular factors interacting with acetylated
IN, we used the GDBD-IN-HATwt as bait to screen a
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human lymphocytes cDNA library fused to the Gal4 acti-
vation domain (GAD). The two-hybrid screening was
performed in the AH109 yeast strain. This strain contains
Ade and His genes as reporters which allows the selection
of positive clones using the selective medium (-Ade and
-His). From almost 10.6 9 106-screened transformants,
754 were positive clones encoding thirteen cellular proteins
which are listed in Table 1. According to their proprieties
and proposed functions, these cellular factors could be
divided in three categories:
1. Transcription regulatory and chromatin remodeling
factors: LEDGF/p75, KAP1, BTF3b, THRAP3 and
HMGN2.
2. Translation regulatory and RNA binding proteins:
eIF3h, eEF1A-1 and hnRNPA2.
3. Nuclear import-export proteins: Exp2 and RanBP9.
In addition to factors grouped in categories, we also
identified RPL23, a structural ribosomal subunit, STMN1,
a factor involved in microtubule organization and finally
CCDC32, a protein with still unknown functions.
These newly identified factors, were subsequently tested
by two-hybrid analysis with the IN-HATwt chimera, as
well as with each single domain (IN and HATwt), to verify
their association properties with the acetylated or unmod-
ified IN and also with the HAT domain contained in the
chimera. In addition, the analysis was performed with the
GDBD to check the bait specificity. Results shown in
Table 2 indicate that all identified factors associate with IN
as a separate domain and that the majority do not bind the
HAT domain except for THRAP3, RanBP9, eEF1A-1,
STMN1 and CCDC32.
In conclusion, thirteen new factors binding to acetylated
IN have been identified. These factors positively interact
also with IN separated from the HAT domain, suggesting
that acetylation modulates but is not absolute requirement
for virus cell interaction.
Binding of two-hybrid factors with acetylated
and un-modified IN
To verify the interaction between IN and the cellular fac-
tors identified by two-hybrid screening (Table 1), pull
down assays with the same factors expressed in human
cells have been performed. Experiments were carried out
with few selected factors based on their possible involve-
ment in HIV-1 replication: transcription related proteins
(BTF3b, THRAP3 and HMGN2) potentially involved in
tethering viral integration in transcription units; a nuclear
transport factor (Exp2) possibly involved in nuclear–cyto-
plasmic translocation. In addition, eIF3h, a factor involved
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Fig. 1 Generation of in vitro and in vivo of highly acetylated HIV-1
IN. a Schematic representation of the constructs engineered to
produce constitutively acetylated IN (IN-HATwt) or control unmod-
ified IN (IN-HATmut). IN codon optimized (CO) was fused to
HATwt or HATmut (D1395Y). The fusion proteins are tagged at N
terminus with 6xHis and at C-terminus with HA. A TEV proteolytic
cleavage site is introduced between IN and the HAT domains. b Two
amounts (1 and 5 lg) of IN-HATwt and IN-HATmut recombinant
proteins were immunoprecipitated (IP) by anti His-tag antibodies
(a-His). Immunoprecipitates were analyzed by Western blot (WB)
using anti-acetylated lysine antibodies (a-Ac-Lys) (upper panel) and
the same filter was incubated with anti-IN antibodies (a-IN) (lower
panel). c 6xHisIN separated from either IN-HATwt or IN-HATmut
fusion proteins by TEV digestion was purified by affinity chroma-
tography (see ‘Materials and methods’) and analyzed by WB using a
IN (left panel) and aAc-Lys (right panel)
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identification (726 clones) in the two-hybrid screening.
These factors were fused to a Flag tag and expressed in
HEK293T cells. The derived cell lysates were incubated
with either IN-HATwt or IN-HATmut recombinant pro-
teins. Subsequently, the immunocomplexes were recovered
with anti-Flag antibodies and analyzed by Western blot
with anti-HA and anti-Flag antibodies. As an experimental
control for binding specificity the same analysis was per-
formed using HEK293T cells expressing an unrelated
control protein, luciferase, fused to the Flag tag (Flag-
Luciferase). As shown in Fig. 2a and b higher amounts of
IN-HATwt than IN-HATmut were found associated with
Flag-Exp2 and Flag-elF3h. Conversely, similar amounts of
IN-HATwt and IN-HATmut bound Flag-BTF3b, Flag-
THRAP3 and Flag-HMGN2 (Fig. 2c, d, e). Finally, no
specific binding was observed with the unrelated control
protein, Flag-Luc (Fig. 2f). As shown in lower panels of
Fig. 2a–f, incubation of the same filters with anti-Flag
antibodies proved that similar amounts of Flag proteins
were immunoprecipitated with either IN-HATwt or IN-
HATmut. These results suggest that Exp2 and eIF3h bind
with higher affinity the acetylated form of IN, whereas
BTF3b, THRAP3 and HMGN2 show no preferential
binding for either forms of the viral protein. In a separate
Table 1 Cellular factors identified by yeast two-hybrid screening using constitutively acetylated IN (IN-HATwt) as bait













Transcription coactivator. Factor interacting with lentiviral
INs determining IN association to chromatin. Putative
tethering factor for HIV-1 integration





Transcription corepressor and DNA damage response
factor. Factor inhibiting infectivity of MoMLV in
embryonic cells
835: 304–835 HSU78773 Sripathy et al.
(2006), Wolf
and Goff (2007)
Basic transcription factor 3
isoform b: BTF3b (1 clone)
Component of the RNA polymerase II complex required
for transcription initiation





Subunit of the large transcription mediator TRAP complex;
positive regulator of RNA polymerase II promoters
transcription







Component of the HMG non histone chromatin remodeling
family of proteins. Inducer of chromatin decondensation
and transcription activity
90: 1–90 BC014644.1 West (2004)
Ran-binding protein 9:
RanBP9 (8 clones)
Ran binding protein involved nuclear transport pathway
NLS mediated
729: 149–729 BC063849.1 Gorlich (1998)
Exportin 2 (synonyme:
CAS): Exp2 (1 clone)
Importin a binding protein. Mediator of importin a nuclear
export after NLS cargo release into the nucleus.





initiation factor 3 subunit
H: eIF3h (726 clones)
Component of the eIF3 complex: promotes translation
preinitiation complex formation, mRNA recruitment and





Elongation factor 1 alpha 1:
eEF1A-1 (1 clone)
Component of the alpha subunit of EF1 complex: promotes
protein biosynthesis by delivering aminoacylated tRNA
to ribosomes. Binds HIV-1 matrix and nucleocapsid and
stimulates HIV-1 transcription. Its yeast homologue binds
HIV-1 IN





RNA binding protein containing two RNA recognition
motifs (RRM): involved in mRNA regulation (splicing
and trafficking). Regulator of HIV-1 RNA trafficking
341: 1–180 NM_002137.2 Shyu et al. (2000)
Stathmin 1: STMN1
(2 clones)
Tubulin binding protein: involved in microtubule
depolymerization and signal transduction cascade
149: 1–149 BC082228.1 Cassimeris (2002)
Ribosomal protein L23:
RPL23 (1 clone)
Structural component of 60S subunit of ribosomes.
Activates p53 by inhibiting MDM2





Unknown functions 185: 12–185 BC001673.2 Ota et al. (2004)
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report we show that another factor, KAP1, also identified
by the two-hybrid screening (Table 1), preferentially binds
acetylated IN (A. Allouch et al., manuscript in
preparation).
Next, the interaction between the two-hybrid hits and
the single HAT and IN domains was verified using lysates
of HEK293T cells expressing the Flag-tagged factors. As
shown in Fig. 3a, upper panel, no binding was observed
with the HAT domain, even though high expression of two-
hybrid Flag-tagged factors could be detected (lower panel).
Thus, these data demonstrate that the interaction between
IN and the two-hybrid hits is specific and not mediated by
the HAT domain. Moreover, this result suggests that the
positive interactions observed by two-hybrid analysis with
the HAT domain (Table 2), were likely a result of the
synergistic transactivation properties of these factors
(THRAP3, RanBP9, eEF1A-1, STMN1 and CCDC32)
together with the HAT domain over the yeast promoter.
Finally, the unmodified form of IN (6xHis-IN) was
verified by pull down assays with Flag-tagged two-hybrid
hits expressed in HEK293T cells. High levels of IN was
found associated with BTF3b, HMGN2 and THRAP3
(Fig. 3b), while much lower amounts could be detected in
complex with Exp2, eIF3h and KAP1.
Therefore, these data are in agreement with results in
Fig. 2, showing that BTF3b, HMGN2 and THRAP3 bind
efficiently unmodified IN and do not require IN acetylation.
Conversely, the low amounts of Exp2, eIF3h and KAP1
Table 2 Interactions in yeast between GAD prey proteins and GDBD
hybrid baits (IN-HATwt, IN and HATwt)
IN-HATwt IN HATwt GDBD
LEDGF/p75 ? ? - -
KAP1 ? ? - -
BTF3b ? ? - -
THRAP3 ? ? ? -
HMGN2 ? ? - -
Exp2 ? ? - -
RanBP9 ? ? ? -
EIF3h ? ? - -
EEF1A-1 ? ? ? -
HnRNPA2 ? ? - -
STMN1 ? ? ? -
RPL23 ? ? - -
CCDC32 ? ? ? -
















































































































Fig. 2 Binding analysis between acetylated IN and proteins identi-
fied by the two-hybrid screening. a Lysates from HEK293T
cells expressing Flag-Exp2 (a), Flag-eIF3h (b), Flag-BTF3b (c),
Flag-THRAP3 (d), Flag-HMGN2 (e) and FLAG-Luc (f) were
incubated with recombinant IN-HATwt or IN-HATmut-HA and
immunoprecipitated (IP) with monoclonal anti-Flag antibodies.
Immunoprecipitates were then analyzed by Western blot (WB) with
anti-HA antibodies (a-HA) (upper panels) and with polyclonal anti-
Flag antibodies (a-Flag) (lower panels)
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bound to IN is indicative that IN acetylation enhances
binding affinity.
Discussion
This study exploits the tethered catalysis system (Guo et al.
2004) to produce an HIV-1 viral protein, IN, constitutively
acetylated by p300. The construct verified to produce
acetylated IN in bacteria, was used to screen by two-hybrid
a human lymphocytes cDNA library. From this screening
we have identified 13 cellular factors, 12 of which have
never been reported to interact with HIV-1 IN. The binding
analysis performed by two-hybrid and pull down assays
revealed that a basal association of all factors was reported
with the unmodified IN while the acetylation of the viral
factor variably affect the affinity with the two-hybrid hits.
The newly identified factors interacting with acetylated
or un-modified IN showed no obvious simple sequence
similarity. Nevertheless, it is plausible that the IN recog-
nizes common elements present in these proteins. In fact,
these factors can be grouped in three categories based on
their functional properties: (a) transcription regulatory and
chromatin remodeling factors; (b) translation regulatory and
RNA binding proteins; (c) nuclear import–export proteins.
Interestingly, LEDGF/p75, one of the factors identified
in this screening, is one of the most described IN interactor
required for efficient HIV-1 integration (Cherepanov et al.
2003; Engelman and Cherepanov 2008). This result vali-
dates the system of analysis employed in this study and
proves that fusion of IN to the HAT domain does not
significantly alter the IN structure. LEDGF/p75 binds
the core catalytic domain of HIV-1 IN. Nevertheless, the
N-terminal domain of IN was proven to enhance the
binding affinity with this factor (Maertens et al. 2003).
Therefore, the identification of LEDGF/p75 in our
screening might suggest that also the C terminus of IN and
its acetylation could affect IN/LEDGF-p75 interaction.
HIV-1 integration preferentially occurs in regions of the
chromatin rich in genes transcriptionally active (Bushman
et al. 2005; Mitchell et al. 2004; Schroder et al. 2002).
Recent studies performed by sequence analysis using the
ENCODE annotation (Wang et al. 2007) and by a visual-
ization analysis (Albanese et al. 2008) demonstrated that
HIV-1 targets decondensed regions of the chromatin. It has
been hypothesized that cellular factors interacting with IN
may tether the virus to appropriate sites for integration.
Indeed, LEDGF/p75 knockdown and knockout cells show a
significant reduction of integration frequency in transcrip-
tion units (Ciuffi et al. 2005; Shun et al. 2007). Neverthe-
less, since in the absence of LEDGF/p75 the virus still does
not integrate randomly in the genome, additional factors
may be required for integration specificity. The screening
reported in this study, uncovered factors involved in tran-
scription and chromatin structure regulation, thus good
candidate proteins to tether HIV-1 integration. BTF3b and
THRAP3, found in the two-hybrid screening, are positive
regulators of gene transcription that act by associating with
RNA polymerase II (Rachez and Freedman 2001; Zheng
et al. 1990). The HMNG2 protein, another two-hybrid hit,
is involved in chromatin structure regulation by binding to
nucleosomes in a DNA sequence independent manner. This
factor induces chromatin decompaction, which in turn
facilitates DNA transcription and replication (West 2004).
In fact, HMNG2 was found to localize in active tran-
scription chromatin regions (Bustin 2001; Hock et al.
1998). Finally, HMGA1, another HMG family member,
was previously reported to stimulate HIV-1 integration by
promoting the formation of IN/cDNA complexes (Hind-

































































































Fig. 3 Binding between proteins identified by the two-hybrid
screening and the HATwt or IN domains. a HEK293T cell lysates
expressing Flag-eIF3h, Flag-BTF3b, Flag-THRAP3, Flag-HMGN2 or
FLAG-Luc were incubated with either HATwt (a) or 6xHis-IN (b)
recombinant proteins and immunoprecipitated (IP) with monoclonal
anti-Flag antibodies. Immunoprecipitates were then analyzed by
Western blot (WB) with anti-HA antibodies (a-HA) (upper panels)
and with polyclonal anti-Flag antibodies (a-Flag) (lower panels)
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HIV-1 nuclear import occurs through still incompletely
understood mechanisms. One of the viral factor hypothe-
sized to be involved in nuclear translocation is the IN
protein which contains several putative nuclear localization
signals (NLSs) (Bouyac-Bertoia et al. 2001; Gallay et al.
1997; Hearps and Jans 2006). In our study, we identified
two proteins that regulate the nuclear importin pathway
Exp2 and RanBP9. These factors may trigger the nuclear
import of IN by importin a and b complex. However, the
implications of both importin factors have been explored
for HIV-1 infectivity leading to contradictory results.
Indeed, recent reports suggested that IN may lack a func-
tional NLS and attributed its karyophilic proprieties to the
LEDGF/p75 interacting factor (Devroe et al. 2003; Llano
et al. 2004). More recently IN has been demonstrated to
interact with a cellular factor, transportin SR2 (TNPO3)
which mediates HIV-1 transport into the nucleus (Christ
et al. 2008).
A recent two-hybrid screening performed with IN of
another retrovirus, the Moloney Murine Leukemia Virus
(MoMLV), identified the murine eIFs2, a subunit part of
the translation initiation factor 3 (eIF3) complex (Studa-
mire and Goff 2008). Moreover, in this study it was
demonstrated that HIV-1 IN does not interact with eIFs2.
The human eIF3f, another component of eIF3 complex,
was reported to inhibit HIV-1 replication at post-integra-
tion step by interfering with the 30 end processing of HIV-1
mRNAs (Valente et al. 2009). From our screening we
identified eIF3h, another subunit belonging to the eIF3
complex, as a factor interacting with acetylated HIV-1 IN.
Thus, since numerous studies report the association of
retroviruses with the eIF3, this protein complex presum-
ably plays an important function in the viral replication
cycle, even though the detailed molecular mechanism has
not yet been unraveled.
One of the two-hybrid hits was eEF1A-1 factor which
has been previously reported to be involved in HIV-1
biology. Most interestingly, in agreement with our results,
a former study using a yeast expression experimental sys-
tem suggested that IN interacts with eEF1A-1 (Parissi et al.
2001). Moreover, eEF1A-1 was identified to be involved in
HIV-1 replication by binding with the viral gag polypro-
teins (matrix and nucleocapsid) (Cimarelli and Luban
1999) and also by activating the viral promoter (Wu-Baer
et al. 1996). All these reports implicate multi-roles of
eEF1A-1 in HIV-1 replication cycle.
STMN1, identified in our two-hybrid screening, regu-
lates microtubule organization by binding tightly tubulin
and inducing microtubule destabilization (Cassimeris 2002;
Howell et al. 1999). This observation is in line with a
previous report showing that HIV-1 IN bind microtubule-
associated proteins such as the yeast STU2p, a centrosomal
protein, and Dyn2p (dynein light chain protein). It has been
hypothesized that IN interaction with these factors may be
responsible for IN nuclear import (de Soultrait et al. 2002;
Desfarges et al. 2009).
In conclusion, here we report a list of cellular proteins
that interact with acetylated HIV-1 IN. These are new
potential factors involved in HIV-1 replication by either
inhibiting or favoring the virus at specific steps involving
IN activity. Further analyses are required to establish their
role in HIV-1 biology.
Materials and methods
Vectors and constructs
pASK-IN-HATwt and pASK-IN-HATmut to express and
purify IN-HATwt and IN-HATmut in bacteria were con-
structed by cloning IN codon optimized (CO) in frame with
the HAT domain of p300 (a.a. 1195–1673) wild-type or
mutated (D1395Y) in the pASK-IBA37 plus vector (IBA,
Gottingen, Germany) containing at 50 of the MCS a 6xHis
tag. During the cloning procedure a 30 HA tag and a TEV
protease cleavage site between IN and HAT were intro-
duced by PCR. HATwt-HA was cloned in pASK-IBA37
plus by PCR. PINSD-IN encoding for 6xHis-IN was
described in (Cereseto et al. 2005). From the pASK-
IBA37-IN-HATwt/mut vectors the IN-HATwt/mut, HAT-
wt and IN were PCR amplified and cloned in frame with
the GDBD in the pBD-Gal4 vector (Stratagene, La Jolla,
CA, USA) for expression in yeast cells. KAP1, BTF3b,
THRAP3, HMGN2, Exp2, eIF3h cDNAs were cloned by
PCR in pFlag-CMV2 vectors starting from their truncated
cDNAs isolated in the two-hybrid screening.
Yeast two-hybrid screening
A human T-lymphocytes cDNA library fused to Gal4
Activating Domain in a pACT vector (BD biosciences
Clontech, Palo Alto, CA, USA) was expressed in AH109
yeast cells and screened with the pGDBD-IN-HATwt (bait)
expression vector. Library transformation and screening
were performed following manufacturer’s instructions
(Matchmaker GAL4 two-hybrid system 3). GAD identified
prey proteins (Table 1) were co-expressed in AH109 yeast
cells with GDBD fused to IN-HATwt, HATwt and IN to
check for interactions.
IN-HATwt and IN-HATmut, IN and HATwt
purifications
pASK-IN-HATwt/mut encoding for 6xHis-IN-HATwt/
mut-HA, pASK-HATwt encoding for 6xHis-HATwt-HA
and pINSD-IN encoding for 6xHis-IN were transformed in
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E. coli BL21 competent cells (Stratagene, La Jolla, CA,
USA). Induction of protein expression was performed
using 43 mM anhydrotetracycline hydrochloride (AHT)
(for pASK plasmids) or 0.5 mM IPTG (for pINSD-IN) for
4 h at 30C. Bacteria culture was lysed in binding buffer
(1 M NaCl, 20 mM Tris HCl pH 7.9 and 0.5% Triton
X-100) containing 1 mM PMSF and protease inhibitor
cocktail (Roche, Mannheim, Germany). TALON Metal
Affinity Resin (BD Biosciences, Palo Alto, CA, USA)
incubated for 2 h at 4C was used to recover the 6xHis
recombinant proteins. Following two washes in binding
buffer containing 5 mM imidazole, proteins were eluted
using binding buffer containing 200 mM imidazole and
dialysed in buffer containing 150 mM NaCl, 50 mM Tris
HCl pH 8, 10% glycerol and 0.5 mM EDTA. 6xHis-IN was
dialyzed in 1 M NaCl, 20 mM Tris–HCl pH 7.5, 1 mM
DTT and 10% glycerol. For TEV digestion 20 lg of 6xHis-
IN-HATwt/mut were incubated with 30 units of AcTEV
protease (Invitrogen, Paisley, UK) in 50 mM Tris–HCl pH
8, 0.5 mM EDTA and 1 mM of DTT in 250 ll total vol-
ume. To recover His-IN from the digested product the TEV
treated samples were adjusted to 1 M NaCl and incubated
with Ni-NTA agarose resin (Qiagen, Hilden, Germany) for
2 h at 4C. Following washes in binding buffer containing
5 mM imidazole, His-IN was eluted using the binding
buffer containing 250 mM imidazole and dialysed in 1 M
NaCl, 20 mM Tris–HCl pH 7.5, 1 mM DTT and 10%
glycerol. 6xHis-IN was dialysed in 1 M NaCl, 20 mM
Tris–HCl pH 7.5, 1 mM DTT and 10% glycerol.
Antibodies
Primary antibodies for Western blot analyses were:
monoclonal HIV-1 IN antibody (8G4) from NIH AIDS
Research and Reference Reagent Program (Germantown,
MD), polyclonal anti-acetylated lysines (Cell Signaling
Technology, Beverly, MA, USA), polyclonal anti-HA
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
polyclonal anti-Flag (Sigma-Aldrich, St Louis, MO, USA)
and monoclonal anti-His (Qiagen, Hilden, Germany).
Secondary antibodies HRP conjugated anti-mouse or anti-
rabbit IgG were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA, YSA).
Immunoprecipitations and anti-Flag beads pull down
A total of 1 and 5 lg of either purified and dialyzed 6xHis-
IN-HATwt-HA or 6x His-IN-HATmut-HA proteins were
incubated with 1 mg of monoclonal anti-His antibody
(Qiagen, Hilden, Germany) for 1 h and then 20 ll of
Protein G UltraLink resin (Pierce Biotechnology, Rock-
ford, IL, USA) were added for additional 1 h. Immuno-
complexes were washed three times in buffer containing
150 mM NaCl, 50 mM Tris–HCl pH 8, 10% glycerol and
0.5 mM EDTA and analyzed by Western blot. For Flag
pull down experiments HEK293T expressing Flag proteins
(KAP1, BTF3b, THRAP3, HMGN2, Exp2 and eIF3h) were
lysed in 50 mM Hepes pH 7.4, 150 mM NaCl and 0.5%
NP-40. A total of 250 lg lysate was mixed with 250 ng of
recombinant and purified proteins (6xHis-IN-HATwt-HA
or 6xHis-IN-HATmutHA, 6xHis-HATwt-HA or 6xHis-IN)
together with 5 lM of Lys-CoA (synthesized at the ICGEB
Peptide Synthesis Core Faculty, Trieste, Italy). Following
1 h incubation at 4C, 20 ll of monoclonal anti-Flag M2
antibodies immobilized on agarose beads (Sigma, St Louis,
MO, USA) were added and incubated for 1 h. Following
washes in lysis buffer samples were analyzed by Western
blot using polyclonal anti-HA or monoclonal anti-IN and
polyclonal anti-Flag antibodies.
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HIV-1 acetylated integrase is targeted by KAP1 (TRIM28) to inhibit 
viral integration
Awatef Allouch*1,4, Vania Liverani1, Daniele Arosio1, Maria Ines Gutierrez2, 
Marina Lusic2, Alvaro Galli3, Mauro Giacca2 and Anna Cereseto1
Address: 1Molecular Biology Laboratory, Scuola Normale Superiore, Pisa, Italy, 2NEST, CNR-INFM and Scuola Normale Superiore, Pisa, Italy, 
3Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy and 4Laboratory of 
Genetic and Molecular Therapy , Istituto di Fisiologia Clinica CNR, Pisa, Italy
* Corresponding author    
Post-translational modifications, such as acetylation,
dynamically modulate the chemical and structural prop-
erties of proteins generating new protein-protein inter-
faces. HIV-1 integrase is acetylated by p300 at three
specific lysines located in the carboxy terminal domain. In
the attempt to understand how acetylation modifies the
integration event, we have searched for cellular cofactors
that may specifically require acetylation to bind integrase.
To this aim a tethered catalysis system has been exploited
to perform a yeast two-hybrid screening. In this assay an
integrase constitutively acetylated by fusion with the HAT
catalytic domain of p300, was used as a ''bait'' to screen a
human T-cell cDNA library. One of the identified binding
factors was KAP1, which showed a higher affinity to inte-
grase following its acetylation. This affinity was confirmed
by either pull down assays and in vivo co-immunoprecita-
tion in 293T cells. To evaluate the role of KAP1 during
HIV-1 life cycle, infections were performed in HeLa and
293T cells transiently and stably silenced for KAP1. Inter-
estingly, the infectivity was 3-10 fold higher than control
cells and the analysis of the DNA forms showed a specific
enhancement at the level of integration. In a reciprocal
experiment overexpression of KAP1 showed a reduction
of infectivity by a 50% decrease in integration.
Since integrase activity is positively regulated by acetyla-
tion, we then performed experiments to explore whether
KAP1 inhibition of viral integration might correlate with
modulation of integrase acetylation levels. We demon-
strated that KAP1 binding to acetylated integrase indeed
induces integrase deacetylation through HDAC1 complex
formation. Finally, HDAC1 complex formation is a
requirement for KAP1 viral inhibition since no HIV-1
restriction can be observed in cell silenced for HDAC1.
In conclusion, this study reports that KAP1, recently
described to restrict M-MLV infectivity in embryonic stem
cells at the level of viral transcription, inhibits HIV-1
through a novel mechanism targeting the integration step.
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GCN5-dependent acetylation of HIV-1 integrase
enhances viral integration
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Abstract
Background: An essential event during the replication cycle of HIV-1 is the integration of the reverse transcribed
viral DNA into the host cellular genome. Our former report revealed that HIV-1 integrase (IN), the enzyme that
catalyzes the integration reaction, is positively regulated by acetylation mediated by the histone acetyltransferase
(HAT) p300.
Results: In this study we demonstrate that another cellular HAT, GCN5, acetylates IN leading to enhanced 3’-end
processing and strand transfer activities. GCN5 participates in the integration step of HIV-1 replication cycle as
demonstrated by the reduced infectivity, due to inefficient provirus formation, in GCN5 knockdown cells. Within
the C-terminal domain of IN, four lysines (K258, K264, K266, and K273) are targeted by GCN5 acetylation, three of
which (K264, K266, and K273) are also modified by p300. Replication analysis of HIV-1 clones carrying substitutions
at the IN lysines acetylated by both GCN5 and p300, or exclusively by GCN5, demonstrated that these residues are
required for efficient viral integration. In addition, a comparative analysis of the replication efficiencies of the IN
triple- and quadruple-mutant viruses revealed that even though the lysines targeted by both GCN5 and p300 are
required for efficient virus integration, the residue exclusively modified by GCN5 (K258) does not affect this process.
Conclusions: The results presented here further demonstrate the relevance of IN post-translational modification by
acetylation, which results from the catalytic activities of multiple HATs during the viral replication cycle. Finally, this
study contributes to clarifying the recent debate raised on the role of IN acetylated lysines during HIV-1 infection.
Background
Integration of reverse transcribed HIV-1 DNA into the
cellular genome is catalyzed by the viral IN protein.
Even though in vitro integration can be solely driven by
IN, cellular cofactors are required to complete the reac-
tion in vivo. It was recently reported that the cellular
HAT p300 interacts with IN and regulates its function
through acetylation [1,2]. HATs are enzymes able to
transfer acetyl groups from acetyl coenzyme A (acetyl-
CoA) to specific lysine residues within the N-terminal
tails of nucleosomal histones, leading to chromatin
decondensation and transcriptional activation [3,4].
HATs can also acetylate non-histone substrates, such as
transcription factors and other nuclear proteins, as well
as cytoskeletal components, metabolic enzymes and sig-
nalling regulators in the cytoplasm [5]. Acetylation has
been reported to regulate the activity of these factors by
modulating DNA binding [6-8], protein-protein interac-
tions [9-12], protein stability [13-15], and subcellular
localization [16-19]. Growing evidence now indicates
that acetylation significantly participates in signaling
pathways ultimately regulating viral infectivity [20-26].
Among the viral factors functionally modulated by acet-
ylation is the HIV-1 protein Tat. Tat is acetylated at
lysine 28 by PCAF, while residues 50 and 51 are sub-
strates for p300/CBP and GCN5 [27-29]. Acetylation of
lysine 28 enhances the ability of Tat to recruit the P-
TEFb complex [28], while modification of lysine 50
leads to Tat dissociation from TAR RNA [28,30]. There-
fore, even though the final effect of acetylation is an
increased transactivation activity on the viral LTR pro-
moter, the modification of each individual lysine differ-
ently affects Tat functionality at the molecular level.
We have recently discovered that another HIV-1-
encoded protein, IN, is a substrate for p300-mediated
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acetylation. Three lysine residues, located at positions
264, 266, and 273 in the C-terminal domain of IN, were
identified as the target sites for modification [1,2]. Acety-
lation by p300 was shown to increase both IN affinity for
DNA and strand transfer activity [1], thus suggesting a
potential role for this post-translational modification dur-
ing viral integration. The importance of IN acetylation
for HIV-1 replication was further highlighted by the find-
ing that the mutant virus, in which arginine substitutions
were introduced at p300-targeted IN lysines, integrated
less efficiently than the wild type [1].
Since proteins modified by acetylation are often sub-
strates for multiple HATs, we sought to investigate
whether IN might be acetylated by enzymes other than
p300. It has already been reported that MOZ and PCAF
(belonging to the MYST and GNAT families of HATs,
respectively) are incapable of efficiently acetylating the
IN C-terminal domain in vitro [2]. Therefore, in this
study, another member of the GNAT family, GCN5,
was examined. Here we demonstrate that GCN5 binds
and acetylates IN both in vitro and in vivo. GCN5
expression is functionally relevant to HIV-1 infectivity
and specifically affects the integration process, likely by
modulating the catalytic activity of IN. Interestingly, the
four lysines targeted by GCN5 partially overlap with
those modified by p300 in the C-terminal domain of IN.
A comparative analysis of viral clones mutated at IN
lysines acetylated by GCN5 or p300 revealed the same
replication defect at the step of integration, thus indicat-
ing common roles for the two HATs in regulating IN
function.
Results
HIV-1 IN is acetylated by GCN5
To examine whether IN is acetylated by GCN5, in vitro
acetylation assays were performed with recombinant IN
and GCN5, both purified as GST fusion proteins. Incuba-
tion of the single GST domain with GCN5 in the pre-
sence of [14C]-acetyl-CoA, and subsequent protein
resolution by SDS-PAGE followed by autoradiography,
revealed a unique band at the same size as GST-GCN5,
corresponding to the auto-acetylation product of the
enzyme (Figure 1A, lane 1). Incubation of GST-IN with
GST-GCN5 resulted in two major radiolabeled bands,
the higher one corresponding to auto-acetylated GST-
GCN5 and the lower one to GST-IN (Figure 1A, lane 2),
thus demonstrating that GCN5 specifically acetylates IN
in vitro.
To define which region of IN is acetylated by GCN5,
GST-IN fragments with progressive deletions starting
from the C-terminus (as schematized in Figure 1C) were
used as substrates in in vitro acetylation assays, and the
corresponding acetylation signals in the autoradiograms
were evaluated by densitometric analysis (Figure 1B, left
histogram). GST-IN fragment 1-272 was acetylated to a
similar extent as full-length IN (Figure 1A, compare
lanes 2 and 3, and Figure 1B, left histogram). Acetylation
of fragment 1-263 (Figure 1A, lane 4) was reduced by
30% (Figure 1B, left histogram), while a more significant
decrease in the signal (ranging from 60% to 70%) was
observed using shorter fragments (1-243, 1-234 and 1-
212) (Figure 1A, lanes 5-7, and Figure 1B, left histogram).
These results indicated that IN is acetylated by GCN5
within the region located between amino acids 244 and
288. As schematically represented in Figure 1C, this
region contains five lysines at positions 244, 258, 264,
266, and 273 as possible targets for acetylation. There-
fore, in order to exclude that the reduced acetylation of
the deleted IN forms resulted from improper protein
folding, each of these lysines was replaced with an argi-
nine, an amino acid that cannot be acetylated and con-
serves a positively charged side chain. The resulting
mutants were then tested in vitro as substrates for GCN5
activity. In this experiment, IN was tagged with a 6× His
epitope in place of GST, in order to obtain better SDS-
PAGE resolution between acetylated GCN5 and IN
(Figure 1A, lane 8). As reported in the right histogram of
Figure 1B, densitometric analysis of radioactivity incor-
poration highlighted that the mutation of the individual
lysines 258, 264, 266, and 273 (Figure 1A, lanes 10-13)
caused a reduction in the acetylation level of IN ranging
from 40% to 50%, while no significant decrease in the sig-
nal was detected upon mutation of lysine 244 (Figure 1A,
lane 9). These data suggested that GCN5 acetylates IN at
residues 258, 264, 266, and 273. Notably, previous reports
demonstrated that another HAT, p300, acetylates lysines
264, 266, and 273 of IN [1,2]. To confirm that GCN5
acetylates lysine 258 in addition to the above-mentioned
residues, two mutant forms of IN were assayed for in
vitro acetylation: one containing mutations at the sites
acetylated by both GCN5 and p300 (IN K264,266,273R),
and the other carrying these same amino acidic substitu-
tions, with the additional mutation of lysine 258 specifi-
cally targeted by GCN5 (IN K258,264,266,273R). The
decrease in the radioactive signal detected with IN
K264,266,273R was similar to the one obtained with the
single-mutated forms (compare lane 14 with lanes 10-13
in Figure 1A, and right histogram of Figure 1B), while the
residual acetylation level of IN K258,264,266,273R
dropped to 20% with respect to wild type (Figure 1A,
lane 15, and Figure 1B, right histogram). These results
demonstrated that GCN5 acetylates lysines 264, 266, and
273 of IN, also targeted by p300, and lysine 258 as a spe-
cific site of modification.
Next, we investigated whether IN is also acetylated by
GCN5 in vivo. Codon-optimized Flag-IN [31] was
expressed in HEK 293T cells, alone or together with
HA-GCN5 wild type or mutated in the catalytic domain
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Figure 1 HIV-1 IN is acetylated by GCN5 in vitro. (A) Autoradiography (upper panels) and Coomassie blue staining (lower panels) of in vitro
acetylation assay with recombinant GST-GCN5 and IN wild type or mutant proteins. Lanes 1-7: GST fusion IN proteins; lanes 8-15: 6× His-tagged
IN proteins. In the Coomassie panels, IN proteins used as acetylation substrates are indicated by asterisks; in the autoradiograms, IN proteins
found positive for GCN5-mediated acetylation are indicated in the same way. Presented results are representative data from triplicate in vitro
acetylation assay experiments. (B) Results of densitometric analysis of autoradiograms derived from three independent experiments (means ±
standard errors of the means [SEM]) expressed as percent wild type IN acetylation. (C) Schematic representation of IN proteins used for the
acetylation assays. The positions of lysines in the C-terminal domain of IN are indicated. Lysines positive for acetylation are shown in red.
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(Y260A/F261A) [32]. Immunoprecipitation of IN and
subsequent detection by Western blotting with an anti-
body specific to acetylated lysines revealed the highest
acetylation signal in the sample corresponding to IN co-
expressed with wild type GCN5 (Figure 2A, upper
panel, lane 3). Conversely, expression of IN alone or
together with catalytically inactive GCN5 resulted in a
lower acetylation signal, likely derived from the activity
of endogenous HATs (Figure 2A, upper panel, lanes 2
and 4). In this experiment, the total amounts of immu-
noprecipitated IN and the expression levels of wild type
and mutant GCN5 were verified by Western blot analy-
sis with anti-Flag and anti-HA antibodies, respectively
(Figure 2A, middle and lower panels).
Figure 2 IN is acetylated by GCN5 in vivo. (A) Extracts from HEK 293T cells transfected with the indicated plasmids were immunoprecipitated
using anti-Flag antibody and analyzed by Western blotting with anti-acetyl-lysine antibody (upper panel) or anti-Flag antibody (middle panel).
Lower panel: cell extracts immunoblotted with anti-HA antibody. (B) Acetylated BSA and peptides corresponding to IN amino acids 260-281,
either chemically acetylated at lysines 264, 266, and 273, or not acetylated, were blotted onto a nitrocellulose filter and incubated with anti-
acetylated IN antibody. (C) Left panels (lanes 1-4): extracts from HEK 293T cells transfected with the indicated plasmids were immunoprecipitated
using anti-Flag antibody and analyzed by Western blotting with anti-acetylated IN antibody (top panel) or anti-Flag antibody (bottom panel).
Right panels (lanes 5-8): extracts from HEK 293T cells transfected with the indicated plasmids analyzed by Western blotting with anti-acetylated-
IN antibody (top panel) or anti-Flag antibody (bottom panel). (D) Extracts from HEK 293T cells transfected with the indicated plasmids analyzed
by Western blotting with anti-acetylated-IN antibody (upper panel), anti-Flag antibody (middle panel), or anti-HA antibody (lower panel).
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Detection of in vivo IN acetylation by a novel anti-
acetylated IN antibody
To confirm the in vitro observation that IN is a substrate
for both GCN5 and p300, an antibody specific to acety-
lated IN was produced by using an IN-derived peptide
for immunization. The IN-derived peptide was chemi-
cally acetylated at lysines 264, 266, and 273, which are
targeted in common by the two HATs (see the Methods
section). As shown in Figure 2B, the purified antibody
specifically recognized the acetylated IN peptide in dot
blot experiments, while no cross-reactivity was detected
with the unmodified peptide or acetylated BSA. This
antibody allowed detecting basal levels of IN acetylation
by endogenous HATs following immunoprecipitation
(Figure 2C, top-left panel, lane 1); additionally, high levels
of IN acetylation were detected from cells overexpressing
p300 (Figure 2C, top-left panel, lane 2). This result is
consistent with our previous study showing that p300
mediates IN acetylation in vivo at positions 264, 266, and
273 [1]. Conversely, no signal, expressed either alone or
together with p300 (Figure 2C, top-left panel, lanes 3 and
4), was detected with IN K264,266,273R, thus revealing
the high specificity of the antibody. In this experiment,
the amount of IN (wild type or mutated) immunoprecipi-
tated in each sample was verified by Western blotting
with an anti-Flag antibody (Figure 2C, bottom-left panel).
The anti-acetylated IN antibody was also used for direct
Western blot analysis of cell lysates, producing a strong
acetylation signal in the sample corresponding to IN co-
expressed with p300 (Figure 2C, top-right panel, lane 6).
Therefore, the newly developed antibody showed higher
sensitivity than the standard anti-acetyl-lysine antibodies,
which require an immunoprecipitation step to reveal IN
acetylation. Given the high specificity and sensitivity of
the anti-acetylated IN antibody, it was used to confirm
the in vivo acetylation of IN by GCN5, as well as the
mapping of the in vitro targeted lysines. As shown in the
upper panel of Figure 2D, extracts from cells co-expres-
sing wild type IN and GCN5 revealed a remarkable signal
corresponding to IN acetylation (lane 4); while, consis-
tent with the data reported in Figure 2C (top right panel,
lane 5), acetylation of the viral enzyme by endogenous
HATs was almost undetectable (lane 1). Conversely, no
signal with triple- and quadruple-mutant IN, expressed
either alone (lanes 2 and 3) or together with GCN5
(lanes 5 and 6) was detected. In this experiment, Western
blot analysis of the cell lysates was also performed with
anti-Flag and anti-HA antibodies to control the levels of
exogenously expressed proteins (Figure 2D, middle and
lower panels). Taken together, these data demonstrated
that IN is acetylated by GCN5 both in vitro and in vivo,
and the targeted lysines are located in the C-terminal
domain at positions 258, 264, 266, and 273.
IN interacts with GCN5
Since IN is acetylated by GCN5, the interaction between
these two factors was investigated. To this aim, HEK
293T cells were transfected with Flag-IN together with
HA-GCN5 wild type or mutated in the catalytic domain.
After immunoprecipitation with an anti-Flag antibody,
both wild type and mutant GCN5 were found to co-pre-
cipitate with IN, as demonstrated by Western blot ana-
lysis using an anti-HA antibody (Figure 3A, upper panel,
lanes 3 and 4). Accordingly, in the reciprocal experi-
ment, where immunoprecipitation was performed with
an anti-HA antibody, IN was found to associate with
GCN5 (both wild-type and mutant forms) (Figure 3B,
upper panel, lanes 3 and 4). In both experiments, the
total amounts of immunoprecipitated proteins and the
expression levels of IN and GCN5 were verified by Wes-
tern blotting (Figures 3A and 3B, middle and lower
panels).
To map the region of IN mediating the interaction
with GCN5, pull-down assays were carried out between
GST-GCN5 immobilized on glutathione-Sepharose
beads and IN deletion mutants labeled with [35S]-Met
by in vitro translation. As shown in Figure 3C, the affi-
nities of IN fragments 1-272 and 1-263 to GST-GCN5
(13% binding efficiency) were similar to that of full-
length IN (16% binding efficiency). Conversely, the
GCN5/IN interaction significantly decreased using frag-
ments containing further deletions towards the N-termi-
nus (1-243 and 1-234). These results indicated that the
C-terminal region of IN located between amino acids
244 and 288 is involved in binding to GCN5.
Acetylation by GCN5 increases IN catalytic activity in vitro
To explore the effect of GCN5-mediated acetylation on
the catalytic activity of IN, constitutively acetylated
recombinant IN was produced by exploiting the “teth-
ered catalysis” approach [33,34]. This method allows the
production of a constitutively acetylated protein by
tethering the factor of interest to the catalytic domain of
a specific HAT enzyme. Based on this approach, as
schematized in Figure 4A, a chimeric construct was gen-
erated where 6× His-tagged IN was fused at its C-term-
inal end with the HAT domain of GCN5 (amino acids
6-300). To obtain a control that cannot be acetylated,
the same chimera was constructed using the inactive
mutant of GCN5 Y260A/F261A. In addition, a sequence
coding for Tobacco Etch Virus (TEV) protease recogni-
tion site was inserted between IN and GCN5 coding
sequences to allow for the separation of the two
domains. The fusion proteins expressed from the two
chimeric constructs were purified, digested with TEV
protease, and the acetylation levels of the resulting IN
proteins analyzed by Western blotting with an anti-
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Figure 3 IN interacts with GCN5 both in vitro and in vivo. (A) Extracts from HEK 293T cells transfected with the indicated plasmids were
immunoprecipitated using anti-Flag antibody and analyzed by Western blotting with anti-HA antibody (upper panel) or anti-Flag antibody
(middle panel). Lower panel: extracts immunoblotted with anti-HA antibody. (B) Extracts from HEK 293T cells transfected with the indicated
plasmids were immunoprecipitated using anti-HA antibody and analyzed by Western blotting with anti-Flag antibody (upper panel) or anti-HA
antibody (middle panel). Lower panel: extracts immunoblotted with anti-Flag antibody. (C) Autoradiography and Coomassie Blue staining of in
vitro binding assays with GST-GCN5 and 35S-IN or the indicated 35S-IN fragments. The histogram represents the results of three independent
experiments (means ± SEM), where the amounts of bound proteins are expressed as percentages of the corresponding radiolabeled inputs.
Statistical significance of the binding percentages was calculated by using the Student’s two-sided t test. Asterisks directly above bars indicate
differences in binding efficiency to GST-GCN5 between IN deleted forms and full-length IN. **, P < 0,01; *, P < 0,05. Conversely, where asterisks
are not present, values obtained did not significantly differ (P > 0,05) from those obtained with control, non-silenced cells.
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acetyl-lysine antibody. IN derived from the wild type
GCN5 fusion scored positive for acetylation, while no
significant signal was detected with IN derived from the
GCN5 mutant chimera (Figure 4B, top panel, compare
lanes 1 and 3 with lanes 2 and 4). In this experiment,
the levels of loaded proteins were verified by incubating
the same membrane with an antibody directed against
IN (Figure 4B, bottom panel).
Constitutively acetylated recombinant IN and the non-
acetylated control were tested in vitro for 3’-end proces-
sing and strand transfer activities. In the 3’-end
processing reaction, recombinant IN was incubated with
a [32P]-labeled DNA substrate (S) and the excision of 2
nucleotides evaluated by measuring the radioactive sig-
nal of the shorter product (P). In Figure 4C the com-
parative analysis by densitometry of the bands
corresponding to the 3’-end processed template, indi-
cated that acetylated IN (100 ng in lane 1 and 200 ng in
lanes 3) was two- to three-fold more active than non-
acetylated controls (lanes 2 and 4 respectively). In the
strand transfer assay, a [32P]-labeled oligonucleotide was
used as a substrate (S) and IN activity was evaluated by
Figure 4 GCN5-mediated acetylation increases the catalytic activity of IN. (A) Schematic representation of IN-GCN5 tethered catalysis
constructs. Full-length IN, tagged with a N-terminal 6× His epitope, is fused in frame with TEV proteolytic site and cloned upstream of the 6-300
amino acid region of wild type GCN5 (IN-HAT wt) or its catalytically inactive allele (IN-HAT mut). (B) 1 μg and 2 μg of IN derived from IN-HAT wt
(lanes 1 and 3, respectively), or 1 μg and 2 μg of IN derived from IN-HAT mut (lanes 2 and 4, respectively) were analyzed by Western blotting
with anti-acetyl-lysine antibody (top panel) or anti-IN antibody (bottom panel). (C) 3’ -end processing activity of IN derived from IN-HAT wt (lane
1: 100 ng; lane 3: 200 ng) or IN-HAT mut (lane 2: 100 ng; lane 4: 200 ng). Lane 5: DNA substrate; lane 6: DNA substrate with 40 ng of 6× His-
tagged IN. (D) Strand transfer activity of IN derived from IN-HAT wt (lane 1: 100 ng; lane 3: 200 ng) or IN-HAT mut (lane 2: 100 ng; lane 4: 200
ng). Lane 5: DNA substrate; lane 6: DNA substrate with 40 ng of 6× His-tagged IN. In (C) and (D), the DNA substrate (S) and the catalytic
products (P) are indicated.
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measuring the radioactive signal derived from the ladder
of higher molecular weight products (P). Constitutively
acetylated IN, at two different doses (100 ng and 200
ng), was more active than non-acetylated IN (Figure 4D,
compare lanes 1 and 3 with lanes 2 and 4). This was
consistent with the 3’-end processing results. Finally,
densitometric analysis of the autoradiograms indicated
that the two amounts of acetylated IN were five- to ten-
fold more active than the corresponding non-acetylated
controls.
Taken together, these results demonstrated that
GCN5-mediated acetylation enhances the catalytic activ-
ity of IN in vitro.
HIV-1 infectivity is reduced in GCN5 knockdown cells
In order to assess the physiological relevance of the IN/
GCN5 interaction during HIV-1 replication cycle, viral
infectivity upon GCN5 depletion in target cells was
monitored. Transient knockdown of GCN5 expression
was obtained in HeLa cells using a specific short inter-
fering RNA (siRNA), while stably silenced HEK 293T
cell clones were selected after transduction with a lenti-
viral vector (pGIPZ from Open Biosystems, Inc.) encod-
ing a short hairpin RNA (shRNA) targeting GCN5
(GCN5 shRNAmir). As a control for the transient
knockdown experiments, HeLa cells were transfected
with a non-targeting siRNA (unrelated to any human
genomic sequence), while stable silencing experiments
were checked by using two HEK 293T polyclonal cell
lines, one expressing a mismatched, non-targeting
GCN5 shRNAmir (GCN5 shRNAmir mut) and the
other carrying an empty pGIPZ vector. As shown in the
top panels of Figure 5A, siRNA- and shRNAmir-
mediated knockdown reduced GCN5 expression to a
similar extent. Silenced cells were then infected with an
env-deleted, VSV-G pseudotyped NL4.3 virus expressing
the luciferase reporter gene (indicated hereafter as
NL4.3-Luc), and luciferase activity was measured 48
hours after infection. As shown in Figure 5B, a two- to
three-fold reduction in luciferase activity was detected
in both transiently and stably silenced cells, thus indicat-
ing that knockdown of GCN5 expression in target cells
reduces HIV-1 infectivity. To determine which step of
viral replication was affected by GCN5 depletion, cells
were collected at various time points after infection, and
measurements of the different HIV-1 DNA species were
performed by real time quantitative PCR (RT-Q-PCR).
Total HIV-1 DNA was quantified with the use of pri-
mers annealing to the luciferase reporter gene, in order
to avoid cross-reaction with the integrated pGIPZ lenti-
viral vectors present in stably transduced cell lines. As
shown in Figure 5C, no significant alterations in total
HIV-1 DNA levels were detected in cells either transi-
ently or stably silenced, thus indicating that reverse
transcription was not affected by the reduction of GCN5
expression. SiRNA-treated cells were analyzed 48 hours
post-infection by Alu-LTR nested PCR to detect inte-
grated HIV-1 DNA, while stable knockdown cell clones
were processed two weeks after infection using primers
specific to the luciferase gene. This was necessary in
order to dilute non-integrated HIV-1 DNA and avoid
cross-reaction with the integrated pGIPZ lentiviral vec-
tors. Proviral DNA was about two-fold less in all GCN5
knockdown cells, either treated with siRNA or trans-
duced with shRNAmir-encoding lentiviral vectors (Fig-
ure 5D). Finally, a two-fold increase in the amount of
two-LTR circles was detected in both stably and transi-
ently silenced cells (Figure 5E). Since the increase in
two-LTR circles often correlates with a defect at the
step of integration [35], these data are collectively con-
sistent with reduced integration efficiency in GCN5
knockdown cells.
Mutations at IN acetylation sites cause a defect in HIV-1
replication at the integration step
Since the IN lysines acetylated by GCN5 partially over-
lap with those targeted by p300, a comparative analysis
was performed to evaluate the role of these residues
during the HIV-1 replication cycle. To this aim, single-
round infections were performed, using env-deleted
NL4.3-Luc viruses expressing either IN K264,266,273R
(NL4.3-Luc-3mut), or IN K258,264,266,273R (NL4.3-
Luc-4mut). Luciferase activity was measured 48 hours
after infection, revealing an average five-fold reduction
in infectivity for both mutant viruses as compared to
wild type (Figure 6A). To determine which step of viral
replication was affected by the lysine-to-arginine substi-
tutions, DNA was extracted from cells at several time
points after infection and the different HIV-1 DNA spe-
cies were measured by RT-Q-PCR. Infection with
NL4.3-Luc-3mut and 4mut, as well as with wild type
virus, resulted in similar levels of total HIV-1 DNA at
24 hours post-infection (Figure 6B), indicating that
reverse transcription was not affected by the amino
acidic substitutions. Integrated HIV-1 DNA was quanti-
fied at 48 hours post-infection by Alu-LTR nested PCR,
showing a five-fold reduction in the number of pro-
viruses for both mutant clones with respect to wild type
(Figure 6C). These data indicated decreased integration
efficiency upon mutation of IN lysines targeted by acety-
lation. Consistently, a three-fold increase in the amount
of two-LTR circles was detected at 24 hours post-infec-
tion with both NL4.3-Luc-3mut and 4mut (Figure 6D),
confirming a specific defect at the step of integration
and no alterations during viral nuclear import.
To investigate the role of IN acetylated lysines during
HIV-1 replication in a T-cell line, two NL4.3-derived
clones were generated, expressing either the triple- or
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Figure 5 GCN5 depletion in infected cells reduces HIV-1 integration. (A) Left panels: extracts from siRNA-treated Hela cells analyzed by
Western blotting with anti-GCN5 antibody (top) or anti-a-tubulin antibody (bottom). Lane 1: cells transfected with non-targeting siRNA (Ctrl
siRNA); lane 2: cells transfected with GCN5-targeting siRNA (siGCN5). Right panels: extracts from stable GCN5 knockdown HEK 293T cell clones or
control cells immunoblotted with anti-GCN5 antibody (top panel) or anti-a-tubulin antibody (bottom panel). Lane 3: untransduced HEK 293T
cells; lane 4: HEK 293T cells carrying empty pGIPZ vector; lane 5: HEK 293T cells expressing mutant, non-targeting GCN5 shRNAmir; lanes 6-8: HEK
293T clones (Cl8, Cl9 and Cl13) expressing GCN5 shRNAmir. (B) siRNA-treated Hela cells (left histogram) or HEK 293T cells stably transduced with
pGIPZ lentiviral vectors (right histogram) were infected with NL4.3-Luc and analyzed for luciferase activity 48 hours after infection. The
histograms represent percentages of luciferase activity relative to control, non-silenced cells. Means ± SEM from three independent experiments
are reported. (C-E) Total DNA extracted from siRNA-treated HeLa cells (left histograms) or HEK 293T cells stably transduced with pGIPZ lentiviral
vectors (right histograms) was analyzed by RT-Q-PCR for total HIV-1 DNA (C), integrated HIV-1 DNA (D), and two-LTR circles (E). In (C-E), results
are presented as percentages relative to control, non-silenced cells. Reported values are means ± SEM from three independent experiments.
Statistical significance values shown in (B-E) were calculated by using the Student’s two-sided t test. Asterisks directly above bars indicate
differences between knockdown and control, non-silenced cells. ***, P < 0,001; **, P < 0,01; *, P < 0,05. Conversely, where asterisks are not
present, values obtained did not significantly differ (P > 0,05) from those obtained with control, non-silenced cells.
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quadruple-mutant IN (NL4.3-3mut and NL4.3-4mut,
respectively). One million CEM T-cells were infected
with the resulting viruses using two different amounts
of p24 antigen (10 ng or 1 ng). Viral replication was fol-
lowed by measuring HIV-1 reverse transcriptase (RT)
activity in the culture supernatants every three days over
a period of 21 days. As shown in Figure 6E, cells
infected with the higher viral load (10 ng of p24) of wild
type virus showed a peak of HIV-1 replication around
day 9 post-infection. Conversely, infections with the
same amounts of NL4.3-3mut and -4mut resulted in
delayed peaks at day 12. Notably, at the infectivity peak,
the RT amounts produced by both mutant HIV-1 clones
were approximately half of that obtained with wild type
virus. By using the lower viral load (1 ng of p24), the
replication curve of wild type virus started to raise quite
steeply around day 12 post infection, while for both
mutant clones the curves started to appear at day 15.
Detectable RT production was observed for both mutant
viruses at day 18, thus with 6 days of delay compared to
the kinetics of the wild type virus (Figure 6F). In
conclusion, mutations introduced in the virus at IN
acetylation sites targeted by both GCN5 and p300
(K264, K266, and K273), or additional mutation at lysine
258 specifically acetylated by GCN5 in vitro, determined
similar decreases in viral integration and infectivity.
Discussion
The results presented in this study reveal that GCN5 is
a novel HAT which interacts with IN. GCN5 binding to
the C-terminal domain of IN leads to the acetylation of
IN at lysines 258, 264, 266 and 273, located within the
same region required for the two proteins to interact.
We have recently demonstrated that the carboxy termi-
nus of IN is a substrate for another cellular HAT, p300,
which acetylates IN lysines at positions 264, 266, and
273 [1], a finding that was also later confirmed by Top-
per and coworkers [2]. Therefore, based on previous
and present studies, three IN lysines (K264, K266, and
K273) are acetylated by both HATs, while lysine 258
appears to be specifically targeted by GCN5. Our map-
ping of the HAT-interacting regions of IN based on
Figure 6 Mutations at IN acetylation sites cause a replication defect at the step of integration. (A) HEK 293T cells infected with NL4.3-
Luc/IN WT, NL4.3-Luc/IN K264,266,273R, or NL4.3-Luc/IN K258,264,266,273R were analyzed for luciferase activity 48 hours after infection. (B-D)
Total DNA extracted from HEK 293T cells infected with the same viral clones as in (A) was analyzed by RT-Q-PCR for total HIV-1 DNA at 24 hours
after infection (B), integrated HIV-1 DNA at 48 hours after infection (C) and two-LTR circles at 24 hours after infection (D). In (A-D), results are
presented as percentages relative to cells infected with NL4.3-Luc/IN WT virus. Reported values are means ± SEM from three independent
experiments. Statistical significance values shown in (A-D) were calculated by using the Student’s two-sided t test. Asterisks directly above bars
indicate differences between cells infected with mutant viruses and cells infected with wild type virus. ***, P < 0,001; **, P < 0,01. Conversely,
where asterisks are not present, values obtained did not significantly differ (P > 0,05) from those obtained with cells infected with wild type
virus. (E) RT activity detected in the culture supernatants of CEM cells at different time points after infection with NL4.3/IN WT, NL4.3/IN
K264,266,273R, or NL4.3/IN K258,264,266,273R. (F) Infections performed as in (E), using 10-fold lower viral loads.
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in vitro binding assays is consistent with a recent report
which presented two models of full-length IN com-
plexed with GCN5 and p300 [36]. Both models predict
that the IN C-terminal tail located between amino acids
271 and 288, due to its high flexibility, could easily
adapt to the binding pocket of GCN5, as well as to that
of p300 (Figure 7). Interestingly, lysine 273 is included
in this unstructured region and is therefore expected to
be the residue most prone to acetylation. In fact, since
lysines 264 and 266 are located in close proximity to a
sandwich of two three-stranded antiparallel b-sheets,
their binding and acetylation would require a more
complex unfolding of this stable secondary structure.
Based on this model, we may hypothesize that IN lysine
273 is the first residue contacted and acetylated by the
HAT enzyme, whether GCN5 or p300. This event might
in turn induce a conformational change in the C-term-
inal portion of IN, which could facilitate the modifica-
tion of the other two lysines. This hypothesis is also
compatible with the data reported by Topper and cow-
orkers, demonstrating a hierarchy of reactivity between
the three residues modified by p300, with lysine 273 as
the key site targeted for acetylation [2].
A comparative analysis, aimed at establishing the roles
of the two HATs during the HIV-1 replication cycle,
revealed that the mutant viruses expressing either IN
K264,266,273R or IN K258,264,266,273R exhibited the
same replication deficiency, specifically affecting the step
of integration. These results indicated that acetylation of
IN C-terminal lysines 264, 266, and 273 is required for
maximal HIV-1 integration efficiency, while acetylation
of lysine 258, although observed in vitro, does not
appear to play any significant role during infection.
Proteins modified by acetylation, including viral fac-
tors, are often targeted by multiple HATs in a redun-
dant manner. For instance, HIV-1 Tat is acetylated at
lysines 50 and 51 by p300/CBP and GCN5, leading in
both cases to an increased transactivation activity of the
modified protein on the viral LTR promoter [27-30].
The action of two different HATs on common sites of
the same substrate may be ascribed to the importance
of acetylation for the functionality of the target protein.
However, in the case of IN, the reduced viral integration
capacity detected in GCN5 knockdown cells indicated
that endogenous p300 is not able to fully compensate
for the lack of GCN5 so as to completely restore HIV-1
infectivity.
The role of IN acetylation at lysines 264, 266 and 273
during the HIV-1 replication cycle has been the subject
of a recent debate. Our former study showed that the
replication level of a HIV-1BRU clone expressing a triple-
mutant Flag-tagged IN (Flag-IN K264,266,273R) was
severely impaired, and that the replication deficiency
was specifically due to a block at the integration step
[1]. In subsequent reports, the untagged triple-mutant
virus showed either no replication defect [2], or a five-
fold infectivity decrease in single-round infections [37].
Moreover, by using a genetic assay where integration
was evaluated through the number of cell clones con-
taining proviruses, one report [2] detailed almost half
decreased integration efficiency, while the other [37]
indicated a 14-fold lower residual integration rate. In
Figure 7 Three-dimensional models of IN complexes with GCN5 and p300. (A) Three-dimensional model of the IN/GCN5 complex. IN is
represented in green and GCN5 in light grey. (B) Three-dimensional model of the IN/p300 complex. IN is represented in green and p300 in light
grey. In (A) and (B), the three lysine residues in the C-terminal domain of IN that are acetylated by both GCN5 and p300 (Lys 264, Lys 266, and
Lys 273) are shown in yellow. GCN5 and p300 are rendered as surfaces, while IN as a cartoon to highlight the C-terminal unfolded portion
which inserts in the binding pockets of the two HATs.
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the present study, we performed single- and multiple-
round infections with HIV-1 clones encoding IN either
mutated at the positions targeted by both GCN5 and
p300 (IN K264,266,273R), or carrying an additional
lysine-to-arginine substitution at the site specifically
modified by GCN5 (IN K258,264,266,273R). In multiple-
round replication experiments, both mutant clones
showed reduced virus production and delays in the
peaks of infectivity with respect to wild type. The discre-
pancy of these findings with the data reported by Top-
per et al. [2] might be due to the different time-courses
of analyses: although working in the same experimental
conditions (10 ng of p24 antigen per 1× 106 CEM cells),
the detection of RT activity in the culture supernatants
over a period of 21 days allowed us to monitor the peak
of HIV-1 replication, while Topper and coworkers ter-
minated the replication curve before the highest point
of viral infectivity was reached (at 12 days post
infection).
Moreover, consistent with Apolonia et al. [37], we
detected a five-fold infectivity decrease in single-round
replication assays performed with IN triple- and quadru-
ple-mutant viruses. The five-fold infectivity decrease
paralleled a five-fold reduction in the number of pro-
viruses, as measured by RT-Q-PCR. Taken together, the
results presented in all the different reports suggest that
acetylation of IN C-terminal lysines 264, 266, and 273
represents a mechanism which, by finely regulating the
integration process, contributes to determine the effi-
ciency of HIV-1 replication.
Identification of lysines 258, 264, 266, and 273 as the
targets of GCN5 activity on IN does not exclude that
additional residues might be acetylated, as indicated by
the residual acetylation level of the quadruple-mutant
IN (Figure 1A, lane 15). Finally, IN could also be subject
to different post-translational modifications, such as
methylation, sumoylation, or ubiquitination [38-41],
which might open up new mechanisms of modulation
of IN function.
Conclusions
This study demonstrates that, in addition to the formerly
reported p300, another HAT, GCN5, acetylates the
C-terminal domain of IN. Similar to p300, GCN5-
mediated acetylation is required for efficient viral integra-
tion, thus reinforcing the role of this post-translational
modification for HIV-1 replication.
Methods
Plasmids
Construction of pGEX-IN has already been described
[1]. pcDNA3-HA-IN was obtained by subcloning IN
sequence from pGEX-IN plasmid into pcDNA3-HA vec-
tor. pGEX-IN and pcDNA3-HA-IN deletion mutants
were produced by PCR amplification of IN with primers
specific to the deleted versions. pASK-IBA37-IN was
constructed by subcloning IN sequence from pGEX-IN
plasmid into pASK-IBA37 vector (IBA GmbH, Göttin-
gen, DE). pFlag-IN codon optimized (c.o.) was kindly
provided by A. Engelman. pASK-IBA37-IN point
mutants and pFlag-IN c.o. K264,266,273R or
K258,264,266,273R were obtained by PCR-based site-
directed mutagenesis starting from the corresponding
plasmids encoding wild type IN.
pGEX-GCN5 was a kind gift of M. Benkirane. pGEX-
GCN5 deletion mutants were produced by PCR amplifi-
cation of GCN5 with primers specific to the truncated
forms. pcDNA3-HA-GCN5 was constructed by subclon-
ing GCN5 sequence from pGEX-GCN5 plasmid into
pcDNA3-HA vector. pcDNA3-HA-GCN5 (Y260A/
F261A) [32] was obtained by PCR-based site-directed
mutagenesis starting from the plasmid encoding wild
type GCN5.
For production of IN-GCN5 tethered catalysis con-
structs, the sequence coding for the 6-300 amino acid
region of GCN5 was amplified by PCR from pcDNA3-
HA-GCN5 or pcDNA3-HA-GCN5 (Y260A/F261A) and
cloned into a pASK-IBA37 vector in frame with c.o. IN.
The sequence encoding TEV protease recognition site
was inserted by PCR between IN and GCN5 cDNAs.
pGIPZ and pGIPZGCN5 lentiviral vectors were pur-
chased from Open Biosystems (Huntsville, AL). The
sequence of GCN5 shRNAmir inserted into the
pGIPZGCN5 vector is as follows: 5’-CCCATTCATT
CCCTGGCATTAATAGTGAAGCCACAG ATGTATT
AATGCCAGGGAATGAATGGT-3’. For production of
the pGIPZGCN5 mut vector, four point mutations were
introduced in the shRNAmir cassette of pGIPZGCN5,




The NL4.3-Luc env-deleted virus expressing the luci-
ferase reporter gene was produced from the pNL4.3.Luc.
R-E- molecular clone obtained from the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH. IN sequence was subcloned from the mole-
cular clone pHXB2 for construction of pNL4.3.Luc.R-E-/
IN WT and pNL4.3/IN WT plasmids. The IN mutations
in pNL4.3.Luc.R-E-/IN K264,266,273R, pNL4.3.Luc.R-E-/
IN K258,264,266,273R and in pNL4.3/IN K264,266,273R,
pNL4.3/IN K258,264,266,273R were introduced by PCR-
based site-directed mutagenesis using either pNL4.3.Luc.
R-E-/IN WT or pNL4.3/IN WT as template.
The envelope plasmid pMDG and the packaging plas-
mid pCMVΔR8.91 were kindly provided by Z. Debyser.
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In vitro acetylation assay
HAT assays were performed as previously described [1],
with minor modifications. Briefly, GST or 6× His-tag
fusion proteins were incubated with GST-GCN5 and
[14C]-acetyl-CoA in HAT buffer (50 mM Tris-HCl, pH
8.0, 5% glycerol, 0.1 M EDTA, 50 mM KCl and 2 mM
sodium butyrate) in a final volume of 30 μl for 45 min
at 30°C. Acetylated proteins were visualized by phos-
phoimaging (Cyclone) after separation by SDS-PAGE.
In vitro binding assay
[35S]-labeled IN proteins used for in vitro binding assays
were produced from the corresponding pcDNA3-HA
plasmids by using the TNT Reticulocyte Lysate System
(Promega Corp., Madison, WI). Analysis of in vitro
binding between GST fusion proteins and [35S]-IN or
[35S]-IN fragments was performed as previously
described [1]. Briefly, GST fusion proteins (1 μg) immo-
bilized on agarose beads, after pre-treatment in a solu-
tion containing DNase I 0.25 U/μl and RNase H 0.25 U/
μl, were incubated with 600 c.p.m. of in vitro translated
[35S]-proteins in a solution containing 0.2 mg/ml ethi-
dium bromide. Following extensive washes, the reaction
mixtures were resolved by SDS-PAGE and radiolabeled
proteins visualized by phosphoimaging (Cyclone).
Recombinant proteins production and proteolytic
processing
GST fusion proteins were expressed and purified from
Escherichia Coli BL21 as already described [1].
N-terminal 6× His-tagged IN proteins were expressed
in Escherichia Coli BL21 and purified by metal ion affi-
nity chromatography (BD TALON Metal Affinity Resin,
BD Biosciences, Palo Alto, CA) according to a pre-
viously reported protocol [42]. Proteolytic processing of
IN-GCN5 chimeras was performed by incubating 20 μg
of fusion protein with 30 U of TEV protease (AcTEV
Protease, Invitrogen, Inc., Carlsbad, CA) in a buffer con-
taining 50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 0.1 M
NaCl, 1 mM DTT and 10% glycerol, overnight at 4°C.
6× His-tagged IN was then recovered from the reaction
mixture by adsorption on BD TALON Resin.
Immunoprecipitation and Western blotting
For immunoprecipitation, cell pellets were lysed 36
hours after transfection in RIPA buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1%
SDS, 0.5% deoxycolic acid) containing 10 mM sodium
butyrate (Sigma, Inc.) and protease inhibitors (Complete
Protease Inhibitor Cocktail Tablets, Roche Diagnostics).
Anti-Flag M2 affinity resin or rat monoclonal anti-HA
antibody were incubated overnight at 4°C with the cell
lysates (2 mg for coimmunoprecipitation or 4 mg for in
vivo acetylation experiments). The HA-immune
complexes were precipitated by incubation with Ultra-
Link Immobilized Protein G (Pierce Biotechnology, Inc.,
Rockford, IL). The precipitated complexes were then
extensively washed and analyzed by Western blotting
using the appropriate antibodies.
Antibodies
The following primary antibodies were used: rabbit anti-
acetylated-lysine (Cell Signaling Technology, Inc., Dan-
vers, MA); mouse anti-Flag M2 (Sigma, Inc., St Louis,
MO), either free or bound to agarose beads; rat anti-HA
Clone 3F10 (Roche Diagnostics, Indianapolis, IN);
mouse anti-IN 8G4, obtained from the AIDS Research
and Reference Reagent Program; rabbit anti-GCN5 H-75
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and
mouse anti-a-tubulin Clone B-5-1-2 (Sigma, Inc.).
For the production of a polyclonal, anti-acetylated IN
antibody, three rabbits were immunized with a peptide
corresponding to amino acids 261-280 of the IN
sequence, chemically acetylated at lysines 264, 266 and
273, after conjugation with Maleimide Activated
mcKLH (Pierce Biotechnology, Inc.). The IgG fraction
was obtained from collected sera with the use of Immu-
noPure (A) IgG Purification Kit (Pierce Biotechnology,
Inc.). The purified samples were then passed over a col-
umn conjugated with the unmodified IN peptide to
remove the antibody cross-reacting with non-acetylated
IN.
Secondary horseradish peroxidase (HRP)-conjugated
antibodies against mouse or rabbit Igs were purchased
by Santa Cruz Biotechnology, Inc. For Western blot ana-
lysis with anti-acetylated-lysine antibody, Biotin-SP-con-
jugated AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit
IgG (H+L) (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA) and ECL Streptavidin-HRP conjugate
(Amersham Biosciences Corp., Piscataway, NJ) were
employed.
Cell cultures and virus production
HeLa and HEK 293T cells were cultured in DMEM sup-
plemented with 10% fetal calf serum (FCS), 100 U/ml
penicillin and 100 μg/ml streptomycin. HEK 293T cells
stably transduced with pGIPZ vectors were grown with
the addition of puromycin 2 μg/ml. CEM cells were cul-
tured in RPMI 1640 supplemented with 10% FCS,
2 mM glutamine, 100 U/ml penicillin and 100 μg/ml
streptomycin.
To produce env-deleted, VSV-G pseudotyped NL4.3-
Luc viruses, 6× 106 HEK 293T cells were transfected
with 20 μg of pNL4.3.Luc.R-E- (wild-type or mutated)
and 5 μg of the envelope plasmid pMDG using the PEI
reagent (Sigma, Inc.). The cell culture supernatant was
collected 48 h after transfection and filtered through a
0.45 μM pore size filter.
Terreni et al. Retrovirology 2010, 7:18
http://www.retrovirology.com/content/7/1/18
Page 13 of 16
NL4.3 replication competent viruses were prepared as
described for NL4.3-Luc viral clones, using 25 μg of
pNL4.3 plasmid (wild-type or mutated) for transfections.
For the generation of viral vector stocks, HEK 293T
cells were transfected with 10 μg of the packaging plas-
mid pCMVΔR8.91, 5 μg of pMDG and 20 μg of the
gene transfer plasmid (pGIPZ, pGIPZGCN5, or
pGIPZGCN5 mut), following the protocol used for virus
production. The cell culture supernatant was collected
twice, at 48 h and 72 h after transfection, filtered
through a 0.45 μM pore size filter and concentrated by
ultracentrifugation at 110000 × g for 2 h at 4°C.
Both viruses and viral vectors were titered by quantifi-
cation of p24 antigen in cell culture supernatants with
an enzyme-linked immunoabsorbent assay (Innoge-
netics, Gent, Belgium).
Transient and stable knockdown of GCN5 expression
GCN5-targeting siRNA (Dharmacon Research, Boulder,
CO) had the following plus-strand sequence: 5’-AAC-
CAUGGAGCUGGUCAAUGAAA-3’. As a non-silencing
control, Dharmacon ON-TARGETplus siCONTROL
Non-Targeting Pool was employed.
HeLa cells, seeded in 6-well plates (1.5 × 106 cells/well),
were transfected twice at a 24 h interval with 150 nM
siRNA using Gene Silencer reagent as recommended by
the manufacturer (Gene Therapy Systems, Inc., San
Diego, CA). Cells trypsinized after 20 h were either plated
for infections, or lysed for Western blot analysis.
For production of stably silenced cell lines, HEK 293T
cells, seeded in 24-well plates (5 × 104 cells/well), were
transduced with shRNAmir-encoding pGIPZ lentiviral
vectors and grown in medium containing 2 μg/ml
puromycin.
Infectivity and IN activity assays
For single-round replication assays, siRNA-treated HeLa
cells (2.5 × 106/well) or HEK 293T cells (5 × 106/well)
were seeded in 6-well plates and incubated for 3 h, in a
total volume of 500 μl, with 50 or 100 ng p24 antigen of
NL4.3-Luc virus (wild type or mutated), respectively.
Cells were collected 48 h after infection for measure-
ment of luciferase activity (Luciferase Assay System,
Promega Corp.).
Viral stocks used in infections for measurement of
HIV-1 DNA species by RT-Q-PCR were pre-treated for
1 h at 37°C with 160 U/ml Turbo DNase (Ambion, Inc.,
Austin, TX).
For multiple-round infections, 1 × 106 CEM cells were
incubated with 1 ng or 10 ng p24 antigen of NL4.3
virus (wild-type or mutated) in a total volume of 500 μl
for 3 h. Every 3 days, supernatants were collected and
viral titers determined by a 32P-based RT assay per-
formed by standard procedures.
To evaluate IN catalytic activity in vitro, 3’-end pro-
cessing and strand transfer reactions were performed
with recombinant IN proteins as previously described
[1].
Real-time quantitative PCR analysis
Total DNA was extracted from HEK 293T cells with the
DNeasy Tissue Kit (QIAGEN, Valencia, CA) at different
time points after infection. Amplification reactions were
performed with the Light Cycler 480 instrument (Roche
Diagnostics). Quantification of total HIV-1 DNA was
performed with a pair of primers and a fluorogenic
hybridization probe annealing to the luciferase reporter
gene of NL4.3-Luc viral clone. The sequences of the pri-
mers and the probe are as follows: forward primer,
LucFw, 5’-GAAGAGATACGCCCTGGTTCC-3’; reverse
primer, LucRev, 5’-TGTGATTTGTATTCAGCCCA-
TATCG-3’; and probe, LucProbe, 5’-FAM-TTCA-
TAGCTTCTGCCAACCGAACGGACA-3’ - BlackBerry
Quencher. Reaction mixtures contained 500 ng of total
genomic DNA, 1× Light Cycler 480 Probe Master
(Roche Diagnostics), 300 nM each forward and reverse
primers and 200 nM probe in a total volume of 20 μl.
After an initial denaturation step (95°C for 10 min), the
cycling profile was 40 cycles consisting of 95°C for 30 s,
60°C for 30 s, and 72°C for 30 s. Quantifications of pro-
viral DNA at 48 h post infection (Alu-LTR nested PCR)
and of two-LTR circles were performed according to
previously described protocols [43]. For detection of
integrated HIV-1 DNA in HEK 293T cells transduced
with pGIPZ vectors, cells were maintained in culture for
two weeks and proviruses were quantified using LucFw,
LucRev primers and LucProbe.
As an internal standard for normalizing the amount of
cellular genomic DNA, the level of human b-globin
DNA was determined in each sample using primers and
fluorogenic hybridization probe that were previously
described [44]. The amplification conditions included a
hot start at 50°C for 2 min and 95°C for 10 min, fol-
lowed by 40 cycles of denaturation at 95°C for 15 s and
extension at 60°C for 1 min.
Statistical analysis
Paired comparisons were carried out using two-tailed
Student’s t-tests, assuming equal variance between sam-
ples to determine differences at the 5% level; all data
points (including outliers) were included in the analysis
for significance.
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HIV-1 integrase (IN), the enzyme that catalyzes the integration of the 
viral cDNA into the host cellular genome is positively regulated by 
acetylation induced by the cellular histone acetyl transferase (HAT) 
p300 (Cereseto et al., 2005). Acetylation increases IN affinity to DNA 
and promotes IN enzymatic activity (Cereseto et al., 2005). To 
investigate the relevance of IN acetylation in the context of HIV-1 
infection, we searched for cellular partners selectively binding 
acetylated IN in vivo.  By two-hybrid screening using constitutively 
acetylated IN as bait, we identified KAP1, a protein belonging to the 
TRIM family of antiviral proteins as a novel IN interactor that regulates 
HIV-1 infection. We found that KAP1 binds acetylated IN and induces 
its deacetylation through the formation of a protein complex including 
the deacetylase HDAC1. Modulation of intracellular KAP1 levels in 
different cell types including T-cells, the primary HIV-1 target, revealed 
that KAP1 curtails viral infectivity by selectively affecting HIV-1 
integration. The KAP1-dependent viral inhibition was found to require 
HDAC1 activity since cells deficient for this deacetylase were 
insensitive to KAP1-induced resistance.  This study reveals that KAP1 is 
a novel cellular factor restricting HIV-1 infection and underscores the 






A key step in retroviral life cycle is the integration of the double-stranded viral 
cDNA into the host cellular genome; a reaction catalyzed by the viral integrase 
(IN) protein (Vandegraaff and Engelman, 2007).  
The double–stranded DNA molecule is reverse transcribed from the viral RNA 
genome soon after virion entry into the cytoplasm. The DNA ends of the neo 
synthesized viral genome are processed by IN, producing recessed 3’ OH termini 
at each end of the linear molecule (Vandegraaff and Engelman, 2007). The 
recessed 3’ ends are then used in a nucleophylic attack on the host DNA to 
covalently join the viral and the host genomes (Vandegraaff and Engelman, 
2007). The terminal cleavage and the strand transfer steps can be modeled in 
vitro  with purified IN (Vandegraaff and Engelman, 2007). Nevertheless, in cells 
integration occurs within a large nucleoprotein complex termed the pre-
integration complex (PIC), which is formed by the viral cDNA, viral proteins and 
numerous cellular factors playing important regulatory roles (Suzuki and Craigie, 
2007; Van Maele et al., 2006; Vandegraaff and Engelman, 2007). One of the 
cellular factors exploited by HIV-1 during the integration process is the histone 
acetyl transferase (HAT) p300, which specifically acetylates the carboxy terminus 
of IN (Cereseto et al., 2005). We have previously reported that acetylation of IN 
lysines 264, 266 and 273 increases catalytic activity of this enzyme and that their 
mutation (K264,266,273R) significantly impairs viral replication (Cereseto et al., 
2005; Terreni et al., 2010). Since post-translational modifications, like 
acetylation, dynamically change the chemical and structural properties of 
proteins generating new protein-protein interfaces, we wanted to search for 
possible cellular partners selectively interacting with acetylated IN. Although, 
most IN interacting factors were identified through the yeast two-hybrid 
approach (Van Maele et al., 2006) conventional two-hybrid screening, however,  
does not allow identification of factors that bind specifically to acetylated baits. 
We therefore developed a tethered catalysis two-hybrid system where 
constitutively acetylated IN is used as bait. The tethered catalysis system exploits 
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the cis enzymatic activity of a HAT domain, which determines constitutive 
acetylation of the substrate to which it is fused. From this screening, KAP1 (also 
known as TRIM28 or Tif-1 beta) has emerged as a new factor that interact 
specifically with acetylated IN. KAP1 was initially identified as a transcriptional 
corepressor that is recruited to its target genes by interacting with the Kruppel-
associated box-domain-containing (KRAB) zinc-finger DNA proteins (Friedman et 
al., 1996; Peng et al., 2000). KAP1 mediates gene silencing (Ivanov et al., 2007; 
Sripathy et al., 2006) by recruiting on target promoters the NuRD histone 
deacetylase (HDAC) complex (Schultz et al., 2001), the histone 
methyltransferase SETDB1 (Schultz et al., 2002) and the heterochromatin-
associated protein HP-1 (Lechner et al., 2000). KAP1 belongs to the tripartite 
motif (TRIM) protein family  which display antiviral properties, targeting 
retroviruses in particular (Nisole et al., 2005).  Importantly, KAP1 has been 
recently reported to restrict a gamma-retrovirus, M-MLV, in embryonic cells by 
silencing the proviral transcription (Wolf and Goff, 2007).  Mounting evidence 
now suggest that KAP1 in addition to its documented transcriptional corepressor 
activity is involved more broadly in various nuclear functions (e.g. DNA damage 
response (White et al., 2006; Ziv et al., 2006). 
KAP1 acts by forming protein complexes containing HDACs leading to the 
reversible acetylation of non histone proteins such as p53 and E2F1 (Tian et al., 
2009; Tsuruma et al., 2008; Wang et al., 2005; Wang et al., 2007). As 
acetylation is a dynamic regulatory mechanism that involves the deacetylation 
activity of the HDAC protein family, in this study accordingly we analyzed the 
dynamic mechanisms regulating the acetylation levels of IN through KAP1. In 
particular, we examined whether that KAP1 mediated inhibition of viral 






Two hybrid screening with acetylated IN 
 
To identify cellular factors binding specifically to acetylated IN we have 
performed a tethered catalysis two-hybrid screening where IN used as bait is 
constitutively acetylated.  To this aim a chimera where IN is fused to the HAT 
domain of p300 (IN-HATw) (Figure 1A, left panel) was engineered. To allow the 
separation of IN from the HAT domain, a proteolytic cleavage site for TEV was 
introduced between IN and HAT. As control the same chimera was constructed 
containing a catalytically inactive HAT domain (IN-HATm) (Figure 1A, right 
panel). 
The IN-HAT chimeras were purified from bacteria and verified for acetylation by  
Western blot using antibodies specific for acetylated IN. Figure 1B, left panel, 
shows a high molecular size band corresponding to the full length IN-HATw 
chimera while no signal was detected in the IN-HATm control. The TEV digested 
products of both chimeras were also analyzed using antibodies against 
acetylated IN. IN-HATw showed a band at the same size of IN while no signal 
could be detected from the cleavage of IN-HATm (Figure 1B, right panel), thus 
indicating that IN is indeed acetylated within the IN-HATw chimera.  
In addition, specific acetylation of lysines 264, 266 and 273 formerly identified by 
site directed mutagenesis (Cereseto et al., 2005), was verified by mass 
spectrometry analysis of the IN-HATw chimera (Figure S1). To perform the two 
hybrid screen, IN-HATw and IN-HATm were then cloned in a yeast expression 
vector (PBD-Gal4) in frame with GAL4 DNA binding domain (GDBD) at the N-
terminus and a HA-tag at the C-terminus. Following transformation of yeast cells 
the level of IN expression and acetylation was checked by immunoblot analysis 




The vector expressing the GDBD-IN-HATw chimera was then co-transformed in 
yeast cells (AH109) with a human lymphocytes cDNA library cloned in a yeast 
expression vector (pACT) fused to GAl4 Activation Domain (GAD). The AH109 
reporter strain carries ADE2, HIS3, lacZ and MEL1 genes. From the two hybrid 
selective medium (-Ade,-His) we obtained 754 positive clones (Ade+, His+) 
encoding for thirteen factors. Three clones encoded for the same domain (a.a 
304-835) of the KAP1 gene (HSU78773).  KAP1 has drawn our attention because 
it was recently reported to restrict M-MLV in embryonic stem cells (Wolf and 
Goff, 2007), and so potentially involved in HIV-1 biology. 
To test the specificity of interaction between KAP1 and acetylated IN, a 
comparative analysis was performed by co-transforming GAD-KAP1 in yeast with 
the following GDBD/HA fusion proteins: IN-HATw, IN-HATm, HATw, HATm or 
Gal4-BD alone. These two-hybrid analyses showed that KAP1 interacts more 
efficiently with the acetylated IN (IN-HATw) than the unmodified IN (IN-HATm 
and IN), and no interaction was detected between KAP1 and the individual single 
domains (HATw, HATm and Gal4-BD) (Figure 1D). These results indicate that 
KAP1-IN interaction is highly favored by IN acetylation catalyzed by p300. 
 
 
Interaction between acetylated IN and KAP1  
To validate the interaction between the acetylated IN and KAP1 the binding of 
the two proteins was further analyzed in a mammalian system. KAP1 fused to a 
Flag-tag was expressed in HEK293T cells and the lysate incubated with the IN-
HATw and IN-HATm recombinant proteins. Flag immunoprecipitates were then 
analyzed by Western blot. As shown in Figure 2A, upper-left panel, higher 
amounts of IN-HATw bind KAP1 as compared to IN-HATm. The same experiment 
was performed using IN isolated from the HATw or HATm domains following 
proteolytic cleavage of the recombinant chimera with the TEV protease. In Figure 
2A (upper-right panel) a doublet at the same molecular size of IN was clearly 
visible with anti-Flag-KAP1 immunocomplexes incubated with IN derived from the 
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IN-HATw chimera, while no bands were detected using IN-HATm. The doublet 
observed in the IN-HATw immunoprecipitation is probably due to degradation of 
the IN protein during purification procedures since similar doublets are also 
observed in Figure 1B. These data clearly demonstrate that KAP1 binds 
preferentially the acetylated IN than the non-acetylated protein.  
To further analyze the IN/KAP1 interaction in vivo, Flag-tagged IN was expressed 
in HEK293T cells and the amount of complexed endogenous KAP1 was evaluated 
following anti-Flag immunoprecipitation. As shown in Figure 2B, using anti-KAP1 
antibodies endogenous KAP1 was detected on IN immunoprecipitates, while no 
bands were found in samples expressing the control Flag. To verify the role of IN 
acetylated lysines located in the carboxy-terminus, the same 
immunoprecipitation experiment was performed using a plasmid expressing Flag-
IN mutated in lysines targeted for acetylation (264, 266 and 273) (Cereseto et 
al., 2005). Lower amounts of endogenous KAP1 bound mutated IN as compared 
to wild-type IN (Figure 2B). This observation was further verified using untagged 
INw and INm (Figure S2A). 
To further prove the role of acetylation in IN binding with KAP1 both IN-HATw 
and IN-HATm chimeras were incubated with in vitro 35S labeled KAP1. As shown 
in Figure 2C, IN-HATw binds KAP1 with higher affinity than IN-HATm. Since 
acetylated IN lysines enhanced the association with KAP1, we then specifically 
analyzed the role of the IN carboxy domain, which contains the acetylable lysines 
(264, 266 and 273). To this aim, pull-down experiments were performed by 
incubating recombinant IN domains fused to glutathione-S-transferase (GST) 
with in vitro 35S labeled KAP1.  KAP1 was found to bind the GST-C-terminus IN at 
the same extent (~10%of the input) of the GST- full length IN, while no 
interaction was observed between KAP1 and either the N-terminus or the 
catalytic domain (Figure 2D).  
In conclusion, IN and KAP1 interact both in vivo and in vitro and IN/KAP1 
complex formation, which is favored by IN acetylation, occurs through the C- 




KAP1 inhibits  HIV-1 integration 
To evaluate the role of KAP1 during HIV-1 infection, this factor was knocked 
down in HeLa cells by either transient siRNA treatment or stable shRNA (Figure 
3A). Western blot analysis revealed that the expression of KAP1 was lowered in 
cells treated with a pool of siRNA directed against KAP1, as compared to cells 
untreated or transfected with control siRNA (Figure 3A, left panel). Similarly, 
HeLa cell clones stably expressing KAP1 shRNA (sh-1-KAP1) through a lentiviral 
vector (GIP-Z) showed reduced expression of KAP1 as compared to cell clones 
stably expressing mismatched shRNA (Figure 3A, right panel). Single round 
infectivity experiments with a VSV-G-pseudotyped HIV-1 clone carrying the 
luciferase gene as reporter (NL4.3-Luc), showed that cells in which KAP1 was 
knocked down were substantially more sensitive to infection (Figure S3A).  
Since KAP1 was reported to possess transcriptional co-repressor activity and to 
limit M-MLV infectivity by blocking viral transcription, we first tested its possible 
involvement in viral events other than those regulated by IN. For this purpose, 
experiments were carried out using the HIV-1 IN (D64E) mutant, which is 
integration-defective, yet does express luciferase from its circular unintegrated 
forms. These infections showed no variation of luciferase activity in KAP1 
knockdown cells, indicating that KAP1 does not affect replication steps unrelated 
to IN activity, including viral transcription (Figure S4A). This conclusion is further 
sustained by the lack of the regulation of  transcriptional activity reported from a 
HIV-1 clone transiently transfected in KAP1 knockdown HeLa cells, as well as 
from a stably integrated HIV-1 based viral vector carried in Jurkat T-cells (J-lat 
A1) (Figures S4B and S4C).  
These results strongly suggest that KAP1 regulates viral infectivity during the 
early events of viral replication, before transcription. We therefore sought to 
quantify, by real-time quantitative PCR (qPCR), the different DNA viral forms 
characterizing the HIV-1 replication cycle (late reverse transcription products, 
unintegrated 2-LTRs circles and integrated DNA) in KAP1 knockdown cells 
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infected with HIV-1. No significant variations (P > 0.05) were observed in cDNA 
synthesis (late reverse transcripts) (Figure 3B), implying that KAP1 has no 
observable effect on reverse transcription. In contrast, quantification of the 2-
LTR circles showed that, these un-integrated forms were significantly less 
abundant in KAP1 knockdown cells (Figure 3C). 2-LTR circles are molecules of 
circularized retroviral cDNA that fail to integrate. These viral DNA forms directly 
correlate with cDNA nuclear translocation, while are inversely correlated with the 
efficiency of integration. Finally, consistent with the luciferase activity results 
(Figure S3A)  a 8- and 2-fold (P < 0.05) increases were observed in integrated 
viral DNA using, respectively, siRNA or shRNA, against KAP1 (Figure 3D).  
Additionally, to verify that the observation so far reported are not cell type 
dependent the same experiments were also reproduced in a different cell line 
(HEK293T) (Figures S4A and S5). 
To verify also that inhibition of viral integration is determined by specific 
downregulation of KAP1, the integrated viral DNA was measured in KAP1 
knockdown cells where the KAP1 expression was re-established by using a KAP1 
cDNA resistant to shRNA (sh3’KAP1). In these cells viral integration returned to 
baseline demonstrating specific activity of the KAP1 shRNA (Figure 3E). Taken 
together, the increase in the levels of integrated viral DNA and the decrease in 2-
LTR circles in the KAP1 knockdown cells, support the conclusion that KAP1 
negatively regulates viral integration.  
Since KAP1 has been shown to restrict infectivity of M-MLV in embryonic stem 
cells (ECSs) by inhibiting viral transcription, we tested whether M-MLV might also 
be affected by KAP1 at the integration step. To discern the integration from the 
transcription step, these experiments were performed by using a M-MLV vector 
carrying a CMV driven luciferase gene. As shown in Figure S6, M-MLV infectivity 
is not affected in KAP1 HeLa knocked down cells correlating with no specific 
effect at the integration step. 
To further verify the activity of KAP1 on viral integration, experiments were 
performed by infecting cells over-expressing KAP1. Consistently with KAP1 
10 
 
knockdown experiments, high levels of KAP1 (Figure 3F, left panel) inhibit HIV-1 
infection as measured by luciferase activity (Figure S3B). Notably, decreased 
infectivity correlates with significantly reduced levels of integrated viral DNA (P < 
0.05), while reverse transcripts products are not significantly altered (Figure 3F, 
middle and right panels).  
In conclusion these results demonstrate that KAP1 decreases viral infectivity by 
specifically downregulating the efficiency of the integration event.  
 
 
KAP1 inhibits HIV-1 integration via IN acetylation-dependent 
mechanism in lymphocytic cells  
To specifically test the role of IN acetylation in KAP1-dependent viral inhibition, 
we exploited a viral clone (pNL4.3-Luc-3mut) carrying IN mutated in the lysines 
targeted for acetylation (K264, 266, 273R). As previously shown this virus was 
less infectious than the parental NL4.3-Luc (Figures 4A and Figure S3C). 
However, as observed above (Figure 3D), while the wild-type virus showed 
increased proviral DNA formation in KAP1 knockdown HeLa cells, the integration 
of the mutated virus was not significantly altered (P > 0.05) in cells expressing 
low levels of KAP1 (Figures 4A and Figure S3C). Therefore these data further 
demonstrate that IN acetylation is necessary for KAP1 mediated inhibition of viral 
integration.  
To test the role of KAP1 in cells naturally targeted by HIV-1, similar experiments 
were performed in primary blood lymphocytes (PBLs) purified from 4 healthy 
donors and in a T-cell line (CEMss). PBLs knocked down for KAP1 by 
electroporated siRNAs (Figure 4B, left panel) showed almost 3 fold (P < 0.05) 
increased viral integration following infection with NL4.3-Luc, however, viral 
integration remained unaltered in KAP1 knockdown cells infected with NL4.3-Luc-
3mut (Figure 4B). Similar results were observed in CEMss cells knocked down by 
either a cocktail of 5 KAP1 shRNA (sh-5-KAP1) or by a single shRNA contained in 
the cocktail (sh-3’KAP1) (Figure 4C). The specificity of KAP1 mediated viral 
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inhibition was further proven by the lack of enhancement of viral integration 
observed in KAP1 knockdown CEMss cells (sh-3’KAP1) expressing a non-
targetable KAP1 cDNA (Figure 4C, right panel, fourth column). In these 
experiments the levels of total viral DNA were checked showing no significant 
variations (data not shown).  
In conclusion these data strongly support the role of IN acetylation in KAP1 viral 
inhibition in different cell types. 
  
KAP1 interaction decreases IN acetylation through HDAC1 
Results so far reported in this study demonstrate that KAP1 inhibition of viral 
infectivity is mediated by the interaction of the cellular protein with acetylated 
IN. Therefore, in the attempt to delineate the molecular mechanism of this 
phenomena, the IN acetylation was analyzed relative to KAP1 expression. To this 
aim IN was expressed in HEK293T cells together with KAP1 and the acetylation 
levels evaluated using antibodies against acetylated IN. The over-expression of 
KAP1 significantly decreased the acetylation of IN as compared to IN expressed 
in the absence of exogenous KAP1 (Figure 5A, upper panel). The level of IN 
acetylation was then analyzed in HeLa cell clones stably knocked down for KAP1 
(Figure 3A). Transfection of Flag-IN in KAP1 silenced HeLa cells revealed that the 
levels of IN acetylation were substantially increased (Figure 5B, upper panel). 
Since HDACs are responsible for protein deacetylation, we verified the activity of 
these enzymes on IN. We observed that HDAC activity is associated with IN 
(Figure S7A) and trichostatin A (TSA), a potent inhibitor of these enzymes, 
increases the acetylation levels of IN (Figure S7B). Moreover, HDAC1 purified 
from HEK293T cells but not the catalytically inactive form (H141A) (Hassig et al., 
1998) lowered the acetylation levels of recombinant IN, thus demonstrating that 
HDAC1 specifically regulates the acetylation of IN (Figure S7C).  
Interestingly, KAP1 has been reported to form complexes with HDACs 
determining the deacetylation of its binding partners (Tian et al., 2009; Tsuruma 
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et al., 2008; Wang et al., 2005; Wang et al., 2007). We thus sought to 
investigate whether IN deacetylation induced by KAP1 would be mediated by 
complex formation with HDACs. 
Co-immunoprecipitation experiments of Flag-HDAC1 and Flag-HDAC3 co-
expressed with HA-IN showed higher amounts of IN associated with HDAC1 than 
with HDAC3. In addition, the same membrane blotted with anti-KAP1 antibodies 
revealed endogenous KAP1 together with the HDAC1 complex and not with 
HDAC3 (Figure 5C second panel from top). These data thus suggest that IN 
forms a complex with HDAC1 and KAP1. To explore the hypothesis that the 
association of IN with HDAC1 is mediated by KAP1, the binding of HDAC1 with IN 
was checked in HEK293T cells over-expressing KAP1. Immunoprecipitation of 
HDAC1 revealed much higher associated IN in cells over-expressing KAP1 as 
compared to control cells (Figure 5D and FigureS2B). These results strongly 
suggest that KAP1 plays a role in IN/HDAC1 complex formation. To further prove 
this hypothesis, KAP1 knockdown cells were transfected with both HA-IN and 
Flag-HDAC1, and HDAC1 immunoprecipitates were verified for the amounts of 
associated IN. When KAP1 expression was downregulated the levels of IN 
complexed with HDAC1 were strikingly lower than control cells expressing 
mismatched KAP1 shRNA (Figure 5E, upper panel).  
In conclusion these data clearly demonstrate that KAP1 induces IN deacetylation 
by favoring HDAC1 binding to IN.  
 
KAP1 inhibits HIV-1 integration through HDAC1 
Results here reported indicate that KAP1 lowers IN acetylation through HDAC1 
tethering. Since our previous reports demonstrate that acetylation of IN 
positively regulates viral integration (Cereseto et al., 2005; Terreni et al., 2010), 
we assumed that HDAC1 deacetylase activity might downregulate HIV-1 
integration. To verify this hypothesis we analyzed viral integration in cells treated 
with HDACs inhibitors. Infection of cells treated with TSA or with a specific 
inhibitor of HDAC1, MS-275 (Nishioka et al., 2008), determined an increase of 
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viral integration (As shown in Figure 6A), while total viral DNA remained 
unaltered (data not shown). To better pinpoint the role of HDAC1 in viral 
integration, infections were then performed in HDAC1 knockdown cells (Figure 
6B, left panel). We observed that in conditions of low HDAC1 expression the 
integration (Alu-LTR)  was increased of almost four fold, while the un-integrated 
2-LTR circles were decreased of two-fold (Figure 6B, middle and right panels). 
To verify that HDAC1 affects specifically the integration reaction the total viral 
DNA was also quantified showing no major alteration in cells silenced for HDAC1 
(data not shown).  
Since results so far reported strongly suggest that KAP1 inhibition of viral 
integration might occur through HDAC1 deacetylase activity, we sought to 
analyze the interplay between these factors during HIV-1 integration. To this aim 
infections were performed in cells where the expression of both HDAC1 and 
KAP1 was simultaneously modulated by silencing (HDAC1) and over-expression 
(KAP1) (Figure 6C, left panel). In agreement with results reported in Figure 3F, 
integration of viral cDNA was substantially reduced in cells over-expressing KAP1 
(Figure 6C, right panel), while the amounts of the late reverse transcripts 
remained unaltered (data not shown). In cells that were silenced for HDAC1, 
however, over-expression of KAP1 did not show any viral inhibitory effect (Figure 
6C, right panel). These experiments were also performed in HDAC3 knockdown 
cells, where no significant modulation of viral integration was observed (Figure 
S8), consistently with the weak association of this enzyme with IN and the 
absence of KAP1 in the IN-HDAC3 complex (Figure 5C). Therefore, these data 
clearly demonstrate that KAP1 integration-specific inhibitory effects occurs 
through HDAC1 activity. The role of HDAC1 in KAP1 inhibitory effects was further 
sustained by the results showing that the KAP1 N-terminal domain (1-381) 
involved in viral inhibition correlate with HDAC1 binding properties, while the 
inactive KAP1 C-terminal domain (617-835) was not able to bind HDAC1 (Figure 
S9).    
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Collectively, these data clearly show that KAP1 inhibits viral integration by 





Acetylation of HIV-1 IN enhances viral integration (Cereseto et al., 2005; Terreni 
et al., 2010). The role of this modification during the viral life cycle is proven by 
the decreased infectivity and provirus formation following inhibition of IN 
acetylation (Apolonia et al., 2007; Cereseto et al., 2005; Terreni et al., 2010; 
Topper et al., 2007). 
Post-translational modifications, such as acetylation, regulate protein functions 
by modifying protein-protein interactions. Since HIV-1 IN is functionally regulated 
by the association with cellular co-factors, we hypothesized that acetylation 
might modulate the association of IN with known or still unidentified cellular 
factors. To this aim we have carried out a modified two-hybrid screening that 
differ from all screening so far performed for using as “bait” an IN constitutively 
acetylated through its fusion with the HAT domain of p300 (Allouch and 
Cereseto, 2009). This screening revealed that KAP1 interacts with acetylated IN 
and with a lower affinity to the un-modified form. Investigation on the role of 
KAP1 during viral replication cycle showed that KAP1 downregulation enhances 
viral infectivity due to specific increase in viral integration. This observation has 
been further confirmed by reciprocal experiments showing that KAP1 over-
expression reduces provirus formation. Cellular antiretroviral defense blocks viral 
infectivity at specific time points during the viral replication cycle. In addition to 
the well defined restriction factors, a growing numbers of host cellular genes 
have been described to reduce susceptibility to retrovirus infection (Boulanger et 
al., 2005; Ganesh et al., 2003; Naghavi et al., 2005; Naghavi et al., 2007; Turelli 
et al., 2001). Among the factors so far identified only one, p21Cip1, has been 
described to decrease infectivity by interfering with viral integration (Zhang et 
al., 2005; Zhang et al., 2007). Since p21Cip1 is a cell cycle checkpoint protein 
playing a role in DNA damage response, it has been speculated that DNA 
damage pathways activated by the virus are responsible for p21Cip1 antiviral 
activity; however, the molecular mechanism underlying viral integration inhibition 
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has not been delineated (Zhang et al., 2007). Here we demonstrate that KAP1 
inhibits viral infectivity by specifically interfering with viral integration. By binding 
to the acetylated IN, KAP1 induces HDAC1 complex formation leading to IN 
deacetylation and reduced integration efficiency. We have proven that HDAC1 is 
essential for KAP1 mediated viral inhibition since over-expression of KAP1 does 
not reduce integration in cells silenced for HDAC1. Conversely, HDAC3 which is 
not part of the IN/KAP1 complex, does not affect the inhibitory activity of KAP1. 
The HDAC1-KAP1 interplay in HIV-1 inhibition is further sustained by the 
demonstration that the efficacy of the truncated KAP1 domains on HIV-1 
replication correlates with their binding properties with HDAC1 (see 
Supplementary Figure S9 for further discussion).   Interestingly, recently it has 
been reported that HDAC1 affects HIV-1 reverse transcription (Sorin et al., 
2009). However, our data show a specific involvement of this enzyme during the 
integration event and not during reverse transcription. These apparent 
discrepancy could be explained by the fact that Sorin et al. (2009) analyze 
HDAC1 interacting with nascent viral particles, while in this study HDAC1 is 
analyzed in post-entry steps. 
Emerging new evidence indicate that KAP1 is involved in 
acetylation/deacetylation activities unrelated to transcriptional control. In fact, 
KAP1 has recently been shown to inactivate proteins involved in DNA damage 
response (p53 and E2F1) by deacetylating these proteins through HDACs 
tethering (Tian et al., 2009; Wang et al., 2005; Wang et al., 2007). Notably, it 
has been suggested that unintegrated HIV-1 cDNA is substrate for double-DNA 
strand break repair factors, which in turn activate DNA damage response (Daniel 
et al., 1999; Jeanson et al., 2002; Kilzer et al., 2003; Li et al., 2001; Lloyd et al., 
2006). Moreover, ATM that predominantly detects DNA double strand breaks, 
has been demonstrated to be activated following HIV-1 infection and its 
inhibition through a small molecule (KU-55933) drastically decreases cellular 
susceptibility to viral infection (Lau et al., 2005; Perfettini et al., 2008). Since 
KAP1 is ubiquitously expressed showing no major restriction of HIV-1 infectivity, 
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we propose a model where ATM activated by unintegrated HIV-1 phosphorylates 
KAP1 leading to disassembly of the IN/HDAC1 complex. This would ultimately 
reverse HDAC1 deacetylase activity associated to IN, thus allowing the 
reconstitution of IN acetylation and restored levels of integration efficiency. Very 
similar results have been reported to regulate p53 activity through an 
acetylation/deacteylation cycle regulated by KAP1 (Tian et al., 2009). In fact, this 
study shows that in unstressed cells p53 is inactivated by deacetylation through 
KAP1 mediated HDAC1 binding. In response to DNA damage ATM rapidly 
activates p53 through phosphorylation of KAP1 leading to p53/HDAC1 complex 
disruption and p53 acetylation. Further studies are required to verify a similar 
model for IN regulation. 
KAP1 has also been described to restrict M-MLV in embryonic carcinoma and 
embryonic stem cells. However, in that case viral inhibition occurs at the level of 
transcription specifically in embryonic stem cells (ECSs), while here we show that 
integration of the M-MLV cDNA is not affected by KAP1. In ESCs infected with M-
MLV, KAP1 is part of a large protein complex that binds the proviral primer 
binding site (PBS) leading to transcriptional repression (Wolf and Goff, 2007, 
2009; Wolf et al., 2008). KAP1 mediated inhibition of viral transcription appears 
to be shared among retroviruses containing PBS sequences complementary to 
tRNAPro such as M-MLV and HTLV-1, or tRNALys-1,2 such as visna, spuma and 
Mason-Pfeizer monkey virus (Wolf and Goff, 2009; Wolf et al., 2008). 
Conversely, the HIV-1 PBS does not contain either tRNAPro or tRNALys-1,2 
complementary sequences, and is thus not susceptible to KAP-1 mediated 
transcriptional repression as also confirmed by our results.  Interestingly, the 
KAP1 inhibitory activity on transcription is responsible for controlling endogenous 
retroelements during early embryonic development (Rowe et al., 2010), 
suggesting a potential role of KAP1 in HIV-1 post-integration latency. However, 
we observed that KAP1 is expressed at the same levels in cells harboring silent 
or activated provirus as well as in the main cell types involved in HIV-1 latency 
(Figure S10). Hence, these data together with the absence of KAP1 in 
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transcriptional repression suggested by other reports (Wolf and Goff, 2009; Wolf 
et al., 2008), disfavor a hypothetical role of KAP1 in post-integration latency.  
The different molecular mechanism of KAP1 restriction might parallel the dual 
activities of this factor at the cellular level:  transcriptional as a corepressor and 
protein activity regulator through acetylation.  
In summary, our study demonstrates that KAP1 inhibits HIV-1 integration 
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EXPERIMENTAL PROCEDURES  
 
Vectors and constructs 
pASK-IN-HATw/m to produce recombinant IN-HATw/m were constructed by 
cloning IN codon optimized (CO) in frame with the HAT domain of p300 (a.a. 
1195-1673) wild-type or mutated (D1395Y) in the pASK-IBA37 plus vector (IBA, 
Gottingen, Germany)  containing at 5’ of the MCS a 6xHis tag. A 3’HA tag and a 
Tobacco Etch Virus (TEV) protease cleavage site were introduced by PCR. From 
the pASK-IBA37-IN-HATw/m vectors the IN-HATw/m, HATw/m and IN were 
cloned in the pBD-Gal4 vector (Stratagene, La Jolla, CA). Full-length KAP1 cDNA 
was purchased from Open Biosystem (Huntsville, AL) and cloned by PCR in 
pcDNA3.0, pFlag-CMV2 vectors and in pAIP lentiviral vector (kindly provided by J. 
Luban, Geneve University, Switzerland) in frame with HA (pAIP-HA-KAP1). pFlag-
IN CO was kindly provided by A. Engelman (Dana-Farber Cancer Institute, 
Boston, MA) and K264,266,273R mutations were introduced by PCR. Expression 
vectors of GST-IN full length and GST-IN truncated domains (N-terminus, Core 
and C-terminus) have been previously described (Cereseto et al., 2005). pFlag-
HDAC1 and pFlag-HDAC3 have been previously described (Sabo et al., 2008).  
pNL4.3.Luc.R-E- was obtained from the NIH AIDS Research and Reference 
Reagent Program (Germantown, MD). PNL4.3-Luc-3mut (K264,266,273R) has 
been previously described (Terreni et al., 2010). 
 
Yeast two hybrid screen 
A human T-lymphocytes cDNA library fused to Gal4 Activating Domain in a pACT 
vector (BD biosciences Clontech, Palo Alto, CA) was expressed in AH109 yeast 
cells and screened with the pGBD-IN-HATw (bait) expression vector. Library 
transformation and screening were performed following manufacturer’s 
instructions (Matchmaker GAL4 two hybrid system 3). GAD-KAP1 was co-
expressed in AH109 yeast cells with GDBD fused to IN-HATw/m, HATw/m and IN 




IN-HATw and IN-HATm  purification and TEV digestion 
pASK-IN-HATw/m encoding for 6xHis-IN-HATw/m were transformed in E. coli 
Arctic Express RIL competent cells (Stratagene) and induction of protein 
expression was performed using 43 mM anhydrotetracycline hydrochloride (AHT) 
for 24 hours at 13 °C. Bacteria culture was lysed in binding buffer (1M NaCl, 20 
mM Tris HCl pH 7.9 and 0.5% Triton X-100). 6xHis-IN-HATw/m were purified 
using TALON Metal Affinity Resin (BD Biosciences). For TEV digestion 20 μg of 
6xHis-IN-HATw/m were incubated with 30 units of AcTEV protease (Invitrogen, 
Paisley, UK) in 120 mM NaCl, 50 mM Tris-HCl pH 8, 0.5 mM EDTA and 1 mM of 
DTT in 250 μl total volume. 6xHis-IN TEV digested products were adjusted to 1 
M NaCl and recovered using Ni-NTA agarose resin (Qiagen, Hilden, Germany).   
 
Virus productions and infections 
NL4.3-Luc and NL4.3-Luc-3mut viruses pseudotyped with the Vesicular Stomatitis 
Virus-G (VSV-G) envelope were produced by transfecting 5x106 HEK293T cells 
with 20 g pNL4.3.Luc.R-E- or pNL4.3-Luc-3mut and 5 g p-MDG-VSV-G using 
150 nM polyethylenimine (PEI) reagent (Sigma, St. Louis, MO). Viral 
supernatants were collected 48 hours post transfection, quantified for their HIV-1 
p24 antigen content using Innotest HIV Antigen mAb kit (INNOGENETICS N.V., 
Gent, Belgium) and DNAse I treated before infection (40 U/ml) (TURBO DNAse-
Applied Biosystems, Foster City, CA). 
Infections of transiently knocked down cells were performed for 2 hours using: 
100 ng p24 for 6x105 HeLa cells 48 hours after siRNA transfection; 250 ng p24 
for 5x105 CEMss cells 60 hours post-transduction with KAP1 shRNAs lentiviral 
vectors; 500 ng p24 for 2x105 PBLs 24 hours after siRNA transfection. For back-
complementation experiments (HeLa or CEMss cells) were infected 60 hours post 
LKO.1-sh-3’KAP1 and AIP-HA-KAP1 (1-835) transductions using 250 ng p24 
NL4.3-Luc (VSV-G) HIV-1 virus for 5x105 cells. Infections of stable knockdown 
HeLa cell clones (3x105) were performed using 300-1200 ng p24. Infections of 
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HEK293T cells transfected 24 hours in advance with pcDNA3-KAP1 (6.25 μg for 
1.2x106 cells with PEI) were performed using 125 ng p24 for 2,5x105 cells. 
 
Transient/stable knockdowns and back-complementation 
Transient knockdowns mediated by siRNAs and controls experiments were 
performed by using smart pool siRNAs pre-designed by Dharmacon Inc. 
(Chicago, IL). The KAP1 pool contains the following four siRNAs: 1) 5’-
GACCAAACCUGUGCUUAUG-3’; 2) 5’-GAUGAUCCCUACUCAAGUG-3’; 3) 5’-
GCGAUCUGGUUAUGUGCAA-3’; 4) 5’- AGAAUUAUUUCAUGCGUGA-3’. The HDAC1 
pool contains the following four siRNAs: 1) 5’-CUAAUGAGCUUCCAUACAA-3’; 2) 
5’-GAAAGUCUGUUACUACUAC-3’; 3) 5’-GGACAUCGCUGUGAAUUGG-3’; 4) 5’-
CCGGUCAUGUCCAAAGUAA-3’. 1x105 HeLa cells were treated with 200 nM KAP1 
siRNAs or 150 nM HDAC1 siRNAs  and equivalent amounts of control siRNAs 
(ON-TARGET plus Non-targeting Pool) by using the Gene Silencer siRNA 
transfection reagent (Gene Therapy Systems,Inc., San Diego, CA). PBLs were 
isolated from Ficoll-purified peripheral blood monocytes using a high density 
hyper-osmotic Percoll density gradient (Sigma) as previously described (Repnik 
et al., 2003). Following activation with PHA-P (2 g/ml) (Sigma) and 5 days 
culture in IL-2 (25 U/ml) (Roche, Mannheim, Germany), 5x106 cells were 
electroporated using the nucleofector II Amaxa biosystems instrument (Lonza, 
Switzerland) with 600 nM KAP1 siRNAs or control siRNAs in 100 l T-cell 
Nucleofector solution (Lonza). 
CEMss cells were transiently knocked down by transducing a pool of 5 LKO.1 
lentiviral vectors each expressing a shRNAmir against the KAP1 gene (sh-5-KAP1) 
(400 ng p24 each vector for 1x105 cells): 1) 5’-CCTGGCTCTGTTCTCTGTCCT-3’ 
(sh-3’-KAP1); 2) 5’-GAGAATTATTTCATGCGTGAT-3’; 3) 5’-
GAGGACTACAACCTTATTGTT-3’; 4) 5’-CTGAGACCAAACCTGTGCTTA-3’; 5) 5’-
GACCACCAGTACCAGTTCTTA-3’. For back-complementation experiments 1x105 
HeLa or CEMss cells were knocked down by transducing 3 g p24 of LKO.1-sh-
3’KAP1 targeting the 3’ untranslated region (3’UTR) of KAP1 gene and KAP1 was 
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expressed using 2 g p24 AIP-HA-KAP1. 
Stable KAP1 knockdown cells were obtained by expressing a shRNAmir (sh-1-
KAP1: 5’-CCACTGAGGACTACAACCTTA-3’) (Open Biosystem) through a lentiviral 
vector system (GIPZ-sh-1-KAP1). As control a mismatch oligonucletide (sh-MM: 
5’-CCACTGAGCTGAACAACCTTA-3’) containing four mutations in sh-1-KAP1 
sequence was expressed through the GIPZ lentiviral vector (GIPZ-sh-MM). 
Lentiviral vectors containing shRNAs or KAP1 cDNA were obtained by collecting 
supernatants from HEK293T cells 48 hours post transfection with 20 g transfer 




Real time quantitative PCR (qPCR)  
Integrated HIV-1 copies by Alu-LTR and 2 LTRs circles were analyzed by qPCR as 
previously described (Brussel and Sonigo, 2003). Total viral DNA was analyzed as 
previously described (Butler et al., 2001). Total and integrated HIV-1 DNA 
quantifications in cells carrying GIPZ, LKO.1 or AIP lentiviral DNAs was performed 
by using primers/probes specific for the luciferase gene in NL4.3-Luc 24 hours or 
15 days post infection respectively to avoid cross reactivity between viral LTR 
(Terreni et al., 2010). MLV late reverse transcripts and integrated MLV DNA at 24 
hours and 15 days post infection respectively were quantified using 
primers/probes specific to the luciferase gene that recognize LNC-CMV-eGFPT2A-
fLuc MLV viral vector (Terreni et al., 2010). A kinetic PCR assay for human beta-
globin DNA was carried out as endogenous control as previously described (Tan 
et al., 2006). The fold increase/decrease ratios of the real time data were 
calculated using the mathematical model for the relative quantification in the real 
time-PCR (Pfaffl, 2001) where the HIV-1 gene is the “target gene” and globin 





Immunoprecipitations and Flag-KAP1 pull downs 
GBD-IN-HATw/m expression and immunoprecipitations in yeast cells were 
performed as previously described (Guo et al., 2004) with minor modifications. 
For Flag immunoprecipitation experiments HEK293T or HeLa cells expressing 
Flag tagged proteins were lysed in NEHN buffer (300 mM NaCl, 50 mM Hepes pH 
7.5, 0.5% NP-40, 20% glycerol and 1 mM EDTA). 500 μg-2000 μg lysates were 
incubated with 30 μl anti-Flag M2 agarose beads (Sigma) followed by Western 
blot analysis. KAP1 binding to Flag-INw/m was performed using transfected cells 
treated with 1 μM TSA for 8 hours. 
For Flag pull down experiments HEK293T expressing Flag-KAP1 were lysed in 50 
mM Hepes pH 7.4, 150 mM NaCl and 0.5% NP-40. Lysates (250 μg) containing a 
HAT inhibitor (Lys-CoA) were incubated with 250 ng of either 6xHis-IN-HATw/m 
or 6xHis-IN TEV digested products and pulled down by anti-Flag M2 agarose 
beads (Sigma) followed by Western blot analysis. 
 
Antibodies 
Primary antibodies for Western blot analyses were: monoclonal HIV-1 IN 
antibody (8G4) from NIH AIDS Research and Reference Reagent Program, 
polyclonal anti-KAP1 (Bethyl laboratories, Inc., Montgomery, TX), polyclonal anti-
HA (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), polyclonal anti-HDAC1 
(Upstate, Temecula, CA). Anti-Flag (polyclonal and monoclonal-Clone M2), anti-
Tubulin (CloneB-5-1-2) were all purchased from Sigma. Antibodies anti-
acetylated IN have been previously described (Terreni et al., 2010). 
 
In vitro binding assays 
In vitro translated 35S-KAP1 was produced using TNT T7 Reticulocyte Lysate 
System (Promega) and pcDNA3-KAP-1 as template. GST-IN full length and GST-
IN truncated domains (N-terminus, Core and C-terminus) preparations and in 
vitro binding have been previously described (Cereseto et al., 2005). In vitro 
binding between 6xHis-IN-HATw or 6xHis-IN-HATm and 35S-KAP1 was performed 
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by incubating 1000 ng of either recombinant purified proteins with 1000 cpm of 
35S-KAP-1, 20 μg BSA and 15 μl of Ni-NTA agarose (settled beads volume) in 
1000 μl pull down buffer (150 mM NaCl, 2 mM MgCl2, 25 mM imidazole, 0.1 % 
NP-40, 25 mM imidazole and 50 mM Tris-HCl pH 7.4) for 5 hours at 4 °C. 
Following three washes in pull down buffer, the reaction mixture was separated 
by SDS-PAGE gel analyzed by phosphoimaging (Cyclone). 
 
Statistical analysis.  
Statistical significance of the results obtained in the HIV-1 infectivity assays was 
assessed by the two-tailed Student's t-test assuming equal variance between 
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Figure 1. Identification of KAP1 in yeast two hybrid screen using 
constitutively acetylated integrase as a bait 
(A) Schematic representation of IN-HATw (left) and IN-HATm (right) chimeras. 
IN codon optimized is fused to the p300 HAT domain either wild-type (HATw) or 
mutated (HATm). Between the IN and the HAT domains a TEV protease cleavage 
site is inserted to allow separation of the two domains. 
(B) IN-HATw and IN-HATm fusion recombinant proteins undigested (-TEV) or 
TEV digested (+TEV) were immunoblotted with anti-acetylated IN specific 
antibodies (AcIN) (left panel). The immunoblot was re-probed with IN 
antibodies for total IN (right panel).  
(C) The IN-HATw and IN-HATm chimeras expressed in yeast cells (AH109) were 
immunoprecipitated with HA antibodies and immunoblotted with AcIN 
antibodies to detect acetylated IN. Total IN was detected with IN antibodies.  
(D) Interaction efficiencies of the IN-HATw and IN-HATm chimeras and single 
domains (HAT, IN and GDBD) with KAP1 in yeast two-hybrid assay. 
 
Figure 2. KAP1 preferentially binds acetylated IN than the unmodified 
form in vivo and in vitro  
(A) HEK293T cell lysates expressing Flag-KAP1 were incubated with the IN-HATw 
or IN-HATm chimeras (left panel) and with IN isolated from the IN-HATw (IN-
Ac+) or from IN-HATm (IN-Ac-) by TEV digestion (right panel). The Flag 
immunocomplexes were blotted with HA antibodies to detect bound IN-HAT 
chimeras and re-probed with Flag antibodies to check for KAP1 expression. 
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(B) HEK293T cells expressing either Flag-IN wild type (Flag-INw) or mutated at 
acetylable lysines (K264, 266, 273R) (Flag-INm) were immunoprecipitated with 
Flag antibodies and blotted using -KAP1 antibodies.  
(C) In vitro binding between 35S-KAP1 and IN-HATw or IN-HATm recombinant 
proteins. The graph expresses the amounts of KAP1 bound protein as 
percentages of the binding reaction: 35S-KAP1 + IN-HATw.  
(D) In vitro binding between 35S-KAP1 and recombinant full length IN fused to 
GST (GST-IN) or each single recombinant IN domain fused to GST: N-terminus 
(GST-IN-Nt), catalytic (GST-IN-Cat) and C-terminus (GST-Ct). The graph 
expresses the amounts of KAP1 bound protein as percentages of input (35S-
KAP1). In (C) and (D) the upper panels show the gels exposed to 
Phosphoimaging (Cyclone) and the lower panels the Coomassie staining of the 
SDS-PAGE gels. 
 
Figure 3. KAP1 inhibits HIV-1 integration  
(A) Left panel: expression of KAP1 in HeLa cells transiently knocked down with 
smart pool siRNAs (si-KAP1) and in control HeLa cells treated with a pool of non 
targeting siRNAs (si-CTR). Right panel: expression of KAP1 in HeLa cell clones 
(H14a, H18 and H19) stably knocked down with shRNA expressed by a lentiviral 
vector (sh-1-KAP1) and in control HeLa cells expressing a mismatched sh-1-KAP1 
(shMM).  
(B-D) Transient and stable KAP1 knockdown HeLa cells were infected with 
NL4.3-Luc HIV-1 virus and analyzed by qPCR for late reverse transcripts 24 hours 
post infection (hpi) (B), 2-LTR DNA circles 24 hpi (C) and integrated HIV-1 DNA 
48 hpi (siRNA treated cells) or 15 days post-infection (dpi) (sh-1-KAP1) (D).  
(E) Integrated NL4.3-Luc HIV-1 DNA following infection (15 dpi) of HeLa cells 
KAP1 knockdown (sh-3’KAP1), back-complemented (sh-3’KAP1 + HA-KAP1) or 
control treated (GIPZ). Expression of KAP1 was verified by immunoblot.  
(F) Expression of KAP1 in HEK293T cells transfected with KAP1 (pcDNA-KAP1), 
empty vector (pcDNA) or un-transfected (UT) (left panel). Over-expressing KAP1 
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cells (pcDNA-KAP1) and control cells (pcDNA) were infected with NL4.3-Luc HIV-
1 virus and analyzed by qPCR for integrated HIV-1 DNA (Alu-LTR) (middle panel) 
and late reverse transcripts (right panel) at 48 hpi.  
All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
qPCR absolute values are reported in Table S1.  
 
 
Figure 4. KAP1 inhibition of HIV-1 integration depends on integrase 
lysines (K264, K266 and K273) targeted for acetylation by p300 and 
occurs in HIV-1 natural target cells 
(A) KAP1 knockdown (H14a and H18) and control (shMM) HeLa cell clones were 
infected with NL4.3-Luc or NL4.3-Luc-3mut and analyzed by qPCR for integrated 
HIV-1 DNA (15 dpi).  
(B) Primary T-cells (PBLs) transiently knocked down for KAP1 (si-KAP1) and 
control treated (si-CTR) were infected with NL4.3-Luc or NL4.3-Luc-3mut HIV-1 
and analyzed for integrated HIV-1 DNA (Alu-LTR, 48 hpi). Protein expression was 
verified by immunoblot.  
(C) Integrated NL4.3-Luc HIV-1 or NL4.3-Luc-3mut HIV-1 DNA following infection 
(15 dpi) of CEMss cells KAP1 knockdown (sh-5-KAP1) and control treated (GIPZ) 
and integrated NL4.3-Luc HIV-1following infection (15 dpi) of CEMss KAP1 
knockdown (sh-3’KAP1) and back-complemented (sh3’KAP1 + HA-KAP1). Protein 
expression was verified by immunoblot.  
All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
qPCR absolute values are reported in Table S1.  
 
 
Figure 5.  KAP1 decreases HIV-1 IN acetylation by inducing IN/HDAC1 
complex formation  
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(A) Flag-IN expressed in HEK293T with or without exogenous KAP1 (pcDNA-
KAP1), immunoprecipitated with Flag antibodies and blotted with anti-
acetylated IN specific antibodies (AcIN) to determine IN acetylation levels. 
Expression of KAP1 and total IN was determined by immunoblot using KAP1 
and IN antibodies respectively.  
(B) Flag-IN expressed in either HeLa cell clones stably knocked down for KAP1 
by sh-1-KAP1 (H14a, H18 and H19) or in control cells (sh-MM) was 
immunoprecipitated with Flag antibodies and blotted with AcIN antibodies. 
Total IN was detected by re-probing with Flag antibodies. 
(C) HA-IN was co-expressed with either Flag-HDAC1 or Flag-HDAC3 in HEK293T 
cells. Flag immunoprecipitates were blotted with HA (IN), KAP1 and Flag 
(HDAC1 and HDAC3) antibodies. Total IN was detected by HA immunoblot.  
(D) HA-IN and Flag-HDAC1 were co-expressed in HEK293T cells with or without 
exogenous KAP1 (pcDNA-KAP1). Flag (HDAC1) immunoprecipitates were 
blotted with HA (IN) antibodies. The expression levels of KAP1, HDAC1 and IN 
were controlled by immunoblot using the indicated antibodies.  
(E) HA-IN and Flag-HDAC1 were co-expressed in KAP1 stably knocked down cell 
clones (H14a, H18 and H19) and in control cells (sh-MM). Flag (HDAC1) 
immunoprecipitates were blotted with HA (IN) antibodies. Expression levels of 
IN and HDAC1 were controlled by immunoblot using the indicated antibodies. 
 
Figure 6. KAP1 inhibition of HIV-1 integration is mediated by HDAC1 
(A) HeLa cells treated with 600 nM MS-275 or with 800 nM TSA were infected 
with NL4.3-Luc HIV-1 and analyzed by qPCR for integrated HIV-1 DNA (Alu-LTR) 
at 24 hpi. 
(B) Expression of HDAC1 in HeLa cells transiently knocked down with smart pool 
siRNA (si-HDAC1) and in control HeLa cells treated with a pool of non-targeting 
siRNA (si-CTR) (left panel). HeLa cells transiently knocked down for HDAC1 were 
infected with NL4.3-Luc HIV-1 and analyzed by qPCR for integrated HIV-1 DNA 
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(Alu-LTR) at 48 hpi (middle panel) and 2-LTR DNA circles at 24 hpi (right 
panel).C) Expression of KAP1 and HDAC1 in HEK293T cells transfected with 
pcDNA-KAP1 and transiently knocked down with si-HDAC1 (left panel). HEK293T 
cells over-expressing KAP1 (pcDNA-KAP1) were co-treated or not with si-HDAC1, 
subsequently infected with NL4.3Luc HIV-1 and analyzed by qPCR for integrated 
HIV-1 DNA (Alu-LTR) at 48 hpi (right panel). 
All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
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I- Supplemental Data 
 
Figure S1 related to Figure 1  
Identification of Ac-K264, Ac-K266 and Ac-K273 by MS-MS (MALDI-
TOF/TOF) in the IN-HATw fusion recombinant protein 
The identification of acetylated lysines in IN-HATw recombinant protein was 
performed by mass-spectrometry analysis of IN-HATw recombinant protein. The 
acetylation of the IN lysines was supported by an adequate ladder of y (and b) 
ion family and by the presence of known marker ions for acetylated lysine: the 
acetylated lysine immonium ion at m/z 143.1 and the ion at m/z 126.1, which is 
a fragment ion induced by the loss of NH3 from the ions at m/z 143.11-2 (Kim et 
al., 2002; Trelle and Jensen, 2008).  
(A) Mass spectrum of AcK264 and AcK266 lysines. Fragmentation for bi-
acetylated ionAcK264AAcK266IIR. 
(B) Mass spectrum of AcK273. Fragmentation for acetylated ion 
DYGAcK273QMAGDDCamCVASR. CamC stands for carbamidomethylated 
cysteine.  
In (A) and (B) AcK stands for acetylated lysines. Mapped y ion family sequence 
in red. Mapped b ion family sequence in green. Lysine acetylation marker ions 
marked in yellow. 
 
Figure S2 related to Figures 2 and 5 
Associations of untagged integrases with KAP1 and HDAC1 
To prove that the HA or Flag tag fused to IN does not affect the association with 
either KAP1 or HDAC1  co-immunoprecipitations were performed using untagged 
IN. 
Supplemental Text and Figures
2 
 
(A) Endogenous KAP1 binds preferentially acetylated IN (untagged). HEK293T 
cells expressing either IN wild type untagged (INw) or mutated at lysine 
acetylation sites (K264, 266, 273R) (INm) were immunoprecipitated with αKAP1 
antibodies and blotted using α-IN antibodies. 
(B) KAP1 increases the association of HDAC1 with IN (untagged). IN and Flag-
HDAC1 were co-expressed in HEK293T cells with or without exogenous KAP1 
(pcDNA-KAP1). αFlag (HDAC1) immunoprecipitates were blotted with α-IN 
antibodies. The expression levels of KAP1, HDAC1 and IN were controlled by 
immunoblot using the indicated antibodies. 
 
Figure S3 related to Figures 3 and 4  
KAP1 affects viral infectivity through a mechanism involving IN 
acetylable lysines (K264, K266, K273)  
The KAP1 effect on HIV-1 infectivity was evaluated by measuring the luciferase 
activity produced by an HIV-1 vector expressing the luciferase gene and 
containing an IN wt (NL4.3-Luc) or mutated in the three acetylable lysines 
(NL4.3-Luc-3mut) 
(A) KAP1 knockdown increases HIV-1 infectivity. Transient and stable KAP1 
knockdown HeLa cells (Figure 3A) were infected with NL4.3-Luc HIV-1 virus and 
analyzed for luciferase activity (Luc Activity) 48 hpi.  
(B) KAP1 over-expression decreases HIV-1 infectivity. HEK293T cells over-
expressing KAP1 (pcDNA-KAP1) and control cells (pcDNA) (Figure 3F) were 
infected with NL4.3-Luc HIV-1 virus and analyzed for luciferase activities (Luc 
Activity) 48 hpi.  
(C) KAP1 does not affect the infectivity of NL4.3-Luc-3mut carrying IN mutated 
at acetylable lysines (K264,266,273R). KAP1 knockdown (H14a and H18) and 
control (shMM) HeLa cell clones were infected with NL4.3-Luc or NL4.3-Luc-3mut 
and analyzed for luciferase activity 48 hpi. 
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All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
 
Figure S4 related to Figure 3 
KAP1 does not regulate the HIV-1 LTR promoter 
To verify whether KAP1 might affect HIV-1 transcription three different 
approaches were employed: 
(A) Left panel: stable KAP1 knockdown HeLa cell clones (H14a, H18 and H19) 
and control cells expressing a mismatched KAP1 shRNA (sh-MM) were infected 
with D64E HIV-1 virus. Luciferase activity was evaluated at 48 hpi (Luc Activity).  
Right panel: the same experiment was performed using HEK293T cells (T-pool) 
and cell clones (T14 and T15) KAP1 stably knocked down and control cells 
expressing a mismatched KAP1-shRNA (shMM). 
Graphs are represented in fold increase of infectivity of KAP1 knockdown cells 
with respect to control cells (error bars represent standard deviations from at 
least two independent experiments). 
(B) HeLa cells KAP1 stably knocked down (H14a, H18 and H19) and control cells 
(sh-MM) were transfected with pNL4.3.Luc.R-E- HIV-1 together with pCMV-
Renella luciferase to normalize for transfection efficiency. Results are 
represented as a ratio of firefly luciferase 
(pNL4.3.Luc.R-E-) to Renella luciferase (pCMV-Renella).  
(C) KAP1 knockdown does not affect transcription of latent or activated 
integrated HIV-1 in J-lat A1 cells (Jordan et al., 2003). Percentage of GFP 
positive J-lat A1 cells measured by FACS, non activated or TPA-activated 
following KAP1 knockdown (sh-5-KAP1). Expression of KAP1 in non activated or 
TPA-activated J-lat A1 cells following KAP1 knockdown (sh-5-KAP1) and in 
control cells (AIP) was verified by immunoblot (error bars represent standard 




Figure S5 related to Figure 3 
KAP1 knockdown increases HIV-1 integration in HEK293T cells 
To prove that KAP1 inhibition of HIV-1 integration is not cellular specific, KAP1 
was knocked down in HEK293T cells and viral steps analyzed by luc activity or by 
qPCR for different HIV-1 DNA products. 
(A) Expression of KAP1 in HEK293T cells (T-pool) and cell clones (T14 and T15) 
stably knocked down with KAP1 shRNA expressed by a lentiviral vector (GIPZ-sh-
1-KAP1) and in control HEK293T cells expressing a four mutations mismatched 
KAP1-shRNA (GIPZ-sh-MM).  
(B-E) HEK293T cells stably silenced for KAP1 were infected with NL4.3-Luc HIV-1 
virus and analyzed for luciferase activity (Luc Activity) at 48 hours post-infection 
(hpi) (B) and by qPCR for late reverse transcripts at 24 hpi (C), 2-LTR circles at 
24 hpi (D) and integrated HIV-1 DNA at 15 dpi (E).  
All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
qPCR absolute values are reported in Table S1.  
 
Figure S6 related to Figure 3 
Human KAP1 does not affect M-MLV integration in HeLa cells  
(A) Expression of KAP1 in HeLa cells knocked down with smart-pool siRNAs 
(siKAP1) and control HeLa cells treated with a pool of non targeting siRNAs 
(siCTR).  
(B-D) HeLa KAP1 knockdown cells were infected with HIV-1 or with MLV viruses 
and analyzed for luciferase activity (B), integrated viral DNA by qPCR at 15 dpi 
(C) and late reverse transcripts at 24 hpi (D). 
All graphs are represented in fold increase with respect to control cells (error 






Figure S7 related to Figure 5 
HIV-1 integrase is deacetylated by HDAC1  
(A) HDACs are associated with IN in vivo. HEK293T cell lysates expressing Flag-
IN were immunoprecipitated using anti Flag antibodies (αFlag). The HDAC 
activities of the αFlag immunoprecipitates in the presence or not of the TSA were 
detected using an in vitro fluorescence-based assay. 
(B) IN acetylation is regulated by the cellular HDACs. HEK293T cells expressing 
pCMV-IN were treated or not with TSA and analyzed by Western Blot for IN 
acetylation and for total IN using anti acetylated IN (α−Ac-IN) and anti IN (α−IN) 
antibodies respectively.  
(C) IN is directly deacetylated by HDAC1. Left panel: 14C labeled in vitro 
acetylated GST-IN (Ac-IN) was incubated with the purified Flag-HDAC1 in the 
presence or not of TSA (4µM), with Flag-HDAC1 catalytically inactive (H141A) or 
with the control eluates. The upper panel shows the gel exposed to 
Phosphoimaging (Cyclone) and the lower panel the Coomassie staining of the 
SDS-PAGE gel. Right panel: the purified Flag-HDAC1 and Flag-HDAC1 (H141A), 
used for the in vitro IN deacetylation assays, were analyzed by Western Blot 
using the anti Flag (αFlag) and anti KAP1 (αKAP1) antibodies.      
 
 Figure S8 related to Figure 6 
HDAC3 is dispensable in KAP1 mediated inhibition of HIV-1 integration  
(A) Expressions of KAP1 and HDAC3 in HEK293T cells over-expressing KAP1 and 
knocked down or not for HDAC3 using a pool of HDAC3 siRNAs (si-HDAC3).  
(B-C) HEK293T cells were infected with NL4.3-Luc HIV-1 virus at 24 hours post 
transfection with pcDNA3-KAP1 and si-HDAC3. The integrated provirus (Alu-LTR) 
(B) and late reverse transcripts (C) were analyzed by qPCR 48 hpi. 
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All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
qPCR absolute values are reported in Table S1.  
 
 
Figure S9 related to Figure 6 
Identification of the KAP1 domain determining KAP1 mediated 
inhibition of HIV-1 integration 
Results 
In order to determine which region of KAP1 is required for HIV-1 inhibition, 
different fragments of the cellular protein (schematized in Figure S9A) were 
tested in viral integration. As shown in Figure S9B, integration of HIV-1 was 
inhibited at the same extent as full length by the 1-381 and 1-616 fragments, 
while the 617-835 fragment showed no decreased integration. The reverse 
transcription remained unaltered (data not shown). To further verify the role of 
each KAP1 fragments in HIV-1 infectivity reciprocal experiments were performed 
in KAP1 knockdown CEMss cells expressing each single domain resistant to KAP1 
shRNA (Figure S9C, left panel). Expression of 1-381, 1-616 and of  a KAP1 
mutant (W664A) defective in Mi2α binding restored viral integration to baseline 
at the same extent as full length KAP1, while the 617-835 fragment could not 
revert KAP1 knockdown integration phenotype (Figure S9C, right panel). The 
amounts of late reverse transcripts remained unaltered (data not shown). 
Since our results indicate that KAP1 activity on HIV-1 integration occurs through 
HDAC1, we then evaluated the binding capacity of each KAP1 fragment with 
HDAC1. As shown in Figure S9D, left panel, similar amounts of fragment 1-616 
and full length KAP1 co precipitated with Flag-HDAC1. Due to different migration 
conditions, a separate gel reported in the right panel of Figure S9D, shows that 
fragment 1-381 is associated with HDAC1, while the 617-835 fragment is not. 
Therefore, the associations of HDAC1 with the 1-381 and 1-616 correlate with 
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the capacity of these fragments to inhibit viral integration and to reverse the 
KAP1 knockdown phenotype. Since the RBCC domain corresponding to 1-381 
fragment has been shown to trimerize (Peng et al., 2000), its binding with 
HDAC1, here reported, may result from the oligomerization with endogenous 
KAP1. Therefore, to verify this interaction MEFs KAP1 knock-out cells 
(Wiznerowicz et al., 2007) were employed showing a positive binding between 
HDAC1 and the 1-381 fragment (Figure S9E), as observed in HEK293T cells.  
It has been reported that the KAP1 region involved in transcriptional silencing 
mediated by the NuRD-HDAC1 correspond to the PHD-Bromo domain localized in 
the C-terminal region (Schultz et al., 2001). Therefore, our data suggest that the 
molecular mechanisms leading to the recruitment of HDAC1 by KAP1 in the 
integration inhibition (N-terminal) do not correspond to the mechanisms involved 
in the transcription repression (C-terminal).  
 
Figure S9  
(A) Schematic representation of HA-tagged KAP1 FL (1-835) and deletion 
mutants (1-381, 1-616 and 617-835). 
(B) Integrated NL4.3-Luc HIV-1 DNA (Alu-LTR) 48 hpi of HEK293T cells 
expressing KAP1 full length (1-835) or KAP1 deletion mutants (1-381, 1-616 and 
617-835). Protein expression was verified by immunoblot. 
(C) Integrated NL4.3-Luc HIV-1 DNA 15 dpi in CEMss cells knocked down for 
KAP1 (sh3’KAP1) and back-complemented with KAP1 full length (1-835), KAP1 
deletion mutants (1-381, 1-616 and 617-835) or a mutant KAP1 (W664A) 
defective in Mi2α binding. Protein expression was verified by immunoblot. 
(D) Lysates from HEK293T cells co-expressing Flag-HDAC1 with HA-KAP1 full 
length (1-835) or HA-KAP1 (1-616) (left panel) and lysates from HEK293T cell 
co-expressing Flag-HDAC1 with HA-KAP1 full length (1-835),  HA-KAP1 (1-381), 
or HA-KAP1 (617-835) (right panel) were immunoprecipitated with α-Flag 
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antibodies and blotted with α-HA antibodies. Expression levels of KAP1 full length 
or deletion mutants and HDAC1 were verified by using the indicated antibodies.   
(E) Lysates from MEFs KAP1 KO cells co-expressing Flag-HDAC1 with HA-KAP1 
(1-381) were immunoprecipitated with α-Flag antibodies and blotted with α-
KAP1 antibodies. Expression levels of KAP1 (1-381) and HDAC1 were verified 
using the indicated antibodies.   
All graphs are represented in fold increase with respect to control cells (error 
bars represent standard deviations from at least two independent experiments). 
qPCR absolute values are reported in Table S1.  
 
Figure S10 related to Discussion section 
KAP1 and HDAC1 expressions in Resting or Activated PBLs and in Naive 
(CD45RA+) or Memory (CD45RO+) CD4+ T cells 
Equal number of Resting or Activated PBLs (2 x 106) were analyzed by western 
blot for KAP1 and HDAC1 expressions using the indicated antibodies (αKAP1 and 
αHDAC1). Equal amounts of proteins (60 µg) from CD45RA+ Naive or CD45RO+ 
Memory CD4+ T cells were analyzed by Western blot for KAP1 and HDAC1 






























II- Supplemental Experimental Procedures  
 
Vectors and constructs 
Untagged INw and INm were cloned by PCR in pCDNA3.0 vector starting from 
their respective pFlag IN CO constructs. pD64E was obtained from the NIH AIDS 
Research and Reference Reagent Program (Germantown, MD). The pFlag-HDAC1 
(H141A) and the pAIP-HA-KAP1 (W644A) were produced by PCR starting from 
the original vectors. KAP1 deletion mutants (1-381, 1-616 and 617-835) were 
cloned by PCR in pAIP lentiviral vector in frame with HA and in pcDNA3HA 
vector. 
MLV transfer gene pLNC-CMV-eGFPT2A-fLuc was a kind of gift from Z. Debyser 
(KU Leuven University, Belgium). 
Identification of constitutively acetylated IN acetylation sites by mass 
spectrometry 
Recombinant purified IN-HATw (250ng) was separated by SDS-PAGE and stained 
by Coomassie blue. The corresponding band was excised and treated with 
trypsin as previously described (Shevchenko et al., 1996) with minor 
modifications. Peptides were analyzed by mass spectrometry (MS) and tandem 
mass spectrometry (MSMS) performed with a 4800 MALDI TOF/TOF Analyzer 
mass spectrometer from Applied Biosystems. Searching extracted unambiguously 
identified proteins and manually curated monoisotopic peak lists against the 
SwissProt database (version 57.0), UniProtKB database (version 15.0) or NCBI 
database using the software program Mascot Server 2.1.04 (Matrix Science). 
Co-immunoprecipitations 
Untagged INw and INm co-immunoprecipitations were performed using the 
same conditions described in EXPERIMENTAL PROCEDURES. Untagged INw and INm 
were detected with a mouse monoclonal IN antibody IN2 (Santa Cruz 






Naïve (CD45RA+) and Memory (CD45RO+) CD4+ T cells were isolated starting 
from PBLs that were purified as described in EXPERIMENTAL PROCEDURES. CD4+ T 
cells were isolated from PBLs by negative selection with CD4+ T cells isolation kit 
(Miltenyi Biotec). Naïve (CD45RA+) and Memory (CD45RO+) T cells were 
isolated from the CD4+ population using respectively CD45RA and CD45RO 
microbeads (Miltenyi Biotec). 
The Mouse embryonic fibroblasts KAP1 Knockout cells (MEFs KAP1 KO) derived 
from homozygous KAP1 floxed mice were previously described (Wiznerowicz et 
al., 2007) and are kind of gifts from Didier Trono (School of Life Sciences, EPFL, 
Lausanne, Switzerland). 
HIV-1 LTR transcription assay in KAP-1 knockdown HeLa and J-lat A1 
Cells 
HeLa KAP1 knockdown cells were transfected with pNL4.3.Luc.R-E- and CMV-
Renella. Luciferase activity was measured 48 hours post transfection using the 
DualGlo Luciferase assay Kit (Promega). J-lat A1 cells (Jordan et al., 2003) (1 x 
105) untreated or TPA treated (10 nM TPA, for 24 hours) were transduced with 2 
µg p24 of sh-5-KAP1 described in EXPERIMENTAL PROCEDURES or AIP lentiviral vector 
as control. Western blot analysis and percentage of GFP positive cells (analyzed 
by FACS) were performed 60 hours post LKO.1-sh-5-KAP1 transduction.  
Deacetylase Assays 
Quantification of HDAC activity associated with IN was performed on Flag and 
Flag-IN immunoprecipitates obtained from 2 mg of HEK293T transfected cells by 
using the HDAC Fluorometric Activity Assay kit (Upstate). 
In vitro HDAC1 activity was performed by using Flag-HDAC1 and Flag-HDAC1 
H141A purified from HEK293T transfected cells by using the FLAG M Purification 
Kit (Sigma). Elutions were performed with Flag peptides in 100 mM KCl, 0.2% 
NP-40 buffer.  Purified Flag-HDAC1 and Flag-HDAC1 H141A (1µg) were 
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incubated with GST-IN (1µg) in vitro acetylated by the HAT p300 in the presence 
of the 14C-Acetyl CoA as previously described (Cereseto et al., 2005) in HDAC 
buffer (10 mM Tris HCl pH 7, 100 mM NaCl, 5 mM MgCl2 and 5 % glycerol) at 
30°C for 2 hours. The reactions were resolved on SDS-PAGE and analyzed by 
coomassie blue staining and phosphoimaging (Cyclone).  
Transient knockdowns and KAP1 back-complementation in CEMss cells  
1x105 CEMss cells were knocked down by transducing 3 µg p24 of LKO.1-sh-
3’KAP1  targeting the 3’ untranslated region (3’UTR) of KAP1 gene and KAP1 was 
expressed using 2 µg p24 AIP-HA-KAP1 or AIP-HA-KAP1 deletion mutants (1-
381, 1-616 and 617-835) and 4 µg AIP-HA-KAP1 (W664A). 
At 60 hours post transductions 5x105  CEMss cells were infected with 250 ng p24 
NL4.3-Luc (VSV-G) HIV-1 virus. 
The HDAC3 siRNA pool (smart pool siRNAs pre-designed by Dharmacon Inc. 
Chicago, IL) contains: 1) GGAAUGCGUUGAAUAUGUC; 2) 
GCAUUGAUGACCAGAGUUA; 3) AAAGCGAUGUGGAGAUUUA; 4) 
GGAAAGCGAUGUGGAGAUU.  
3x105 HEK293T cells were transfected with pcDNA3-KAP1 (1,5 µg with PEI) and 
then treated with 100 nM siHDAC3 using Gene silencer. At 24 hours post siRNAs 
transfection, infections were performed using 125 ng p24 for 2,5x105 cells.  
HIV-1 and MLV infectivity assays 
Transient and stable knockdown HeLa cells and transfected HEK293T cells were 
infected as described in EXPERIMENTAL PROCEDURES. HEK293T KAP-1 knockdown 
and control cells (2,5x105) were infected using 25 ng p24 of either NL4.3-Luc or 
D64E HIV-1 pseudotyped with VSV-G for 2 hours in 1 ml total volume. Infectivity 
was measured by luciferase activity quantification using the Luciferase Assay 
System Kit (Promega) and normalized to total protein concentrations. Real time 
quantitative PCR (qPCR) to analyze late reverse transcripts, 2-LTR and integrated 
viral DNA were performed as described in EXPERIMENTAL PROCEDURES. 
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MLV was produced as previously described (Christ et al., 2008). Real time 
quantitative PCR (qPCR) to analyze MLV late reverse transcripts at 24 hpi and 
integrated MLV DNA at 15 dpi were performed by using primers/probes specific 
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Medium of at least 
two independent 
experiments   
Standard 
deviations 
Figure 3B left panel 
 Late Reverse transcripts 
(Copies/106 Cells) 
 si-CTR 66545 19771,4525 
si-KAP1 84251 23672,3885 
Figure 3B right panel 
  sh-MM 848911,2835 58864,6731 
H14a 866446,8395 79054,6096 
H18 869849,1565 67167,2621 
H19 856845,65 72831,6591 
Figure 3C left panel 
 2 LTR circles (Copies/106 
Cells) 
 si-CTR 17179,48333 4444,56191 
si-KAP1 11157,319 3402,39641 
Figure 3C right panel  
  sh-MM 5700,5365 1228,24377 
H14a 2647,268 1939,27146 
H18 2182,86 840,311557 
H19 291,5285 339,465702 
Figure 3D left panel 
Integrated viral DNA 
(Copies/106 Cells) 
 si-CTR 6566,727333 1517,65767 
si-KAP1 54482,978 23085,5902 
Figure 3D right panel 
  sh-MM 144075,135 21948,5591 
H14a 292730,065 70364,3867 
H18 341198,195 90057,6783 
H19 345544,035 6155,06047 
Figure 3E  
  GIPZ 8347,371333 1895,8304 
sh3'KAP1 22874,59667 6370,68095 
sh3'KAP1+KAP1 7634,748333 4230,43603 
Figure 3F middle panel  
 Late Reverse transcripts 
(Copies/106 Cells) 
 pcDNA3 15178,5 2734,38192 
KAP1 15551,5 2783,8794 
Figure 3F right panel  
Integrated viral DNA 
(Copies/106 Cells) 
 pcDNA3 14185,695 52,8420898 
KAP1 8178,749 1136,05331 
Figure 4 
Medium of at least two 
independent 




Integrated viral DNA 
(Copies/106 Cells) 
 sh-MM + NL4.3-Luc 11117,03 1326,815164 
H14a + NL4.3-Luc 22626,46 6450,850312 
H18 + NL4.3-Luc 23438,525 6900,902565 
sh-MM + NL4.3-Luc-3mut 5683,688 559,4657137 
H14a + NL4.3-Luc-3mut 8888,4635 4836,011464 
H18 + NL4.3-Luc-3mut 5716,7585 1014,276088 
Figure 4B 
  si-CTR+ NL4.3-Luc 8485,9715 2444,27821 
si-KAP1+ NL4.3-Luc 19285,1125 3171,217047 
si-CTR+ NL4.3-Luc-3mut 3082,93725 1174,354288 
si-KAP1+ NL4.3-Luc-3mut 3844,06075 918,6291123 
Figure 4C 
  GIPZ+ NL4.3-Luc 24436,83333 3951,675208 
sh-5-KAP1+ NL4.3-Luc 59869,26667 8683,191391 
GIPZ+ NL4.3-Luc-3mut 10410,80233 1313,384708 
sh-5-KAP1+ NL4.3-Luc-3mut 13603,49333 4390,79871 
   GIPZ + NL4.3-Luc 83256,94 14241,73868 
sh-3'KAP1 + NL4.3-Luc 179578,4 16623,939 
sh-3'KAP1+KAP1+ NL4.3-Luc  80487,515 891,8808542 
Figure 6 
Medium of at least two 
independent 




Integrated viral DNA 
(Copies/106 Cells) 
 HeLa 5219,5775 74,7447223 
TSA 16391,605 7498,51386 
   HeLa 2988,42 777,548759 
MS-275 10968,36 1059,81164 
Figure 6B middle panel  
  si-CTR 3980,107 2303,46847 
si-HDAC1 30642,86767 26038,3323 
Figure 6B right  panel  
 2 LTR circles (Copies/106 
Cells) 
 si-CTR 5028,779 3005,92574 
si-HDAC1 2855,263333 1932,31539 
Figure 6C  
Integrated viral DNA 
(Copies/106 Cells) 
 pcDNA + si-CTR  52342,5 2701,85501 
pcDNA-KAP1 + si-CTR 26960,5 5103,18964 
pcDNA-KAP1 + si-HDAC1 61738,5 12516,4971 
Figure S5 
Medium of at least two 
independent 
experiments   
Standard 
deviations 
Figure S5C  
 Late Reverse transcripts 
(Copies/106 Cells) 
 sh-MM 93095,0435 17288,70918 
T-pool 95006,9675 22280,02321 
T14 90671,765 11187,06992 
T15 85352,2355 14099,71558 
Figure S5D  
 2 LTR circles (Copies/106 
Cells) 
 sh-MM 5678,0645 752,7752726 
T-pool 1406,474 200,6542771 
T14 715,7585 148,6571799 
T15 850,107 148,1883681 
Figure S5E  
Integrated viral DNA 
(Copies/106 Cells) 
 sh-MM 16241,163 1157,413593 
T-pool 40368,72635 796,2677844 
T14 34849,34929 2482,251163 
T15 32509,842 1193,3926 
Figure S8 
Medium of at least two 
independent 




 Late Reverse transcripts 
(Copies/106 Cells) 
 pcDNA + si-CTR  148355,5 12533,4677 
pcDNA-KAP1 + si-CTR 144806,5 14338,0042 
pcDNA-KAP1 + si-HDAC3 209178 13614,63396 
Figure S8C 
Integrated viral DNA 
(Copies/106 Cells) 
 pcDNA + si-CTR  126551,5 15096,02267 
pcDNA-KAP1 + si-CTR 57042,5 692,2575388 
pcDNA-KAP1 + si-HDAC3 59263,5 14455,38393 
Figure S9 
Medium of at least two 
independent 




Integrated viral DNA 
(Copies/106 Cells) 
 pcDNA3 31100,5 9654,12888 
KAP1 9533 3799,99184 
KAP1 (1-381) 14079 5026,115 
KAP1 (1-616) 14975 7141,77849 




GIPZ 84142,93 10103,071 
sh-3'KAP1 + AIP 242767 12700,7692 
sh-3'KAP1 + KAP1 81536,565 4394,35045 
sh-3'KAP1 + KAP1 (1-381) 126929,9 2944,53406 
sh3'KAP1+ KAP1 (1-616) 128783,6 6792,1849 
sh-3'KAP1 + KAP1 (617-
835) 207383,55 2327,01771 
   GIPZ 48295,04 5443,68984 
sh-3'KAP1 + AIP 119105,7 4738,88823 
sh-3'KAP1 + KAP1 49497,28 2681,60347 
sh-3'KAP1 + KAP1 (W664A) 63646,4 940,833857 
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